{
  "filename": "ehy037.pdf",
  "title": null,
  "type": "ventricular_arrhythmias",
  "year": null,
  "chapters": [
    {
      "number": "1",
      "title": "1. Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1886 2. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 1,
      "end_page": 1,
      "content": "",
      "keywords": [
        "preamble",
        "introduction"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "2.1 What is new in the 2018 version? . . . . . . . . . . . . . . . . . . . . . . . . . . . 1889 3. Definitions, classification, and pathophysiology . . . . . . . . . . . . . . . . . . 1889",
      "start_page": 1,
      "end_page": 1,
      "content": "",
      "keywords": [
        "version",
        "definitions",
        "classification",
        "what",
        "pathophysiology"
      ],
      "tables": []
    },
    {
      "number": "3",
      "title": "3.1 Definitions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1889 3.2 Classification and pathophysiology of syncope and transient loss of consciousn",
      "start_page": 1,
      "end_page": 1,
      "content": "3.2.1 Syncope. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1890 3.2.2 Non-syncopal forms of (real or apparent) transient loss of consciousness. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1890 4. Diagnostic evaluation and management according to risk stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1892\n",
      "keywords": [
        "definitions",
        "loss",
        "classification",
        "consciousn",
        "risk stratification",
        "pathophysiology",
        "transient loss of consciousness",
        "syncope",
        "transient"
      ],
      "tables": []
    },
    {
      "number": "4",
      "title": "4.1 Initial evaluation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1892",
      "start_page": 1,
      "end_page": 2,
      "content": "4.1.1 Diagnosis of syncope. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1893 4.1.2 Management of syncope in the emergency department based on risk stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1895 4.2 Diagnostic tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1900\n4.2.1 Carotid sinus massage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1900 4.2.2 Orthostatic challenge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1901 4.2.2.1 Active standing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1901 4.2.2.2 Tilt testing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1903 4.2.3 Basic autonomic function tests. . . . . . . . . . . . . . . . . . . . . . . . . 1904 4.2.3.1 Valsalva manoeuvre. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1904 4.2.3.2 Deep breathing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1904 4.2.3.3 Other autonomic function tests . . . . . . . . . . . . . . . . 1904 4.2.3.4 Twenty-four-hour ambulatory and home blood pressure monitoring. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1904\n4.2.4 Electrocardiographic monitoring (non-invasive and invasive) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1905 4.2.4.1 In-hospital monitoring . . . . . . . . . . . . . . . . . . . . . . . . . 1905 4.2.4.2 Holter monitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1905 4.2.4.3 Prospective external event recorders. . . . . . . . . . . 1905 4.2.4.4 Smartphone applications. . . . . . . . . . . . . . . . . . . . . . . 1906 4.2.4.5 External loop recorders. . . . . . . . . . . . . . . . . . . . . . . . 1906 4.2.4.6 Remote (at home) telemetry. . . . . . . . . . . . . . . . . . . 1906 4.2.4.7 Implantable loop recorders . . . . . . . . . . . . . . . . . . . . 1906 4.2.4.8 Diagnostic criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1906 4.2.5 Video recording in suspected syncope . . . . . . . . . . . . . . . . . 1907 4.2.5.1 In-hospital video recording. . . . . . . . . . . . . . . . . . . . . 1907 4.2.5.2 Home video recording. . . . . . . . . . . . . . . . . . . . . . . . . 1908 4.2.6 Electrophysiological study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1908 4.2.6.1 Asymptomatic sinus bradycardia – suspected sinus arrest causing syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . 1908 4.2.6.2 Syncope in bifascicular bundle branch block (impending high-degree atrioventricular block) . . . . . . . . . 1908 4.2.6.3 Suspected tachycardia . . . . . . . . . . . . . . . . . . . . . . . . . . 1908 4.2.7 Endogenous adenosine and other biomarkers. . . . . . . . . . 1909 4.2.7.1 Adenosine (triphosphate) test and plasma concentration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1909 4.2.7.2 Cardiovascular biomarkers. . . . . . . . . . . . . . . . . . . . . . 1910 4.2.7.3 Immunological biomarkers. . . . . . . . . . . . . . . . . . . . . . 1910 4.2.8 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1910 4.2.8.1 Exercise stress echocardiography . . . . . . . . . . . . . . . 1910 4.2.9 Exercise stress testing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1911 4.2.10 Coronary angiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1911 5. Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1911\n1884 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ......................................................................................................................................................................... 5.1 General principles of treatment of syncope. . . . . . . . . . . . . . . . . . 1911 5.2 Treatment of reflex syncope. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1911\n5.2.1 Education and lifestyle modifications. . . . . . . . . . . . . . . . . . . 1912 5.2.2 Discontinuation/reduction of hypotensive therapy . . . . . 1913 5.2.3 Physical counter-pressure manoeuvres . . . . . . . . . . . . . . . . 1914 5.2.4 Tilt training . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1914 5.2.5 Pharmacological therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1914 5.2.5.1 Fludrocortisone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1914 5.2.5.2 Alpha-agonists. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1914 5.2.5.3 Beta-blockers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1915 5.2.5.4 Other drugs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1915 5.2.5.5 Emerging new therapies in specific subgroups . . . . 1915 5.2.6 Cardiac pacing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1915 5.2.6.1 Evidence from trials in suspected or certain reflex syncope and electrocardiogram- documented asystole. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1915 5.2.6.2 Evidence from trials in patients with carotid sinus syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1915 5.2.6.3 Evidence from trials in patients with tilt-induced vasovagal syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1916 5.2.6.4 Evidence from trials in patients with adenosine-sensitive syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . 1917 5.2.6.5 Choice of pacing mode . . . . . . . . . . . . . . . . . . . . . . . . . 1917 5.2.6.6 Selection of patients for pacing and proposed algorithm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1917 5.3 Treatment of orthostatic hypotension and orthostatic intolerance syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1919\n5.3.1 Education and lifestyle measures. . . . . . . . . . . . . . . . . . . . . . . 1919 5.3.2 Adequate hydration and salt intake . . . . . . . . . . . . . . . . . . . . 1919 5.3.3 Discontinuation/reduction of vasoactive drugs . . . . . . . . . 1919 5.3.4 Counter-pressure manoeuvres. . . . . . . . . . . . . . . . . . . . . . . . 1920 5.3.5 Abdominal binders and/or support stockings. . . . . . . . . . . 1920 5.3.6 Head-up tilt sleeping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1920 5.3.7 Midodrine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1920 5.3.8 Fludrocortisone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1920 5.3.9 Additional therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1920 5.3.10 Emerging new pharmacological therapy in specific subgroups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1920 5.4 Cardiac arrhythmias as the primary cause . . . . . . . . . . . . . . . . . . . 1921\n5.4.1 Syncope due to intrinsic sinoatrial or atrioventricular conduction system disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1921 5.4.1.1 Sinus node disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1921 5.4.1.2 Atrioventricular conduction system disease. . . . . . 1921 5.4.1.3 Bundle branch block and unexplained syncope. . . 1922 5.4.2 Syncope due to intrinsic cardiac tachyarrhythmias . . . . . . 1922 5.4.2.1 Paroxysmal supraventricular tachycardia. . . . . . . . . 1923 5.4.2.2 Paroxysmal ventricular tachycardia . . . . . . . . . . . . . . 1923 5.5 Treatment of syncope secondary to structural cardiac, cardiopulmonary, and great vessel disease . . . . . . . . . . . . . . . . . . . . . . 1925 5.6 Treatment of unexplained syncope in patients at high risk of sudden cardiac death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1925\n5.6.1 Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1925 5.6.2 Left ventricular systolic dysfunction. . . . . . . . . . . . . . . . . . . . 1925 5.6.3 Hypertrophic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . 1926 5.6.4 Arrhythmogenic right ventricular cardiomyopathy. . . . . . 1926 5.6.5 Patients with inheritable arrhythmogenic disorders. . . . . 1926\n5.6.5.1 Long QT syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1926 5.6.5.2 Brugada syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1926 5.6.5.3 Other forms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1927 6. Special issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1927\n",
      "keywords": [
        "vasovagal",
        "bradycardia",
        "sudden cardiac death",
        "electrocardiogram",
        "systolic",
        "tachycardia",
        "orthostatic",
        "blood pressure",
        "risk stratification",
        "evaluation",
        "syncope",
        "ventricular tachycardia",
        "carotid",
        "initial",
        "echocardiography",
        "cardiomyopathy",
        "systolic dysfunction",
        "exercise",
        "angiography"
      ],
      "tables": []
    },
    {
      "number": "5",
      "title": "6.1 Syncope in patients with comorbidity and frailty . . . . . . . . . . . . . 1927",
      "start_page": 2,
      "end_page": 2,
      "content": "6.1.1 Comorbidity and polypharmacy . . . . . . . . . . . . . . . . . . . . . . . 1927 6.1.2 Falls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1928 6.1.3 Cognitive assessment and physical performance tests. . . 1928 6.2 Syncope in paediatric patients. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1929\n6.2.1 Diagnostic evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1929 6.2.2 Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1929 7. Psychogenic transient loss of consciousness and its evaluation. . . . 1929\n",
      "keywords": [
        "patients",
        "comorbidity",
        "frailty",
        "transient loss of consciousness",
        "syncope"
      ],
      "tables": []
    },
    {
      "number": "6",
      "title": "7.1 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1929",
      "start_page": 2,
      "end_page": 2,
      "content": "7.1.1 Historical criteria for attacks. . . . . . . . . . . . . . . . . . . . . . . . . . . 1929 7.1.2 Documentation of key features during an attack. . . . . . . . 1929 7.1.2.1 Management of psychogenic pseudosyncope . . . . 1930 8. Neurological causes and mimics of syncope . . . . . . . . . . . . . . . . . . . . . 1930\n",
      "keywords": [
        "syncope",
        "diagnosis"
      ],
      "tables": []
    },
    {
      "number": "7",
      "title": "8.1 Clinical conditions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1930",
      "start_page": 2,
      "end_page": 2,
      "content": "8.1.1 Autonomic failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1930 8.1.2 Epilepsy and ictal asystole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1930 8.1.3 Cerebrovascular disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1930 8.1.4 Migraine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1931 8.1.5 Cataplexy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1932 8.1.6 Drop attacks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1932 8.2 Neurological tests. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1932\n8.2.1 Electroencephalography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1932 8.2.2 Brain computed tomography and magnetic resonance imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1932 8.2.3 Neurovascular studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1932 8.2.4 Blood tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1932 9. Organizational aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1932\n",
      "keywords": [
        "clinical",
        "conditions"
      ],
      "tables": []
    },
    {
      "number": "8",
      "title": "9.1 Syncope (transient loss of consciousness) management unit. . 1932",
      "start_page": 2,
      "end_page": 3,
      "content": "9.1.1 Definition of a syncope unit . . . . . . . . . . . . . . . . . . . . . . . . . . . 1933 9.1.2 Definition of syncope specialist . . . . . . . . . . . . . . . . . . . . . . . . 1934 9.1.3 Goal of a syncope unit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1934 9.1.4 Model of a syncope unit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1934 9.1.5 Access and referrals to a syncope unit . . . . . . . . . . . . . . . . . 1935 9.1.6 Outcomes and quality indicators . . . . . . . . . . . . . . . . . . . . . . 1935 9.2 The clinical nurse specialist in the syncope unit. . . . . . . . . . . . . . . 1935\n9.2.1 Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1935 9.2.2 Role and skills of the clinical nurse specialist . . . . . . . . . . . . 1935 10. Key messages. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1936 11. Gaps in evidence and areas for future research. . . . . . . . . . . . . . . . . 1937 12. ‘What to do’ and ‘what not to do’ messages from the Guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1938 13. Supplementary Data and Web Practical Instructions. . . . . . . . . . . . 1940 14. Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1940 15. References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1941\nAbbreviations and acronyms\nABPM Ambulatory blood pressure monitoring AF Atrial ﬁbrillation ARVC Arrhythmogenic right ventricular cardiomyopathy ATP Adenosine triphosphate\nESC Guidelines 1885\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ........................................................................................................................................................................... AV Atrioventricular AVID Antiarrhythmics versus Implantable Deﬁbrillators trial BBB Bundle branch block BNP B-type natriuretic peptide BP Blood pressure b.p.m. Beats per minute CI Conﬁdence interval CI-CSS Cardioinhibitory carotid sinus syndrome CPG Committee for Practice Guidelines CRT-D Cardiac resynchronization therapy deﬁbrillator CSM Carotid sinus massage CSS Carotid sinus syndrome DCM Dilated cardiomyopathy DDD-PM Dual chamber pacemaker ECG Electrocardiogram/electrocardiographic ED Emergency department EEG Electroencephalogram EFAS European Federation of Autonomic Societies EFIM European Federation of Internal Medicine EHRA European Heart Rhythm Association ENS European Neurological Society EPS Electrophysiological study ESC European Society of Cardiology EUGMS European Union Geriatric Medicine Society EuSEM European Society of Emergency Medicine HBPM Home blood pressure monitoring HCM Hypertrophic cardiomyopathy HR Heart rate ICD Implantable cardioverter deﬁbrillator ILR Implantable loop recorder ISSUE International Study on Syncope of Unknown Etiology L-DOPA L-3,4-dihydroxyphenylalanine LOC Loss of consciousness LQTS Long QT syndrome LVEF Left ventricular ejection fraction MRI Magnetic resonance imaging NYHA New York Heart Association OH Orthostatic hypotension PC-Trial Physical Counterpressure Manoeuvres Trial PCM Physical counter-pressure manoeuvres PNES Psychogenic non-epileptic seizures POST Prevention of Syncope Trial POTS Postural orthostatic tachycardia syndrome PPS Psychogenic pseudosyncope RCT Randomized controlled trial SCD Sudden cardiac death SNRT Sinus node recovery time SU Syncope unit SUP Syncope Unit Project SVT Supraventricular tachycardia TIA Transient ischaemic attack t.i.d. Ter in die (three times daily) TLOC Transient loss of consciousness TNG Trinitroglycerin VA Ventricular arrhythmia\nVF Ventricular ﬁbrillation VT Ventricular tachycardia VVS Vasovagal syncope\n",
      "keywords": [
        "ejection fraction",
        "vasovagal",
        "unit",
        "crt",
        "sudden cardiac death",
        "management",
        "electrocardiogram",
        "pacemaker",
        "tachycardia",
        "orthostatic",
        "scd",
        "blood pressure",
        "transient loss of consciousness",
        "nyha",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "arrhythmia",
        "icd",
        "carotid",
        "mri",
        "bnp",
        "cardiomyopathy",
        "ecg",
        "consciousness",
        "loss",
        "transient"
      ],
      "tables": []
    },
    {
      "number": "9",
      "title": "1. Preamble",
      "start_page": 3,
      "end_page": 4,
      "content": "Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in selecting the best management strat- egies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health pro- fessionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health profes- sional(s) in consultation with the patient and caregiver as appropriate. A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other soci- eties and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been estab- lished in order to make all decisions transparent to the user. The rec- ommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/Guidelines-&- Education/Clinical-Practice-Guidelines/Guidelines-development/Writ ing-ESC-Guidelines). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated. Members of this Task Force were selected by the ESC, including representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a com- prehensive review of the published evidence for management of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic pro- cedures was performed, including assessment of the risk–benefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded accord- ing to predefined scales, as outlined in  Tables  1  and  2 . The experts of the writing and reviewing panels provided declar- ation of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file and can be found on the ESC website (http:// www.escardio.org/guidelines). Any changes in declarations of interest that arise during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry. The ESC CPG supervises and coordinates the preparation of new Guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the experts involved in the Task Force. The finalized document is approved by the CPG for publica- tion in the  European Heart Journal . The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommen- dations including condensed pocket guideline versions, summary slides, booklets with essential messages, summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.).\n1886 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ..................................................... These versions are abridged and thus, if needed, one should always refer to the full-text version, which is freely available via the ESC web- site and hosted on the EHJ website. The National Societies of the ESC are encouraged to endorse, translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations. Surveys and registries are needed to verify that real-life daily prac- tice is in keeping with what is recommended in the guidelines, thus completing the loop between clinical research, writing of guidelines, disseminating them and implementing them into clinical practice. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the de- termination and the implementation of preventive, diagnostic, or thera- peutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consider- ation of each patient’s health condition and in consultation with that\npatient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.\n",
      "keywords": [
        "guideline",
        "preamble",
        "recommended"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 1887",
          "page_number": 4,
          "content": " | Table 1 Classes of recommendations |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | ",
          "bbox": [
            47.76350021362305,
            53.858296712239586,
            552.3984680175781,
            314.36297607421875
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 1887",
          "page_number": 4,
          "content": " | Table 2 Levels of evidence |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | ",
          "bbox": [
            47.76350021362305,
            334.77198791503906,
            552.3984680175781,
            506.0979919433594
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "10",
      "title": "2. Introduction",
      "start_page": 4,
      "end_page": 6,
      "content": "The first ESC Guidelines for the management of syncope were pub- lished in 2001, with subsequent versions in 2004 and 2009. In March 2015, the ESC CPG considered that there were enough new data to justify the production of new Guidelines. The most important aspect characterizing this document is the composition of the Task Force, which is truly multidisciplinary. Cardiologists form a minority of the panel; experts in emergency medicine, internal medicine and physiology, neurology and auto- nomic diseases, geriatric medicine, and nursing cover all aspects of management of the various forms of syncope and transient loss of consciousness (TLOC).\nTable 1 Classes of recommendations\nTable 2 Levels of evidence\nESC Guidelines 1887\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ...................................... Compared with the previous versions of these Guidelines, the 2018 document contains Supplementary Data as an integral part. While the print text mainly aims to give formal evidence-based rec- ommendations according to the standardized rules of the ESC, this new web-only feature allows expansion of the content to practical issues, and aims to fill the gap between the best available scientific evi- dence and the need for dissemination of these concepts into clinical practice  (‘We have the knowledge, we need to teach it’).  Thanks to the Supplementary Data further explanation on specific points is given, and thanks to the Web Practical Instructions advice is given on how to evaluate patients with loss of consciousness (LOC), and how to perform and interpret tests properly; whenever possible, we provide tracings, videos, flow charts, and checklists.\nThe document aims to be patient-orientated and focused on ther- apy, and to reduce the risk of recurrence and the life-threatening consequences of syncope recurrence. For this purpose, even in the absence of strong evidence from trials, we give as much advice as possible on the most appropriate therapy based on the practical ex- pertise of the members of the Task Force  (‘Our patients seek solutions, not only explanations’).  When possible, we provide therapeutic and decision-making algorithms. Finally, we recognize that one major challenge in syncope manage- ment is the reduction of inappropriate admissions and inappropriate use of tests while maintaining the safety of the patient. We give strong focus to pathways and organizational issues  (‘We have the knowledge; we need to apply it’).  In particular, we propose a care pathway for the\nFigure 1  What is new in the 2018 syncope Guidelines? AA = antiarrhythmic; AF = atrial fibrillation; ARVC = arrhythmogenic right ventricular car- diomyopathy; CSM = carotid sinus massage; ECG = electrocardiogram; ED = emergency department; LVEF = left ventricular ejection fraction; EPS = electrophysiological study; HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder; OH = orthostatic hypotension; PCM = physical counter-pressure manoeuvres; POTS = postural orthostatic tachycardia syndrome; PPS = psycho- genic pseudosyncope; SNRT = sinus node recovery time; SU = syncope unit; SVT = supraventricular tachycardia; VT = ventricular tachycardia.\n1888 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ................................................................... management of patients with TLOC from their arrival in the emer- gency department (ED), and give practical instructions on how to set up outpatient syncope clinics (syncope units) aimed at reducing hos- pitalization, under- and misdiagnoses, and costs.\n",
      "keywords": [
        "icd",
        "carotid",
        "introduction",
        "ejection fraction",
        "electrocardiogram",
        "orthostatic",
        "atrial fibrillation",
        "ventricular tachycardia",
        "transient loss of consciousness",
        "cardiomyopathy",
        "ecg",
        "tachycardia",
        "syncope",
        "lvef"
      ],
      "tables": [
        {
          "title": "1888 ESC Guidelines",
          "page_number": 5,
          "content": " |  | \n |  | \n |  | \n | Figure 1 What is new in the 2018 syncope Guidelines? AA = antiarrhythmic; AF = atrial fibrillation; ARVC = arrhythmogenic right ventricular car- | \n | diomyopathy; CSM = carotid sinus massage; ECG = electrocardiogram; ED = emergency department; LVEF = left ventricular ejection fraction; EPS =\nelectrophysiological study; HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder;\nOH = orthostatic hypotension; PCM = physical counter-pressure manoeuvres; POTS = postural orthostatic tachycardia syndrome; PPS = psycho-\ngenic pseudosyncope; SNRT = sinus node recovery time; SU = syncope unit; SVT = supraventricular tachycardia; VT = ventricular tachycardia. | \n |  | ",
          "bbox": [
            43.369998931884766,
            232.327880859375,
            547.9371032714844,
            754.4129638671875
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 1889",
          "page_number": 6,
          "content": " |  | \n |  | \n |  | \n | Central illustration New/revised concepts in the management of syncope. ECG = electrocardiogram; ED = emergency department; ICD = | \n | implantable cardioverter defibrillator; SCD = sudden cardiac death. | \n |  | ",
          "bbox": [
            47.904998779296875,
            59.8118896484375,
            552.4721069335938,
            442.4319763183594
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "11",
      "title": "2.1 What is new in the 2018 version? The changes in recommendations made in the 2018 version com- pared with the 2009 version, the new recommendations, and the most important new/revised concepts are ",
      "start_page": 6,
      "end_page": 6,
      "content": "",
      "keywords": [
        "version",
        "revised",
        "made",
        "pared",
        "concepts",
        "what",
        "important",
        "recommendations",
        "changes",
        "most"
      ],
      "tables": []
    },
    {
      "number": "12",
      "title": "3. Definitions, classification, and pathophysiology",
      "start_page": 6,
      "end_page": 6,
      "content": "",
      "keywords": [
        "classification",
        "definitions",
        "pathophysiology"
      ],
      "tables": []
    },
    {
      "number": "13",
      "title": "3.1 Definitions",
      "start_page": 6,
      "end_page": 7,
      "content": "•   Syncope  is defined as TLOC due to cerebral hypoperfusion, char- acterized by a rapid onset, short duration, and spontaneous com- plete recovery.\nSyncope shares many clinical features with other disorders; it therefore presents in many differential diagnoses. This group of dis- orders is labelled TLOC.\n•   TLOC  is defined as a state of real or apparent LOC with loss of awareness, characterized by amnesia for the period of uncon- sciousness, abnormal motor control, loss of responsiveness, and a short duration.\nThe two main groups of TLOC are ‘TLOC due to head trauma’ and ‘non-traumatic TLOC’ ( Figure  2 ). Traumatic TLOC will not be considered further in this document, so TLOC will be used to mean non-traumatic TLOC. The clinical features characterizing TLOC are usually derived from his- tory taking from patients and eyewitnesses. Specific characteristics that aid diagnosis are outlined in section 3 of the  Web Practical Instructions . TLOC groups are defined using pathophysiology: the qualifying cri- terion for syncope is cerebral hypoperfusion; for epileptic seizures, it is abnormal excessive brain activity; and for psychogenic TLOC it is the psychological process of conversion. The syncope definition rests on pathophysiology because no set of clinical features encompasses all forms of syncope while also excluding all epileptic seizures and psychogenic TLOC events.\n•   The adjective  presyncope  is used to indicate symptoms and signs that occur before unconsciousness in syncope. Note that the noun  presyncope  is often used to describe a state that resembles the prodrome of syncope, but which is not followed by LOC.\nCentral illustration  New/revised concepts in the management of syncope. ECG = electrocardiogram; ED = emergency department; ICD = implantable cardioverter defibrillator; SCD = sudden cardiac death.\nESC Guidelines 1889\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ....................................................................................... A variety of terms are used that generally do not match the definitions in this document closely enough to be used as synonyms of the defined terms. For example, a ‘faint’ approximately conforms to syncope but emphasizes vasovagal syncope (VVS) over other forms. A glossary of un- certain terms is shown in section 1 of the  Web Practical Instructions .\n",
      "keywords": [
        "icd",
        "presyncope",
        "definitions",
        "vasovagal",
        "sudden cardiac death",
        "scd",
        "electrocardiogram",
        "ecg",
        "syncope"
      ],
      "tables": [
        {
          "title": "1890 ESC Guidelines",
          "page_number": 7,
          "content": " |  | \n | Generalized: Psychogenic\n- Tonic pseudosyncope (PPS)\n- Clonic Psychogenic non-epileptic\n- Tonic-clonic seizures (PNES)\n- Atonic | \n |  | \n | Figure 2 Syncope in the context of transient loss of consciousness. Non-traumatic transient loss of consciousness is classified into one of four | \n | groupings: syncope, epileptic seizures, psychogenic transient loss of consciousness, and a miscellaneous group of rare causes. This order represents\ntheir rate of occurrence. Combinations occur; e.g. non-traumatic transient loss of consciousness causes can cause falls with concussion, in which case\ntransient loss of consciousness is both traumatic and non-traumatic. TIA = transient ischaemic attack; TLOC = transient loss of consciousness. | \n |  | ",
          "bbox": [
            43.369998931884766,
            59.81117248535156,
            547.9371032714844,
            384.0379943847656
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "14",
      "title": "3.2 Classification and pathophysiology of syncope and transient loss of consciousness 3.2.1 Syncope Table  3  provides a classification of the principal causes of syncope, emphasizing groups of disord",
      "start_page": 7,
      "end_page": 8,
      "content": "Systemic BP is the product of cardiac output and total peripheral resistance; a fall in either can cause syncope. However, in syncope, both mechanisms often act together to a varying degree. There are three primary causes of a low total peripheral resist- ance. The first is decreased reflex activity causing vasodilatation through withdrawal of sympathetic vasoconstriction: this is the\n‘vasodepressive type’ of reflex syncope, seen in the outer ring in Figure  3 . The second is a functional impairment, and the third a struc- tural impairment of the autonomic nervous system, with drug- induced, primary, and secondary autonomic failure in the outer ring. In autonomic failure, there is insufficient sympathetic vasoconstriction in response to the upright position. There are four primary causes of low cardiac output. The first is a reflex bradycardia, known as cardioinhibitory reflex syncope. The second concerns cardiovascular causes: arrhythmia, struc- tural disease including pulmonary embolism, and pulmonary hypertension. The third is inadequate venous return due to vol- ume depletion or venous pooling. Finally, chronotropic and ino- tropic incompetence through autonomic failure may impair cardiac output. Note that these primary mechanisms may interact in different ways: firstly, venous pooling and inadequate venous return is also a factor that can trigger an inappropriate reflex in orthostatic reflex syncope; secondly, a low total peripheral resistance may cause ven- ous pooling of blood below the diaphragm, in turn decreasing venous return and consequently cardiac output. The three main groups of syncope, i.e. reflex, cardiovascular, and secondary to orthostatic hypotension (OH), are shown outside the rings in  Figure  3 . Both reflex syncope and OH span the two main pathophysiological mechanisms.\n3.2.2 Non-syncopal forms of (real or apparent) transient loss of consciousness Only those forms of epilepsy in which normal motor control is lost, so patients may fall, are included in  Figure  2 . These are tonic, clonic,\nGeneralized: - Tonic - Clonic - Tonic-clonic - Atonic\nPsychogenic   pseudosyncope (PPS) Psychogenic non-epileptic   seizures (PNES)\nFigure 2  Syncope in the context of transient loss of consciousness. Non-traumatic transient loss of consciousness is classified into one of four groupings: syncope, epileptic seizures, psychogenic transient loss of consciousness, and a miscellaneous group of rare causes. This order represents their rate of occurrence. Combinations occur; e.g. non-traumatic transient loss of consciousness causes can cause falls with concussion, in which case transient loss of consciousness is both traumatic and non-traumatic. TIA = transient ischaemic attack; TLOC = transient loss of consciousness.\n1890 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\nTable 3 Classiﬁcation of syncope\nReﬂex (neurally mediated) syncope\n",
      "keywords": [
        "groups",
        "bradycardia",
        "emphasizing",
        "pulmonary embolism",
        "principal",
        "provides",
        "orthostatic",
        "hypertension",
        "disord",
        "pathophysiology",
        "transient loss of consciousness",
        "pulmonary hypertension",
        "syncope",
        "arrhythmia",
        "causes",
        "classification",
        "table",
        "consciousness",
        "loss",
        "transient"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 1891",
          "page_number": 8,
          "content": " | Table 3 Classification of syncope | \n |  | \n | Reflex (neurally mediated) syncope\nVasovagal:\n- orthostatic VVS: standing, less common sitting\n- emotional: fear, pain (somatic or visceral), instrumentation, blood phobia\nSituational:\n- micturition\n- gastrointestinal stimulation (swallow, defaecation)\n- cough, sneeze\n- post-exercise\n- others (e.g. laughing, brass instrument playing)\nCarotid sinus syndrome\nNon-classical forms (without prodromes and/or without apparent triggers and/or atypical presentation)\nSyncope due to OH\nNote that hypotension may be exacerbated by venous pooling during exercise (exercise-induced), after meals (postprandial hypotension), and after prolonged\nbed rest\n(deconditioning).\nDrug-induced OH (most common cause of OH):\n- e.g. vasodilators, diuretics, phenothiazine, antidepressants\nVolume depletion:\n- haemorrhage, diarrhoea, vomiting, etc.\nPrimary autonomic failure (neurogenic OH):\n- pure autonomic failure, multiple system atrophy, Parkinson’s disease, dementia with Lewy bodies\nSecondary autonomic failure (neurogenic OH):\n- diabetes, amyloidosis, spinal cord injuries, auto-immune autonomic neuropathy, paraneoplastic autonomic neuropathy, kidney failure\nCardiac syncope\nArrhythmia as primary cause:\nBradycardia:\n- sinus node dysfunction (including bradycardia/tachycardia syndrome)\n- atrioventricular conduction system disease\nTachycardia:\n- supraventricular\n- ventricular\nStructural cardiac: aortic stenosis, acute myocardial infarction/ischaemia, hypertrophic cardiomyopathy, cardiac masses (atrial myxoma, tumours,\netc.), pericardial disease/tamponade, congenital anomalies of coronary arteries, prosthetic valve dysfunction\nCardiopulmonary and great vessels: pulmonary embolus, acute aortic dissection, pulmonary hypertension\nRemarks\n• All forms of syncope, but mostly reflex syncope and OH, are more likely to occur or are more severe when various factors are present: medica-\ntion causing low BP (due to vasodilatation or hypovolaemia), alcohol use, volume depletion (haemorrhage, low fluid intake, diarrhoea, vomiting),\npulmonary diseases causing reduction in brain oxygen supply, environmental factors (thermal stress).\n• There are two main pathophysiological mechanisms in reflex syncope. “Vasodepression” refers to conditions in which insufficient sympathetic\nvasoconstriction results in hypotension.1,2 “Cardioinhibition” is used when bradycardia or asystole predominates, reflecting a shift towards para-\nsympathetic predominance. The haemodynamic pattern, i.e. cardioinhibitory, vasodepressive, or both, is independent of the trigger evoking reflex\nsyncope. For example, micturition syncope and orthostatic VVS may equally well present as cardioinhibitory or as vasodepressor syncope\n• The non-classical form of reflex syncope involves a heterogeneous group of patients. The term is used to describe reflex syncope that occurs\nwith uncertain or apparently absent triggers and/or atypical presentation. The diagnosis of reflex syncope is probable when other causes of syn-\ncope are excluded (absence of structural heart disease) and/or symptoms are reproduced in the tilt test.3 At present, this group also contains\nsyncope associated with low adenosine plasma levels4,5\n• The cardiovascular causes of orthostatic intolerance include classical OH, initial OH, delayed OH, POTS, and VVS, which in this context can be\ncalled orthostatic VVS.6,7 Syndromes of orthostatic intolerance that may cause syncope are presented in Web Practical Instruction section 2. | \n |  | Reflex (neurally mediated) syncope\n |  | Vasovagal:\n- orthostatic VVS: standing, less common sitting\n- emotional: fear, pain (somatic or visceral), instrumentation, blood phobia\nSituational:\n- micturition\n- gastrointestinal stimulation (swallow, defaecation)\n- cough, sneeze\n- post-exercise\n- others (e.g. laughing, brass instrument playing)\nCarotid sinus syndrome\nNon-classical forms (without prodromes and/or without apparent triggers and/or atypical presentation)\n |  | Syncope due to OH\n |  | Note that hypotension may be exacerbated by venous pooling during exercise (exercise-induced), after meals (postprandial hypotension), and after prolonged\nbed rest\n(deconditioning).\nDrug-induced OH (most common cause of OH):\n- e.g. vasodilators, diuretics, phenothiazine, antidepressants\nVolume depletion:\n- haemorrhage, diarrhoea, vomiting, etc.\nPrimary autonomic failure (neurogenic OH):\n- pure autonomic failure, multiple system atrophy, Parkinson’s disease, dementia with Lewy bodies\nSecondary autonomic failure (neurogenic OH):\n- diabetes, amyloidosis, spinal cord injuries, auto-immune autonomic neuropathy, paraneoplastic autonomic neuropathy, kidney failure\n |  | Cardiac syncope\n |  | Arrhythmia as primary cause:\nBradycardia:\n- sinus node dysfunction (including bradycardia/tachycardia syndrome)\n- atrioventricular conduction system disease\nTachycardia:\n- supraventricular\n- ventricular\nStructural cardiac: aortic stenosis, acute myocardial infarction/ischaemia, hypertrophic cardiomyopathy, cardiac masses (atrial myxoma, tumours,\netc.), pericardial disease/tamponade, congenital anomalies of coronary arteries, prosthetic valve dysfunction\nCardiopulmonary and great vessels: pulmonary embolus, acute aortic dissection, pulmonary hypertension\n |  | Remarks\n |  | • All forms of syncope, but mostly reflex syncope and OH, are more likely to occur or are more severe when various factors are present: medica-\ntion causing low BP (due to vasodilatation or hypovolaemia), alcohol use, volume depletion (haemorrhage, low fluid intake, diarrhoea, vomiting),\npulmonary diseases causing reduction in brain oxygen supply, environmental factors (thermal stress).\n• There are two main pathophysiological mechanisms in reflex syncope. “Vasodepression” refers to conditions in which insufficient sympathetic\nvasoconstriction results in hypotension.1,2 “Cardioinhibition” is used when bradycardia or asystole predominates, reflecting a shift towards para-\nsympathetic predominance. The haemodynamic pattern, i.e. cardioinhibitory, vasodepressive, or both, is independent of the trigger evoking reflex\nsyncope. For example, micturition syncope and orthostatic VVS may equally well present as cardioinhibitory or as vasodepressor syncope\n• The non-classical form of reflex syncope involves a heterogeneous group of patients. The term is used to describe reflex syncope that occurs\nwith uncertain or apparently absent triggers and/or atypical presentation. The diagnosis of reflex syncope is probable when other causes of syn-\ncope are excluded (absence of structural heart disease) and/or symptoms are reproduced in the tilt test.3 At present, this group also contains\nsyncope associated with low adenosine plasma levels4,5\n• The cardiovascular causes of orthostatic intolerance include classical OH, initial OH, delayed OH, POTS, and VVS, which in this context can be\ncalled orthostatic VVS.6,7 Syndromes of orthostatic intolerance that may cause syncope are presented in Web Practical Instruction section 2.\n |  | \n |  | \n | BP = blood pressure; OH = orthostatic hypotension; POTS = postural orthostatic tachycardia syndrome; VVS = vasovagal syncope. | \n |  | ",
          "bbox": [
            47.904998779296875,
            59.81097412109375,
            549.0771858461442,
            767.6131286621094
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "15",
      "title": "Vasovagal:",
      "start_page": 8,
      "end_page": 8,
      "content": "- orthostatic VVS: standing, less common sitting - emotional: fear, pain (somatic or visceral), instrumentation, blood phobia\n",
      "keywords": [
        "vasovagal",
        "orthostatic"
      ],
      "tables": []
    },
    {
      "number": "16",
      "title": "Situational:",
      "start_page": 8,
      "end_page": 8,
      "content": "- micturition - gastrointestinal stimulation (swallow, defaecation)\n- cough, sneeze\n- post-exercise - others (e.g. laughing, brass instrument playing)\nCarotid sinus syndrome\nNon-classical forms (without prodromes and/or without apparent triggers and/or atypical presentation)\nSyncope due to OH\nNote that hypotension may be exacerbated by venous pooling during exercise (exercise-induced), after meals (postprandial hypotension), and after prolonged bed rest\n(deconditioning).\nDrug-induced OH (most common cause of OH): - e.g. vasodilators, diuretics, phenothiazine, antidepressants\n",
      "keywords": [
        "situational",
        "syncope",
        "carotid",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "17",
      "title": "Volume depletion:",
      "start_page": 8,
      "end_page": 8,
      "content": "- haemorrhage, diarrhoea, vomiting, etc. Primary autonomic failure (neurogenic OH):\n- pure autonomic failure, multiple system atrophy, Parkinson’s disease, dementia with Lewy bodies Secondary autonomic failure (neurogenic OH):\n- diabetes, amyloidosis, spinal cord injuries, auto-immune autonomic neuropathy, paraneoplastic autonomic neuropathy, kidney failure\nCardiac syncope\n",
      "keywords": [
        "diabetes",
        "volume",
        "syncope",
        "depletion"
      ],
      "tables": []
    },
    {
      "number": "18",
      "title": "Arrhythmia as primary cause:",
      "start_page": 8,
      "end_page": 9,
      "content": "Bradycardia: - sinus node dysfunction (including bradycardia/tachycardia syndrome)\n- atrioventricular conduction system disease\nTachycardia: - supraventricular\n- ventricular\nStructural cardiac: aortic stenosis, acute myocardial infarction/ischaemia, hypertrophic cardiomyopathy, cardiac masses (atrial myxoma, tumours, etc.), pericardial disease/tamponade, congenital anomalies of coronary arteries, prosthetic valve dysfunction\nCardiopulmonary and great vessels: pulmonary embolus, acute aortic dissection, pulmonary hypertension\nRemarks\n•   All forms of syncope, but mostly reﬂex syncope and OH, are more likely to occur or are more severe when various factors are present: medica- tion causing low BP (due to vasodilatation or hypovolaemia), alcohol use, volume depletion (haemorrhage, low ﬂuid intake, diarrhoea, vomiting),\npulmonary diseases causing reduction in brain oxygen supply, environmental factors (thermal stress). •   There are two main pathophysiological mechanisms in reﬂex syncope. “Vasodepression” refers to conditions in which insufﬁcient sympathetic vasoconstriction results in hypotension. 1 , 2   “Cardioinhibition” is used when bradycardia or asystole predominates, reﬂecting a shift towards para-\nsympathetic predominance. The haemodynamic pattern, i.e. cardioinhibitory, vasodepressive, or both, is independent of the trigger evoking reﬂex\nsyncope. For example, micturition syncope and orthostatic VVS may equally well present as cardioinhibitory or as vasodepressor syncope •   The non-classical form of reﬂex syncope involves a heterogeneous group of patients. The term is used to describe reﬂex syncope that occurs\nwith uncertain or apparently absent triggers and/or atypical presentation. The diagnosis of reﬂex syncope is probable when other causes of syn-\ncope are excluded (absence of structural heart disease) and/or symptoms are reproduced in the tilt test. 3   At present, this group also contains syncope associated with low adenosine plasma levels 4 , 5\n•   The cardiovascular causes of orthostatic intolerance include classical OH, initial OH, delayed OH, POTS, and VVS, which in this context can be\ncalled orthostatic VVS. 6 , 7   Syndromes of orthostatic intolerance that may cause syncope are presented in  Web Practical Instruction section 2 .\nBP = blood pressure; OH = orthostatic hypotension; POTS = postural orthostatic tachycardia syndrome; VVS = vasovagal syncope.\nESC Guidelines 1891\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ................\ntonic-clonic, and atonic generalized seizures, and can be classified as primary or secondary. The forms of epilepsy in which people remain actively upright, i.e. sitting or standing (e.g. complex partial seizures or absence epilepsy) are not regarded as TLOC, but sometimes they are incorrectly diagnosed as syncope. Psychogenic TLOC consists of two forms: one resembles epileptic seizures (psychogenic non-epileptic seizures [PNES]) and one, with- out gross movements, resembles syncope (psychogenic pseudosyn- cope [PPS]). The rare causes of TLOC only seldomly cause confusion with the main TLOC forms, probably because in most cases they differ enough clinically to be clearly not syncope. Both vertebrobasilar tran- sient ischaemic attacks (TIAs) and subclavian steal syndrome are associated with focal neurological signs. A subarachnoid haemor- rhage may present with a short LOC, but the associated abrupt ex- treme headache suggests the cause. In cyanotic breath-holding spells, expiratory apnoea with hypoxia is the primary mechanism. 10   So- called ‘pallid breath-holding spells’ in children do not constitute a pri- mary respiratory problem, but are cardioinhibitory reflex syncope. 11\nTable  4  lists the main features that distinguish syncope from dis- orders that may be mistaken for syncope.\n",
      "keywords": [
        "aortic",
        "primary",
        "arrhythmia",
        "alcohol",
        "stenosis",
        "pulmonary hypertension",
        "tilt test",
        "orthostatic",
        "vasovagal",
        "hypertension",
        "bradycardia",
        "blood pressure",
        "prosthetic valve",
        "cause",
        "aortic stenosis",
        "cardiomyopathy",
        "tachycardia",
        "syncope"
      ],
      "tables": [
        {
          "title": "1892 ESC Guidelines",
          "page_number": 9,
          "content": " |  | \n |  | \n |  | \n | Figure 3 Pathophysiological basis of the classification of syncope. | \n | ANS = autonomic nervous system; auton. = autonomic; BP =\nblood pressure; OH = orthostatic hypotension; periph. =\nperipheral; resist. = resistance. | \n |  | ",
          "bbox": [
            43.369998931884766,
            59.81165771484375,
            283.63409423828125,
            354.6709899902344
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "1892 ESC Guidelines",
          "page_number": 9,
          "content": " | Table 4 Conditions that may be incorrectly diagnose\nas syncope |  |  | \n |  |  |  | \n |  |  |  | \n |  | Condition | Characteristic features that distin-\nguish from syncope | \n |  | Generalized seizures | See section 8, Table 10. | \n |  | Complex partial seiz-\nures, absence epilepsy | No falls, yet unresponsive and later\namnesia | \n |  | PPS or\n“pseudocoma” | Duration of apparent LOC\nlasting many minutes to hours; high\nfrequency, up to several times a day | \n |  | Falls without TLOC | No unresponsiveness or amnesia | \n |  | Cataplexy | Falls with flaccid paralysis and non-\nresponsive, yet no later amnesia | \n |  | Intracerebral or sub-\narachnoid\nhaemorrhage | Consciousness may be progressively\nreduced rather than immediately\nlost. Accompanying severe head-\nache, other neurological signs | \n |  | Vertebrobasilar TIA | Always focal neurological signs and\nsymptoms, usually without LOC; if\nconsciousness is lost this usually lasts\nlonger than in TLOC. | \n |  | Carotid TIA | Consciousness is for all practical\npurposes not lost in carotid TIAs,\nbut there are pronounced focal\nneurological signs and symptoms | \n |  | Subclavian steal\nsyndrome | Associated with focal neurological\nsigns | \n |  | Metabolic disorders\nincluding hypogly-\ncaemia, hypoxia,\nhyperventilation with\nhypocapnia | Duration much longer than in\nTLOC; consciousness may be im-\npaired instead of lost | \n |  | Intoxication | Duration much longer than in\nTLOC; consciousness may be im-\npaired instead of lost | \n |  | Cardiac arrest | LOC yet no spontaneous recovery | \n |  | Coma | Duration much longer than TLOC | \n |  |  |  | \n |  |  |  | \n | LOC = loss of consciousness; PPS = psychogenic pseudosyncope; TIA = transient\nischaemic attack; TLOC = transient loss of consciousness. |  |  | \n |  |  |  | ",
          "bbox": [
            307.72900390625,
            59.81165771484375,
            544.0050489637587,
            644.2589721679688
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "19",
      "title": "4. Diagnostic evaluation and management according to risk stratification",
      "start_page": 9,
      "end_page": 9,
      "content": "",
      "keywords": [
        "risk",
        "according",
        "evaluation",
        "diagnostic",
        "management",
        "stratification"
      ],
      "tables": []
    },
    {
      "number": "20",
      "title": "4.1 Initial evaluation The clinical features characterizing TLOC are usually derived from his- tory taking from patients and eyewitnesses. When a patient first presents",
      "start_page": 9,
      "end_page": 17,
      "content": "with possible TLOC, history taking should first establish whether there was indeed a TLOC. Often, this allows a distinction between the major TLOC groups. The flow diagram for the evaluation of TLOC is shown in Figure  4 . The initial evaluation should answer key questions:\n(1) Was the event TLOC?\nFigure 3  Pathophysiological basis of the classification of syncope. ANS = autonomic nervous system; auton. = autonomic; BP = blood pressure; OH = orthostatic hypotension; periph. = peripheral; resist. = resistance.\nTable 4 Conditions that may be incorrectly diagnosed as syncope\nCondition Characteristic features that distin- guish from syncope\nGeneralized seizures See section 8,  Table  10 .\nComplex partial seiz-\nures, absence epilepsy\nNo falls, yet unresponsive and later\namnesia\nPPS or “pseudocoma” Duration of apparent LOC lasting many minutes to hours; high\nfrequency, up to several times a day\nFalls without TLOC No unresponsiveness or amnesia\nCataplexy Falls with ﬂaccid paralysis and non- responsive, yet no later amnesia\nIntracerebral or sub-\narachnoid\nhaemorrhage\nConsciousness may be progressively\nreduced rather than immediately\nlost. Accompanying severe head- ache, other neurological signs\nVertebrobasilar TIA Always focal neurological signs and\nsymptoms, usually without LOC; if\nconsciousness is lost this usually lasts longer than in TLOC.\nCarotid TIA Consciousness is for all practical\npurposes not lost in carotid TIAs, but there are pronounced focal\nneurological signs and symptoms\nSubclavian steal\nsyndrome\nAssociated with focal neurological\nsigns\nMetabolic disorders including hypogly-\ncaemia, hypoxia,\nhyperventilation with hypocapnia\nDuration much longer than in TLOC; consciousness may be im-\npaired instead of lost\nIntoxication Duration much longer than in\nTLOC; consciousness may be im- paired instead of lost\nCardiac arrest LOC yet no spontaneous recovery\nComa Duration much longer than TLOC\nLOC = loss of consciousness; PPS = psychogenic pseudosyncope; TIA = transient ischaemic attack; TLOC = transient loss of consciousness.\n1892 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .......................................................... (2) In case of TLOC, is it of syncopal or non-syncopal origin? (3) In case of suspected syncope, is there a clear aetiological diagnosis (see section 4.1.1)? (4) Is there evidence to suggest a high risk of cardiovascular events or death (see section 4.1.2)?\nTLOC has four specific characteristics: short duration, abnor- mal motor control, loss of responsiveness, and amnesia for the period of LOC (for an explanation of the clinical features of TLOC see  Web Table 4  in section 4.1 of the  Web Practical Instructions ). TLOC is probably syncope when: (i) there are signs and symptoms specific for reflex syncope, syncope due to OH, or cardiac syncope, and (ii) signs and symptoms specific for other forms of TLOC (head trauma, epileptic seizures, psychogenic TLOC, and/or rare causes) are absent. Practical instructions for history taking are given in sec- tions 3 and 4 of the  Web Practical Instructions . When epileptic seizures or psychogenic attacks are likely, appro- priate steps should be taken. By using a detailed clinical history, phys- icians can differentiate syncope from other forms of TLOC in\napproximately 60% of cases. 12   For non-syncopal TLOC, refer to sec- tions 7 and 8.\n4.1.1 Diagnosis of syncope The starting point of the diagnostic evaluation of TLOC of suspected syncopal nature is the initial syncope evaluation, which consists of:\n•   Careful history taking concerning present and previous attacks, as well as eyewitness accounts, in person or through a telephone interview. •   Physical examination, including supine and standing BP measurements. •   Electrocardiogram (ECG).\nBased on these findings, additional examinations may be per- formed when needed (see section 4.2):\n•   Immediate ECG monitoring when there is a suspicion of arrhyth- mic syncope. •   Echocardiogram when there is previous known heart disease, data suggestive of structural heart disease, or syncope secondary to cardiovascular cause.\nFigure 4  Flow diagram for the initial evaluation and risk stratification of patients with syncope. BP = blood pressure; ECG = electrocardiogram; H&P exam = history and physical examination; TLOC = transient loss of consciousness.\nESC Guidelines 1893\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ..................... •   Carotid sinus massage (CSM) in patients aged >40 years. •   Head-up tilt testing when there is suspicion of syncope due to OH or reflex syncope. •   Blood tests when clinically indicated, e.g. haematocrit or haemo- globin when haemorrhage is suspected, oxygen saturation and blood gas analysis when hypoxia is suspected, troponin when car- diac ischaemia-related syncope is suspected, or D-dimer when pulmonary embolism is suspected, etc.\nEven if there is no independent gold/reference standard to diag- nose syncope, there is strong consensus that the initial evalu- ation may lead to certain or highly likely diagnosis when the diagnostic criteria listed in the table of recommendations are met.\nDiagnostic criteria with initial evaluation\nRecommendations Class a Level b\nReﬂex syncope and OH\nVVS is highly probable if syncope is precipitated by pain, fear, or standing, and is associated with typical progressive prodrome\n(pallor, sweating, and/or nausea). 8 , 13 – 17 I C\nSituational reﬂex syncope is highly probable if syncope occurs during or immediately after speciﬁc triggers, listed in Table  3 . 8 , 13 – 17 I C\nSyncope due to OH is conﬁrmed when syncope occurs while standing and there is concomitant signiﬁcant OH. 18 – 24 I C\nIn the absence of the above criteria, reﬂex syncope and OH should be considered likely when the features that suggest reﬂex\nsyncope or OH are present and the features that suggest cardiac syncope are absent (see  Table  5 ). IIa C\nCardiac syncope\nArrhythmic syncope is highly probable when the ECG shows 25 – 39 : •   Persistent sinus bradycardia <40 b.p.m. or sinus pauses >3 s in awake state and in absence of physical training; •   Mobitz II second- and third-degree AV block; •   Alternating left and right BBB; •   VT or rapid paroxysmal SVT; •   Non-sustained episodes of polymorphic VT and long or short QT interval; or •   Pacemaker or ICD malfunction with cardiac pauses.\nI C\nCardiac ischaemia-related syncope is conﬁrmed when syncope presents with evidence of acute myocardial ischaemia with or without myocardial infarction. 25 – 39 I C\nSyncope due to structural cardiopulmonary disorders is highly probable when syncope presents in patients with prolapsing\natrial myxoma, left atrial ball thrombus, severe aortic stenosis, pulmonary embolus, or acute aortic dissection. I C\nAdditional advice and clinical perspectives The initial syncope evaluation, as described in this document, can deﬁne the cause of syncope in most patients. Strict adherence to the above deﬁn-\nitions of VVS and situational reﬂex syncope, and of syncope due to OH, can be considered certain or highly likely irrespective of the presence of\nany other abnormal ﬁnding. In young subjects with unexplained syncope and no history of cardiac disease, no family history of sudden death, no su- pine syncope or syncope during sleep or exercise, no unusual triggers, and a normal ECG, the chance of cardiac syncope is very low. SCD rates in\nsubjects <35 years amount to 1 – 3/100 000.\nAV = atrioventricular; BBB = bundle branch block; b.p.m. = beats per minute; ECG = electrocardiogram; ICD = implantable cardioverter deﬁbrillator; OH = orthostatic hypo- tension; SCD = sudden cardiac death; SVT = supraventricular tachycardia; VT = ventricular tachycardia; VVS = vasovagal syncope. a Class of recommendation. b Level of evidence.\n1894 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................ When a diagnosis is nearly certain or highly likely, no further evalu- ation is needed, and treatment—if any—can be planned. In other cases, the initial evaluation may suggest a diagnosis when the features listed in  Table  5  are present, or otherwise is unable to suggest any diagnosis.\n4.1.2 Management of syncope in the emergency department based on risk stratification The management of TLOC of suspected syncopal nature in the ED should answer the following three key questions:\n(1) Is there a serious underlying cause that can be identified? (2) What is the risk of a serious outcome? (3) Should the patient be admitted to hospital?\nFigure  5  shows a flow chart for the management and risk stratifica- tion of patients referred to the ED for TLOC suspected to be syn- cope (modified from Casagranda  et al. 40 ).\nQuestion 1: Is there a serious underlying cause that can be identified in the ED? Normally the presenting complaint of syncope can be established. The primary aim for an ED clinician is then to establish an underlying diagnosis, especially those associated with the potential for rapid clin- ical deterioration. 41 , 42   It is the acute underlying disease that most fre- quently determines short-term adverse events rather than the syncope itself. 43   Subsequent management will focus on treating this underlying cause ( Figure  5 ). Many (40–45%) non-cardiovascular and some cardiovascular life-threatening underlying conditions are obvi- ous in the ED. 44   Table  6  lists high-risk features that suggest the pres- ence of a serious underlying cause and low-risk features that suggest a benign underlying cause.\nQuestion 2: What is the risk of a serious outcome? High-risk features are shown in  Table  6 , and how to use this risk pro- file to guide subsequent management and disposition is shown in Figure  6 . Risk stratification is important, for two reasons:\n(1) To recognize patients with a likely  low -risk condition able to be dis- charged with adequate patient education. (2) To recognize patients with a likely  high -risk cardiovascular condition requiring urgent investigation. This may require admission.\nHigh-risk patients are more likely to have cardiac syncope. Structural heart disease 25 – 27 , 31 , 35 , 36 , 45   and primary electrical disease 46\nare major risk factors for sudden cardiac death (SCD) and overall mortality in patients with syncope. Low-risk patients are more likely to have reflex syncope and have an excellent prognosis. 47   OH is associated with a two-fold higher risk of death owing to the severity of comorbidities compared with the general population. 48\nQuestion 3: Should the patient be admitted to hospital? Approximately 50% of patients who present to the ED with syncope are admitted (although the rate varies between 12–86%) (see  Supplementary Data Table 4 ). The use of clinical decision rules and standardized protocols has not changed this rate significantly. The com- posite estimate of outcomes is that in the next 7–30 days, only 0.8% die and 6.9% have a non-fatal severe outcome whilst in the ED, while another 3.6% have a post-ED serious outcome (see  Supplementary Data Table 4 ). Unnecessary admission in low-risk patients can be harm- ful. 87   Whereas it is crucial to identify these high-risk patients to ensure early, rapid, and intensive investigation, not all patients at high risk need hospitalization. 80\nTable 5 Clinical features that can suggest a diagnosis on initial evaluation\nReﬂex syncope •   Long history of recurrent syncope, in particular occurring be- fore the age of 40 years •   After unpleasant sight, sound, smell, or pain •   Prolonged standing •   During meal •   Being in crowded and/or hot places •   Autonomic activation before syncope: pallor, sweating, and/\nor nausea/vomiting •   With head rotation or pressure on carotid sinus (as in tu-\nmours, shaving, tight collars) •   Absence of heart disease\nSyncope due to OH •   While or after standing •   Prolonged standing •   Standing after exertion •   Post-prandial hypotension •   Temporal relationship with start or changes of dosage of vas-\nodepressive drugs or diuretics leading to hypotension •   Presence of autonomic neuropathy or parkinsonism\nCardiac syncope •   During exertion or when supine •   Sudden onset palpitation immediately followed by syncope •   Family history of unexplained sudden death at young age •   Presence of structural heart disease or coronary artery\ndisease •   ECG ﬁndings suggesting arrhythmic syncope: - Bifascicular block (deﬁned as either left or right BBB com- bined with left anterior or left posterior fascicular block) - Other intraventricular conduction abnormalities (QRS dur- ation >_0.12 s) - Mobitz I second-degree AV block and 1 \u0002   degree AV block with markedly prolonged PR interval - Asymptomatic mild inappropriate sinus bradycardia (40–50 b.p.m.) or slow atrial ﬁbrillation (40–50 b.p.m.) in the ab- sence of negatively chronotropic medications - Non-sustained VT - Pre-excited QRS complexes - Long or short QT intervals - Early repolarization - ST-segment elevation with type 1 morphology in leads V1-V3 (Brugada pattern) - Negative T waves in right precordial leads, epsilon waves suggestive of ARVC - Left ventricular hypertrophy suggesting hypertrophic cardiomyopathy\nARVC = arrhythmogenic right ventricular cardiomyopathy; AV = atrioventricular; BBB = bundle branch block; b.p.m. = beats per minute; ECG = electrocardio- gram; OH = orthostatic hypotension; VT = ventricular tachycardia.\nESC Guidelines 1895\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\nFigure 5  The management of patients presenting to the emergency department for transient loss of consciousness suspected to be syncope (modified from Casagranda  et al. 40 ). ED = emergency department; TLOC = transient loss of consciousness. a For example, this includes pulmonary embolism presenting with shortness of breath, pleuritic chest pain, and syncope, but not trauma secondary to syncope.\nManagement of syncope in the emergency department\nRecommendations Class a Level b\nIt is recommended that patients with low-risk features, likely to have reﬂex or situational syncope, or syncope due to OH, are discharged from the ED. 27 , 35 , 36 , 49 – 54 , 58 , 62 , 69 I B\nIt is recommended that patients with high-risk features receive an early intensive and prompt evaluation in a syncope unit or\nin an ED observation unit (if available), or are hospitalized. 26 , 27 , 35 , 36 , 44 – 46 , 50 , 55 – 57 , 59 , 60 , 70 – 76 I B\nIt is recommended that patients who have neither high- nor low-risk features are observed in the ED or in a syncope unit instead of being hospitalized. 40 , 63 – 65 , 77 I B\nRisk stratiﬁcation scores may be considered for risk stratiﬁcation in the ED. 78 – 86 IIb B\nAdditional advice and clinical perspectives •   In the ED, presyncope should be managed with the same accuracy as syncope as it carries the same prognosis. 66 – 68\n•   Diagnostic radiology and laboratory tests such as chest X-ray, brain computed tomography, routine blood haematology, biochemistry, and D-dimer and cardiac markers have a low diagnostic yield, impact on risk stratiﬁcation of patients with syncope, and should not routinely be used unless speciﬁcally suggested by clinical evaluation. •   Around 10% of patients with syncope in the ED will suffer from a serious outcome within 7–30 days of their visit, with just under half occurring after their stay in the ED (see  Supplementary Data Table 4 ). It is crucial to identify these high-risk patients to ensure early, rapid, and intensive investigation. •   As syncope units are both effective and efﬁcient, this early, rapid, and intensive investigation can be performed on an outpatient basis (either in a syncope unit or an ED observation unit) in most cases. Only patients with a risk of a short-term serious outcome should be considered for hospital admission. •   To reduce inappropriate admissions, patients who have a cardiac device and syncope should undergo prompt device interrogation. •   Risk stratiﬁcation scores perform no better than good clinical judgement and should not be used alone to perform risk stratiﬁcation in the ED.\nED = emergency department; OH = orthostatic hypotension. a Class of recommendation. b Level of evidence.\n1896 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\nTable 6 High-risk features (that suggest a serious condition) and low-risk features (that suggest a benign condition) in patients with syncope at initial evaluation in the emergency department\nESC Guidelines 1897\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\nAF = atrial ﬁbrillation; ARVC = arrhythmogenic right ventricular cardiomyopathy; AV = atrioventricular; BP = blood pressure; b.p.m. = beats per minute; ECG = electrocardio- gram; ED = emergency department; ICD = implantable cardioverter deﬁbrillator; LQTS = long QT syndrome; LVEF = left ventricular ejection fraction; SCD = sudden cardiac death; SVT = supraventricular tachycardia; VT = ventricular tachycardia. a Some ECG criteria are  per se  diagnostic of the cause of the syncope (see recommendations: Diagnostic criteria); in such circumstances appropriate therapy is indicated without further investigations. We strongly suggest the use of standardized criteria to identify ECG abnormalities with the aim of precise diagnosis of ECG-deﬁned cardiac syndromes in ED practice. 61\n1898 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ....................... The diagnostic tests, procedures, and interventions that may re- quire admission in patients with high-risk features are listed in  Table  7 . Furthermore, this Task Force believes that the implementation of novel care pathways and organizational approaches, such as ED ob- servation units and syncope in- and outpatient units ( Figure  6 ), offer safe and effective alternatives to admission in the cases listed in  Table  7 . Based on a consensus document, 40   a single-centre experience consisting of a short stay in the ED under observation of\n<_48 h coupled with fast-tracking to a syncope unit reduced the ad- mission rate to 29%. 77   Among patients not admitted, 20% were dis- charged after a short observation in the ED, 20% were fast-tracked to the syncope unit, and 31% were discharged directly from the ED. 77\nRisk stratification scores:  There are several ED syncope clinical decision rules that aim to stratify patients with syncope based on medical history, examination, and ECG findings (see  Supplementary\nif\nFigure 6  Emergency department risk stratification flow chart. Low- and high-risk features are listed in  Table  6 . ED = emergency department; SU = syncope unit. Patients with low-risk features . These patients do not need further diagnostic tests in the ED as they are likely to have reﬂex, situational, or orthostatic syncope. They may beneﬁt from reassurance, or counselling (see  Web Practical Instructions section 9.1: ESC information sheet for patients affected by reﬂex syncope ). Patients with high-risk features . These patients should be classiﬁed as HIGH RISK; they require an intensive diagnostic approach and may need urgent treatment and admission. These patients should be monitored (although it is unclear for how long this should be, most studies suggesting up to 6 hours in the ED and up to 24 hours in hospital) in a setting where resuscitation can be performed in case of deterioration. 40 , 62\nPatients that have neither high- nor low-risk features . These patients will require expert syncope opinion, which can probably be safely man- aged in an outpatient setting. 63   There is no direct evidence that admitting patients to hospital changes their outcome, whilst there is evi- dence that management in an ED observation unit and/or fast-track to a syncope outpatient unit is beneﬁcial. 64 , 65\na Recent studies have suggested that outcomes in patients presenting with presyncope are similar to those presenting with syncope. 66 – 68\nb These patients may still require admission to hospital for associated illness, injury or welfare reasons. Low-risk patients can be referred to the outpatient syncope clinic for therapy purposes, if needed.\nESC Guidelines 1899\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ....................................................................................... Data Table 3 ). 26 , 34 – 36 , 44 , 88   None of these rules are used widely in EDs due to poor sensitivity and specificity reported from external valida- tion, or due to a lack of external validation. 70 , 78 – 85   Syncope clinical decision rules perform no better than clinician judgment at predicting short-term serious outcomes. 86   Clinical decision rules can predict poor outcomes, but most syncope deaths and many poor outcomes are associated with underlying illness rather than syncope  per se , 58\nparticularly in the long term. 56\nEven if the quality of evidence is moderate, there is strong con- sensus from several studies that currently available risk stratifi- cation scores have not shown better sensitivity, specificity, or prognostic yield compared with clinical judgment in predicting short-term serious outcomes after syncope. Therefore, they should not be used alone to perform risk stratification in the ED.\n",
      "keywords": [
        "first",
        "ejection fraction",
        "should be considered",
        "family history",
        "vasovagal",
        "bradycardia",
        "sudden cardiac death",
        "patient",
        "tloc",
        "electrocardiogram",
        "pacemaker",
        "when",
        "tachycardia",
        "pulmonary embolism",
        "eyewitnesses",
        "age",
        "usually",
        "orthostatic",
        "scd",
        "blood pressure",
        "risk stratification",
        "evaluation",
        "troponin",
        "transient loss of consciousness",
        "tory",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "clinical",
        "aortic"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 1893",
          "page_number": 10,
          "content": " |  | \n |  | \n |  | \n | Figure 4 Flow diagram for the initial evaluation and risk stratification of patients with syncope. BP = blood pressure; ECG = electrocardiogram; | \n | H&P exam = history and physical examination; TLOC = transient loss of consciousness. | \n |  | ",
          "bbox": [
            47.904998779296875,
            59.81117248535156,
            552.4721069335938,
            490.0539855957031
          ],
          "function_potential": "raw"
        },
        {
          "title": "1894 ESC Guidelines",
          "page_number": 11,
          "content": " | Diagnostic criteria with initial evaluation |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Reflex syncope and OH |  |  | \n |  | VVS is highly probable if syncope is precipitated by pain, fear, or standing, and is associated with typical progressive prodrome\n(pallor, sweating, and/or nausea).8,13–17 | I | C | \n |  | Situational reflex syncope is highly probable if syncope occurs during or immediately after specific triggers, listed in\nTable 3.8,13–17 | I | C | \n |  | Syncope due to OH is confirmed when syncope occurs while standing and there is concomitant significant OH.18–24 | I | C | \n |  | In the absence of the above criteria, reflex syncope and OH should be considered likely when the features that suggest reflex\nsyncope or OH are present and the features that suggest cardiac syncope are absent (see Table 5). | IIa | C | \n |  | Cardiac syncope |  |  | \n |  | Arrhythmic syncope is highly probable when the ECG shows25–39:\n• Persistent sinus bradycardia <40 b.p.m. or sinus pauses >3 s in awake state and in absence of physical training;\n• Mobitz II second- and third-degree AV block;\n• Alternating left and right BBB;\n• VT or rapid paroxysmal SVT;\n• Non-sustained episodes of polymorphic VT and long or short QT interval; or\n• Pacemaker or ICD malfunction with cardiac pauses. | I | C | \n |  | Cardiac ischaemia-related syncope is confirmed when syncope presents with evidence of acute myocardial ischaemia with or\nwithout myocardial infarction.25–39 | I | C | \n |  | Syncope due to structural cardiopulmonary disorders is highly probable when syncope presents in patients with prolapsing\natrial myxoma, left atrial ball thrombus, severe aortic stenosis, pulmonary embolus, or acute aortic dissection. | I | C | \n |  | Additional advice and clinical perspectives\nThe initial syncope evaluation, as described in this document, can define the cause of syncope in most patients. Strict adherence to the above defin-\nitions of VVS and situational reflex syncope, and of syncope due to OH, can be considered certain or highly likely irrespective of the presence of\nany other abnormal finding. In young subjects with unexplained syncope and no history of cardiac disease, no family history of sudden death, no su-\npine syncope or syncope during sleep or exercise, no unusual triggers, and a normal ECG, the chance of cardiac syncope is very low. SCD rates in\nsubjects <35 years amount to 1 – 3/100 000. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | AV = atrioventricular; BBB = bundle branch block; b.p.m. = beats per minute; ECG = electrocardiogram; ICD = implantable cardioverter defibrillator; OH = orthostatic hypo-\ntension; SCD = sudden cardiac death; SVT = supraventricular tachycardia; VT = ventricular tachycardia; VVS = vasovagal syncope. |  |  |  | \n | aClass of recommendation.\nbLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            164.6929931640625,
            543.7516524152057,
            645.052001953125
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 1895",
          "page_number": 12,
          "content": " | Table 5 Clinical features that can suggest a diagnosis\non initial evaluation | \n |  | \n | Reflex syncope\n• Long history of recurrent syncope, in particular occurring be-\nfore the age of 40 years\n• After unpleasant sight, sound, smell, or pain\n• Prolonged standing\n• During meal\n• Being in crowded and/or hot places\n• Autonomic activation before syncope: pallor, sweating, and/\nor nausea/vomiting\n• With head rotation or pressure on carotid sinus (as in tu-\nmours, shaving, tight collars)\n• Absence of heart disease\nSyncope due to OH\n• While or after standing\n• Prolonged standing\n• Standing after exertion\n• Post-prandial hypotension\n• Temporal relationship with start or changes of dosage of vas-\nodepressive drugs or diuretics leading to hypotension\n• Presence of autonomic neuropathy or parkinsonism\nCardiac syncope\n• During exertion or when supine\n• Sudden onset palpitation immediately followed by syncope\n• Family history of unexplained sudden death at young age\n• Presence of structural heart disease or coronary artery\ndisease\n• ECG findings suggesting arrhythmic syncope:\n- Bifascicular block (defined as either left or right BBB com-\nbined with left anterior or left posterior fascicular block)\n- Other intraventricular conduction abnormalities (QRS dur-\nation >0.12 s)\n_\n- Mobitz I second-degree AV block and 1\u0002 degree AV block\nwith markedly prolonged PR interval\n- Asymptomatic mild inappropriate sinus bradycardia (40–50\nb.p.m.) or slow atrial fibrillation (40–50 b.p.m.) in the ab-\nsence of negatively chronotropic medications\n- Non-sustained VT\n- Pre-excited QRS complexes\n- Long or short QT intervals\n- Early repolarization\n- ST-segment elevation with type 1 morphology in leads\nV1-V3 (Brugada pattern)\n- Negative T waves in right precordial leads, epsilon waves\nsuggestive of ARVC\n- Left ventricular hypertrophy suggesting hypertrophic\ncardiomyopathy | \n |  | Reflex syncope\n• Long history of recurrent syncope, in particular occurring be-\nfore the age of 40 years\n• After unpleasant sight, sound, smell, or pain\n• Prolonged standing\n• During meal\n• Being in crowded and/or hot places\n• Autonomic activation before syncope: pallor, sweating, and/\nor nausea/vomiting\n• With head rotation or pressure on carotid sinus (as in tu-\nmours, shaving, tight collars)\n• Absence of heart disease\n |  | Syncope due to OH\n• While or after standing\n• Prolonged standing\n• Standing after exertion\n• Post-prandial hypotension\n• Temporal relationship with start or changes of dosage of vas-\nodepressive drugs or diuretics leading to hypotension\n• Presence of autonomic neuropathy or parkinsonism\n |  | Cardiac syncope\n• During exertion or when supine\n• Sudden onset palpitation immediately followed by syncope\n• Family history of unexplained sudden death at young age\n• Presence of structural heart disease or coronary artery\ndisease\n• ECG findings suggesting arrhythmic syncope:\n- Bifascicular block (defined as either left or right BBB com-\nbined with left anterior or left posterior fascicular block)\n- Other intraventricular conduction abnormalities (QRS dur-\nation >0.12 s)\n_\n- Mobitz I second-degree AV block and 1\u0002 degree AV block\nwith markedly prolonged PR interval\n- Asymptomatic mild inappropriate sinus bradycardia (40–50\nb.p.m.) or slow atrial fibrillation (40–50 b.p.m.) in the ab-\nsence of negatively chronotropic medications\n- Non-sustained VT\n- Pre-excited QRS complexes\n- Long or short QT intervals\n- Early repolarization\n- ST-segment elevation with type 1 morphology in leads\nV1-V3 (Brugada pattern)\n- Negative T waves in right precordial leads, epsilon waves\nsuggestive of ARVC\n- Left ventricular hypertrophy suggesting hypertrophic\ncardiomyopathy\n |  | \n |  | \n | ARVC = arrhythmogenic right ventricular cardiomyopathy; AV = atrioventricular;\nBBB = bundle branch block; b.p.m. = beats per minute; ECG = electrocardio- | \n | gram; OH = orthostatic hypotension; VT = ventricular tachycardia. | \n |  | ",
          "bbox": [
            47.904998779296875,
            128.63631184895834,
            284.97886775090143,
            737.68798828125
          ],
          "function_potential": "raw"
        },
        {
          "title": "1896 ESC Guidelines",
          "page_number": 13,
          "content": " |  | \n |  | \n |  | \n( | Figure 5 The management of patients presenting to the emergency department for transient loss of consciousness suspected to be syncope | \n | modified from Casagranda et al.40). ED = emergency department; TLOC = transient loss of consciousness. | \n | aFor example, this includes pulmonary embolism presenting with shortness of breath, pleuritic chest pain, and syncope, but not trauma\nsecondary to syncope. | \n |  | ",
          "bbox": [
            43.369998931884766,
            59.81117248535156,
            544.9234701620566,
            351.83697509765625
          ],
          "function_potential": "raw"
        },
        {
          "title": "1896 ESC Guidelines",
          "page_number": 13,
          "content": " | Management of syncope in the emergency department |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | It is recommended that patients with low-risk features, likely to have reflex or situational syncope, or syncope due to OH,\nare discharged from the ED.27,35,36,49–54,58,62,69 | I | B | \n |  | It is recommended that patients with high-risk features receive an early intensive and prompt evaluation in a syncope unit or\nin an ED observation unit (if available), or are hospitalized.26,27,35,36,44–46,50,55–57,59,60,70–76 | I | B | \n |  | It is recommended that patients who have neither high- nor low-risk features are observed in the ED or in a syncope unit\ninstead of being hospitalized.40,63–65,77 | I | B | \n |  | Risk stratification scores may be considered for risk stratification in the ED.78–86 | IIb | B | \n |  | Additional advice and clinical perspectives\n• In the ED, presyncope should be managed with the same accuracy as syncope as it carries the same prognosis.66–68\n• Diagnostic radiology and laboratory tests such as chest X-ray, brain computed tomography, routine blood haematology, biochemistry, and D-dimer and cardiac\nmarkers have a low diagnostic yield, impact on risk stratification of patients with syncope, and should not routinely be used unless specifically suggested by clinical\nevaluation.\n• Around 10% of patients with syncope in the ED will suffer from a serious outcome within 7–30 days of their visit, with just under half occurring after their stay in the\nED (see Supplementary Data Table 4). It is crucial to identify these high-risk patients to ensure early, rapid, and intensive investigation.\n• As syncope units are both effective and efficient, this early, rapid, and intensive investigation can be performed on an outpatient basis (either in a syncope unit or an\nED observation unit) in most cases. Only patients with a risk of a short-term serious outcome should be considered for hospital admission.\n• To reduce inappropriate admissions, patients who have a cardiac device and syncope should undergo prompt device interrogation.\n• Risk stratification scores perform no better than good clinical judgement and should not be used alone to perform risk stratification in the ED. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | ED = emergency department; OH = orthostatic hypotension.\naClass of recommendation. |  |  |  | \n | bLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            374.00299072265625,
            544.9234701620566,
            709.8519897460938
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 1897",
          "page_number": 14,
          "content": " | Table 6 High-risk features (that suggest a serious condition) and low-risk features (that suggest a benign condition) i\npatients with syncope at initial evaluation in the emergency department | n\n |  | \n |  | \n |  | ",
          "bbox": [
            47.904998779296875,
            59.811492919921875,
            552.5402709960938,
            636.5479736328125
          ],
          "function_potential": "raw"
        },
        {
          "title": "1898 ESC Guidelines",
          "page_number": 15,
          "content": " |  | \n |  | \n |  | \n |  | \n | AF = atrial fibrillation; ARVC = arrhythmogenic right ventricular cardiomyopathy; AV = atrioventricular; BP = blood pressure; b.p.m. = beats per minute; ECG = electrocardio-\ngram; ED = emergency department; ICD = implantable cardioverter defibrillator; LQTS = long QT syndrome; LVEF = left ventricular ejection fraction; SCD = sudden cardiac | \n | death; SVT = supraventricular tachycardia; VT = ventricular tachycardia.\naSome ECG criteria are per se diagnostic of the cause of the syncope (see recommendations: Diagnostic criteria); in such circumstances appropriate therapy is indicated without\nfurther investigations. We strongly suggest the use of standardized criteria to identify ECG abnormalities with the aim of precise diagnosis of ECG-defined cardiac syndromes in\nED practice.61 | \n |  | ",
          "bbox": [
            43.369998931884766,
            59.811319986979164,
            547.979248046875,
            678.4439697265625
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 1899",
          "page_number": 16,
          "content": " |  | \n | if | \n |  | \n | Figure 6 Emergency department risk stratification flow chart. Low- and high-risk features are listed in Table 6. ED = emergency department; | \n | SU = syncope unit. | \n | Patients with low-risk features. These patients do not need further diagnostic tests in the ED as they are likely to have reflex, situational,\nor orthostatic syncope. They may benefit from reassurance, or counselling (see Web Practical Instructions section 9.1: ESC information\nsheet for patients affected by reflex syncope). | \n | Patients with high-risk features. These patients should be classified as HIGH RISK; they require an intensive diagnostic approach and may\nneed urgent treatment and admission. These patients should be monitored (although it is unclear for how long this should be, most\nstudies suggesting up to 6 hours in the ED and up to 24 hours in hospital) in a setting where resuscitation can be performed in case of\ndeterioration.40,62 | \n | Patients that have neither high- nor low-risk features. These patients will require expert syncope opinion, which can probably be safely man-\naged in an outpatient setting.63 There is no direct evidence that admitting patients to hospital changes their outcome, whilst there is evi-\ndence that management in an ED observation unit and/or fast-track to a syncope outpatient unit is beneficial.64,65 | \n | aRecent studies have suggested that outcomes in patients presenting with presyncope are similar to those presenting with\nsyncope.66–68 | \n | bThese patients may still require admission to hospital for associated illness, injury or welfare reasons. Low-risk patients can be referred\nto the outpatient syncope clinic for therapy purposes, if needed. | \n |  | ",
          "bbox": [
            47.904998779296875,
            59.811859130859375,
            552.4721069335938,
            613.8709716796875
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "1900 ESC Guidelines",
          "page_number": 17,
          "content": " | Table 7 High-risk syncope patients: criteria favouring a stay in an emergency department observation unit and/or\nfast-tracking to a syncope unit vs. requiring admission to hospital\n | \n | Favour initial management in ED observation unit and/or Favour admission to hospital\nfast-track to syncope unit\nHigh-risk features AND: High-risk features AND:\n• Stable, known structural heart disease • Any potentially severe coexisting disease that requires admission\n• Severe chronic disease • Injury caused by syncope\n• Syncope during exertion • Need of further urgent evaluation and treatment if it cannot\n• Syncope while supine or sitting be achieved in another way (i.e. observation unit), e.g. ECG monitoring,\n• Syncope without prodrome echocardiography, stress test, electrophysiological study, angiography,\n• Palpitations at the time of syncope device malfunction, etc.\n• Inadequate sinus bradycardia or sinoatrial block • Need for treatment of syncope\n• Suspected device malfunction or inappropriate intervention\n• Pre-excited QRS complex\n• SVT or paroxysmal atrial fibrillation\n• ECG suggesting an inheritable arrhythmogenic disorders\n• ECG suggesting ARVC\n | \n | ARVC = arrhythmogenic right ventricular cardiomyopathy; ECG = electrocardiogram; ED = emergency department; SVT = supraventricular tachycardia.",
          "bbox": [
            43.369998931884766,
            59.811492919921875,
            545.0440724690756,
            320.13616943359375
          ],
          "function_potential": "raw"
        },
        {
          "title": "1900 ESC Guidelines",
          "page_number": 17,
          "content": " | Favour initial management in ED observation unit and/or\nfast-track to syncope unit | Favour admission to hospital\n | High-risk features AND:\n• Stable, known structural heart disease\n• Severe chronic disease\n• Syncope during exertion\n• Syncope while supine or sitting\n• Syncope without prodrome\n• Palpitations at the time of syncope\n• Inadequate sinus bradycardia or sinoatrial block\n• Suspected device malfunction or inappropriate intervention\n• Pre-excited QRS complex\n• SVT or paroxysmal atrial fibrillation\n• ECG suggesting an inheritable arrhythmogenic disorders\n• ECG suggesting ARVC | High-risk features AND:\n• Any potentially severe coexisting disease that requires admission\n• Injury caused by syncope\n• Need of further urgent evaluation and treatment if it cannot\nbe achieved in another way (i.e. observation unit), e.g. ECG monitoring,\nechocardiography, stress test, electrophysiological study, angiography,\ndevice malfunction, etc.\n• Need for treatment of syncope",
          "bbox": [
            49.379742758614675,
            97.34188232421874,
            536.8816680908203,
            289.98429107666016
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "21",
      "title": "4.2 Diagnostic tests 4.2.1 Carotid sinus massage A ventricular pause lasting >3 s and/or a fall in systolic BP of >50 mmHg is known as carotid sinus hypersensitivity. Carotid sinus hypersensitivity is",
      "start_page": 17,
      "end_page": 23,
      "content": "syndrome (CSS) requires the reproduction of spontaneous symp- toms and, in addition, that patients have syncope of unknown ori- gin compatible with a reflex mechanism. In such circumstances, CSM usually shows a period of asystole >6 s. 91   The prevalence of CSS, as defined here, was 8.8% when CSM was performed after the initial evaluation in 1855 consecutive patients >40 years of age with syncope compatible with a reflex mechanism. 92 , 93   In a multicentre study 94   aimed at validation of the 2009 ESC Guidelines, CSM was indicated after initial evaluation in 73% of 700 patients and was diagnostic in 12%. The precise methodology and results of CSM are shown in section 5 of the  Web Practical Instructions . The main complications of CSM are neurological. When pooling the data from four studies 90 , 95 – 97   in which 8720 patients were ana- lysed, TIAs or strokes were observed in 21 (0.24%). The relationship between abnormal response to CSM and spontaneous syncope is a crucial point that has been studied using two methods. The first was a pre-post comparison of the recur- rence rate of syncope after pacing. Non-randomized studies dem- onstrated fewer recurrences at follow-up in paced patients than in those without pacing. These results were confirmed in two randomized trials. 98 , 99   The second method was to analyse the occurrence of asystolic episodes registered in patients with a car- dioinhibitory response to CSM using an implanted device. Recordings of long pauses were very common in the two trials that employed this method. 100 , 101   These results suggest that a positive response to CSM, reproducing symptoms, in patients with syncope is highly predictive of the occurrence of spontane- ous asystolic episodes.\nTable 7 High-risk syncope patients: criteria favouring a stay in an emergency department observation unit and/or fast-tracking to a syncope unit vs. requiring admission to hospital\nFavour initial management in ED observation unit and/or fast-track to syncope unit Favour admission to hospital\nHigh-risk features AND: •   Stable, known structural heart disease •   Severe chronic disease •   Syncope during exertion •   Syncope while supine or sitting •   Syncope without prodrome •   Palpitations at the time of syncope •   Inadequate sinus bradycardia or sinoatrial block •   Suspected device malfunction or inappropriate intervention •   Pre-excited QRS complex •   SVT or paroxysmal atrial ﬁbrillation •   ECG suggesting an inheritable arrhythmogenic disorders •   ECG suggesting ARVC\nHigh-risk features AND: •   Any potentially severe coexisting disease that requires admission •   Injury caused by syncope •   Need of further urgent evaluation and treatment if it cannot\nbe achieved in another way (i.e. observation unit), e.g. ECG monitoring, echocardiography, stress test, electrophysiological study, angiography,\ndevice malfunction, etc. •   Need for treatment of syncope\nARVC = arrhythmogenic right ventricular cardiomyopathy; ECG = electrocardiogram; ED = emergency department; SVT = supraventricular tachycardia.\n1900 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .............\n. ...........................................................\nThere is strong consensus that the diagnosis of CSS requires both the reproduction of spontaneous symptoms during CSM and clinical features of spontaneous syncope compatible with a reflex mechanism. The quality of evidence is moderate and is given by studies of ECG correlation between CSM and sponta-\nneous events, and indirectly by studies of efficacy of cardiac pacing. Further research is likely to have an important impact on our confidence in the estimation of effect and may change the estimate.\n4.2.2 Orthostatic challenge Changing from the supine to the upright position produces a dis- placement of blood from the thorax to the lower limbs and abdomi- nal cavity that leads to a decrease in venous return and cardiac output. In the absence of compensatory mechanisms, a fall in BP may lead to syncope. 20 , 103 , 104   The diagnostic criteria for OH have been defined by consensus. 6\nCurrently, there are three methods for assessing the response to change in posture from supine to erect 20 , 103 , 104 : active standing (see section 4.2.2.1), head-up tilt (see section 4.2.2.2), and 24-h ambula- tory BP monitoring (ABPM) (see section 4.2.3.4).\n4.2.2.1 Active standing\nIndications:  This test is used to diagnose different types of ortho- static intolerance (see  Web Practical Instructions Web Table 1 ). A sphygmomanometer is adequate for routine clinical testing for classi- cal OH and delayed OH because of its ubiquity and simplicity. Automatic arm-cuff devices, which are programmed to repeat and confirm measurements when discrepant values are recorded, are at\na disadvantage due to the rapidly falling BP during OH. With a sphyg- momanometer, more than four measurements per minute cannot be obtained without venous obstruction in the arm. When more fre- quent readings are required, as for initial OH, continuous beat-to- beat non-invasive BP measurement is needed. 20 , 103 , 104\nDiagnostic criteria:  Abnormal BP fall is defined as a progressive and sustained fall in systolic BP from baseline value >_20 mmHg or diastolic BP >_10 mmHg, or a decrease in systolic BP to <90 mmHg. This definition of OH differs from the 2011 consensus 6   in adding the 90 mmHg threshold. This Task Force believes that an absolute threshold of 90 mmHg of systolic BP is useful, especially in patients with a supine BP <110 mmHg. An isolated diastolic BP drop is very rare and its clinical relevance for OH diagnosis is lim- ited. Orthostatic heart rate (HR) increase is blunted or absent [usually not >10 beats per minute (b.p.m.)] in patients with neuro- genic OH, but increases or even exaggerates with anaemia or hypovolaemia. The probability that syncope and orthostatic com- plaints are due to OH can be assessed using the information given in  Table  8 .\nCardiac sinus massage\nRecommendations Class a Level b\nIndications\nCSM is indicated in patients >40 years of age with syncope of unknown origin compatible with a reﬂex mechanism. 92 – 94 I B\nDiagnostic criteria\nCSS is conﬁrmed if CSM causes bradycardia (asystole) and/or hypotension that reproduce spontaneous symptoms, and\npatients have clinical features compatible with a reﬂex mechanism of syncope. 89 , 90 , 92 , 93 , 98 – 102 I B\nAdditional advice and clinical perspectives •   History of syncope and its reproduction by CSM deﬁnes CSS; positive CSM without a history of syncope deﬁnes carotid sinus hypersensitiv- ity. 89 , 90 , 92 , 93   Carotid sinus hypersensitivity in patients with unexplained syncope may be a non-speciﬁc ﬁnding because it is present in <_40% of\nolder populations and should be used with caution for diagnosis of the mechanism of syncope. •   CSM should be performed with the patient in the supine and upright positions, and with continuous beat-to-beat BP monitoring. This may be more readily performed in the tilt laboratory. 90\n•   Although neurological complications are very rare, 90 , 95 – 97  the risk of provocation of TIA with the massage suggests that CSM should be under-\ntaken with caution in patients with previous TIA, stroke, or known carotid stenosis >70%.\nBP = blood pressure; CSM = carotid sinus massage; CSS = carotid sinus syndrome; TIA = transient ischaemic attack. a Class of recommendation. b Level of evidence.\nESC Guidelines 1901\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\nActive standing\nRecommendations Class a Level b\nIndications\nIntermittent determination by sphygmomanometer of BP and HR while supine and during active standing for 3 min are indi-\ncated at initial syncope evaluation. 20 , 103 , 104 I C\nContinuous beat-to-beat non-invasive BP and HR measurement may be preferred when short-lived BP variations are sus- pected, such as in initial OH. 20 , 103 , 104 IIb C\nDiagnostic criteria\nSyncope due to OH is conﬁrmed when there is a fall in systolic BP from baseline value >_20 mmHg or diastolic BP >_10\nmmHg, or a decrease in systolic BP to <90 mmHg that reproduces spontaneous symptoms. 6 , 20 , 103 , 104 I C\nSyncope due to OH should be considered likely when there is an asymptomatic fall in systolic BP from baseline value >_20\nmmHg or diastolic BP >_10 mmHg, or a decrease in systolic BP to <90 mmHg, and symptoms (from history) are consistent with OH. 6 , 20 , 103 , 104\nIIa C\nSyncope due to OH should be considered likely when there is a symptomatic fall in systolic BP from baseline value >_20\nmmHg or diastolic BP >_10 mmHg, or a decrease in systolic BP to <90 mmHg, and not all of the features (from history) are suggestive of OH. 6 , 20 , 103 , 104\nIIa C\nPOTS should be considered likely when there is an orthostatic HR increase (>30 b.p.m. or to >120 b.p.m. within 10 min of\nactive standing) in the absence of OH that reproduces spontaneous symptoms. 6 , 20 , 103 , 104 IIa C\nSyncope due to OH may be considered possible when there is an asymptomatic fall in systolic BP from baseline value >_20\nmmHg or diastolic BP >_10 mmHg, or a decrease in systolic BP to <90 mmHg, and symptoms (from history) are less consis- tent with OH. 6 , 20 , 103 , 104\nIIb C\nBP = blood pressure; b.p.m. = beats per min; OH = orthostatic hypotension; HR = heart rate; POTS = postural orthostatic tachycardia syndrome. a Class of recommendation. b Level of evidence.\nTable 8 Association of orthostatic intolerance and orthostatic hypotension\nHistory of syncope and orthostatic complaints\nHighly suggestive of OH:  syncope and pre-\nsyncope are present during standing, absent while lying, and less severe or absent while sit-\nting; a predilection for the morning; sitting or\nlying down must help; complaints may get worse immediately after exercise, after meals\nor in high temperatures; no “autonomic\nactivation”\nPossibly due to OH:  not all of the features\nhighly suggestive of OH are present\nSupine and standing BP measurement Symptomatic abnormal BP fall Syncope is due to OH  (Class I) Syncope is likely due to OH  (Class IIa)\nAsymptomatic abnormal BP fall Syncope is likely due to OH  (Class IIa) Syncope may be due to OH  (Class IIb)\nNo abnormal BP drop Unproven Unproven\nBP = blood pressure; OH = orthostatic hypotension.\n1902 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ..................................................................... 4.2.2.2 Tilt testing Since its introduction in 1986, 105   many protocols have been reported with variations in the initial stabilization phase, duration, tilt angle, type of support, and pharmacological provocation. The most com- monly used are the trinitroglycerin (TNG) test using 300–400  m g of sublingual TNG after a 20-min unmedicated phase, 106 , 107   and the low-dose intravenous isoproterenol test, which uses incremental doses to increase average HR by about 20–25% over baseline (usu- ally <_3  m g/min). 108 , 109   In a recent systematic literature review, 110   the overall positivity rate in patients with syncope was 66% for the TNG protocol and 61% for the isoproterenol protocol; the respective pos- itivity rate in subjects without syncope (controls) ranged from 11–14%; and the test differentiated patients with syncope from con- trols with an odds ratio of 12. The methodology and classification of responses are described in section 6 of the  Web Practical Instructions . Adding video recording to a tilt table permits objective and repeated review of clinical signs in relation to BP and HR, and helps to assess the relative contribution of bradycardia and hypotension to syncope (see section 5.2.6.3 and the explanatory video in  Web Practical Instructions  section 6.3.15), and to distinguish between VVS and PPS (see section 4.2.5). The clinical situation corresponding to tilt-induced syncope is that which is triggered by prolonged standing. The test should be\nconsidered: (i) to confirm a diagnosis of reflex syncope in patients in whom this diagnosis was suspected but not confirmed by initial eval- uation 105 – 109 , 111 , and (ii) for the assessment of autonomic failure, especially for the reproduction of delayed OH (which could not be detected by active standing because of its delayed onset) 23 , 24 , 112 , 113\nand postural orthostatic tachycardia syndrome (POTS). 114   Tilt testing may be helpful in separating syncope from PPS. 115 – 117\nTilt testing has limited value in assessing treatment efficacy. 118\nHowever, tilt testing is widely accepted as a useful tool to demon- strate susceptibility of the patient to reflex syncope, especially a hypotensive (vasodepressive) tendency, and thereby to initiate treat- ment (e.g. physical manoeuvres, see section 5). 119 – 121\nThe endpoint of tilt testing is the reproduction of symptoms along with the characteristic circulatory pattern of the indication mentioned above, namely the induction of reflex hypo- tension/bradycardia, OH, POTS, or PPS. The typical tilt test result patterns are shown in the Web Practical Instructions section 6.\nInterpretation of tilt testing results in patients with reflex syncope: Some studies 122 , 123   compared the response to tilt testing with sponta- neous syncope recorded by an implantable loop recorder (ILR). While a positive cardioinhibitory response to tilt testing predicts, with a high probability, an asystolic spontaneous syncope, the presence of a\nTilt testing\nRecommendations Class a Level b\nIndications\nTilt testing should be considered in patients with suspected reﬂex syncope, OH, POTS, or PPS. 23 , 24 , 105 – 109 , 111 – 117 IIa B\nTilt testing may be considered to educate patients to recognize symptoms and learn physical manoeuvres. 119 – 121 IIb B\nDiagnostic criteria\nReﬂex syncope, OH, POTS, or PPS should be considered likely if tilt testing reproduces symptoms along with the charac-\nteristic circulatory pattern of these conditions. 23 , 24 , 105 – 109 , 111 – 117 IIa B\nAdditional advice and clinical perspectives •   A negative tilt table response does not exclude a diagnosis of reﬂex syncope. •   While sensitivity and speciﬁcity are at acceptable levels when measured in patients with VVS and healthy controls, in usual clinical settings of syncope\nof uncertain origin tilt testing suggests the presence of a  hypotensive susceptibility , which may exist not only in reﬂex syncope but also with other causes of syncope including some forms of cardiac syncope. The concept of hypotensive susceptibility rather than diagnosis has important practical\nutility, because the presence or absence of hypotensive susceptibility plays a major role in guiding pacemaker therapy in patients affected by reﬂex\nsyncope and in the management of hypotensive therapies, which are frequently present in the elderly with syncope (see sections 5.1 and 5.2). •   A positive cardioinhibitory response to tilt testing predicts, with high probability, asystolic spontaneous syncope; this ﬁnding is relevant for thera-\npeutic implications when cardiac pacing is considered (see section 5.2.6). Conversely, the presence of a positive vasodepressor, a mixed\nresponse, or even a negative response does not exclude the presence of asystole during spontaneous syncope. 122 , 123\n•   Tilt testing may be helpful in separating syncope with abnormal movements from epilepsy. 137\n•   Tilt testing may have value in distinguishing syncope from falls. 23\n•   Tilt testing may be helpful in separating syncope from PPS. In suspected PPS, the tilt test should preferably be performed together with EEG mon-\nitoring; a normal EEG helps to conﬁrm the diagnosis. 116 , 117   In the absence of an EEG, a video recording will be helpful in conﬁrming the diagnosis. •   Tilt testing should not be used to assess the efﬁcacy of a drug treatment. 118\nEEG = electroencephalogram; OH = orthostatic hypotension; POTS = postural orthostatic tachycardia syndrome; PPS = psychogenic pseudosyncope; VVS = vasovagal syncope. a Class of recommendation. b Level of evidence.\nESC Guidelines 1903\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................\npositive vasodepressor, mixed response, or even a negative response, does not exclude the presence of asystole during spontaneous syncope. 122 , 123\nTilt testing has an acceptable sensitivity 124   and specific- ity 106 , 124 , 125   when these are calculated in patients with true VVS or without a history of syncope. However, there is an inability to apply the test to populations with syncope of uncertain cause where it is hoped that tilt testing might prove decisive. In these clinical settings, tilt testing fails to deliver ( Figure  7 ). Indeed, tilt testing was positive in 51–56% of patients with atypical clinical fea- tures suggesting a reflex mechanism, 106 , 124 – 128   in 30–36% with unexplained syncope after full investigation, 124 , 129   and in 45–47% with true cardiac arrhythmic syncope. 130 , 131   In other words, tilt testing offers little diagnostic value in patients for whom it is most needed. In these patients, a positive tilt test reveals a susceptibility to orthostatic stress. 132   This  hypotensive susceptibility  plays a role in causing syncope irrespective of the aetiology and mechanism of syncope. For example, in arrhythmic syncope caused by paroxys- mal atrial tachyarrhythmias, the mechanism is a combination of onset of the arrhythmia itself and hypotensive susceptibility, corroborated by positive tilt testing. 130 , 131   Similarly, multifactorial mechanisms are likely in other types of cardiac syncope, e.g. aortic stenosis, 133 hypertrophic cardiomyopathy (HCM), 134 and sick sinus syndrome. 135 , 136   The presence or absence of suscepti- bility explains the occurrence of syncope in some and not in others affected by the same severity of arrhythmia or structural defect. Tilt testing should now be considered a means of exposing a hypotensive tendency rather than being diagnostic of\nVVS. This concept has practical implications for therapy (see sec- tions 5.1 and 5.2).\n4.2.3 Basic autonomic function tests Autonomic function assessment helps to identify autonomic failure as the underlying cause of syncope.\n4.2.3.1 Valsalva manoeuvre The methodology of the Valsalva manoeuvre is described in section 7.1.1 of the  Web Practical Instructions  and in  Web Video 2 . There is strong evidence that the absence of a BP overshoot and an absence of a HR increase during the Valsalva is pathognomonic for neurogenic OH, occurring in primary and secondary autonomic failure, and the degree of hypotension and/or lack of compensation during forced expiration usually correlate with the degree of autonomic dysfunc- tion and related symptoms. 138 – 143   In contrast, a pronounced BP fall beyond what is normally expected during forced expiration, but a normal chronotropic response during the manoeuvre, may occur in patients with suspected situational syncope, i.e. syncope occurring during some forms of situational syncope, e.g. coughing, brass instru- ment playing, singing, and weightlifting. 144\n4.2.3.2 Deep breathing The methodology of the deep-breathing test is described in section 7.1.2 of the  Web Practical Instructions . Under physiological conditions, HR rises during inspiration and falls during expiration. HR variability during deep breathing (also called the expiratory/inspiratory index or E/I index) is >_15 b.p.m. in healthy individuals aged >50 years. 145\nThere is strong consensus that blunted or abolished variation is sug- gestive of parasympathetic dysfunction. 142 , 143 , 146 , 147\n4.2.3.3 Other autonomic function tests Further tests to evaluate cardiovascular sympathetic function include calculation of the 30:15 ratio, the cold pressure test, the sustained hand grip test, and mental arithmetic. There is weak evidence that these tests may be useful. 13 , 142 , 143 , 147\n4.2.3.4 Twenty-four-hour ambulatory and home blood pressure monitoring Twenty-four-hour ABPM and home BP monitoring (HBPM) are increasingly used to diagnose and monitor the treatment of hyperten- sion. 148   There is strong evidence that OH is frequently associated with a nocturnal ‘non-dipping’ or even ‘reverse-dipping’ BP pattern in patients with autonomic failure, with relevant therapeutic and prognos- tic implications 140 , 148 – 151   (see  Web Practical Instructions  section 7.1.3). In these patients, ABPM allows the assessment of nocturnal hypertension, postprandial hypotension, and exercise- and drug-induced hypoten- sion, as well as monitoring for side effects of antihypotensive regimens and pointing to additional disorders such as sleep apnoea. 152   There is weak evidence that ABPM may also detect the degree of OH in daily life better than single office BP measurements. 153\nHBPM may be used to investigate the cause of orthostatic intoler- ance, i.e. to clarify whether symptoms are due to OH or to other causes, such as vertigo or motor imbalance in Parkinson’s disease or multiple system atrophy. The evidence is weak. Finally, HBPM can be used to clarify that BP is not low during episodes of PPS. 154\nFigure 7  Rates of tilt testing positivity in different clinical condi- tions. These studies used the Westminster protocol for passive tilt, 125   the Italian protocol for trinitroglycerin tilt, 106   and the clo- mipramine protocol, 124   for a total of 1453 syncope patients and 407 controls without syncope. Studies using other tilt protocols, e.g. isoproterenol challenge, were not included. Clom = clomipr- amine; TNG = trinitroglycerin; VVS = vasovagal syncope.\n1904 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ......................................... 4.2.4 Electrocardiographic monitoring (non-invasive and invasive) The role of ECG monitoring cannot be defined in isolation. As a rule, ECG monitoring is indicated only when there is a high pre-test proba- bility of identifying an arrhythmia associated with syncope, such as those listed in  Table  5 .\n4.2.4.1 In-hospital monitoring In-hospital monitoring (in bed or by telemetry) is warranted in patients with high-risk clinical features (defined in  Table  6 ) suggesting arrhythmic syncope, especially if the monitoring is applied immedi- ately after syncope. Although the diagnostic yield of ECG monitoring varies from 1.9–17.6%, 158 – 160   it is justified by the need to avoid immediate risk to the patient.\n4.2.4.2 Holter monitoring Since, in most patients, symptoms do not recur during monitoring, the true yield of Holter monitoring in syncope may be as low as 1–2% in an unselected population. In 15% of patients, symptoms were not asso- ciated with arrhythmia. 161   Thus, in these patients, a rhythm disturbance could potentially be excluded as a cause of syncope. Holter monitoring in syncope is inexpensive in terms of set-up costs, but expensive in terms of cost per diagnosis. 162   Holter monitoring in syncope may be of more value if symptoms are frequent. Daily single or multiple episodes of LOC might increase the potential for symptom–ECG correlation.\n4.2.4.3 Prospective external event recorders Event recorders are external devices that are applied by the patient when symptoms occur. Whereas these recorders can be useful in\nBasic autonomic function tests\nRecommendations Class a Level b\nValsalva manoeuvre\nValsalva manoeuvre should be considered for the assessment of autonomic function in patients with suspected neurogenic\nOH. 138 – 143 IIa B\nValsalva manoeuvre may be considered for conﬁrming the hypotensive tendency induced by some forms of situational syn- cope, e.g. coughing, brass instrument playing, singing, and weightlifting. 144 IIb C\nDeep-breathing test\nDeep-breathing tests should be considered for the assessment of autonomic function in patients with suspected neurogenic\nOH. 142 , 143 , 146 , 147 IIa B\nOther autonomic function tests\nOther autonomic function tests (30:15 ratio, cold pressure test, sustained hand grip test, and mental arithmetic test) may be considered for the assessment of autonomic function in patients with suspected neurogenic OH. 13 , 142 , 143 , 147 IIb C\nABPM\nABPM is recommended to detect nocturnal hypertension in patients with autonomic failure. 140 , 148 – 151 I B\nABPM should be considered to detect and monitor the degree of OH and supine hypertension in daily life in patients with\nautonomic failure. 152 , 153 IIa C\nABPM and HBPM may be considered to detect whether BP is abnormally low during episodes suggestive of orthostatic intolerance. IIb C\nAdditional advice and clinical perspectives •   Whenever possible, reproduction of the trigger situation (e.g. coughing, swallowing, laughing, bass instrument playing, weightlifting) under beat-\nto-beat non-invasive HR and BP measurement should be performed in patients with suspected situational syncope. •   The effects of age and sex should be considered when interpreting autonomic function tests. 145 , 155 – 157\n•   Compliance with autonomic function tests may be limited in patients with dementia. Patients with tremor or Parkinsonism may not succeed in\nperforming the sustained hand grip test. The cold pressure test may be uncomfortable in patients with Raynaud’s phenomena. 147\nABPM = ambulatory blood pressure monitoring; BP = blood pressure; HBPM = home blood pressure monitoring; HR = heart rate; OH = orthostatic hypotension. a Class of recommendation. b Level of evidence.\nESC Guidelines 1905\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .................................................................................................................................................... the investigation of palpitations, 163   they have a marginal role in the evaluation of syncope.\n4.2.4.4 Smartphone applications Because up to now smartphone applications have recorded real-time ECG, their current role in syncope is limited for the same reason as for prospective event recorders. 164 , 165   However, home video records are very useful in all forms of TLOC (see section 4.2.5.2).\n4.2.4.5 External loop recorders In general, external loop recorders have a higher diagnostic yield than Holter monitoring. 162   External loop recorders can be useful in patients with relatively frequent syncope episodes. 166 – 168   In a recent multicentre international registry, the diagnostic yield in syncope was 24.5%, with the most common finding being bradyarrhythmias; the stronger predictor for diagnostic findings was early monitoring after the index event. 166\n4.2.4.6 Remote (at home) telemetry Most recently, external and implantable device systems have been developed that provide continuous ECG recording or 24-h loop memory with wireless transmission (real time) to a service centre. Some recent studies have shown that implementing remote monitor- ing increases the diagnostic yield and achieves diagnosis earlier than without remote monitoring. 169 – 171\n4.2.4.7 Implantable loop recorders In a meta-analysis of five randomized controlled trials (RCTs), 172 – 176\n660 patients with unexplained syncope were randomized to a con- ventional strategy consisting of an external loop recorder, tilt testing, and an electrophysiological study (EPS), or to prolonged monitoring with an ILR. The results showed that initial implantation of an ILR in the workup provided a 3.7 [95% confidence interval (CI) 2.7–5.0] increased relative probability of a diagnosis compared with the con- ventional strategy (see  Supplementary Data Table 5 ). ILR was more cost-effective than a conventional strategy. 172 , 173 , 177 , 178\nIn pooled data from nine studies 179 performed in 506 patients with unexplained syncope at the end of complete nega- tive work-up, a correlation between syncope and ECG was found in 176 patients (35%); of these, 56% had asystole (or bradycardia in a few cases) at the time of the recorded event, 11% had tachycardia, and 33% had no arrhythmia. Presyncope was much less likely to be associated with an arrhythmia than syncope. Similar findings were subsequently observed with ILR use expanded in an early phase of evaluation in patients with recurrent syncope of uncertain origin, in the absence of high- risk criteria and structural heart disease, 176 , 180 – 183   and in sus- pected reflex syncope. 184 – 186   In particular, an asystolic pause was present during syncope in about 50% of these patients.\n",
      "keywords": [
        "should be considered",
        "older",
        "class i",
        "vasovagal",
        "bradycardia",
        "hypersensitivity",
        "diagnostic",
        "electrocardiogram",
        "pacemaker",
        "systolic",
        "tachycardia",
        "massage",
        "age",
        "mmhg",
        "tilt test",
        "orthostatic",
        "sinus",
        "hypertension",
        "blood pressure",
        "pause",
        "syncope",
        "stress test",
        "diastolic",
        "tests",
        "aortic",
        "arrhythmia",
        "carotid",
        "presyncope",
        "sex",
        "lasting"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 1901",
          "page_number": 18,
          "content": " | Cardiac sinus massage |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Indications |  |  | \n |  | CSM is indicated in patients >40 years of age with syncope of unknown origin compatible with a reflex mechanism.92–94 | I | B | \n |  | Diagnostic criteria |  |  | \n |  | CSS is confirmed if CSM causes bradycardia (asystole) and/or hypotension that reproduce spontaneous symptoms, and\npatients have clinical features compatible with a reflex mechanism of syncope.89,90,92,93,98–102 | I | B | \n |  | Additional advice and clinical perspectives\n• History of syncope and its reproduction by CSM defines CSS; positive CSM without a history of syncope defines carotid sinus hypersensitiv-\nity.89,90,92,93 Carotid sinus hypersensitivity in patients with unexplained syncope may be a non-specific finding because it is present in <40% of\n_\nolder populations and should be used with caution for diagnosis of the mechanism of syncope.\n• CSM should be performed with the patient in the supine and upright positions, and with continuous beat-to-beat BP monitoring. This may be\nmore readily performed in the tilt laboratory.90\n• Although neurological complications are very rare,90,95–97 the risk of provocation of TIA with the massage suggests that CSM should be under-\ntaken with caution in patients with previous TIA, stroke, or known carotid stenosis >70%. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | BP = blood pressure; CSM = carotid sinus massage; CSS = carotid sinus syndrome; TIA = transient ischaemic attack.\naClass of recommendation. |  |  |  | \n | bLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            47.904998779296875,
            139.18096923828125,
            548.8759982201361,
            435.3450012207031
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "1902 ESC Guidelines",
          "page_number": 19,
          "content": " | Table 8 Association of orthostatic intolerance and orthostatic hypotension |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  | History of syncope and orthostatic complaints |  | \n |  |  |  | Highly suggestive of OH: syncope and pre-\nsyncope are present during standing, absent\nwhile lying, and less severe or absent while sit-\nting; a predilection for the morning; sitting or\nlying down must help; complaints may get\nworse immediately after exercise, after meals\nor in high temperatures; no “autonomic\nactivation” | Possibly due to OH: not all of the features\nhighly suggestive of OH are present | \n |  | Supine and standing\nBP measurement | Symptomatic abnormal BP fall | Syncope is due to OH (Class I) | Syncope is likely due to OH (Class IIa) | \n |  |  | Asymptomatic abnormal BP fall | Syncope is likely due to OH (Class IIa) | Syncope may be due to OH (Class IIb) | \n |  |  | No abnormal BP drop | Unproven | Unproven | \n |  |  |  |  |  | \n |  |  |  |  |  | \n | BP = blood pressure; OH = orthostatic hypotension. |  |  |  |  | \n |  |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            59.811299641927086,
            544.0954412930254,
            292.86614990234375
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "1902 ESC Guidelines",
          "page_number": 19,
          "content": " | Active standing |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Indications |  |  | \n |  | Intermittent determination by sphygmomanometer of BP and HR while supine and during active standing for 3 min are indi-\ncated at initial syncope evaluation.20,103,104 | I | C | \n |  | Continuous beat-to-beat non-invasive BP and HR measurement may be preferred when short-lived BP variations are sus-\npected, such as in initial OH.20,103,104 | IIb | C | \n |  | Diagnostic criteria |  |  | \n |  | Syncope due to OH is confirmed when there is a fall in systolic BP from baseline value >20 mmHg or diastolic BP >10\n_ _\nmmHg, or a decrease in systolic BP to <90 mmHg that reproduces spontaneous symptoms.6,20,103,104 | I | C | \n |  | Syncope due to OH should be considered likely when there is an asymptomatic fall in systolic BP from baseline value >20\n_\nmmHg or diastolic BP >10 mmHg, or a decrease in systolic BP to <90 mmHg, and symptoms (from history) are consistent\n_\nwith OH.6,20,103,104 | IIa | C | \n |  | Syncope due to OH should be considered likely when there is a symptomatic fall in systolic BP from baseline value >20\n_\nmmHg or diastolic BP >10 mmHg, or a decrease in systolic BP to <90 mmHg, and not all of the features (from history) are\n_\nsuggestive of OH.6,20,103,104 | IIa | C | \n |  | POTS should be considered likely when there is an orthostatic HR increase (>30 b.p.m. or to >120 b.p.m. within 10 min of\nactive standing) in the absence of OH that reproduces spontaneous symptoms.6,20,103,104 | IIa | C | \n |  | Syncope due to OH may be considered possible when there is an asymptomatic fall in systolic BP from baseline value >20\n_\nmmHg or diastolic BP >10 mmHg, or a decrease in systolic BP to <90 mmHg, and symptoms (from history) are less consis-\n_\ntent with OH.6,20,103,104 | IIb | C | \n |  |  |  |  | \n |  |  |  |  | \n | BP = blood pressure; b.p.m. = beats per min; OH = orthostatic hypotension; HR = heart rate; POTS = postural orthostatic tachycardia syndrome.\naClass of recommendation. |  |  |  | \n | bLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            327.6849772135417,
            544.0954412930254,
            708.8319702148438
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 1903",
          "page_number": 20,
          "content": " | Tilt testing |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Indications |  |  | \n |  | Tilt testing should be considered in patients with suspected reflex syncope, OH, POTS, or PPS.23,24,105–109,111–117 | IIa | B | \n |  | Tilt testing may be considered to educate patients to recognize symptoms and learn physical manoeuvres.119–121 | IIb | B | \n |  | Diagnostic criteria |  |  | \n |  | Reflex syncope, OH, POTS, or PPS should be considered likely if tilt testing reproduces symptoms along with the charac-\nteristic circulatory pattern of these conditions.23,24,105–109,111–117 | IIa | B | \n |  | Additional advice and clinical perspectives\n• A negative tilt table response does not exclude a diagnosis of reflex syncope.\n• While sensitivity and specificity are at acceptable levels when measured in patients with VVS and healthy controls, in usual clinical settings of syncope\nof uncertain origin tilt testing suggests the presence of a hypotensive susceptibility, which may exist not only in reflex syncope but also with other\ncauses of syncope including some forms of cardiac syncope. The concept of hypotensive susceptibility rather than diagnosis has important practical\nutility, because the presence or absence of hypotensive susceptibility plays a major role in guiding pacemaker therapy in patients affected by reflex\nsyncope and in the management of hypotensive therapies, which are frequently present in the elderly with syncope (see sections 5.1 and 5.2).\n• A positive cardioinhibitory response to tilt testing predicts, with high probability, asystolic spontaneous syncope; this finding is relevant for thera-\npeutic implications when cardiac pacing is considered (see section 5.2.6). Conversely, the presence of a positive vasodepressor, a mixed\nresponse, or even a negative response does not exclude the presence of asystole during spontaneous syncope.122,123\n• Tilt testing may be helpful in separating syncope with abnormal movements from epilepsy.137\n• Tilt testing may have value in distinguishing syncope from falls.23\n• Tilt testing may be helpful in separating syncope from PPS. In suspected PPS, the tilt test should preferably be performed together with EEG mon-\nitoring; a normal EEG helps to confirm the diagnosis.116,117 In the absence of an EEG, a video recording will be helpful in confirming the diagnosis.\n• Tilt testing should not be used to assess the efficacy of a drug treatment.118 |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | EEG = electroencephalogram; OH = orthostatic hypotension; POTS = postural orthostatic tachycardia syndrome; PPS = psychogenic pseudosyncope; VVS = vasovagal\nsyncope. |  |  |  | \n | aClass of recommendation.\nbLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            48.18899917602539,
            346.1103210449219,
            548.7297307794744,
            742.677001953125
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "1904 ESC Guidelines",
          "page_number": 21,
          "content": " |  | \n |  | \n |  | \n | Figure 7 Rates of tilt testing positivity in different clinical condi | -\ne\n-\nd\n,\n-\n | tions. These studies used the Westminster protocol for passiv\ntilt,125 the Italian protocol for trinitroglycerin tilt,106 and the clo\nmipramine protocol,124 for a total of 1453 syncope patients an\n407 controls without syncope. Studies using other tilt protocols\ne.g. isoproterenol challenge, were not included. Clom = clomipr\namine; TNG = trinitroglycerin; VVS = vasovagal syncope. | \n |  | ",
          "bbox": [
            43.369998931884766,
            59.8118896484375,
            283.63409423828125,
            384.4919738769531
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 1905",
          "page_number": 22,
          "content": " | Basic autonomic function tests |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Valsalva manoeuvre |  |  | \n |  | Valsalva manoeuvre should be considered for the assessment of autonomic function in patients with suspected neurogenic\nOH.138–143 | IIa | B | \n |  | Valsalva manoeuvre may be considered for confirming the hypotensive tendency induced by some forms of situational syn-\ncope, e.g. coughing, brass instrument playing, singing, and weightlifting.144 | IIb | C | \n |  | Deep-breathing test |  |  | \n |  | Deep-breathing tests should be considered for the assessment of autonomic function in patients with suspected neurogenic\nOH.142,143,146,147 | IIa | B | \n |  | Other autonomic function tests |  |  | \n |  | Other autonomic function tests (30:15 ratio, cold pressure test, sustained hand grip test, and mental arithmetic test) may\nbe considered for the assessment of autonomic function in patients with suspected neurogenic OH.13,142,143,147 | IIb | C | \n |  | ABPM |  |  | \n |  | ABPM is recommended to detect nocturnal hypertension in patients with autonomic failure.140,148–151 | I | B | \n |  | ABPM should be considered to detect and monitor the degree of OH and supine hypertension in daily life in patients with\nautonomic failure.152,153 | IIa | C | \n |  | ABPM and HBPM may be considered to detect whether BP is abnormally low during episodes suggestive of orthostatic\nintolerance. | IIb | C | \n |  | Additional advice and clinical perspectives\n• Whenever possible, reproduction of the trigger situation (e.g. coughing, swallowing, laughing, bass instrument playing, weightlifting) under beat-\nto-beat non-invasive HR and BP measurement should be performed in patients with suspected situational syncope.\n• The effects of age and sex should be considered when interpreting autonomic function tests.145,155–157\n• Compliance with autonomic function tests may be limited in patients with dementia. Patients with tremor or Parkinsonism may not succeed in\nperforming the sustained hand grip test. The cold pressure test may be uncomfortable in patients with Raynaud’s phenomena.147 |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | ABPM = ambulatory blood pressure monitoring; BP = blood pressure; HBPM = home blood pressure monitoring; HR = heart rate; OH = orthostatic hypotension.\naClass of recommendation. |  |  |  | \n | bLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            47.904998779296875,
            59.81097412109375,
            548.1252916124132,
            519.7039794921875
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "22",
      "title": "There are several areas of interest other than unexplained syn- cope in which ILRs have been investigated:",
      "start_page": 23,
      "end_page": 28,
      "content": "•   Patients with bundle branch block (BBB) in whom paroxysmal atrioventricular (AV) block is likely despite negative complete EPS: an arrhythmia was observed in 41% of these patients (being paroxysmal AV block in 70%) under ILR observation, based on pooled data from three studies 174 , 187 , 188   (see  Supplementary Data Table 6 ). •   Patients in whom epilepsy was suspected but the treatment has proven ineffective: in pooled data, an attack could have been documented by ILR in 62% of patients, with an arrhythmic cause being responsible in 26% 137 , 189 – 191   (see  Supplementary Data Table 7 ). •   Patients with unexplained falls: in pooled data, an attack could have been documented by ILR in 70% of patients, with an arrhythmic cause being responsible in 14% 191 – 194 (see Supplementary Data Table 8 ). •   Patients with HCM, arrhythmogenic right ventricular cardiomy- opathy (ARVC), or primary electrical diseases (see section 5.4).\n4.2.4.8 Diagnostic criteria The gold standard for the diagnosis of arrhythmic syncope is when there is a correlation between the symptoms and an ECG record- ing. 195 , 196   The presence of asymptomatic significant arrhythmias— defined as prolonged asystole (>_3 s), rapid supraventricular tachycardias (SVTs) (i.e. >160 b.p.m. for >32 beats), or ventricular tachycardias (VTs)—has been considered by several authors to be a diagnostic finding. 185 , 188 , 197 – 199   On the other hand, although the absence of documentation of an arrhythmia during a syncopal epi- sode cannot be considered to be a specific diagnosis, it allows the exclusion of an arrhythmia as the mechanism of the syncope. Most evidence in support of the above diagnostic criteria is indirectly based on the benefit of specific therapies guided by ECG monitoring in pre- venting syncopal recurrences. 172 , 184 – 186 , 188 , 200\nEven if the quality of evidence is moderate, there is strong con- sensus based on evidence from several controlled trials that a correlation between symptoms and a documented arrhythmia, or the presence of some asymptomatic significant arrhythmias (defined above), is diagnostic of the cause of syncope and spe- cific treatment must be prescribed.\nThe principal limitation of any ECG monitoring device is the inability to record BP together with ECG. In reflex syncope, the documentation of bradycardia/asystole during a syncopal episode does not rule out the possibility that a hidden hypotensive reflex is the principal cause for syncope, and that bradycardia/asystole is a secondary late event. This issue has important implications for therapy (see section 5). A classification of ECG recordings with their probable related pathophysiology is available in  Web Table 6 and Web Practical Instructions  section 8.\n1906 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ................. 4.2.5 Video recording in suspected syncope 4.2.5.1 In-hospital video recording For PNES, a video-electroencephalogram (EEG) forms the highest level of diagnostic probability. 204   For syncope and PPS, video can play a similar, probably underused, role (see section 7). Adding video recording to a tilt table test adds the ability to review clinical signs in\nrelation to BP and HR objectively and repeatedly, thus helping to dis- tinguish VVS from PPS. This approach has revealed new pathophysio- logical insights in syncope. 9   Attaching the camera to the tilt table allows detailed study of the face and head, which is useful when assessing the start and end of LOC. 9 , 205   Video recording of tilt- induced PPS 116   ensures that apparent TLOC occurs while BP and HR\nElectrocardiographic monitoring\nRecommendations Class a Level b\nIndications\nImmediate in-hospital monitoring  (in bed or by telemetry) is indicated in high-risk patients (deﬁned in  Table  6 ). I C\nHolter monitoring  should be considered in patients who have frequent syncope or presyncope (>_1 episode per week). 161 IIa B\nExternal loop recorders  should be considered, early after the index event, in patients who have an inter-symptom interval <_4\nweeks. 162 , 166 , 168 , 201 IIa B\nILR  is indicated in an early phase of evaluation in patients with recurrent syncope of uncertain origin, absence of high-risk criteria (listed in  Table  6 ), and a high likelihood of recurrence within the battery life of the device. 175 , 176 , 181 – 184 , 202 ,\nSupplementary Data Table 5\nI A\nILR  is indicated in patients with high-risk criteria (listed in  Table  6 ) in whom a comprehensive evaluation did not demon-\nstrate a cause of syncope or lead to a speciﬁc treatment, and who do not have conventional indications for primary preven- tion ICD or pacemaker indication. 174 , 180 , 187 , 188 , 195 ,  Supplementary Data Tables 5 and 6\nI A\nILR  should be considered in patients with suspected or certain reﬂex syncope presenting with frequent or severe syncopal\nepisodes. 184 – 186 IIa B\nILR  may be considered in patients in whom epilepsy was suspected but the treatment has proven ineffective. 137 , 189 – 191 , Supplementary Data Table 7 IIb B\nILR  may be considered in patients with unexplained falls. 191 – 194 ,  Supplementary Data Table 8 IIb B\nDiagnostic criteria\nArrhythmic syncope is conﬁrmed when a correlation between syncope and an arrhythmia (bradyarrhythmia or tachyar-\nrhythmia) is detected. 172 , 184 – 186 , 188 , 200 I B\nIn the absence of syncope, arrhythmic syncope should be considered likely when periods of Mobitz II second- or third- degree AV block or a ventricular pause >3 s (with the possible exception of young trained persons, during sleep or rate-\ncontrolled atrial ﬁbrillation), or rapid prolonged paroxysmal SVT or VT are detected. 185 , 188 , 197 – 199\nIIa C\nAdditional advice and clinical perspectives •   Be aware that the pre-test selection of the patients inﬂuences the subsequent ﬁndings. Include patients with a high likelihood of arrhythmic events. The duration (and technology) of monitoring should be selected according to the risk and the predicted recurrence rate of\nsyncope. 158 – 160 , 183\n•   Exclude patients with a clear indication for ICD, pacemaker, or other treatments independent of a deﬁnite diagnosis of the cause of syncope. •   Include patients with a high probability of recurrence of syncope in a reasonable time. Owing to the unpredictability of syncope recurrence, be\nprepared to wait up to 4 years or more before obtaining such a correlation. 203\n•   In the absence of a documented arrhythmia, presyncope cannot be considered a surrogate for syncope, whereas the documentation of a signiﬁ-\ncant arrhythmia at the time of presyncope can be considered a diagnostic ﬁnding. 199\n•   The absence of arrhythmia during syncope excludes arrhythmic syncope.\nAV = atrioventricular; ICD = implantable cardioverter deﬁbrillator; ILR = implantable loop recorder; SVT = supraventricular tachycardia; VT = ventricular tachycardia. a Class of recommendation. b Level of evidence.\nESC Guidelines 1907\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................ are not low; adding an EEG increases the diagnostic probability of PPS even further. The method has been proven to show the com- bined presence of VVS and PPS. 117\n4.2.5.2 Home video recording Home video records (by means of smartphone technology) are very useful in all forms of TLOC to allow signs of an attack to be studied. Patients and their relatives should be urged to record attacks, if possi- ble, in cases of diagnostic uncertainty. In epilepsy, advances are made towards prolonged video and EEG recording in patients’ homes. 206 , 207   For syncope or PPS, experience suggests that the chan- ces of obtaining a video record are higher for PPS than for syncope, which is probably the effect of a high frequency and long duration of attacks in PPS. It is rare for the beginning of events to be recorded. 206\nHome video records allow complex events such as syncope-induced epileptic seizures to be diagnosed. 208\n4.2.6 Electrophysiological study\nIndications:  In an overview of eight studies, including 625 patients with syncope undergoing EPS, 209   positive results occurred predomi- nantly in patients with structural heart disease. In recent years, the development of powerful non-invasive methods, i.e. prolonged ECG monitoring, showing a higher diagnostic value, has decreased the importance of EPS as a diagnostic test. In clinical practice, registry data show that approximately 3% of patients with unexplained syncope evaluated by cardiologists undergo EPS and even fewer if they are evaluated by other specialists. 71   Nevertheless, EPS remains useful for diagnosis in the following specific clinical situations: asymptomatic sinus bradycardia (suspected sinus arrest causing syncope), bifascicu- lar BBB (impending high-degree AV block), and suspected tachycardia.\nDiagnostic criteria:  4.2.6.1 Asymptomatic sinus bradycardia: sus- pected sinus arrest causing syncope The pre-test probability of bradycardia-related syncope is relatively high when there is asymptomatic sinus bradycardia (<50 b.p.m.) or\nsinoatrial block, usually documented by 12-lead ECG or ECG moni- toring. The prognostic value of a prolonged sinus node recovery time (SNRT) is not well defined. An abnormal response is defined as >_1.6 or 2 s for SNRT, or >_525 ms for corrected SNRT. 210   One observatio- nal study showed a relationship between the presence of prolonged SNRT at EPS and the effect of pacing on symptoms. 211   Another small prospective study showed that a corrected SNRT >_800 ms had an eight-fold higher risk of syncope than a SNRT below this value. 212\n4.2.6.2 Syncope in bifascicular bundle branch block (impending high- degree atrioventricular block) Patients with bifascicular block and syncope are at higher risk of devel- oping high-degree AV block. 213   A prolonged HV interval >_70 ms, or induction of second- or third-degree AV block by pacing or by phar- macological stress (ajmaline, procainamide, or disopyramide), identi- fies a group at higher risk of developing AV block. By combining the above-mentioned parts of the electrophysiological protocol, a positive EPS yielded a positive predictive value as high as >_80% for the identifi- cation of patients who will develop AV block in old studies. 214 – 216\nThis finding has been indirectly confirmed by recent studies that showed a significant reduction in syncopal recurrences in patients with prolonged HV implanted with a pacemaker compared with a control group of untreated patients with a negative EPS 188 , or with a control group who received an empiric pacemaker. 217   These results justify an upgrade of the recommendation for EPS-guided therapy (i.e. cardiac pacing) in patients with a positive EPS from class IIa to class I.\nEven if the quality of evidence is moderate, there is strong con- sensus that a positive EPS indicates that the likely mechanism of syncope is paroxysmal AV block. Conversely, approximately one-third of patients with a negative EPS in whom an ILR was implanted developed intermittent or permanent AV block on follow-up. 187   Thus, EPS has a low negative predictive value. Mortality is high in patients with syncope and BBB. However, neither syncope nor prolonged H-V interval were associated with a higher risk of death, and pacemaker therapy did not decrease this risk. 213\n4.2.6.3 Suspected tachycardia In patients with syncope preceded by a sudden onset of brief palpita- tions suggesting SVT or VT, an EPS may be indicated to assess the exact mechanism, especially when a curative catheter ablation proce- dure is considered to be beneficial. In patients with a previous myocardial infarction and preserved left ventricular ejection fraction (LVEF), induction of sustained mono- morphic VT is strongly predictive of the cause of syncope, 218\nwhereas the induction of ventricular fibrillation (VF) is considered a non-specific finding. 37   The absence of induction of ventricular arrhythmias identifies a group at lower risk of arrhythmic syncope. 219\nThe role of EPS and the use of pharmacological challenge by class I antiarrhythmic drugs in patients with syncope and sus- pected Brugada syndrome is controversial. In a recent meta-analy- sis, 220   the risk of arrhythmic events was slightly increased in patients with a history of unexplained syncope or a spontaneous type 1 pattern, and who had induction of VT or VF with one or two extra stimuli. However, the absence of induction in such indi- viduals does not necessarily preclude arrhythmia risk, particularly in patients with high-risk features.\nVideo recording in suspected syncope\nRecommendations Class a Level b\nHome video recordings of spontaneous\nevents should be considered. Physicians\nshould encourage patients and their rel- atives to obtain home video recordings\nof spontaneous events. 206,208\nIIa C\nAdding video recording to tilt testing\nmay be considered in order to increase the reliability of clinical observation of\ninduced events. 9 , 116 , 117 , 205\nIIb C\na Class of recommendation. b Level of evidence.\n1908 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ................................ 4.2.7 Endogenous adenosine and other biomarkers Established cardiac biomarkers such as troponin and B-type natriu- retic peptide have been used to distinguish cardiac from non-cardiac syncope and identify structural heart disease. 223 – 225\n4.2.7.1 Adenosine (triphosphate) test and plasma concentration The purinergic signalling system, including adenosine and its receptors, has been proposed to be involved in unexplained syncope without prodrome. 4 , 226   A low plasma adenosine level is associated with paroxysmal AV block or CSS, whereas a high level is seen in those with a hypotensive/vasodepressive tendency\nand VVS. In parallel, the adenosine/adenosine triphosphate (ATP) provocation test has been performed to demonstrate the utility of adenosine sensitivity and paroxysmal cardioinhibitory propensity for the selection of appropriate pacemaker candi- dates. 4 , 227 , 228   The test requires rapid (<2 s) injection of a 20 mg bolus of ATP/adenosine during ECG monitoring. The induction of AV block with ventricular asystole lasting >6 s, or the induction of AV block lasting >10 s, is considered abnormal. ATP testing was positive in most patients with syncope of unknown origin (especially syncope without prodrome and without structural heart disease 4 ) but not in controls, suggesting that paroxysmal AV\nElectrophysiological study\nRecommendations Class a Level b\nIndications\nIn patients with syncope and previous myocardial infarction, or other scar-related conditions, EPS is indicated when syn-\ncope remains unexplained after non-invasive evaluation. 218 I B\nIn patients with syncope and bifascicular BBB, EPS should be considered when syncope remains unexplained after non-inva- sive evaluation. 188 , 214 – 217 , 221 IIa B\nIn patients with syncope and asymptomatic sinus bradycardia, EPS may be considered in a few instances when non-invasive\ntests (e.g. ECG monitoring) have failed to show a correlation between syncope and bradycardia. 210 – 212 IIb B\nIn patients with syncope preceded by sudden and brief palpitations, EPS may be considered when syncope remains unex-\nplained after non-invasive evaluation. IIb C\nEPS-guided therapy\nIn patients with unexplained syncope and bifascicular BBB, a pacemaker is indicated in the presence of either a baseline H-V\ninterval of >_70 ms, second- or third-degree His-Purkinje block during incremental atrial pacing, or with pharmacological\nchallenge. 188 , 214 – 217 , 221\nI B\nIn patients with unexplained syncope and previous myocardial infarction, or other scar-related conditions, it is recom- mended that induction of sustained monomorphic VT is managed according to the current ESC Guidelines for VA. 46 I B\nIn patients without structural heart disease with syncope preceded by sudden and brief palpitations, it is recommended that\nthe induction of rapid SVT or VT, which reproduce hypotensive or spontaneous symptoms, is managed with appropriate\ntherapy according to the current ESC Guidelines. 46 , 222\nI C\nIn patients with syncope and asymptomatic sinus bradycardia, a pacemaker should be considered if a prolonged corrected\nSNRT is present. 210 – 212 IIa B\nAdditional advice and clinical perspectives •   In general, whereas a positive EPS predicts the cause of syncope, a negative study is unable to exclude an arrhythmic syncope and further evalua- tion is warranted. •   The induction of polymorphic VT or VF in patients with ischaemic cardiomyopathy or DCM cannot be considered a diagnostic ﬁnding of the\ncause of syncope. •   EPS is generally not useful in patients with syncope, normal ECG, no heart disease, and no palpitations.\nBBB = bundle branch block; DCM = dilated cardiomyopathy; ECG = electrocardiogram; EPS = electrophysiological study; ESC = European Society of Cardiology; SNRT = sinus node recovery time; SVT = supraventricular tachycardia; VA = ventricular arrhythmia; VF = ventricular ﬁbrillation; VT = ventricular tachycardia. a Class of recommendation. b Level of evidence.\nESC Guidelines 1909\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ................................................................... block could be the cause of unexplained syncope. Although car- diac pacing may lead to substantial reduction of syncopal attacks in elderly patients with unexplained syncope and a positive ATP test, 229 previous studies showed no correlation between AV block induced by ATP and ECG findings (documented by ILR) during spontaneous syncope. 122 , 123 , 227   Thus, the low predictive value of the test does not support its routine use in selecting patients for cardiac pacing, but rather its positivity suggests that it can be used to confirm the suspicion of asystolic syncope by means of prolonged ECG monitoring. The role of endogenous adenosine release in triggering a special form of asystolic syncope (so-called adenosine-sensitive syncope) remains under investigation.\n4.2.7.2 Cardiovascular biomarkers Some cardiovascular biomarkers are increased in autonomic dysfunc- tion underlying syncope, such as elevated copeptin (vasopressin), endothelin-1, and N-terminal pro-B-type natriuretic peptide in OH, 113 , 230 , 231   whereas atrial natriuretic peptide may be reduced in POTS. 113   At present, the use of cardiovascular biomarkers in the diagnosis of syncope awaits more evidence and verification in inde- pendent cohorts.\n4.2.7.3 Immunological biomarkers Autoantibodies against adrenergic receptors in OH and POTS have been reported, but further studies are needed. 232 – 234\n4.2.8 Echocardiography For patients with suspected heart disease, echocardiography serves to confirm or refute the suspicions in equal proportions and plays an important role in risk stratification. 235 , 236   Echocardiography identifies the cause of syncope in very few patients when no more tests are needed (i.e. severe aortic stenosis, obstructive cardiac tumours or thrombi, pericardial tamponade, or aortic dissection). 237 – 239   In a lit- erature review, right and left atrial myxoma presented with syncope in <20% of cases. 240 – 244\n4.2.8.1 Exercise stress echocardiography Upright or semi-supine exercise stress echocardiography to detect provocable left ventricular outflow tract obstruction should be con- sidered in patients with HCM that complain of exertional or postural syncope, particularly when it recurs during similar circumstances (e.g. when rushing upstairs or straining). A gradient of >_50 mmHg is usu- ally considered to be the threshold at which left ventricular outflow tract obstruction becomes haemodynamically important. 245 – 249\nEchocardiography\nRecommendations Class a Level b\nIndications\nEchocardiography is indicated for diagnosis and risk stratiﬁcation in patients with suspected structural heart disease. 235 , 236 I B\nTwo-dimensional and Doppler echocardiography  during exercise  in the standing, sitting, or semi-supine position to detect\nprovocable left ventricular outﬂow tract obstruction is indicated in patients with HCM, a history of syncope, and a resting or provoked peak instantaneous left ventricular outﬂow tract gradient <50 mmHg. 245 – 249\nI B\nDiagnostic criteria\nAortic stenosis, obstructive cardiac tumours or thrombi, pericardial tamponade, and aortic dissection are the most prob-\nable causes of syncope when the electrocardiogram shows the typical features of these conditions. 237 – 244 I C\nAdditional advice and clinical perspectives •   For patients without suspected cardiac disease after history taking, physical examination, and electrocardiography, the electrocardiogram does\nnot provide additional useful information, suggesting that syncope alone is not an indication for echocardiography. •   Computed tomography or MRI should be considered in selected patients presenting with syncope of suspected cardiac structural origin when echocardiography is not diagnostic.\nHCM = hypertrophic cardiomyopathy; MRI = magnetic resonance imaging. a Class of recommendation. b Level of evidence.\n1910 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ......................................................................................................................\n4.2.9 Exercise stress testing Exercise-induced syncope is infrequent, and the literature is lim- ited to case reports. Exercise testing should be performed in patients who have experienced episodes of syncope during or shortly after exertion. Syncope can occur during or immediately after exercise. These two situations should be considered sepa- rately. Indeed, syncope occurring during exercise is likely due to cardiac causes (even though some case reports have shown that it might be a manifestation of an exaggerated reflex vasodilatation), whereas syncope occurring after exercise is almost invariably due to a reflex mechanism. 250 – 252   Tachycardia-related exercise- induced second- and third-degree AV block has been shown to be located distal to the AV node 253   and predicts progression to per- manent AV block. 254 , 255   A resting ECG frequently shows intraven- tricular conduction abnormalities, 253 , 254   but cases with a normal resting ECG have also been described. 256 , 257   There are no data supporting an indication for exercise testing in a general popula- tion with syncope.\n4.2.10 Coronary angiography In patients presenting with syncope and obstructive coronary artery disease, percutaneous coronary intervention is not associated with a significant reduction in readmission for syncope. 258   Angiography alone is not diagnostic of the cause of syncope. Therefore, cardiac catheterization techniques should be carried out in suspected myo- cardial ischaemia or infarction with the same indications as for patients without syncope.\n",
      "keywords": [
        "ejection fraction",
        "should be considered",
        "other",
        "class i",
        "ilrs",
        "bradycardia",
        "electrocardiogram",
        "pacemaker",
        "than",
        "tachycardia",
        "there",
        "cope",
        "risk stratification",
        "troponin",
        "several",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "aortic",
        "arrhythmia",
        "icd",
        "presyncope",
        "which",
        "areas",
        "mri",
        "echocardiography",
        "level b",
        "cardiomyopathy",
        "elderly",
        "ecg"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 1907",
          "page_number": 24,
          "content": " | Electrocardiographic monitoring |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Indications |  |  | \n |  | Immediate in-hospital monitoring (in bed or by telemetry) is indicated in high-risk patients (defined in Table 6). | I | C | \n |  | Holter monitoring should be considered in patients who have frequent syncope or presyncope (>1 episode per week).161\n_ | IIa | B | \n |  | External loop recorders should be considered, early after the index event, in patients who have an inter-symptom interval <4\n_\nweeks.162,166,168,201 | IIa | B | \n |  | ILR is indicated in an early phase of evaluation in patients with recurrent syncope of uncertain origin, absence of high-risk\ncriteria (listed in Table 6), and a high likelihood of recurrence within the battery life of the device.175,176,181–184,202,\nSupplementary Data Table 5 | I | A | \n |  | ILR is indicated in patients with high-risk criteria (listed in Table 6) in whom a comprehensive evaluation did not demon-\nstrate a cause of syncope or lead to a specific treatment, and who do not have conventional indications for primary preven-\ntion ICD or pacemaker indication.174,180,187,188,195, Supplementary Data Tables 5 and 6 | I | A | \n |  | ILR should be considered in patients with suspected or certain reflex syncope presenting with frequent or severe syncopal\nepisodes.184–186 | IIa | B | \n |  | ILR may be considered in patients in whom epilepsy was suspected but the treatment has proven ineffective.137,189–191,\nSupplementary Data Table 7 | IIb | B | \n |  | ILR may be considered in patients with unexplained falls.191–194, Supplementary Data Table 8 | IIb | B | \n |  | Diagnostic criteria |  |  | \n |  | Arrhythmic syncope is confirmed when a correlation between syncope and an arrhythmia (bradyarrhythmia or tachyar-\nrhythmia) is detected.172,184–186,188,200 | I | B | \n |  | In the absence of syncope, arrhythmic syncope should be considered likely when periods of Mobitz II second- or third-\ndegree AV block or a ventricular pause >3 s (with the possible exception of young trained persons, during sleep or rate-\ncontrolled atrial fibrillation), or rapid prolonged paroxysmal SVT or VT are detected.185,188,197–199 | IIa | C | \n |  | Additional advice and clinical perspectives\n• Be aware that the pre-test selection of the patients influences the subsequent findings. Include patients with a high likelihood of arrhythmic\nevents. The duration (and technology) of monitoring should be selected according to the risk and the predicted recurrence rate of\nsyncope.158–160,183\n• Exclude patients with a clear indication for ICD, pacemaker, or other treatments independent of a definite diagnosis of the cause of syncope.\n• Include patients with a high probability of recurrence of syncope in a reasonable time. Owing to the unpredictability of syncope recurrence, be\nprepared to wait up to 4 years or more before obtaining such a correlation.203\n• In the absence of a documented arrhythmia, presyncope cannot be considered a surrogate for syncope, whereas the documentation of a signifi-\ncant arrhythmia at the time of presyncope can be considered a diagnostic finding.199\n• The absence of arrhythmia during syncope excludes arrhythmic syncope. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | AV = atrioventricular; ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder; SVT = supraventricular tachycardia; VT = ventricular tachycardia.\naClass of recommendation. |  |  |  | \n | bLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            47.904998779296875,
            59.811319986979164,
            548.054556339345,
            633.9400024414062
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "1908 ESC Guidelines",
          "page_number": 25,
          "content": " | Video recording in suspected syncope |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Home video recordings of spontaneous\nevents should be considered. Physicians\nshould encourage patients and their rel-\natives to obtain home video recordings\nof spontaneous events.206,208 | IIa | C | \n |  | Adding video recording to tilt testing\nmay be considered in order to increase\nthe reliability of clinical observation of\ninduced events.9,116,117,205 | IIb | C | \n |  |  |  |  | \n |  |  |  |  | \n | aClass of recommendation.\nbLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            266.1729736328125,
            280.48692673903247,
            474.5769958496094
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 1909",
          "page_number": 26,
          "content": " | Electrophysiological study |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Indications |  |  | \n |  | In patients with syncope and previous myocardial infarction, or other scar-related conditions, EPS is indicated when syn-\ncope remains unexplained after non-invasive evaluation.218 | I | B | \n |  | In patients with syncope and bifascicular BBB, EPS should be considered when syncope remains unexplained after non-inva-\nsive evaluation.188,214–217,221 | IIa | B | \n |  | In patients with syncope and asymptomatic sinus bradycardia, EPS may be considered in a few instances when non-invasive\ntests (e.g. ECG monitoring) have failed to show a correlation between syncope and bradycardia.210–212 | IIb | B | \n |  | In patients with syncope preceded by sudden and brief palpitations, EPS may be considered when syncope remains unex-\nplained after non-invasive evaluation. | IIb | C | \n |  | EPS-guided therapy |  |  | \n |  | In patients with unexplained syncope and bifascicular BBB, a pacemaker is indicated in the presence of either a baseline H-V\ninterval of >70 ms, second- or third-degree His-Purkinje block during incremental atrial pacing, or with pharmacological\n_\nchallenge.188,214–217,221 | I | B | \n |  | In patients with unexplained syncope and previous myocardial infarction, or other scar-related conditions, it is recom-\nmended that induction of sustained monomorphic VT is managed according to the current ESC Guidelines for VA.46 | I | B | \n |  | In patients without structural heart disease with syncope preceded by sudden and brief palpitations, it is recommended that\nthe induction of rapid SVT or VT, which reproduce hypotensive or spontaneous symptoms, is managed with appropriate\ntherapy according to the current ESC Guidelines.46,222 | I | C | \n |  | In patients with syncope and asymptomatic sinus bradycardia, a pacemaker should be considered if a prolonged corrected\nSNRT is present.210–212 | IIa | B | \n |  | Additional advice and clinical perspectives\n• In general, whereas a positive EPS predicts the cause of syncope, a negative study is unable to exclude an arrhythmic syncope and further evalua-\ntion is warranted.\n• The induction of polymorphic VT or VF in patients with ischaemic cardiomyopathy or DCM cannot be considered a diagnostic finding of the\ncause of syncope.\n• EPS is generally not useful in patients with syncope, normal ECG, no heart disease, and no palpitations. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | BBB = bundle branch block; DCM = dilated cardiomyopathy; ECG = electrocardiogram; EPS = electrophysiological study; ESC = European Society of Cardiology; SNRT = sinus\nnode recovery time; SVT = supraventricular tachycardia; VA = ventricular arrhythmia; VF = ventricular fibrillation; VT = ventricular tachycardia. |  |  |  | \n | aClass of recommendation.\nbLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            47.904998779296875,
            59.81097412109375,
            548.202606910883,
            558.4249877929688
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "1910 ESC Guidelines",
          "page_number": 27,
          "content": " | Echocardiography |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Indications |  |  | \n |  | Echocardiography is indicated for diagnosis and risk stratification in patients with suspected structural heart disease.235,236 | I | B | \n |  | Two-dimensional and Doppler echocardiography during exercise in the standing, sitting, or semi-supine position to detect\nprovocable left ventricular outflow tract obstruction is indicated in patients with HCM, a history of syncope, and a resting\nor provoked peak instantaneous left ventricular outflow tract gradient <50 mmHg.245–249 | I | B | \n |  | Diagnostic criteria |  |  | \n |  | Aortic stenosis, obstructive cardiac tumours or thrombi, pericardial tamponade, and aortic dissection are the most prob-\nable causes of syncope when the electrocardiogram shows the typical features of these conditions.237–244 | I | C | \n |  | Additional advice and clinical perspectives\n• For patients without suspected cardiac disease after history taking, physical examination, and electrocardiography, the electrocardiogram does\nnot provide additional useful information, suggesting that syncope alone is not an indication for echocardiography.\n• Computed tomography or MRI should be considered in selected patients presenting with syncope of suspected cardiac structural origin when\nechocardiography is not diagnostic. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | HCM = hypertrophic cardiomyopathy; MRI = magnetic resonance imaging.\naClass of recommendation. |  |  |  | \n | bLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            344.75,
            544.1939919211648,
            647.093017578125
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 1911",
          "page_number": 28,
          "content": " | Coronary angiography |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Indications |  |  | \n |  | In patients with syncope, the same indica-\ntions for coronary angiography should be\nconsidered as in patients without\nsyncope.258 | IIa | C | \n |  | Additional advice and clinical perspectives\nAngiography alone is not diagnostic of the cause of syncope. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | aClass of recommendation.\nbLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            312.2640075683594,
            59.81097412109375,
            549.2334798177084,
            250.4129638671875
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 1911",
          "page_number": 28,
          "content": " | Exercise testing |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Indications |  |  | \n |  | Exercise testing is indicated in patients who\nexperience syncope during or shortly after\nexertion. | I | C | \n |  | Diagnostic criteria |  |  | \n |  | Syncope due to second- or third-degree AV\nblock is confirmed when the AV block\ndevelops during exercise, even without\nsyncope.253–257 | I | C | \n |  | Reflex syncope is confirmed when syncope\nis reproduced immediately after exercise in\nthe presence of severe hypotension.250–252 | I | C | \n |  | Additional advice and clinical perspectives\nThere are no data supporting routine exercise testing in patients\nwith syncope. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | AV = atrioventricular.\naClass of recommendation. |  |  |  | \n | bLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            47.904998779296875,
            297.2413330078125,
            284.415497750947,
            611.6029663085938
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "23",
      "title": "5. Treatment",
      "start_page": 28,
      "end_page": 28,
      "content": "",
      "keywords": [
        "treatment"
      ],
      "tables": []
    },
    {
      "number": "24",
      "title": "5.1 General principles of treatment of syncope The general framework of treatment is based on risk stratification and the identification of specific mechanisms when possible ( Figure  8 ). The followi",
      "start_page": 28,
      "end_page": 28,
      "content": "•   The efficacy of therapy aimed at preventing syncope recurrence is largely determined by the mechanism of syncope rather than its aetiology. Bradycardia is a frequent mechanism of syncope. Cardiac pacing is the most powerful therapy for bradycardia but its efficacy is less if hypotension coexists (see  Table  9  and Supplementary Data Table 9 ). The treatment of syncope due to a hypotensive reflex or to OH is more challenging because specific therapies are less effective. •   Often, therapy to prevent recurrence differs from that for the underlying disease. The management of patients at high risk of SCD requires careful assessment of the individual patient’s risk (see section 5.5). •   Syncopal recurrences often decrease spontaneously after medical assessment, even in the absence of a specific therapy; in general, syncope recurs in <50% of patients within 1–2 years (see Supplementary Data Table 10 ). The decrease seems to be more evident when there is a lack of a clear anatomical substrate for syncope, such as in the case of reflex syncope and unexplained syncope. The reason for this decrease is not known. Several potential clinical, statistical, and psychological explanations have been provided and all probably play a role (see  Supplementary Data Table 10 ). Whatever the reason, the possibility of spontane- ous improvement has major practical importance for treatment that can be postponed in low-risk conditions. The consequence of the spontaneous decrease is that any therapy for syncope pre- vention appears to be more effective than it actually is, which makes the results of observational data on therapy questionable in the absence of a control group.\n",
      "keywords": [
        "treatment",
        "mechanisms",
        "risk",
        "framework",
        "possible",
        "general",
        "bradycardia",
        "principles",
        "scd",
        "identification",
        "figure",
        "followi",
        "specific",
        "when",
        "stratification",
        "based",
        "syncope"
      ],
      "tables": []
    },
    {
      "number": "25",
      "title": "5.2 Treatment of reflex syncope Despite its benign course, recurrent and unpredictable reflex syn- cope may be disabling. The cornerstone of management of these",
      "start_page": 28,
      "end_page": 38,
      "content": "Exercise testing\nRecommendations Class a Level b\nIndications\nExercise testing is indicated in patients who\nexperience syncope during or shortly after\nexertion.\nI C\nDiagnostic criteria\nSyncope due to second- or third-degree AV\nblock is conﬁrmed when the AV block\ndevelops during exercise, even without syncope. 253 – 257\nI C\nReﬂex syncope is conﬁrmed when syncope\nis reproduced immediately after exercise in\nthe presence of severe hypotension. 250 – 252\nI C\nAdditional advice and clinical perspectives\nThere are no data supporting routine exercise testing in patients\nwith syncope.\nAV = atrioventricular. a Class of recommendation. b Level of evidence.\nCoronary angiography\nRecommendations Class a Level b\nIndications\nIn patients with syncope, the same indica-\ntions for coronary angiography should be\nconsidered as in patients without syncope. 258\nIIa C\nAdditional advice and clinical perspectives\nAngiography alone is not diagnostic of the cause of syncope.\na Class of recommendation. b Level of evidence.\nESC Guidelines 1911\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................ patients is non-pharmacological treatment, including education, lifestyle modification, and reassurance regarding the benign nature of the condition. Additional treatment may be necessary in patients with  severe forms , as defined in  Web Practical Instructions  section 2.3, in particular: when very frequent syncope alters quality of life; when recurrent syncope without, or with a very short, prodrome exposes the patient to a risk of trauma; and when syncope occurs during a high-risk activity (e.g. driving, machine operation, flying, or competitive athletics, etc.) .  Only 14% of the highly selected population with reflex syncope who are referred to specialized syncope units may need such additional treatment. 186   In gen- eral, no therapy is appropriate for every form of reflex syncope. The most important discriminant for the choice of therapy is age. A decision pathway for the selection of a specific therapy according to age, severity of syncope, and clinical forms is summarized in  Figure  9 .\n5.2.1 Education and lifestyle modifications Education and lifestyle modifications have not been evaluated in randomized studies, but there is a consensus for implementing them as first-line therapy in all cases. These comprise reassurance about the benign nature of the disease, education regarding awareness and the possible avoidance of triggers and situations (e.g. dehydration and/or hot crowded environments), and the early recognition of prodromal symptoms in order to sit or lie down and activate counter-pressure manoeuvres without delay. If possible, triggers should be addressed directly, such as cough suppression in cough syncope, micturition in the sitting position, etc. Increased intake of oral fluids is also advised. Salt supplementation at a dose of 120 mmol/day of sodium chloride has been proposed. 259   In general, >50% of patients with recurrent syncopal episodes in the 1 or 2 years before evaluation do not have syncopal recurrences in the following 1 or 2 years and, in those with recurrences,\nTable 9 Expected syncope recurrence rates with a permanent pacemaker in different clinical settings (for more details see  Supplementary Data Table 9 ).\nClinical setting Expected 2-year syncope recurrence rate with cardiac pacing\nSyncope due to established bradycardia and absence of hypotensive mechanism High efﬁcacy (<_5% recurrence rate)\nSyncope due to established bradycardia and associated hypotensive mechanism Moderate efﬁcacy (5–25% recurrence rate)\nSyncope due to suspected bradycardia and associated hypotensive mechanism Low efﬁcacy (>25% recurrence rate)\nFigure 8  General framework of treatment is based on risk stratification and the identification of specific mechanisms when possible. ARVC = arrhythmogenic right ventricular cardiomyopathy; CAD = coronary artery disease; DCM = dilated cardiomyopathy; ECG = electrocardiographic; HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter defibrillator; LQTS = long QT syndrome; SCD = sudden cardiac death.\n1912 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .................... the burden of syncope decreases by >70% compared with the preceding period. The effect of education and reassurance is probably the most likely reason for the decrease in syncope (see  Supplementary Data Table 10 ). An example of a patient instruction sheet can be found in the  Web Practical Instructions  section 9.1: European Society of Cardiology information sheet for patients affected by reflex syncope.\nDespite the lack of controlled studies, there is strong consensus that education and lifestyle modifications have a high impact in reducing recurrence of syncope.\n5.2.2 Discontinuation/reduction of hypotensive therapy Careful avoidance of agents that lower BP, i.e. any antihyperten- sive agents, nitrates, diuretics, neuroleptic antidepressants, or\nFigure 9  Schematic practical decision pathway for the first-line management of reflex syncope (based on patient’s history and tests) according to age, severity of syncope, and clinical forms.  Younger patients  are those aged <40 years while  older patients  are >60 years, with an overlap between 40 and 60 years.  Severity  of reflex syncope is defined in the text. The  duration  of prodrome is largely subjective and imprecise. A value of <_5 s distinguishes arrhythmic from reflex syncope 49 ; in patients without structural heart disease, a duration >10 s can distinguish reflex syncope from cardiac syncope. 38\nIn practice, the prodrome is ‘absent or very short’ if it does not allow patients enough time to act, such as to sit or lie down. The heading’  low BP phe- notype’  identifies patients with chronic low BP values (in general, systolic around 110 mmHg, who have a clear history of orthostatic intolerance and orthostatic VVS). The group ‘ dominant cardioinhibition ‘ identifies patients in whom clinical features and results of tests suggest that sudden cardioinhibi- tion is mainly responsible for syncope. One such clue is lack of prodrome, so patients without prodromes may, after analysis, fall into this category. Remark: \u0003 Overlap between subgroups is expected. \u0003 In selected cases, pacing may be used in patients aged <40 years. This Task Force cannot give recommendations due to the lack of sufﬁcient evidence from studies. \u0003 In selected cases, ﬂudrocortisone may be used in patients aged >60 years. This Task Force cannot give recommendations due to the lack of sufﬁcient evidence from studies. \u0003 Midodrine can be used at any age even if existing studies were performed in young patients. \u0003 Patients with short or no prodrome should continue investigations to identify the underlying mechanism and guide subsequent therapy. \u0003 Sometimes an ILR strategy should also be considered in patients aged <40 years. BP = blood pressure; ILR = implantable loop recorder; VVS = vasovagal syncope. a Spontaneous or provoked by, sequentially, carotid sinus massage, tilt testing, or ILR.\nESC Guidelines 1913\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................ dopaminergic drugs, is key in the prevention of recurrence of syn- cope. In a small randomized trial 260   performed in 58 patients (mean age 74 ± 11 years) affected by vasodepressor reflex syn- cope diagnosed by tilt testing or CSM, who were taking on average 2.5 hypotensive drugs, discontinuation or reduction of the vasoac- tive therapy caused a reduction of the rate of the primary com- bined endpoint of syncope, presyncope, and adverse events from 50 to 19% (hazard ratio 0.37) compared with a control group who continued hypotensive therapy during a follow-up of 9 months. In the Systolic Blood Pressure Intervention Trial, 261   patients at high cardiovascular risk who were already using antihypertensive drugs targeting a systolic BP of 120 mmHg had an approximately two- fold risk of syncope vs. the control group targeting a systolic BP of 140 mmHg. In a short-term randomized trial 262   conducted in 32 patients affected by CSS, withdrawal of vasodilator therapy reduced the magnitude of the vasodepressor reflex induced by CSM.\nThere is moderate evidence that discontinuation/reduction of hypotensive therapy targeting a systolic BP of 140 mmHg should be effective in reducing syncopal recurrences in patients with hypotensive susceptibility. Further research is likely to have an important impact on our confidence in the estimate.\n5.2.3 Physical counter-pressure manoeuvres Isometric muscle contractions increase cardiac output and arterial BP during the phase of impending reflex syncope. Three clinical stud- ies 119 , 120 , 263   and one prospective multicentre randomized trial 121\nassessed the effectiveness of physical counter-pressure manoeuvres (PCM) of the legs or arms and showed that they allowed the patient to avoid or delay losing consciousness in most cases. In the Physical Counterpressure Manoeuvres Trial (PC-Trial), 121   223 patients aged 38 ± 15 years with recurrent reflex syncope and recognizable pro- dromal symptoms were randomized to receive standardized conven- tional therapy alone or conventional therapy plus training in PCM. Actuarial recurrence-free survival was better in the PCM group (log-rank  P =0.018), resulting in a relative risk reduction of 39% (95% CI 11–53). No adverse events were reported. A limitation of this treatment is that it cannot be used in patients with short or absent prodrome and that PCM are less effective in patients older than 60 years. 264   An instruction sheet on how to perform PCM can be found in the  Web Practical Instructions  section 9.2.\nThere is moderate evidence that PCM is effective in reducing syncopal recurrences in patients  < 60 years old with long- lasting recognizable prodromal symptoms.\n5.2.4 Tilt training In highly motivated young patients with recurrent vasovagal symp- toms triggered by orthostatic stress, the prescription of progressively prolonged periods of enforced upright posture (so-called tilt training) has been proposed to reduce syncope recurrence. 265   While some studies suggested modest benefit with outpatient tilt training, 266 , 267\nmost controlled trials reported no significant effect. 268 – 272\nMoreover, this treatment is hampered by the low compliance of patients in continuing the training programme for a long period.\nThere is sufficient evidence from multiple trials that tilt train- ing has little efficacy in reducing recurrence of syncope in young patients with long-lasting recognizable prodromal symp- toms. Further research is unlikely to have an important impact on our confidence in the estimate.\n5.2.5 Pharmacological therapy Pharmacological therapy may be considered in patients who have recurrent syncope despite education and lifestyle modifications including training in PCM. Many drugs have been tested in the treat- ment of reflex syncope, for the most part with disappointing results. While results have been satisfactory in uncontrolled trials or short- term controlled trials, several long-term placebo-controlled prospec- tive trials have not shown a benefit of the active drug over placebo, with some exceptions.\n5.2.5.1 Fludrocortisone Fludrocortisone, by increasing renal sodium reabsorption and expanding plasma volume, may counteract the physiological cascade leading to the orthostatic vasovagal reflex. 273   The mechanism of action can be compared with that of saline infusion, which has also proved effective in acute tilt test studies. 274   The Prevention of Syncope Trial (POST) 2 275   enrolled 210 young (median age 30 years) patients with low–normal values of arterial BP and without comor- bidities, and randomized them to receive fludrocortisone (titrated at a dosage of 0.05–0.2 mg once per day) or placebo. The primary end- point showed only a marginal non-significant reduction in syncope in the fludrocortisone group compared with the placebo group (hazard ratio 0.69, 95% CI 0.46–1.03;  P =0.069), which became more signifi- cant when the analysis was restricted to patients who achieved 0.2 mg/day dose stabilization at 2 weeks. The clinical benefit of fludrocor- tisone therapy was modest: at 12 months, 44% of patients in the flu- drocortisone arm continued to suffer syncope, a rate only slightly lower than the 60.5% rate observed in the placebo arm. In the mean- time, a similar number of patients discontinued fludrocortisone ther- apy owing to side effects, thus equating the benefit/risk ratio. Fludrocortisone should not be used in patients with hypertension or heart failure. Fludrocortisone was ineffective in a small randomized double-blind trial in children. 276\nThere is moderate evidence that fludrocortisone may be effec- tive in reducing syncopal recurrences in young patients with lownormal values of arterial BP and without comorbidities. Further research is likely to have an important impact on our confidence in the estimate of effect.\n5.2.5.2 Alpha-agonists As failure to achieve proper vasoconstriction of the peripheral ves- sels is common in reflex syncope, alpha-agonist vasoconstrictors (eti- lefrine and midodrine) have been used. Etilefrine has been studied in a large randomized placebo-controlled double-blind trial. 277   During follow-up, patients treated twice daily with etilefrine 25 mg or pla- cebo showed no difference in the frequency of syncope or the time to recurrence. Midodrine [usually 2.5–10 mg, three times daily (t.i.d)] has proved effective in small studies but none satisfied the criteria of a pivotal clinical trial. A recent systematic review of these trials 278\n1914 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................ showed that the confidence in estimates was moderate because of imprecision and publication bias. The most frequent side effects that led to discontinuation of midodrine were supine hypertension, pilo- motor reactions, and urinary problems (urinary retention, hesitancy, or urgency). The major limitation of midodrine is frequent dosing, which limits long-term compliance. Overall, these data suggest that chronic pharmacological treatment with alpha-agonists alone may be of little use in reflex syncope and that long-term treatment cannot be advised for occasional symptoms.\nThere are contrasting results from multiple trials that alpha- agonists may be effective in reducing syncopal recurrences in patients with the orthostatic form of VVS. Further research is likely to have an important impact on our confidence in the estimate.\n5.2.5.3 Beta-blockers Beta-blockers have been presumed to lessen the degree of ventricu- lar mechanoreceptor activation owing to their negative inotropic effect in reflex syncope. This theory has not been supported by the outcome of clinical trials. Beta-blockers failed to be effective in VVS in two randomized double-blind controlled trials. 279 , 280   A rationale for the use of beta-blockers in other forms of neutrally-mediated syn- cope is lacking. It should be emphasized that beta-blockers may enhance bradycardia in CSS.\nThere is sufficient evidence from multiple trials that beta- blockers are not appropriate in reducing syncopal recurrences. Desirable and undesirable effects are closely balanced.\n5.2.5.4 Other drugs Paroxetine, a selective serotonin reuptake inhibitor, was effective in one placebo-controlled trial, which included highly symptomatic patients from one institution. 281   This finding has not been confirmed in other studies and has no experimental support. Conversely, human studies with different subtypes of serotonin-receptor antago- nists demonstrated a decreased tolerance to tilt. 1 , 282   In a small randomized trial, benzodiazepine was as effective as metoprolol. 283\nA somatostatin analogue (octreotide) 284   was used in a few patients affected by orthostatic intolerance and its effect cannot be properly evaluated.\n5.2.5.5 Emerging new therapies in specific subgroups Low-adenosine phenotype . In a series of case reports, theophylline appeared effective in patients with recurrent sudden onset (pre)syn- cope who presented with the common biological characteristic of low circulating adenosine levels. 285 , 286   Theophylline is a non-selective adenosine receptor antagonist that is potentially effective when adenosine is suspected to be involved in the mechanism of syncope. An intra-patient comparison between a period with and a period without theophylline therapy, with the support of prolonged ECG monitoring, showed that symptoms disappeared and the number of prolonged asystolic pauses was impressively reduced from a median of 1.11 per month during 13 months of no treatment to 0 per month during 20 months of theophylline treatment. Low-norepinephrine phenotype.  A mismatch between sympathetic nerve activity and norepinephrine spillover is present in patients with\northostatic VVS. 287   Norepinephrine transport inhibitors (reboxetine and sibutramine) lead to a selective increase in sympathetic tone dur- ing stress by inhibiting the reuptake of norepinephrine in sympathetic neuronal synapses. In double-blind, randomized, crossover fashion, reboxetine and sibutramine block or attenuate the vasovagal reflex during tilt testing. 288   In an open-label prospective clinical study in seven very symptomatic patients who had not responded to any pre- vious treatment, sibutramine achieved 94% suppression of syncopal episodes at 6 months. 289\nGanglionic plexus ablation.  Radiofrequency ablation of vagal ganglia located close to the sinus node and AV node was reported to abolish the vagal efferent output during VVS in some observational studies and case reports. 290 , 291   However, owing to a weak rationale, small populations, weak documentation of follow-up results, procedural risks, and lack of control groups, the current evidence is insufficient to confirm the efficacy of vagal ganglia ablation.\n5.2.6 Cardiac pacing Permanent pacemaker therapy may be effective if asystole is a domi- nant feature of reflex syncope. Establishing a relationship between symptoms and bradycardia should be the goal of the clinical evalua- tion of patients with syncope and a normal baseline ECG. The efficacy of pacing depends on the clinical setting. A comparative table of results in different settings is reported in the  Supplementary Data Table 9 .  Figure  10  summarizes the recommended indication for pacing.\n5.2.6.1 Evidence from trials in suspected or certain reflex syncope and electrocardiogram-documented asystole In two observational studies, cardiac pacing reduced syncope burden in patients with documented asystolic syncope by 92 184   and 83%, 200\nbut did not prevent all syncopal events. In the randomized double-blind Third International Study on Syncope of Uncertain Etiology (ISSUE)-3 trial, 185   77 patients who had documentation, by means of ILR, of syncope with >_3-s asystole or >_6-s asystole without syncope were randomly assigned to receive either dual-chamber pac- ing with rate drop response or sensing only. During follow-up, the 2- year estimated rate of syncope recurrence was 57% with pacemaker off and 25% with pacemaker on (log-rank  P ¼ 0.039). The risk of recurrence was reduced by 57%. In the ILR subgroup of the multi- centre Syncope Unit Project (SUP) 2 study, 292   the estimated rates of syncope recurrence with pacing were 11% at 1 year, 24% at 2 years, and 24% at 3 years, and were significantly lower than the correspond- ing rates observed in untreated control patients. The above evidence supports a class IIa recommendation\nThere is sufficient evidence that dual-chamber cardiac pacing should be considered to reduce recurrence of syncope when the correlation between symptoms and ECG is established in patients  \u0004 40 years of age with the clinical features of those in the ISSUE studies.\n5.2.6.2 Evidence from trials in patients with carotid sinus syndrome The evidence supporting the benefit of cardiac pacing in patients affected by cardioinhibitory CSS is limited to a few small controlled trials and retrospective observational studies. In a review 293   including\nESC Guidelines 1915\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................. 12 studies for a total of 601 paced and 305 unpaced patients, the syn- copal recurrence rate during follow-up ranged from 0–20% with pac- ing, whereas the recurrence of syncope was always higher in untreated patients, who showed a rate between 20–60%. In a meta- analysis of the three studies 293   with a control group of untreated patients, syncope recurred in 9% of 85 paced patients and in 38% of 91 controls (relative risk 0.24, 95% CI 0.12–0.48). In a single-centre registry of 169 consecutive patients treated with pacemakers, the actuarial estimate of syncopal recurrence was 7% at 1 year, 16% at 3 years, and 20% at 5 years. 90   In the CSS subgroup of the multicentre SUP 2 study, 292   the estimated syncope recurrence rates with pacing were 9% at 1 year, 18% at 2 years, and 20% at 3 years, and were signif- icantly lower than the corresponding rates observed in untreated controls, which were 21%, 33%, and 43%, respectively. Given the similar outcome of patients with reflex spontaneous asystolic pauses and those with CSS, this Task Force voted to downgrade the recom- mendation for pacing in patients with CSS from class I (as in the 2013 ESC Pacing Guidelines 294 ) to class IIa.\nDespite the lack of large RCTs, there is sufficient evidence that dual-chamber cardiac pacing should be considered to reduce syncopal recurrences in patients affected by dominant cardi- oinhibitory CSS.\nTwo variables are well known to hamper the efficacy of pacing ther- apy in CSS: the mixed forms 93 , 98   (see also  Web Practical Instructions section 5) and the association with positivity of tilt testing. Patients who have positive tilt tests have a three-fold greater probability of syncope recurrence after dual chamber pacing than those with nega- tive tilt tests 293 , 295 ; thus, when tilt testing is positive, caution must be recommended over pacemaker implantation.\n5.2.6.3 Evidence from trials in patients with tilt-induced vasovagal syncope Effectiveness of pacing in patients with tilt-induced VVS has been studied in five multicentre RCTs. 296 – 300   When combining the results of these trials, 318 patients were evaluated; syncope recurred in 21% of the paced patients and in 44% of unpaced patients ( P  < 0.001). A meta-analysis of all studies suggested a non-significant 17% reduction in syncope from the double-blind studies, and an 84% reduction in the studies where the control group did not receive a pacemaker. 301\nIn general, pacing was ineffective in trials that enrolled patients with- out an asystolic tilt response. 299 , 300   All of these studies have limita- tions, and a direct comparison is somewhat difficult because of important differences in study design, largely focused on patient selection. Overall, in typical vasovagal populations, pacing seems to have marginal efficacy. The rationale for the efficacy of cardiac pacing is that the cardioin- hibitory reflex is dominant in some patients, as there is no role for pacing in the preventing vasodilatation and hypotension. In a substudy of the ISSUE-3 trial, 302   an asystolic response during tilt testing pre- dicted a similar asystolic form during spontaneous ILR-documented syncope, with a positive predictive value of 86%. In the tilt subgroup of the SUP 2 study, 292   among 38 patients with dominant cardioinhibi- tory reflex (with a mean asystolic pause of 22 ± 16 s) the estimated rates of syncope recurrence with pacing were 3% at 1 year, 17% at 2 years, and 23% at 3 years; these figures were significantly lower than the corresponding rates observed in untreated controls, and were similar to those observed in patients with CSS or with ECG- documented asystole. In a recent multicentre crossover RCT per- formed in 46 patients aged >40 years, affected by severely recurrent (>5 episodes during life) cardioinhibitory VVS, 303   during 24-month follow-up, syncope recurred in 4 (9%) patients treated with a dual-\nFigure 10  Summary of indications for pacing in patients with reflex syncope. CI-CSS = cardioinhibitory carotid sinus syndrome.\n1916 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ...................................................................................................................................................................... chamber pacemaker with closed-loop stimulation compared with 21 (46%) patients who had received a sham pacemaker programmed off ( P =0.0001). Adding video recording to tilt testing, Saal  et al. 205   recently showed, in patients with asystole, that asystole occurred 3 s before syncope or later in one-third of patients, in whom cardioinhi- bition was too late to have primarily caused syncope; in the other two-thirds of asystolic tilt responses, the cause must have been mainly cardioinhibition or a combination of cardioinhibition and vasodepression. The clinical presentation is probably as important as tilt test positivity when selecting patients who can benefit from cardiac pacing. The SUP 2 study population was characterized by higher mean age, history of recurrent syncope beginning in middle or older age, and frequent injuries, probably due to presentation without warning. 292\nOwing to the contrasting results of the randomized trials, the estimated benefit of dual-chamber pacing in cardioinhibitory tilt-positive patients is weak. Divergence of opinion exists among experts. Further research is very likely to have an important impact on recommendations. Conversely, there is strong consensus that pacing cannot be offered to patients with non-cardioinhibitory tilt-positive response, and further tests (e.g. ILR) are warranted to document the mechanism of the spontaneous reflex.\n5.2.6.4 Evidence from trials in patients with adenosine-sensitive syncope Under this term, classified as a non-classical form of reflex syn- cope in  Table  3 , different clinical conditions are included, which have a supposed role of adenosine in the genesis of syncope in common. A new clinical entity, called idiopathic AV block, has recently been described in patients with a long history of syncope and in whom paroxysmal AV block could be recorded at the time of syn- cope recurrence. 5   These patients had an otherwise normal heart and no sign of conduction disease on ECG and EPS; they had very low plasma adenosine levels and a high induction rate of transient complete heart block during exogenous injections of adenosine. No syncope recurrence was observed after permanent cardiac pacing over very long periods of follow-up and there was no per- manent AV block. Similarly, the entity of ‘ low-adenosine syncope ’ has recently been described in patients who have an otherwise unexplained syncope with sudden onset without prodrome, a normal heart, and normal ECG. 4   The clinical, laboratory, and biological features of these patients are similar to those observed in patients affected by idiopathic paroxysmal AV block. Unlike in VVS, tilt testing is usually negative. 4 , 226   No syncope recurrence was observed after permanent cardiac pacing in 10 patients who had ECG documentation of asystolic pause due to sinus arrest or AV block. 286\nIn a small multicentre trial 227   performed in 80 highly selected eld- erly patients with unexplained unpredictable syncope who had a pos- itive response to intravenous injection of a bolus of 20 mg of ATP,\ndual-chamber cardiac pacing significantly reduced the 2-year syncope recurrence rate from 69% in the control group to 23% in the active group.\nThere is weak evidence that dual-chamber cardiac pacing may be useful in reducing recurrences of syncope in patients with the clinical features of adenosine-sensitive syncope. The documentation of possible bradyarrhythmia in sponta- neous syncope remains the preferred eligibility criterion for pacing.\n5.2.6.5 Choice of pacing mode In CSS, a few small controlled studies 304 , 305   and one registry 306\nshowed that dual-chamber pacing is better than the single chamber ventricular mode in counteracting BP fall during CSM and in prevent- ing symptom recurrences. Even if the quality of evidence is weak, dual-chamber pacing is widely preferred in clinical practice. In patients with VVS, dual-chamber pacing was used mostly with a rate drop response feature that instituted rapid dual-chamber pacing if the device detected a rapid decrease in HR. A compari- son between dual-chamber closed-loop stimulation and conven- tional dual-chamber pacing has been performed by means of a crossover design in two small studies; these studies showed fewer syncope recurrences with closed-loop stimulation, both in the acute setting during repeated tilt testing 307   and during 18-month clinical follow-up. 308\n5.2.6.6 Selection of patients for pacing and proposed algorithm The fact that pacing is effective does not mean that it is always neces- sary. In patients with reflex syncope, cardiac pacing should be the last choice and should only be considered in highly selected patients, i.e. those >_40 years of age (mostly >60 years), affected by severe forms of reflex syncope with frequent recurrences associated with a high risk of injury, often due to the lack of prodrome. 186   While there is growing scepticism over the diagnostic accuracy of tilt testing for syncope diagnosis, emerging evidence supports the use of tilt testing for the assessment of reflex  hypotensive susceptibility 132 , which may be considered to identify patients with an associated hypotensive response who would be less likely to respond to permanent cardiac pacing (see section 4.2.2.2). In a meta-analysis 309   of individual patient data from four studies performed in patients with asystolic reflex syncope documented by an ILR, the estimated 3-year recurrence rate of syncope was 2% (95% CI ± 4%) in tilt-negative patients and 33% (95% CI ± 20%) in tilt-positive patients; a positive tilt test response was the only significant predictor of syncope recurrence with a hazard ratio of 4.3. Patients with hypotensive susceptibility should need measures directed to counteract hypotensive suscepti- bility in addition to cardiac pacing, e.g. the discontinuation/reduction of hypotensive drugs and the administration of fludrocortisone or midodrine. The algorithm shown in  Figure  11  has recently been prospectively validated in a multicentre pragmatic study, which showed a low recurrence rate of syncope with pacing of 9% at 1 year and 15% at 2 years, significantly lower than the 22% and 37%, respectively, observed in unpaced controls. 186\nESC Guidelines 1917\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\nTreatment of reﬂex syncope\nRecommendations Class a Level b\nEducation and lifestyle modiﬁcations\nExplanation of the diagnosis, the provision of reassurance, and explanation of the risk of recurrence and the avoidance of\ntriggers and situations are indicated in all patients.  Supplementary Data Table 10 I B\nDiscontinuation/reduction of hypotensive therapy\nModiﬁcation or discontinuation of hypotensive drug regimen should be considered in patients with vasodepressor syncope, if possible. 260 – 262 IIa B\nPhysical manoeuvres\nIsometric PCM should be considered in patients with prodromes who are <60 years of age. 119 – 121 , 263 , 264 IIa B\nTilt training may be considered for the education of young patients. 265 – 272 IIb B\nPharmacological therapy\nFludrocortisone may be considered in young patients with the orthostatic form of VVS, low–normal values of arterial BP,\nand the absence of contraindication to the drug. 275 IIb B\nMidodrine may be considered in patients with the orthostatic form of VVS. 278 IIb B\nBeta-adrenergic blocking drugs are not indicated. 279 , 280 III A\nCardiac pacing\nCardiac pacing should be considered to reduce syncopal recurrences in patients aged >40 years, with spontaneous docu-\nmented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest, AV block, or the combina-\ntion of the two. 184 , 185 , 200 , 292\nIIa B\nCardiac pacing should be considered to reduce syncope recurrence in patients with cardioinhibitory carotid sinus syn-\ndrome who are >40 years with recurrent frequent unpredictable syncope. 90 , 292 , 293 IIa B\nCardiac pacing may be considered to reduce syncope recurrences in patients with tilt-induced asystolic response who are\n>40 years with recurrent frequent unpredictable syncope. 292 , 297 , 298 , 303 IIb B\nCardiac pacing may be considered to reduce syncope recurrences in patients with the clinical features of adenosine-sensi- tive syncope. 5 , 227 , 286 IIb B\nCardiac pacing is not indicated in the absence of a documented cardioinhibitory reﬂex. 299 , 300 III B\nAdditional advice and clinical perspectives •   In general, no therapy can completely prevent syncope recurrence during long-term follow-up. A decrease of the syncope burden is a reasonable goal of therapy. •   The fact that pacing may be effective does not mean that it is also always necessary. It must be emphasized that the decision to implant a pace-\nmaker needs to be made in the clinical context of a benign condition that frequently affects young patients. Thus, cardiac pacing should be limited to a highly selected small proportion of patients affected by severe reﬂex syncope. Patients suitable for cardiac pacing are older with a history of\nrecurrent syncope beginning in middle or older age and with frequent injuries, probably due to presentation without warning. Syncope recur-\nrence is still expected to occur despite cardiac pacing in a minority of patients. •   Tilt test response is the strongest predictor of pacemaker efﬁcacy. 309  Patients with a negative tilt test response will have a risk of syncope recur-\nrence of as low as that observed in patients paced for intrinsic AV block. Further research is very unlikely to change the conﬁdence in the esti-\nmate of effect. On the contrary, patients with a positive tilt test response will have a higher risk of recurrence of syncope with a large conﬁdence range, which makes any estimate of the beneﬁt of pacing uncertain. Further research is warranted.\nAV = atrioventricular; BP = blood pressure; PCM = physical counter-pressure manoeuvres; VVS = vasovagal syncope. a Class of recommendation. b Level of evidence.\n1918 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ..................................................... 5.3 Treatment of orthostatic hypotension and orthostatic intolerance syndromes Current management strategies for OH are summarized in  Figure  12 .\n5.3.1 Education and lifestyle measures Education regarding the nature of the condition in conjunction with the lifestyle advice outlined in section 5.2.1 can markedly improve ortho- static symptoms, even though the rise in BP is relatively small (10–15 mmHg); raising standing BP to just within the autoregulatory zone can make a substantial functional difference. Ambulatory BP recordings may be helpful in identifying abnormal diurnal patterns. These recordings may also help identify supine or nocturnal hypertension in treated patients.\n5.3.2 Adequate hydration and salt intake The expansion of extracellular volume is an important goal. In the absence of hypertension, patients should be instructed to have a sufficient salt and water intake, targeting 2–3 L of fluids per day and 10 g of sodium\nchloride. 310   Rapid ingestion of cool water is reported to be effective in combating orthostatic intolerance and postprandial hypotension. 311\n5.3.3 Discontinuation/reduction of vasoactive drugs Several studies that have evaluated the association of vasoactive drugs (i.e. any antihypertensive agents, nitrates, diuretics, neuroleptic antidepressants, or dopaminergic drugs) with OH and falls have yielded contrasting results. 312   However, intensely prescribed antihypertensive therapy can increase the risk of OH. Intensive anti- hypertensive treatment can be defined as higher doses of antihyper- tensive medications, an increased number of antihypertensive drugs, or lowering BP to a target <140/90 mmHg. The total number of BP-lowering medications 313   or the use of three or more antihypertensive drugs may be a significant predictor of OH. 314\nAngiotensin-converting enzyme inhibitors, angiotensin receptors blockers, and calcium channel blockers are less likely to be associated with OH compared with beta-blockers and thiazide diuretics. 315 – 318\nNo\nNo\nNo\nNo\nAsystolic tilt testing?\nFigure 11  Decision pathway for cardiac pacing in patients with reflex syncope. CI-CSS = cardioinhibitory carotid sinus syndrome; CSM = carotid sinus massage; DDD PM = dual-chamber pacemaker; ILR = implantable loop recorder.\nESC Guidelines 1919\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .............................................................................................. The principal treatment strategy in drug-induced autonomic failure is eliminating the offending agent. The quality of evi- dence is moderate. Longer-term future RCTs are likely to have an important impact on determining the net risk 2 benefit ratio of the withdrawal of culprit medications.\n5.3.4 Counter-pressure manoeuvres PCM such as leg crossing and squatting should be encouraged in patients with warning symptoms who are able to perform them. 319\n5.3.5 Abdominal binders and/or support stockings Gravitational venous pooling in older patients can be treated with abdominal binders or compression stockings. 23 , 320 , 321\n5.3.6 Head-up tilt sleeping Sleeping with the head of the bed elevated (>10 degrees) prevents nocturnal polyuria, maintains a more favourable distribution of body fluids, and ameliorates nocturnal hypertension. 104 , 322 , 323\n5.3.7 Midodrine The alpha-agonist midodrine is a useful addition to first-line treatment in patients with chronic autonomic failure. It cannot be regarded as a cure, nor is it helpful in all affected patients, but it is very useful in some. There is no doubt that midodrine increases BP both in the supine and upright posture, and ameliorates the symptoms of OH. Midodrine (2.5–10 mg t.i.d) was shown to be effective in three randomized placebo-controlled trials. 324 – 326\nThe desirable effects of midodrine outweigh the undesirable effects. The quality of evidence is moderate and further research is likely to have an important impact on the estimate of benefit.\n5.3.8 Fludrocortisone Fludrocortisone (0.1–0.3 mg once daily) is a mineralocorticoid that stimulates renal sodium retention and expands fluid volume. 327   The evidence in favour of fludrocortisone is from two small observational studies (in combination with head-up sleeping) and one double-blind trial in 60 patients; the observational studies showed haemodynamic benefit and, in the trial, treated patients were less symptomatic with higher BP. 322 , 327 , 328\nThe desirable effects of fludrocortisone outweigh the undesirable effects. The quality of evidence is moderate and further research is likely to have an important impact on the estimate of benefit.\n5.3.9 Additional therapies Additional and less frequently used treatments, alone or in combina- tion, include desmopressin in patients with nocturnal polyuria, octreotide in postprandial hypotension, erythropoietin in anaemia, pyridostigmine, the use of walking sticks, frequent small meals, and the judicious exercise of leg and abdominal muscles, especially swim- ming. Their efficacy is less established. 104\n5.3.10 Emerging new pharmacological therapy in specific subgroups Droxidopa, a precursor of norepinephrine, is a centrally and periph- erally acting alpha/beta-agonist approved by the US Food and Drug Administration for the treatment of symptomatic neurogenic OH. Droxidopa has recently been investigated for the treatment of neu- rogenic OH in four short-term RCTs 329 – 332   with a total of 485 patients. They showed a modest increase in standing systolic BP and the symptom benefit of droxidopa over placebo regarding some items of quality of life after 2 weeks of treatment, but its benefit was\nFigure 12  Schematic practical guide for the treatment of orthostatic hypotension.\n1920 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .........................................................................................................................................................................\nlost after 8 weeks. 333   Thus, current evidence is insufficient to confirm the efficacy of droxidopa for long-term use.\n",
      "keywords": [
        "antihypertensive",
        "calcium channel",
        "should be considered",
        "contraindication",
        "older",
        "class i",
        "vasovagal",
        "reflex",
        "recurrent",
        "bradycardia",
        "these",
        "sudden cardiac death",
        "management",
        "electrocardiogram",
        "pacemaker",
        "systolic",
        "unpredictable",
        "age",
        "course",
        "tilt test",
        "orthostatic",
        "hypertension",
        "cope",
        "scd",
        "blood pressure",
        "risk stratification",
        "syncope",
        "disabling",
        "icd",
        "carotid"
      ],
      "tables": [
        {
          "title": "1912 ESC Guidelines",
          "page_number": 29,
          "content": " |  | \n |  | \n |  | \n | Figure 8 General framework of treatment is based on risk stratification and the identification of specific mechanisms when possible. ARVC | =\n;\n | arrhythmogenic right ventricular cardiomyopathy; CAD = coronary artery disease; DCM = dilated cardiomyopathy; ECG = electrocardiographic\nHCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter defibrillator; LQTS = long QT syndrome; SCD = sudden cardiac death. | \n |  | ",
          "bbox": [
            43.369998931884766,
            59.811859130859375,
            545.3655124240452,
            362.66497802734375
          ],
          "function_potential": "raw"
        },
        {
          "title": "1912 ESC Guidelines",
          "page_number": 29,
          "content": " | Table 9 Expected syncope recurrence rates with a permanent pacemaker in different clinical settings (for more\ndetails see Supplementary Data Table 9).\n | \n | Clinical setting Expected 2-year syncope recurrence rate\nwith cardiac pacing\nSyncope due to established bradycardia and absence of hypotensive mechanism High efficacy (<5% recurrence rate)\n_\nSyncope due to established bradycardia and associated hypotensive mechanism Moderate efficacy (5–25% recurrence rate)\nSyncope due to suspected bradycardia and associated hypotensive mechanism Low efficacy (>25% recurrence rate)\n | ",
          "bbox": [
            43.369998931884766,
            394.0159912109375,
            545.3655124240452,
            529.3419799804688
          ],
          "function_potential": "raw"
        },
        {
          "title": "1912 ESC Guidelines",
          "page_number": 29,
          "content": " | Clinical setting | Expected 2-year syncope recurrence rate\nwith cardiac pacing\n | Syncope due to established bradycardia and absence of hypotensive mechanism | High efficacy (<5% recurrence rate)\n_\n | Syncope due to established bradycardia and associated hypotensive mechanism | Moderate efficacy (5–25% recurrence rate)\n | Syncope due to suspected bradycardia and associated hypotensive mechanism | Low efficacy (>25% recurrence rate)",
          "bbox": [
            49.379828861781526,
            431.5468994140625,
            535.8654663085938,
            516.6992950439453
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 1913",
          "page_number": 30,
          "content": " |  | \n |  | \n |  | \n | Figure 9 Schematic practical decision pathway for the first-line management of reflex syncope (based on patient’s history and tests) according to | \n | age, severity of syncope, and clinical forms. Younger patients are those aged <40 years while older patients are >60 years, with an overlap between 40\nand 60 years. Severity of reflex syncope is defined in the text. The duration of prodrome is largely subjective and imprecise. A value of <5 s distinguishes\n_\narrhythmic from reflex syncope49; in patients without structural heart disease, a duration >10 s can distinguish reflex syncope from cardiac syncope.38\nIn practice, the prodrome is ‘absent or very short’ if it does not allow patients enough time to act, such as to sit or lie down. The heading’ low BP phe-\nnotype’ identifies patients with chronic low BP values (in general, systolic around 110 mmHg, who have a clear history of orthostatic intolerance and\northostatic VVS). The group ‘dominant cardioinhibition‘ identifies patients in whom clinical features and results of tests suggest that sudden cardioinhibi-\ntion is mainly responsible for syncope. One such clue is lack of prodrome, so patients without prodromes may, after analysis, fall into this category. | \n | Remark: | \n | \u0003 Overlap between subgroups is expected. | \n | \u0003 In selected cases, pacing may be used in patients aged <40 years. This Task Force cannot give recommendations due to the lack of\nsufficient evidence from studies. | \n | \u0003 In selected cases, fludrocortisone may be used in patients aged >60 years. This Task Force cannot give recommendations due to\nthe lack of sufficient evidence from studies. | \n | \u0003 Midodrine can be used at any age even if existing studies were performed in young patients. | \n | \u0003 Patients with short or no prodrome should continue investigations to identify the underlying mechanism and guide subsequent\ntherapy. | \n | \u0003 Sometimes an ILR strategy should also be considered in patients aged <40 years. | \n | BP = blood pressure; ILR = implantable loop recorder; VVS = vasovagal syncope. | \n | aSpontaneous or provoked by, sequentially, carotid sinus massage, tilt testing, or ILR. | \n |  | ",
          "bbox": [
            47.904998779296875,
            59.811859130859375,
            552.4721069335938,
            630.1419677734375
          ],
          "function_potential": "raw"
        },
        {
          "title": "1916 ESC Guidelines",
          "page_number": 33,
          "content": " |  | \n |  | \n |  | \n | Figure 10 Summary of indications for pacing in patients with reflex syncope. CI-CSS = cardioinhibitory carotid sinus syndrome. | \n |  | ",
          "bbox": [
            43.369998931884766,
            59.81117248535156,
            547.9371032714844,
            322.8659973144531
          ],
          "function_potential": "raw"
        },
        {
          "title": "1918 ESC Guidelines",
          "page_number": 35,
          "content": " | Treatment of reflex syncope |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Education and lifestyle modifications |  |  | \n |  | Explanation of the diagnosis, the provision of reassurance, and explanation of the risk of recurrence and the avoidance of\ntriggers and situations are indicated in all patients. Supplementary Data Table 10 | I | B | \n |  | Discontinuation/reduction of hypotensive therapy |  |  | \n |  | Modification or discontinuation of hypotensive drug regimen should be considered in patients with vasodepressor syncope,\nif possible.260–262 | IIa | B | \n |  | Physical manoeuvres |  |  | \n |  | Isometric PCM should be considered in patients with prodromes who are <60 years of age.119–121,263,264 | IIa | B | \n |  | Tilt training may be considered for the education of young patients.265–272 | IIb | B | \n |  | Pharmacological therapy |  |  | \n |  | Fludrocortisone may be considered in young patients with the orthostatic form of VVS, low–normal values of arterial BP,\nand the absence of contraindication to the drug.275 | IIb | B | \n |  | Midodrine may be considered in patients with the orthostatic form of VVS.278 | IIb | B | \n |  | Beta-adrenergic blocking drugs are not indicated.279,280 | III | A | \n |  | Cardiac pacing |  |  | \n |  | Cardiac pacing should be considered to reduce syncopal recurrences in patients aged >40 years, with spontaneous docu-\nmented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest, AV block, or the combina-\ntion of the two.184,185,200,292 | IIa | B | \n |  | Cardiac pacing should be considered to reduce syncope recurrence in patients with cardioinhibitory carotid sinus syn-\ndrome who are >40 years with recurrent frequent unpredictable syncope.90,292,293 | IIa | B | \n |  | Cardiac pacing may be considered to reduce syncope recurrences in patients with tilt-induced asystolic response who are\n>40 years with recurrent frequent unpredictable syncope.292,297,298,303 | IIb | B | \n |  | Cardiac pacing may be considered to reduce syncope recurrences in patients with the clinical features of adenosine-sensi-\ntive syncope.5,227,286 | IIb | B | \n |  | Cardiac pacing is not indicated in the absence of a documented cardioinhibitory reflex.299,300 | III | B | \n |  | Additional advice and clinical perspectives\n• In general, no therapy can completely prevent syncope recurrence during long-term follow-up. A decrease of the syncope burden is a reasonable\ngoal of therapy.\n• The fact that pacing may be effective does not mean that it is also always necessary. It must be emphasized that the decision to implant a pace-\nmaker needs to be made in the clinical context of a benign condition that frequently affects young patients. Thus, cardiac pacing should be limited\nto a highly selected small proportion of patients affected by severe reflex syncope. Patients suitable for cardiac pacing are older with a history of\nrecurrent syncope beginning in middle or older age and with frequent injuries, probably due to presentation without warning. Syncope recur-\nrence is still expected to occur despite cardiac pacing in a minority of patients.\n• Tilt test response is the strongest predictor of pacemaker efficacy.309 Patients with a negative tilt test response will have a risk of syncope recur-\nrence of as low as that observed in patients paced for intrinsic AV block. Further research is very unlikely to change the confidence in the esti-\nmate of effect. On the contrary, patients with a positive tilt test response will have a higher risk of recurrence of syncope with a large confidence\nrange, which makes any estimate of the benefit of pacing uncertain. Further research is warranted. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | AV = atrioventricular; BP = blood pressure; PCM = physical counter-pressure manoeuvres; VVS = vasovagal syncope.\naClass of recommendation. |  |  |  | \n | bLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            59.81097412109375,
            542.9563759251645,
            725.1589965820312
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 1919",
          "page_number": 36,
          "content": " |  | \n | No\nNo\nAsystolic\ntilt testing?\nNo\nNo | \n |  | \n | Figure 11 Decision pathway for cardiac pacing in patients with reflex syncope. CI-CSS = cardioinhibitory carotid sinus syndrome; CSM = carotid | \n | sinus massage; DDD PM = dual-chamber pacemaker; ILR = implantable loop recorder. | \n |  | ",
          "bbox": [
            47.904998779296875,
            51.87416076660156,
            552.4721069335938,
            507.7419738769531
          ],
          "function_potential": "raw"
        },
        {
          "title": "1920 ESC Guidelines",
          "page_number": 37,
          "content": " |  | \n |  | \n |  | \n | Figure 12 Schematic practical guide for the treatment of orthostatic hypotension. | \n |  | ",
          "bbox": [
            43.369998931884766,
            59.811859130859375,
            547.9371032714844,
            348.9449768066406
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 1921",
          "page_number": 38,
          "content": " | Treatment of orthostatic hypotension |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Explanation of the diagnosis, the provision\nof reassurance, and explanation of the risk\nof recurrence and the avoidance of triggers\nand situations are indicated in all patients. | I | C | \n |  | Adequate hydration and salt intake are\nindicated.310,311 | I | C | \n |  | Modification or discontinuation of hypoten-\nsive drug regimens should be\nconsidered.312–318 | IIa | B | \n |  | Isometric PCM should be considered.319 | IIa | C | \n |  | Abdominal binders and/or support stockings\nto reduce venous pooling should be\nconsidered.23,320,321 | IIa | B | \n |  | Head-up tilt sleeping (>10 degrees) to\nincrease fluid volume should be\nconsidered.104,322,323 | IIa | C | \n |  | Midodrine should be considered if symp-\ntoms persist.324–326 | IIa | B | \n |  | Fludrocortisone should be considered if\nsymptoms persist.322,327,328 | IIa | C | \n |  | Additional advice and clinical perspectives\n• In individuals with established OH and risk factors for falls,\naggressive BP-lowering treatment should be avoided; their\ntreatment targets should be revised to a systolic BP value of\n140–150 mmHg and medication withdrawal should be\nconsidered.\n• The BP-lowering agents (angiotensin-converting enzyme\ninhibitors, angiotensin receptor blockers, and calcium channel\nblockers) should be used preferentially, especially among\npatients at high risk of falls, as diuretics and beta-blockers are\nassociated with OH and falls and should be avoided in at-risk\nindividuals. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | BP = blood pressure; OH = orthostatic hypotension; PCM = physical counter-\npressure manoeuvres. |  |  |  | \n | aClass of recommendation.\nbLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            47.904998779296875,
            59.81097412109375,
            284.0860642653245,
            605.9339599609375
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "26",
      "title": "5.4 Cardiac arrhythmias as the primary cause 5.4.1 Syncope due to intrinsic sinoatrial or atrioventricular conduction system disease Current management strategies in patients with syncope due to intri",
      "start_page": 38,
      "end_page": 41,
      "content": "5.4.1.1 Sinus node disease In general, cardiac pacemaker therapy is indicated and has proved effective in intrinsic sinus node disease when intermittent sinus arrest or sinoatrial block has been demonstrated to account for syncope by means of ECG documentation during spontaneous syncope. 334 – 338\nA frequent situation is that of patients who have prolonged sinus pause following the termination of tachycardia in bradycar- dia-tachycardia syndrome due to the abnormally prolonged time needed for the recovery of automaticity by a diseased sinus node. Permanent pacing does not affect survival.\nWhen the correlation between symptoms and ECG is estab- lished, there is general consensus that cardiac pacing is effec- tive and useful for symptom relief. In the absence of the above situations, despite adequate pacing, syn- cope recurs in approximately 15–28% of patients at 5 years 339 – 341\n(see  Supplementary Data Table 9 ). This is due to the frequent associa- tion of a vasodepressor reflex mechanism with sinus node disease. In patients with sinus node disease and syncope, carotid sinus hypersen- sitivity and a positive response to tilt are present in <_50% of patients. Thus, an increased susceptibility to neurally mediated bradycardia/ hypotension is often the cause of syncope. 135 , 136   A reflex mechanism of syncope fits well with the unpredictable natural history of syncope recurrence. Physicians should be aware that effectiveness of therapy is not well documented in such cases. From a practical perspective, car- diac pacing may be a reasonable solution in patients affected by sinus node disease, who have had documentation of an asymptomatic ven- tricular pause >3 s (with exceptions for young trained persons, during sleep, and medicated patients), when a competitive diagnosis, i.e. hypotension, can be ruled out. 294   An abnormal SNRT enhances the probability of efficacy of cardiac pacing (see section 4.2.6.1). 210 – 212\nWhen the correlation between symptoms and ECG is not established, cardiac pacing may be reasonable in patients with intrinsic sinus node disease, syncope, and documentation of asymptomatic pause(s). The elimination of drugs that may exacerbate or unmask an underly- ing susceptibility to bradycardia is an important element in preventing syncope recurrence. Percutaneous cardiac ablative techniques for the control of atrial tachyarrhythmia have become of increasing importance in selected patients with the bradycardia-tachycardia form of sick sinus syndrome, but are infrequently used for the pre- vention of syncope.\n5.4.1.2 Atrioventricular conduction system disease Cardiac pacing is the treatment of syncope associated with sympto- matic AV block ( Figure  13 ). Although formal RCTs of pacing in third- or second-degree type 2 AV block have not been performed, some observational studies suggest that pacing is highly effective in prevent- ing syncope recurrences when AV block is documented. Langenfeld et al. 341   observed a decline in the rate of syncope from 44 to 3.4% over 5-year follow-up in 115 patients paced for AV block; the recur- rence rate was 7% in the subgroup with syncope before pacemaker implantation. More recently, Sud  et al. 200   reported no syncope recur- rence, and Aste  et al. 255   reported a recurrence of 1% at 5 years after pacemaker implantation among 73 patients with documented\nTreatment of orthostatic hypotension\nRecommendations Class a Level b\nExplanation of the diagnosis, the provision\nof reassurance, and explanation of the risk\nof recurrence and the avoidance of triggers and situations are indicated in all patients.\nI C\nAdequate hydration and salt intake are\nindicated. 310 , 311 I C\nModiﬁcation or discontinuation of hypoten- sive drug regimens should be\nconsidered. 312 – 318\nIIa B\nIsometric PCM should be considered. 319 IIa C\nAbdominal binders and/or support stockings\nto reduce venous pooling should be considered. 23 , 320 , 321\nIIa B\nHead-up tilt sleeping (>10 degrees) to\nincrease ﬂuid volume should be\nconsidered. 104 , 322 , 323\nIIa C\nMidodrine should be considered if symp-\ntoms persist. 324 – 326 IIa B\nFludrocortisone should be considered if\nsymptoms persist. 322 , 327 , 328 IIa C\nAdditional advice and clinical perspectives •   In individuals with established OH and risk factors for falls,\naggressive BP-lowering treatment should be avoided; their\ntreatment targets should be revised to a systolic BP value of 140–150 mmHg and medication withdrawal should be\nconsidered. •   The BP-lowering agents (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium channel\nblockers) should be used preferentially, especially among\npatients at high risk of falls, as diuretics and beta-blockers are associated with OH and falls and should be avoided in at-risk\nindividuals.\nBP = blood pressure; OH = orthostatic hypotension; PCM = physical counter- pressure manoeuvres. a Class of recommendation. b Level of evidence.\nESC Guidelines 1921\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ....................................................................................... persistent or intermittent documented AV block (see  Supplementary Data Table 9 ).\n5.4.1.3 Bundle branch block and unexplained syncope The presence of bifascicular BBB suggests that the cause of syncope may be complete heart block. Nevertheless, less than half of the patients with bifascicular BBB and syncope will have a final diagnosis of AV block, a similar percentage will have a final diagnosis of reflex syncope, and, in approximately 15%, the cause will remain unex- plained at the end of a complete workup. 342   In addition, among patients receiving an ILR, approximately half remained free of syn- cope for >2 years after the implantation. 187 , 188 , 342 , 343   Conversely, implantation of a pacemaker without documentation of AV block (empirical pacing) exposed patients to the risk of recurrence of syn- cope in about one-quarter of cases during long-term follow-up and was unnecessary in another half. 217 , 344   Thus, only one in four pace- makers will finally be appropriate. Finally, pacemaker treatment has not been proven to have a survival benefit. The above considerations justify a class IIb indication in the ESC Guidelines on pacing. 294\nTo overcome the above problems, ESC Guidelines on pacing 294 — in patients with LVEF >35%—recommend a strategy of EPS followed by ILR if the EPS findings are unremarkable. With this strategy, a pace- maker was implanted in approximately half of the patients and these patients had syncope recurrence after pacemaker implantation in 0–7% of cases 188 , 217 . This strategy was safe; however, this Task Force recognizes that in the ‘real world’, an empirical pacemaker may be acceptable in selected patients at high risk of traumatic recurrence (e.g. elderly patients with unpredictable syncopes) and that an individ- ual risk–benefit evaluation is warranted ( Figure  14 ).\nEven if the quality of evidence is moderate, there is strong con- sensus that in patients with bifascicular BBB with a positive EPS or documentation of paroxysmal AV block during prolonged ECG monitoring, cardiac pacing is highly effective in preventing syncope recurrence. The evidence of efficacy of empirical pac- ing strategy is weak and the estimate of benefit is uncertain. Although syncope is not associated with an increased incidence of sud- den death in patients with preserved cardiac function, a high incidence of total deaths (about one-third sudden) was observed in patients with BBB and heart failure, previous myocardial infarction, or low ejection fraction. 345 – 347   Indeed, the high total and sudden mortality seems to be mainly related to underlying structural heart disease and ventricular tachyarrhythmias. In this latter situation, syncope is a risk factor, rather than the cause, of death. 218   Unfortunately, ventricular programmed stimulation does not seem to identify these patients correctly, and the finding of inducible ventricular arrhythmia (VA) should therefore be interpreted with caution. 345 , 346   Therefore, an implantable cardioverter defibrillator (ICD) or a cardiac resynchronization therapy defibrillator is indicated in patients with BBB, congestive heart failure, or previous myocardial infarction and depressed systolic function for the preven- tion of SCD, but may be unable to prevent the recurrence of syncope, which is often due to non-arrhythmic causes such as OH or vasode- pressor reflex. The strategy for the management of patients with unex- plained syncope and BBB is summarized in  Figure  14 .\n5.4.2 Syncope due to intrinsic cardiac tachyarrhythmias Current management strategies in patients with syncope due to intrinsic cardiac tachyarrhythmia are summarized in  Figure  15 .\n° °\nFigure 13  Summary of indications for pacing in patients with syncope due to intrinsic cardiac bradycardia. AF = atrial fibrillation; asympt. = asymp- tomatic; AV = atrioventricular; BBB = bundle branch block; ECG = electrocardiogram; EPS = electrophysiological study; HR = heart rate; ILR = implantable loop recorder; SB = sinus bradycardia; SND = sinus node dysfunction; sympt. = symptomatic.\n1922 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ....................... 5.4.2.1 Paroxysmal supraventricular tachycardia In patients with paroxysmal AV nodal re-entrant tachycardia, AV re- entrant tachycardia, typical atrial flutter, and ectopic tachycardia associated with syncope, catheter ablation is the first-choice treat- ment. In these patients, the role of drug therapy is limited to being a bridge to ablation or being used when ablation has failed. In patients with syncope associated with atrial fibrillation or atypical left atrial flutter, the decision should be individualized.\n5.4.2.2 Paroxysmal ventricular tachycardia Syncope due to torsade de pointes is not uncommon and is, in its acquired form, the result of drugs that prolong the QT interval. Treatment is the immediate discontinuation of the suspected drug. Catheter ablation or drug therapy is recommended in patients with syncope due to VT in the presence or absence of structural heart disease in order to prevent syncope recurrence ( Figure  15 ). Detailed guidelines regarding antiarrhythmic drug usage in patients\nFigure 14  Therapeutic algorithm for patients presenting with unexplained syncope and bundle branch block. BBB = bundle branch block; CRT-D = cardiac resynchronization therapy defibrillator; EPS = electrophysiological study; ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder; PM = pacemaker.\nFigure 15  Choice of therapy for patients presenting with syncope due to cardiac tachyarrhythmias as the primary cause. AA = antiarrhythmic; ICD = implantable cardioverter defibrillator; SVT = supraventricular tachycardia; VT = ventricular tachycardia.\nESC Guidelines 1923\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .................... with VT can be found in the 2015 ESC Guidelines for VA and the pre- vention of SCD. 46\nAn ICD is indicated in patients with syncope and depressed cardiac function, and VT or VF without correctable cause. Although ICD may not prevent syncope recurrence in these patients, 31 , 348   it is indi- cated to reduce the risk of SCD (refer to the 2015 ESC Guidelines for VA and the prevention of SCD 46 ). An ICD is also indicated in\npatients with syncope and previous myocardial infarction who have VT induced during EPS 346   (see section 4.2.6). In patients with preserved systolic function, the indication for ICD is weaker because trials have not addressed this specific issue. However, when VT causes syncope, this Task Force believes that an ICD is warranted if catheter ablation and pharmacological therapy have failed or could not be performed ( Figure  15 ).\nTreatment of syncope due to cardiac arrhythmias\nRecommendations Class a Level b\nBradycardia (intrinsic)\n",
      "keywords": [
        "primary",
        "risk factor",
        "calcium channel",
        "ejection fraction",
        "should be considered",
        "arrhythmias",
        "strategies",
        "bradycardia",
        "crt",
        "management",
        "electrocardiogram",
        "pacemaker",
        "systolic",
        "tachycardia",
        "disease",
        "orthostatic",
        "scd",
        "blood pressure",
        "cause",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "arrhythmia",
        "icd",
        "carotid",
        "atrioventricular",
        "atrial fibrillation",
        "level b",
        "cardiac",
        "elderly"
      ],
      "tables": [
        {
          "title": "1922 ESC Guidelines",
          "page_number": 39,
          "content": " |  | \n | ° ° | \n |  | \n | Figure 13 Summary of indications for pacing in patients with syncope due to intrinsic cardiac bradycardia. AF = atrial fibrillation; asympt. = asymp- | \n | tomatic; AV = atrioventricular; BBB = bundle branch block; ECG = electrocardiogram; EPS = electrophysiological study; HR = heart rate; ILR =\nimplantable loop recorder; SB = sinus bradycardia; SND = sinus node dysfunction; sympt. = symptomatic. | \n |  | ",
          "bbox": [
            43.369998931884766,
            59.811859130859375,
            547.9371032714844,
            370.7149963378906
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 1923",
          "page_number": 40,
          "content": " |  | \n |  | \n |  | \n | Figure 14 Therapeutic algorithm for patients presenting with unexplained syncope and bundle branch block. BBB = bundle branch block; CRT-D | \n | = cardiac resynchronization therapy defibrillator; EPS = electrophysiological study; ICD = implantable cardioverter defibrillator; ILR = implantable\nloop recorder; PM = pacemaker. | \n |  | ",
          "bbox": [
            48.04699897766113,
            52.15789794921875,
            552.6141052246094,
            382.7339782714844
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 1923",
          "page_number": 40,
          "content": " |  | \n |  | \n |  | \n | Figure 15 Choice of therapy for patients presenting with syncope due to cardiac tachyarrhythmias as the primary cause. AA = antiarrhythmic; | \n | ICD = implantable cardioverter defibrillator; SVT = supraventricular tachycardia; VT = ventricular tachycardia. | \n |  | ",
          "bbox": [
            48.04699897766113,
            395.7168884277344,
            552.6141052246094,
            621.9779663085938
          ],
          "function_potential": "raw"
        },
        {
          "title": "1924 ESC Guidelines",
          "page_number": 41,
          "content": " | Treatment of syncope due to cardiac arrhythmias |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Bradycardia (intrinsic) |  |  | \n |  | Cardiac pacing is indicated when there is an established relationship between syncope and symptomatic bradycardia due to:\n• Sick sinus syndrome.210–212,334–338\n• Intrinsic AV block.200,255,341 |  |  | \n |  |  | I | B | \n |  |  | I | B | \n |  | Cardiac pacing is indicated in patients with intermittent/paroxysmal intrinsic third- or second-degree AV block (including\nAF with slow ventricular conduction), although there is no documentation of a correlation between symptoms and ECGs. | I | C | \n |  | Cardiac pacing should be considered when the relationship between syncope and asymptomatic sinus node dysfunction is\nless established.135,136,210–212,339,340 | IIa | C | \n |  | Cardiac pacing is not indicated in patients when there are reversible causes for bradycardia. | III | C | \n |  | Bifascicular BBB |  |  | \n |  | Cardiac pacing is indicated in patients with syncope, BBB, and a positive EPS or ILR-documented AV block.188,217 | I | B | \n |  | Cardiac pacing may be considered in patients with unexplained syncope and bifascicular BBB.217,255,344 | IIb | B | \n |  | Tachycardia |  |  | \n |  | Catheter ablation is indicated in patients with syncope due to SVT or VT in order to prevent syncope recurrence.46 | I | B | \n |  | An ICD is indicated in patients with syncope due to VT and an ejection fraction <35%.46\n_ | I | A | \n |  | An ICD is indicated in patients with syncope and previous myocardial infarction who have VT induced during EPS.218 | I | C | \n |  | An ICD should be considered in patients with an ejection fraction >35% with recurrent syncope due to VT when catheter\nablation and pharmacological therapy have failed or could not be performed.46 | IIa | C | \n |  | Antiarrhythmic drug therapy, including rate-control drugs, should be considered in patients with syncope due to SVT or VT. | IIa | C | \n |  | Additional advice and clinical perspectives\n• The major factors predicting the efficacy of pacing in preventing syncope recurrence are an established relationship between symptoms and bra-\ndycardia and the absence of associated hypotensive susceptibility (Table 8 and Supplementary Data Table 9). When this relationship is less estab-\nlished, or some hypotensive mechanism is present, syncope can recur in a minority of patients.\n• Pacing is not indicated in unexplained syncope without evidence of any conduction disturbance.\n• Less than half of the patients with bifascicular BBB and syncope have a final diagnosis of cardiac syncope, albeit the probability is different among the types\nof BBB. We recommend conducting any useful investigation (e.g. CSM, EPS, or ILR) to provoke/document the mechanism of syncope before deciding to\nimplant a pacemaker or selecting the correct therapy.\n• Elderly patients with bifascicular BBB and unexplained syncope after a reasonable workup might benefit from empirical pacemaker implantation,\nespecially if syncope is unpredictable (with no or short prodromes) or has occurred in the supine position or during effort.\n• When indicated, ICD prevents SCD but it may be unable to prevent syncope due to VT recurrence.31,348 Thus, when syncope is due to VT\n(including when the diagnosis is established by the induction of VT during EPS), catheter ablation should be always attempted when feasible in\naddition to ICD implantation. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | AF = atrial fibrillation; AV = atrioventricular; BBB = bundle branch block; CSM = carotid sinus massage; ECG = electrocardiogram; EPS = electrophysiological study; ICD =\nimplantable cardioverter defibrillator; ILR = implantable loop recorder; SCD = sudden cardiac death; SVT = supraventricular tachycardia; VT = ventricular tachycardia. |  |  |  | \n | aClass of recommendation.\nbLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            157.32332356770834,
            543.3124027958622,
            737.4619750976562
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "27",
      "title": "Cardiac pacing is indicated when there is an established relationship between syncope and symptomatic bradycardia due to:",
      "start_page": 41,
      "end_page": 42,
      "content": "•   Sick sinus syndrome. 210 – 212 , 334 – 338 I B\n•   Intrinsic AV block. 200 , 255 , 341 I B\nCardiac pacing is indicated in patients with intermittent/paroxysmal intrinsic third- or second-degree AV block (including\nAF with slow ventricular conduction), although there is no documentation of a correlation between symptoms and ECGs. I C\nCardiac pacing should be considered when the relationship between syncope and asymptomatic sinus node dysfunction is less established. 135 , 136 , 210 – 212 , 339 , 340 IIa C\nCardiac pacing is not indicated in patients when there are reversible causes for bradycardia. III C\nBifascicular BBB\nCardiac pacing is indicated in patients with syncope, BBB, and a positive EPS or ILR-documented AV block. 188 , 217 I B\nCardiac pacing may be considered in patients with unexplained syncope and bifascicular BBB. 217 , 255 , 344 IIb B\nTachycardia\nCatheter ablation is indicated in patients with syncope due to SVT or VT in order to prevent syncope recurrence. 46 I B\nAn ICD is indicated in patients with syncope due to VT and an ejection fraction <_35%. 46 I A\nAn ICD is indicated in patients with syncope and previous myocardial infarction who have VT induced during EPS. 218 I C\nAn ICD should be considered in patients with an ejection fraction >35% with recurrent syncope due to VT when catheter\nablation and pharmacological therapy have failed or could not be performed. 46 IIa C\nAntiarrhythmic drug therapy, including rate-control drugs, should be considered in patients with syncope due to SVT or VT. IIa C\nAdditional advice and clinical perspectives •   The major factors predicting the efﬁcacy of pacing in preventing syncope recurrence are an established relationship between symptoms and bra- dycardia and the absence of associated hypotensive susceptibility ( Table  8  and  Supplementary Data Table 9 ). When this relationship is less estab- lished, or some hypotensive mechanism is present, syncope can recur in a minority of patients. •   Pacing is not indicated in unexplained syncope without evidence of any conduction disturbance. •   Less than half of the patients with bifascicular BBB and syncope have a ﬁnal diagnosis of cardiac syncope, albeit the probability is different among the types of BBB. We recommend conducting any useful investigation (e.g. CSM, EPS, or ILR) to provoke/document the mechanism of syncope before deciding to implant a pacemaker or selecting the correct therapy. •   Elderly patients with bifascicular BBB and unexplained syncope after a reasonable workup might beneﬁt from empirical pacemaker implantation, especially if syncope is unpredictable (with no or short prodromes) or has occurred in the supine position or during effort. •   When indicated, ICD prevents SCD but it may be unable to prevent syncope due to VT recurrence. 31 , 348  Thus, when syncope is due to VT (including when the diagnosis is established by the induction of VT during EPS), catheter ablation should be always attempted when feasible in addition to ICD implantation.\nAF = atrial ﬁbrillation; AV = atrioventricular; BBB = bundle branch block; CSM = carotid sinus massage; ECG = electrocardiogram; EPS = electrophysiological study; ICD = implantable cardioverter deﬁbrillator; ILR = implantable loop recorder; SCD = sudden cardiac death; SVT = supraventricular tachycardia; VT = ventricular tachycardia. a Class of recommendation. b Level of evidence.\n1924 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ........................................ 5.5 Treatment of syncope secondary to structural cardiac, cardiopulmonary, and great vessel disease Cardiac syncope is diagnosed when syncope presents in patients with severe aortic stenosis, acute myocardial infarction/ischaemia, HCM, cardiac masses (atrial myxoma, ball thrombus, etc.), pericardial dis- ease/tamponade, congenital anomalies of the coronary arteries, pros- thetic valve dysfunction, pulmonary embolus, acute aortic dissection, and pulmonary hypertension (see section 4.1.1). Structural cardiac or cardiopulmonary disease can be present in some patients with syn- cope, and its incidence increases in older patients. The mere presence of heart disease does not imply that syncope is related to the underly- ing cardiac disorder. Some of these patients have typical reflex syn- cope; in others, such as those with inferior myocardial infarction or aortic stenosis, the underlying cardiac disease may play a role in trig- gering or potentiating a reflex mechanism, and—finally—the underly- ing cardiac disease may be the substrate for conduction disturbances, supraventricular arrhythmia, or VA that causes syncope.\nEven in the absence of specific trials, there is strong consensus that with syncope secondary to structural cardiac disease, the goal of treatment is not only to prevent syncopal recurrence, but to treat the underlying disease and decrease the risk of death.\n",
      "keywords": [
        "ejection fraction",
        "should be considered",
        "older",
        "bradycardia",
        "sudden cardiac death",
        "electrocardiogram",
        "pacemaker",
        "when",
        "tachycardia",
        "there",
        "hypertension",
        "scd",
        "symptomatic",
        "relationship",
        "pulmonary hypertension",
        "syncope",
        "ventricular tachycardia",
        "aortic",
        "arrhythmia",
        "icd",
        "carotid",
        "established",
        "between",
        "cardiac",
        "elderly",
        "ecg",
        "may be considered",
        "stenosis",
        "indicated",
        "pacing"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 1925",
          "page_number": 42,
          "content": " | Implantable cardioverter defibrillator indications in\npatients with unexplained syncopea and left ventricular\nsystolic dysfunction |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classb | Levelc | \n |  | ICD therapy is recommended to reduce\nSCD in patients with symptomatic heart fail-\nure (NYHA class II–III) and LVEF <35% after\n_\n>3 months of optimal medical therapy, who\n_\nare expected to survive >1 year with good\n_\nfunctional status.46 | I | A | \n |  | An ICD should be considered in patients\nwith unexplained syncopea with systolic\nimpairment, but without a current indication\nfor ICD, to reduce the risk of sudden\ndeath.27,28,359,360 | IIa | C | \n |  | Instead of an ICD, an ILR may be considered\nin patients with recurrent episodes of unex-\nplained syncopea with systolic impairment,\nbut without a current indication for ICD. | IIb | C | \n |  | Additional advice and clinical perspectives\n• The presence of syncope increases mortality regardless of its\ncause.348 Thus, syncope is a risk factor for life-threatening\nevents.\n• The decision to implant an ICD or to complete the\ninvestigation (e.g. ILR implantation) in patients with unex-\nplained syncope depends on a global clinical evaluation\nof the patient’s conditions, the potential benefit and harm\nof such therapy, and the presence of other risk factors\nfor SCD. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder;\nLVEF = left ventricular ejection fraction; NYHA = New York Heart Association; |  |  |  | \n | SCD = sudden cardiac death.\naUnexplained syncope is defined as syncope that does not meet a class I diagnos-\ntic criterion defined in the tables of recommendations in section 4. In the pres-\nence of clinical features described in this section, unexplained syncope is\nconsidered a risk factor for ventricular tachyarrhythmias.\nbClass of recommendation.\ncLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            312.2640075683594,
            229.83352661132812,
            549.0424131196121,
            737.7449951171875
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "28",
      "title": "5.6 Treatment of unexplained syncope in patients at high risk of sudden cardiac death The underlying clinical situation is that of a patient being evaluated for ICD implantation because they are affec",
      "start_page": 42,
      "end_page": 44,
      "content": "5.6.1 Definition In general, a history of syncope in patients with structural heart disease or inheritable arrhythmia syndromes is associated with a two- to four-fold increased risk of death, 348 , 350 – 353   but varies between specific conditions. 354 – 356   Moreover, there have been very few studies on ICDs in patients with syncope associated with left ventricular dysfunction, 31 , 348   cardiomyopathy, or inheritable arrhythmia syndromes. 357   In these Guidelines, we complement previous ESC Guidelines for VA and the prevention of SCD 46   by providing a precise definition of unexplained syncope, and making recommendations for its investigation and management in differ- ent clinical settings.\n•   For this section,  ‘unexplained syncope ‘ is defined as syncope that does not meet any class I diagnostic criterion defined in the tables of recommendations in section 4. In the presence of clini- cal features described in this section, unexplained syncope is con- sidered a ‘ suspected arrhythmic syncope ’.\nWhen the mechanism of syncope is non-arrhythmic, the manage- ment of patients at high risk of SCD is the same as for patients with- out syncope.\n5.6.2 Left ventricular systolic dysfunction The benefit of an ICD to reduce the risk of death is established. Thus, patients with unexplained syncope who have an established ICD indi- cation per current Guidelines 46   must receive an ICD before, and independently of, the evaluation of the mechanism of syncope, even if the mechanism of syncope is unknown or uncertain at the end of a complete workup. While this strategy may help to prolong life, patients often remain at risk of recurrent syncope, implying a need for precise identification of the mechanism of syncope and specific treatment when possible. Few data exist concerning the prevalence and the prognostic impli- cations of unexplained syncope in unselected patients with left ven- tricular dysfunction or non-ischaemic dilated cardiomyopathy with\nImplantable cardioverter deﬁbrillator indications in patients with unexplained syncope a   and left ventricular systolic dysfunction\nRecommendations Class b Level c\nICD therapy is recommended to reduce\nSCD in patients with symptomatic heart fail-\nure (NYHA class II–III) and LVEF <_35% after >_3 months of optimal medical therapy, who\nare expected to survive >_1 year with good\nfunctional status. 46\nI A\nAn ICD should be considered in patients with unexplained syncope a   with systolic\nimpairment, but without a current indication\nfor ICD, to reduce the risk of sudden death. 27 , 28 , 359 , 360\nIIa C\nInstead of an ICD, an ILR may be considered\nin patients with recurrent episodes of unex- plained syncope a   with systolic impairment,\nbut without a current indication for ICD.\nIIb C\nAdditional advice and clinical perspectives •   The presence of syncope increases mortality regardless of its cause. 348   Thus, syncope is a risk factor for life-threatening\nevents. •   The decision to implant an ICD or to complete the investigation (e.g. ILR implantation) in patients with unex-\nplained syncope depends on a global clinical evaluation\nof the patient’s conditions, the potential beneﬁt and harm of such therapy, and the presence of other risk factors\nfor SCD.\nICD = implantable cardioverter deﬁbrillator; ILR = implantable loop recorder; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; SCD = sudden cardiac death. a Unexplained syncope is deﬁned as syncope that does not meet a class I diagnos- tic criterion deﬁned in the tables of recommendations in section 4. In the pres- ence of clinical features described in this section, unexplained syncope is considered a risk factor for ventricular tachyarrhythmias. b Class of recommendation. c Level of evidence.\nESC Guidelines 1925\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................... less severe systolic impairment who do not meet the current indica- tion for ICD. 358   Data from observational studies in selected cohorts show a high rate of occurrence of ventricular arrhythmias, ICD dis- charge, and death in patients with a history of unexplained syncope but, owing to a lack of control groups, are unable to show the benefit of an ICD. 27 , 28 , 359 , 360   This Task Force believes that an ICD should be considered in patients with unexplained syncope with systolic impair- ment but without a current indication for ICD to reduce the risk of sudden death.\n5.6.3 Hypertrophic cardiomyopathy Unexplained syncope is an independent predictor for SCD and appropriate ICD discharge. In a systematic review, the average haz- ard ratio of unexplained syncope (irrespective of definition) was 2.68 (95% CI 0.97–4.38). 361   In the largest multicentre study to date (>3600 patients with HCM), syncope was an independent predictor of the composite of SCD and ICD discharge (hazard ratio 2.05, 95% CI 1.48–2.82). 350   A prophylactic ICD is appropriate in individuals with other features indicative of a high risk of SCD that are used to estimate the 5-year risk of SCD using the HCM Risk-SCD model 245 ; they include: age, family history of SCD, maximum left ventricular wall thickness, left atrial diameter, and non-sustained VT.\n5.6.4 Arrhythmogenic right ventricular cardiomyopathy Although limited and diverse, current data suggest that unexplained syn- cope is a marker of arrhythmic risk in patients with ARVC. 46 , 351 , 362 , 363\nThe decision to implant an ICD should take into account the other known risk factors for arrhythmic events 46 : frequent non-sustained VT, family history of premature sudden death, extensive right ventricular disease, marked QRS prolongation, late gadolinium enhancement on magnetic resonance imaging (MRI) (including left ventricular involve- ment), left ventricular dysfunction, and VT induction during EPS. 46\n5.6.5 Patients with inheritable arrhythmogenic disorders 5.6.5.1 Long QT syndrome Syncopal events in long QT syndrome (LQTS) are associated with an increased risk of subsequent cardiac arrest. The annual rate of SCD in patients with untreated LQTS is around 0.9% overall and 5% for those with syncope. 352 , 364   Beta-blocker therapy substantially reduces the risk of syncope and SCD, but presentation with cardiac arrest and recur- rent syncope during beta-blocker therapy is associated with the same risk of fatal events as in untreated patients. 46   For this reason, ICD treat- ment should be considered in patients with LQTS and recurrent unex- plained syncope despite beta-blocker therapy, especially in cases of good treatment compliance, in the absence of precipitating factors, and in LQT2 and LQT3 syndromes. Left cardiac sympathetic denerva- tion should also be considered in this situation, particularly in LQT1. 46\n5.6.5.2 Brugada syndrome A history of syncope may increase the risk of arrhythmic events up to two- to three-fold compared with that in asymptomatic patients. In the largest registry (1029 patients), the incidence of arrhythmic events\nImplantable cardioverter deﬁbrillator indications in patients with unexplained syncope a   and hypertrophic cardiomyopathy\nRecommendations Class b Level c\nIt is recommended that decisions for ICD\nimplantation in patients with unexplained\nsyncope a   are made according to the ESC HCM Risk-SCD score. d,245\nI B\nInstead of an ICD, an ILR should be consid-\nered in patients with recurrent episodes of\nunexplained syncope a   who are at low risk of SCD, according to the HCM Risk-SCD\nscore. d,245\nIIa C\nAdditional advice and clinical perspectives\nThe decision to implant an ICD or to complete the investigation (e.g. ILR implantation) in patients with unexplained syncope\ndepends on a global clinical evaluation of the patient’s condition,\nthe potential beneﬁt and harm of such therapy, and the presence of other risk factors for SCD.\nESC = European Society of Cardiology; HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter deﬁbrillator; ILR = implantable loop recorder; SCD = sudden cardiac death. a Unexplained syncope is deﬁned as syncope that does not meet the class I diag- nostic criterion deﬁned in the tables of recommendations in section 4. In the presence of clinical features described in this section, unexplained syncope is con- sidered a risk factor for ventricular tachyarrhythmias. b Class of recommendation. c Level of evidence. d A web-based calculator of the HCM risk score can be found at: http://www. doc2do.com/hcm/webHCM.html. It can also be found in the ESC Pocket Guidelines App found in all app stores.\nImplantable cardioverter deﬁbrillator indications in patients with unexplained syncope a   and arrhythmogenic right ventricular cardiomyopathy\nRecommendations Class b Level c\nICD implantation may be considered in\npatients with ARVC and a history of unex- plained syncope. a, 46\nIIb C\nInstead of an ICD, an ILR should be consid-\nered in patients with recurrent episodes of\nunexplained syncope who are at low risk of SCD, based on a multiparametric analysis\nthat takes into account the other known\nrisk factors for SCD.\nIIa C\nARVC = arrhythmogenic right ventricular cardiomyopathy; ICD = implantable cardioverter deﬁbrillator; ILR = implantable loop recorder; SCD = sudden car- diac death. a Unexplained (or uncertain) syncope is deﬁned any syncope that does not meet class I diagnostic criteria deﬁned in the tables of recommendations in section 4. In the presence of clinical features described in this section, unexplained syncope is considered a risk factor for ventricular tachyarrhythmias. b Class of recommendation. c Level of evidence.\n1926 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ................... (sustained VT or VF, appropriate ICD therapy, or sudden death) in patients with Brugada syndrome was 7.7% per year in those with a history of sudden cardiac arrest, 1.9% per year with syncope, and 0.5% per year in asymptomatic patients. 353   However, in a second study, the rate of appropriate ICD shocks was similar in asymptomatic patients and in those with syncope, a difference possibly explained by patient selection and a high rate of non-arrhythmic syncope. 355\nOn balance, this Task Force believes that it is reasonable to con- sider an ICD in the case of unexplained syncope. New studies 356 , 365\npublished after the 2015 ESC Guidelines for VA and the prevention of SCD 46   showed that non-arrhythmic syncope is frequent in Brugada syndrome and appears to be more benign; thus, ICD should be avoided in patients with non-arrhythmic syncope that is established according to the definition reported in this section. ILR is increasingly used in doubtful cases to exclude a VA as the cause of syncope. 365 , 366\nThe final decision to implant an ICD in patients with Brugada syn- drome and unexplained syncope should also take into account other\nrisk factors for arrhythmic events, including spontaneous type 1 Brugada ECG pattern, family history of sudden death, VF inducibility with one or two ventricular premature beats during EPS, fractionated QRS, early repolarization in the peripheral leads, increased T peak– T end  interval, and long PR interval. 220 , 367 – 371   A drug-induced type 1 ECG pattern has a lower risk of sudden death than a spontaneous type 1 response.\n5.6.5.3 Other forms Due to a lack of studies examining unexplained syncope in other forms of inheritable arrhythmic diseases such as catecholaminergic polymor- phic VT, early repolarization syndrome, and short QT syndrome, this Task Force is unable to give specific recommendations for the investi- gation and treatment of unexplained syncope. For further information refer to the 2015 ESC Guidelines for VA and the prevention of SCD. 46\n",
      "keywords": [
        "risk factor",
        "ejection fraction",
        "should be considered",
        "family history",
        "class i",
        "affec",
        "sudden cardiac death",
        "patient",
        "systolic",
        "sudden",
        "age",
        "risk",
        "level c",
        "death",
        "scd",
        "they",
        "nyha",
        "syncope",
        "lvef",
        "high",
        "clinical",
        "arrhythmia",
        "icd",
        "mri",
        "being",
        "because",
        "cardiomyopathy",
        "ecg",
        "cardiac",
        "underlying"
      ],
      "tables": [
        {
          "title": "1926 ESC Guidelines",
          "page_number": 43,
          "content": " | Implantable cardioverter defibrillator indications in\npatients with unexplained syncopea and arrhythmogeni\nright ventricular cardiomyopathy |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classb | Levelc | \n |  | ICD implantation may be considered in\npatients with ARVC and a history of unex-\nplained syncope.a,46 | IIb | C | \n |  | Instead of an ICD, an ILR should be consid-\nered in patients with recurrent episodes of\nunexplained syncope who are at low risk of\nSCD, based on a multiparametric analysis\nthat takes into account the other known\nrisk factors for SCD. | IIa | C | \n |  |  |  |  | \n |  |  |  |  | \n | ARVC = arrhythmogenic right ventricular cardiomyopathy; ICD = implantable\ncardioverter defibrillator; ILR = implantable loop recorder; SCD = sudden car- |  |  |  | \n | diac death.\naUnexplained (or uncertain) syncope is defined any syncope that does not meet\nclass I diagnostic criteria defined in the tables of recommendations in section 4. In\nthe presence of clinical features described in this section, unexplained syncope is\nconsidered a risk factor for ventricular tachyarrhythmias.\nbClass of recommendation.\ncLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            307.72900390625,
            199.5593058268229,
            544.8042602539062,
            490.96099853515625
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "1926 ESC Guidelines",
          "page_number": 43,
          "content": " | Implantable cardioverter defibrillator indications in\npatients with unexplained syncopea and hypertrophic\ncardiomyopathy |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classb | Levelc | \n |  | It is recommended that decisions for ICD\nimplantation in patients with unexplained\nsyncopea are made according to the ESC\nHCM Risk-SCD score.d,245 | I | B | \n |  | Instead of an ICD, an ILR should be consid-\nered in patients with recurrent episodes of\nunexplained syncopea who are at low risk of\nSCD, according to the HCM Risk-SCD\nscore.d,245 | IIa | C | \n |  | Additional advice and clinical perspectives\nThe decision to implant an ICD or to complete the investigation\n(e.g. ILR implantation) in patients with unexplained syncope\ndepends on a global clinical evaluation of the patient’s condition,\nthe potential benefit and harm of such therapy, and the presence\nof other risk factors for SCD. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | ESC = European Society of Cardiology; HCM = hypertrophic cardiomyopathy;\nICD = implantable cardioverter defibrillator; ILR = implantable loop recorder; |  |  |  | \n | SCD = sudden cardiac death.\naUnexplained syncope is defined as syncope that does not meet the class I diag-\nnostic criterion defined in the tables of recommendations in section 4. In the\npresence of clinical features described in this section, unexplained syncope is con-\nsidered a risk factor for ventricular tachyarrhythmias.\nbClass of recommendation.\ncLevel of evidence.\ndA web-based calculator of the HCM risk score can be found at: http://www.\ndoc2do.com/hcm/webHCM.html. It can also be found in the ESC Pocket\nGuidelines App found in all app stores. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            43.08700180053711,
            342.08599853515625,
            280.0556335449219,
            738.708984375
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 1927",
          "page_number": 44,
          "content": " | Implantable cardioverter defibrillator indications in\npatients with unexplained syncopea and Brugada\nsyndrome |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classb | Levelc | \n |  | ICD implantation should be considered in\npatients with a spontaneous diagnostic\ntype 1 ECG pattern and a history of\nunexplained syncope.a,46,353,355,365,366 | IIa | C | \n |  | Instead of an ICD, an ILR should be consid-\nered in patients with recurrent episodes of\nunexplained syncopea who are at low risk of\nSCD, based on a multiparametric analysis\nthat takes into account the other known\nrisk factors for SCD. | IIa | C | \n |  |  |  |  | \n |  |  |  |  | \n | ECG = electrocardiogram; ICD = implantable cardioverter defibrillator; ILR =\nimplantable loop recorder; SCD = sudden cardiac death. |  |  |  | \n | aUnexplained (or uncertain) syncope is defined as any syncope that does not\nmeet the class I diagnostic criteria defined in section 4. In the presence of clinical\nfeatures described in this section, unexplained syncope is considered a risk factor\nfor ventricular tachyarrhythmias.\nbClass of recommendation.\ncLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            312.2640075683594,
            140.8819783528646,
            549.3400362454928,
            435.2879943847656
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 1927",
          "page_number": 44,
          "content": " | Implantable cardioverter defibrillator indications in\npatients with unexplained syncopea and long QT\nsyndrome |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classb | Levelc | \n |  | ICD implantation in addition to beta-blockers\nshould be considered in LQTS patients who\nexperience unexplained syncopea while\nreceiving an adequate dose of beta-blockers.46 | IIa | B | \n |  | Left cardiac sympathetic denervation should\nbe considered in patients with symptomatic\nLQTS when:\n(1) beta-blockers are not effective, not tol-\nerated, or are contraindicated;\n(2) ICD therapy is contraindicated or\nrefused; or\n(3) when patients on beta-blockers with an\nICD experience multiple shocks.46 | IIa | C | \n |  | Instead of an ICD, an ILR should be consid-\nered in patients with recurrent episodes of\nunexplained syncopea who are at low risk of\nSCD based on a multiparametric analysis\nthat takes into account the other known\nrisk factors for SCD. | IIa | C | \n |  | Additional advice\nBeta-blockers are recommended in all patients with a clinical diagno-\nsis of LQTS, with the possible exception of those with LQTS3 form. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder;\nLQTS = long QT syndrome; SCD = sudden cardiac death. |  |  |  | \n | aUnexplained (or uncertain) syncope is defined as any syncope that does not\nmeet class I diagnostic criteria defined in the tables of recommendations in sec-\ntion 4. In the presence of clinical features described in this section, unexplained\nsyncope is considered a risk factor for ventricular tachyarrhythmias.\nbClass of recommendation.\ncLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            47.904998779296875,
            150.17999267578125,
            284.76565446524785,
            601.0579833984375
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "29",
      "title": "6. Special issues",
      "start_page": 44,
      "end_page": 44,
      "content": "",
      "keywords": [
        "special",
        "issues"
      ],
      "tables": []
    },
    {
      "number": "30",
      "title": "6.1 Syncope in patients with comorbidity and frailty The approach to the assessment and management of an older patient with syncope is similar to that of other age groups; however, there are a number ",
      "start_page": 44,
      "end_page": 46,
      "content": "6.1.1 Comorbidity and polypharmacy Comorbidity influences the diagnosis of syncope and management decisions. 33 , 375   Older patients frequently have abnormal findings on more than one investigation and may have more than one possible cause of syncope. 372 , 374 , 376   Conversely, coincidental findings of\nImplantable cardioverter deﬁbrillator indications in patients with unexplained syncope a   and long QT syndrome\nRecommendations Class b Level c\nICD implantation in addition to beta-blockers\nshould be considered in LQTS patients who\nexperience unexplained syncope a   while receiving an adequate dose of beta-blockers. 46\nIIa B\nLeft cardiac sympathetic denervation should\nbe considered in patients with symptomatic\nLQTS when: (1) beta-blockers are not effective, not tol-\nerated, or are contraindicated;\n(2) ICD therapy is contraindicated or refused; or\n(3) when patients on beta-blockers with an\nICD experience multiple shocks. 46\nIIa C\nInstead of an ICD, an ILR should be consid- ered in patients with recurrent episodes of\nunexplained syncope a   who are at low risk of\nSCD based on a multiparametric analysis that takes into account the other known\nrisk factors for SCD.\nIIa C\nAdditional advice Beta-blockers are recommended in all patients with a clinical diagno-\nsis of LQTS, with the possible exception of those with LQTS3 form.\nICD = implantable cardioverter deﬁbrillator; ILR = implantable loop recorder; LQTS = long QT syndrome; SCD = sudden cardiac death. a Unexplained (or uncertain) syncope is deﬁned as any syncope that does not meet class I diagnostic criteria deﬁned in the tables of recommendations in sec- tion 4. In the presence of clinical features described in this section, unexplained syncope is considered a risk factor for ventricular tachyarrhythmias. b Class of recommendation. c Level of evidence.\nImplantable cardioverter deﬁbrillator indications in patients with unexplained syncope a   and Brugada syndrome\nRecommendations Class b Level c\nICD implantation should be considered in\npatients with a spontaneous diagnostic type 1 ECG pattern and a history of\nunexplained syncope. a , 46 , 353 , 355 , 365 , 366\nIIa C\nInstead of an ICD, an ILR should be consid-\nered in patients with recurrent episodes of unexplained syncope a   who are at low risk of\nSCD, based on a multiparametric analysis\nthat takes into account the other known risk factors for SCD.\nIIa C\nECG = electrocardiogram; ICD = implantable cardioverter deﬁbrillator; ILR = implantable loop recorder; SCD = sudden cardiac death. a Unexplained (or uncertain) syncope is deﬁned as any syncope that does not meet the class I diagnostic criteria deﬁned in section 4. In the presence of clinical features described in this section, unexplained syncope is considered a risk factor for ventricular tachyarrhythmias. b Class of recommendation. c Level of evidence.\nESC Guidelines 1927\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ....................................................... cardiovascular diagnoses such as aortic stenosis or atrial fibrillation 377\nmay not necessarily be the attributable cause of events. 378 – 380\nThe prescription of polypharmacy, cardiovascular medications, and psychotropic (neuroleptics and antidepressants) and dopaminergic drugs also increases the risk of syncope and falls. 381 – 385   Conversely, the discontinuation or reduction of hypotensive therapy reduces such risk. 260   Negative dromotropic and chronotropic medications should be carefully evaluated in older patients presenting with syncope or falls. Focal neurological events can occasionally occur due to hypoten- sion and syncope, even in patients without significant carotid artery stenosis (so called ‘ hypotensive TIA ’). Although these neurological events occur in only 6% of patients with recurrent syncope, their mis- diagnosis is particularly important because they may lead to a lowering of BP with antihypertensive medications (e.g. if focal neurology is mis- takenly attributed to vascular pathology rather than hypotension), and to a further increase of the risk of syncope and neurologic events. 386\nDespite the lack of large controlled trials and an overall mod- est quality of studies, there is strong consensus that reduction or discontinuation of hypotensive drugs and psychotropic drugs clearly outweighs the undesirable effects (e.g. complications) of high BP. Further research is likely to have an important impact on our confidence in the estimate of effect.\n6.1.2 Falls Syncopal events may be unwitnessed in over half of older patients meaning that collateral histories may not available, which makes discrim- ination between falls and syncope challenging. 387   If unwitnessed falls are not due to mechanical slips or trips (i.e. are unexplained or non- accidental), it is likely that the patient experienced a syncopal event and displayed lack of awareness for LOC ( Figure  16 ). 388 , 389   Management of falls in such circumstances is the same as that for syncope. 191 , 194 , 390\nDespite the lack of controlled trials and an overall modest quality of studies, there is strong consensus that the manage- ment of unexplained falls should be the same as that for unex- plained syncope.\n6.1.3 Cognitive assessment and physical performance tests Age-related memory impairment or more established forms of cog- nitive impairment are frequently associated with poor recall and therefore the lack of an accurate history of events. In such circum- stances, details of prodromal symptoms, whether or not LOC occurred, and symptoms after the event may be unre- liable. 373 , 389 , 391 – 394   Cognitive assessment to inform the accuracy of historical data, and general physical assessment to identify comorbid disorders that influence diagnosis and response to treatments (such as Parkinson’s disease, gait and balance abnormalities, previous stroke, and polyneuropathies, etc.), are recommended.\nDespite the lack of large controlled trials and an overall modest quality of studies, there is strong consensus that the assessment of older patients with syncope or unexplained falls may require cognitive assessment and physical performance tests in addition to syncope evaluation. Further research is likely to have an important impact on our confidence in the estimate of effect.\nFigure 16  Flow diagram for the identification of unexplained falls.\nSyncope in patients with comorbidity and frailty\nRecommendations Class a Level b\nMultifactorial evaluation and intervention is\nrecommended in older patients because more\nthan one possible cause for syncope and unex-\nplained fall may be present. 33 , 372 – 374 , 376 – 380\nI B\nCognitive assessment and physical perform-\nance tests are indicated in older patients with\nsyncope or unexplained fall. 373 , 389 , 391–394\nI C\nModiﬁcation or discontinuation of possible culprit\nmedications, particularly hypotensive drugs and\npsychotropic drugs, should be considered in older\npatients with syncope or unexplained fall. 260 , 381 – 385\nIIa B\nIn patients with unexplained fall, the same\nassessment as for unexplained syncope should\nbe considered. 191 , 194 , 387 – 390\nIIa C\nAdditional advice and clinical perspectives •   In some frail elderly patients, the rigour of assessment will depend on compliance with tests and on prognosis .  Otherwise, the evalu- ation of mobile, non-frail, cognitively normal older adults must be performed as for younger individuals. 393 , 395\n•   Orthostatic BP measurements, CSM, and tilt testing are well tol- erated, even in the frail elderly with cognitive impairment. 96 , 396 , 397\n•   Not infrequently, patients who present with unexplained falls— although orthostatic BP measurements, CSM, and tilt testing repro- duce syncope—may deny TLOC, thus demonstrating amnesia for TLOC. 388 , 389\n•   Failure of orthostatic BP to stabilize is present in up to 40% of community-dwelling people >80 years of age when BP is meas- ured using phasic BP technology. 398   Such failure of systolic BP to stabilize is a risk factor for subsequent falls and syncope. •   In the absence of a witness account, the differential diagnosis between falls, epilepsy, TIA, and syncope may be difﬁcult.\nBP = blood pressure; CSM = carotid sinus massage; TIA = transient ischaemic attack; TLOC = transient loss of consciousness. a Class of recommendation. b Level of evidence.\n1928 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ...................................................................................................................................................................... 6.2 Syncope in paediatric patients 6.2.1 Diagnostic evaluation Diagnostic evaluation in paediatric patients is similar to that in adults. Two specific conditions 399   occur in early childhood:\n•   Infantile reflex syncopal attacks (also called pallid breath-holding spells or reflex anoxic seizures), elicited by a brief unpleasant stimulus, caused by vagally mediated cardiac inhibition. •   Cyanotic breath-holding spells, characterized by stopping breathing during crying, leading to cyanosis and usually TLOC.\nCareful taking of personal and family history and a standard ECG are the most important methods of distinguishing benign reflex syncope (also including reflex anoxic seizure or breath- holding spells) from other causes. If the family history is positive, genetic causes of electrical disease of the heart should be consid- ered first. Some children with reflex syncope also have a positive family history. 400   Tilt testing seems to have high false-negative and false-positive rates and should be used with caution for the pri- mary identification of reflex syncope. Since tilt protocols com- monly used in adults may lack specificity in teenagers, in one study, a shorter tilt test duration of 10 min at 60 or 70 degrees was used and showed a specificity of >85%. 401\nIn young patients, syncope can rarely be the initial manifestation of unusual but life-threatening conditions such as LQTS, Kearns–Sayre syndrome (external ophthalmoplegia and progressive heart block), Brugada syndrome, catecholaminergic polymorphic VT, Wolff-Parkinson-White syndrome, ARVC, HCM, pulmonary arterial hypertension, myocarditis, arrhythmia after repaired congenital heart disease, and anomalous origin of a coronary artery. Some aspects of the history can suggest a cardiac origin, and should prompt cardiac evaluation.\n•   Family history: premature SCD at age <40 years and/or familial heart disease. •   Known or suspected heart disease. •   Event triggers: loud noise, fright, and/or extreme emotional stress. •   Syncope during exercise, including swimming. •   Syncope without prodromes, while supine or sleeping, or pre- ceded by chest pain or palpitations.\n6.2.2. Therapy The therapeutic approach is the same as in adults. However, it should be stressed that the effectiveness of pharmacological agents and tilt training for recurrent reflex syncope is undetermined in the absence of well-designed paediatric trials. Furthermore, even in the presence of VVS with prolonged asystole, pacemakers should be avoided due to the relatively transient and benign nature of the syndrome. 402\n",
      "keywords": [
        "risk factor",
        "antihypertensive",
        "assessment",
        "should be considered",
        "other",
        "groups",
        "older",
        "family history",
        "class i",
        "comorbidity",
        "number",
        "sudden cardiac death",
        "genetic",
        "patient",
        "management",
        "electrocardiogram",
        "systolic",
        "there",
        "age",
        "however",
        "tilt test",
        "orthostatic",
        "level c",
        "hypertension",
        "scd",
        "blood pressure",
        "transient loss of consciousness",
        "syncope",
        "aortic",
        "arrhythmia"
      ],
      "tables": [
        {
          "title": "1928 ESC Guidelines",
          "page_number": 45,
          "content": " | Syncope in patients with comorbidity and frailty |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Multifactorial evaluation and intervention is\nrecommended in older patients because more\nthan one possible cause for syncope and unex-\nplained fall may be present.33,372–374,376–380 | I | B | \n |  | Cognitive assessment and physical perform-\nance tests are indicated in older patients with\nsyncope or unexplained fall.373,389,391–394 | I | C | \n |  | Modification or discontinuation of possible culprit\nmedications, particularly hypotensive drugs and\npsychotropic drugs, should be considered in older\npatients with syncope or unexplained fall.260,381–385 | IIa | B | \n |  | In patients with unexplained fall, the same\nassessment as for unexplained syncope should\nbe considered.191,194,387–390 | IIa | C | \n |  | Additional advice and clinical perspectives\n• In some frail elderly patients, the rigour of assessment will depend\non compliance with tests and on prognosis. Otherwise, the evalu-\nation of mobile, non-frail, cognitively normal older adults must be\nperformed as for younger individuals.393,395\n• Orthostatic BP measurements, CSM, and tilt testing are well tol-\nerated, even in the frail elderly with cognitive impairment.96,396,397\n• Not infrequently, patients who present with unexplained falls—\nalthough orthostatic BP measurements, CSM, and tilt testing repro-\nduce syncope—may deny TLOC, thus demonstrating amnesia for\nTLOC.388,389\n• Failure of orthostatic BP to stabilize is present in up to 40% of\ncommunity-dwelling people >80 years of age when BP is meas-\nured using phasic BP technology.398 Such failure of systolic BP to\nstabilize is a risk factor for subsequent falls and syncope.\n• In the absence of a witness account, the differential diagnosis\nbetween falls, epilepsy, TIA, and syncope may be difficult. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | BP = blood pressure; CSM = carotid sinus massage; TIA = transient ischaemic\nattack; TLOC = transient loss of consciousness. |  |  |  | \n | aClass of recommendation.\nbLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            307.72900390625,
            283.46497599283856,
            544.3401863344254,
            768.0759887695312
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "1928 ESC Guidelines",
          "page_number": 45,
          "content": " |  | \n |  | \n |  | \n | Figure 16 Flow diagram for the identification of unexplained | \n | falls. | \n |  | ",
          "bbox": [
            43.369998931884766,
            529.3417358398438,
            283.63409423828125,
            743.3579711914062
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "31",
      "title": "In summary, the key points for the evaluation of syncope in paedi- atrics are as follows:",
      "start_page": 46,
      "end_page": 46,
      "content": "•   Syncope in childhood is common, the majority being of reflex origin, with only a minority having a potentially life-threatening cause. •   Discriminating benign from serious causes is made primarily by history, physical examination, and ECG results.\n•   Children with a history suggesting VVS, a normal ECG, and no family history of arrhythmia should not undergo further cardiac investigations. •   The cornerstone of therapy for young patients with reflex syn- cope includes education and reassurance.\n",
      "keywords": [
        "summary",
        "arrhythmia",
        "paedi",
        "family history",
        "atrics",
        "follows",
        "evaluation",
        "points",
        "ecg",
        "syncope"
      ],
      "tables": []
    },
    {
      "number": "32",
      "title": "7. Psychogenic transient loss of consciousness and its evaluation",
      "start_page": 46,
      "end_page": 46,
      "content": "In psychogenic TLOC there is no gross somatic brain dysfunction, but the attacks fulfil the criteria for TLOC (see section 3.1). There are two types: PPS and PNES. In PPS movements are absent, so PPS resembles syncope or longer-lasting LOC, whereas in PNES impressive limb movements mean the attacks resemble epileptic seizures. PPS and PNES differ pathophysiologically from the TLOC forms that they resemble: in PPS, BP and HR are normal or high rather than low, and the EEG is normal instead of showing the slowing or flattening typical of syncope; in contrast to epileptic seizures, the EEG in PNES shows no epileptiform brain activity during an attack. 9 , 116\nThe frequency of PPS and PNES probably depends on the setting. The rate of PPS varies from 1% of patients referred to general syncope clinics 94   to 8% of patients referred to specialist neurological clinics, 116 but PPS is probably insufficiently recognized. 154\n",
      "keywords": [
        "consciousness",
        "psychogenic",
        "loss",
        "evaluation",
        "transient",
        "syncope"
      ],
      "tables": []
    },
    {
      "number": "33",
      "title": "7.1 Diagnosis 7.1.1 Historical criteria for attacks The presence of a psychological trauma is not a prerequisite for a diagnosis of conversion. The diagnosis of PPS rests on positive clues taken from ",
      "start_page": 46,
      "end_page": 47,
      "content": "(1) In most cases, the duration of PPS is as short as in syncope, but a much longer duration is a useful diagnostic finding: patients may lie immobile on the floor for 15–30 min. (2) The eyes are usually open in epileptic seizures and syncope but are usually closed in psychogenic TLOC. (3) The attack frequency is high, with several attacks occurring over a week or in a day. (4) There is usually no recognisable trigger, and no sweating, pallor, or nausea beforehand. (5) Injury does not exclude PNES or PPS.\nThese features should occur together in most attacks. The pres- ence of another pattern of features suggesting a true syncope type, usually VVS, does not argue against a diagnosis of PPS.\n7.1.2 Documentation of key features during an attack The following features are relevant during an attack:\n•   Video recording or clinical observation, including provocation of an attack during tilt testing. Primary features: sleep-like body posi- tion with closed eyes and lack of response to speech or touch, if\nESC Guidelines 1929\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................ tested. Secondary features: subtle signs incompatible with LOC such as eyelid flicker, eyeball movements, swallowing, intact muscle tone, normal movements absent in true unconsciousness, and resistance to eye opening. •   BP: normal or elevated during TLOC. •   EEG: normal waking eye-closed EEG pattern, i.e. usually with alpha activity, during TLOC.\nThe gold standard for PPS is documenting an attack with a home video recorder or with a tilt testing during which BP, HR, and EEG are normal. 116 , 204 , 404   The gold standard for PNES is documenting an attack with video-EEG monitoring. 204 , 404\n7.1.2.1 Management of psychogenic pseudosyncope Announcing a psychological diagnosis to patients may be considered difficult, but is necessary for reasons of honesty and as the first step of treatment. 404   It should be done by the somatic specialist who diagnoses PPS. 116 , 404   Important aspects are to assure patients that they are taken seriously and that attacks are as involuntary as syncope or an epileptic seizure. Acceptance of the diagnosis by patients may be critical for ther- apy. In one observational study, 405   communicating and explaining the diagnosis resulted in an immediate reduction of attack frequency, with 39% of patients being asymptomatic during a mean follow-up period of 4 years. Some advice on how to inform the patient is provided in  Web Practical Instructions  section 10:  European Society of Cardiology information sheet for patients affected by psychogenic pseudosyncope. Cognitive behavioural therapy is the usual treatment of PNES and PPS, if attacks remain present after explanation. One pilot random- ized treatment trial, conducted in PNES, 406   showed that psychologi- cal therapy provided more attack reduction than no treatment or treatment with sertraline. There are currently no trials on PPS.\n",
      "keywords": [
        "prerequisite",
        "positive",
        "rests",
        "may be considered",
        "historical",
        "psychological",
        "taken",
        "attacks",
        "trauma",
        "clues",
        "presence",
        "conversion",
        "syncope",
        "diagnosis",
        "criteria"
      ],
      "tables": [
        {
          "title": "1930 ESC Guidelines",
          "page_number": 47,
          "content": " | Diagnosis and management of psychogenic\npseudosyncope |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Diagnosis |  |  | \n |  | The recording of spontaneous attacks with\na video by an eyewitness should be consid-\nered for diagnosis of PPS.116,154 | IIa | C | \n |  | Tilt testing, preferably with concurrent EEG\nrecording and video monitoring, may be\nconsidered for diagnosis of PPS.116,403,407 | IIb | C | \n |  | Management |  |  | \n |  | Doctors who diagnose PPS should present\nthe diagnosis of PPS to the patient.116,404 | IIa | C | \n |  | Cognitive behavioural therapy may be con-\nsidered in the treatment of PPS if attacks\npersist after explanation. | IIb | C | \n |  |  |  |  | \n |  |  |  |  | \n | EEG = electroencephalogram; PPS = psychogenic pseudosyncope.\naClass of recommendation. |  |  |  | \n | bLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            438.5199737548828,
            279.8467371323529,
            738.8789672851562
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "34",
      "title": "8. Neurological causes and mimics of syncope",
      "start_page": 47,
      "end_page": 47,
      "content": "This section discusses neurological disorders causing syncope or resembling it, and tests to be performed in patients with syncope.\n",
      "keywords": [
        "neurological",
        "mimics",
        "syncope",
        "causes"
      ],
      "tables": []
    },
    {
      "number": "35",
      "title": "8.1 Clinical conditions 8.1.1 Autonomic failure Neurological evaluation should be considered in OH due to auto- nomic failure. Warning signs are early impotence, disturbed micturi- tion, hyposmia, rap",
      "start_page": 47,
      "end_page": 49,
      "content": "8.1.2 Epilepsy and ictal asystole Table  10  provides a number of clues that aid the differentiation of syncope from epileptic seizures. 9 , 50 , 410 , 411   Epilepsy and syncope may evoke one another on rare occasions, resulting in epileptic seizures triggering syncope as well as syncope triggering an epilep- tic seizure. The first form concerns  ictal asystole . Whereas approx- imately 90% of all epileptic seizures are accompanied by tachycardia, ictal bradycardia and asystole occur in 0.3–0.5% of seizures. 412 , 413   Bradycardia precedes asystole and AV block may occur, resembling the ECG pattern of reflex syncope. 412 , 414\nEpileptic asystole occurs during partial complex seizures, not dur- ing generalized seizures. Epileptic asystole occurs in only a fraction of the seizures of one person, and then occurs after a variable interval of 5–100 s from seizure onset. 415 , 416   If asystole lasts for more than about 8 s, syncope ensues. 416   A typical history is for a partial complex seizure to progress as usual for that patient, and then the patient suddenly falls flaccidly, with or without brief myo- clonic jerking. 416 , 417   Ictal bradycardia, asystole, and ictal AV block are likely self-terminating, 412   and are due to vagal activation brought about by the seizure. Cessation of cortical activity due to syncopal cerebral hypoperfusion will end the seizure. Therapy requires anti-epileptic drugs and possibly a pacemaker. 418\nIctal asystole is probably not involved in sudden death in epilepsy, as this typically occurs in patients after unwitnessed nocturnal generalized tonic-clonic seizures, i.e. another type of epi- lepsy. 414 , 419   Note that most cases of sudden cardiac arrest in patients with epilepsy are due to cardiovascular disease and not to ictal asystole. 420\nThe second form concerns a syncopal epileptic seizure. Hypoxia can trigger epileptic seizures. 208 , 421   Such syncopal epilep- tic seizures have been described in infants with reflex syncope or cyanotic breath-holding spells. A typical syncopal spell suddenly transforms into prolonged clonic movements that last for minutes; note that shorter epileptic seizures may remain unnoticed.\n8.1.3 Cerebrovascular disorders In general, a TIA concerns a focal neurological deficit without LOC, and syncope the opposite. Subclavian steal refers to the rerouting of blood flow to the arm through the vertebral artery due to proximal\nDiagnosis and management of psychogenic pseudosyncope\nRecommendations Class a Level b\nDiagnosis\nThe recording of spontaneous attacks with a video by an eyewitness should be consid-\nered for diagnosis of PPS. 116 , 154\nIIa C\nTilt testing, preferably with concurrent EEG\nrecording and video monitoring, may be considered for diagnosis of PPS. 116 , 403 , 407\nIIb C\nManagement\nDoctors who diagnose PPS should present\nthe diagnosis of PPS to the patient. 116 , 404 IIa C\nCognitive behavioural therapy may be con- sidered in the treatment of PPS if attacks\npersist after explanation. IIb C\nEEG = electroencephalogram; PPS = psychogenic pseudosyncope. a Class of recommendation. b Level of evidence.\n1930 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ................................... stenosis or occlusion of the subclavian artery. A TIA may occur when flow through the vertebral artery cannot supply both the arm and part of the brain during forceful use of the arm. Steal most often affects the left side. When detected with ultrasound, steal is asympto- matic in 64% of cases. 422   A TIA is likely due to steal only when it is vertebrobasilar (see below) and associated with exercise of one arm. There are no reliable reports of isolated LOC without focal neuro- logical symptoms and signs in subclavian steal. A TIA related to a carotid artery does not usually cause TLOC. An exception concerns  orthostatic TIAs , concerning a combination of multiple stenoses of cerebral arteries and OH. This may rarely result in repetitive, orthostatic, short-lasting, and stereotyped TIAs. 423 , 424\nA TIA of the vertebrobasilar system can cause LOC, but there are always focal signs, usually limb weakness, gait and limb ataxia, vertigo, diplopia, nystagmus, dysarthria, and oropharyngeal dysfunction. Fewer than 1% of patients with vertebrobasilar ischaemia present with a single presenting symptom. 425\n8.1.4 Migraine Syncope, presumable VVS, and orthostatic intolerance occur more often in patients with migraine, who have a higher lifetime prevalence of syncope and often frequent syncope. 426   In migraineurs, syncope and migraine attacks rarely occur simultaneously.\nTable 10 Differentiating syncope from epileptic seizures 9,50 , 410 , 411\nClinical feature Syncope Epileptic seizures\nUseful features\nPresence of trigger Very often Rare\nNature of trigger Differs between types: pain, standing, emo-\ntions for VVS; speciﬁc trigger for situational syncope; standing for OH\nFlashing lights is best known; also range of rare\ntriggers\nProdromes Often presyncope (autonomic activation in\nreﬂex syncope, light-headedness in OH, palpi- tations in cardiac syncope)\nEpileptic aura: repetitive, speciﬁc for each patient.\nIncludes  de´j \u0003 a vu . Rising sensation in the abdomen (epigastric aura) and/or an unusual unpleasant\nsmell\nDetailed characteristics of\nmyoclonus •   <10, irregular in amplitude, asynchronous,\nasymmetrical •   Starts after the onset of LOC\n•   20–100, synchronous, symmetrical, hemilateral •   The onset mostly coincides with LOC •   Clear long-lasting automatisms as chewing or lip\nsmacking at the mouth\nTongue bite Rare, tip of tongue Side of tongue (rarely bilateral)\nDuration of restoration of consciousness 10–30 seconds May be many minutes\nConfusion after attack No understanding of situation for <10 seconds\nin most syncope, full alertness and awareness\nafterwards\nMemory deﬁcit, i.e. repeated questions without\nimprinting for many minutes\nFeatures of limited utility\nIncontinence Not uncommon Common\nPresence of myoclonus (see below\nfor nature of myoclonus)\nVery often \u0005 60%, dependent on accuracy of observation\nEyes open during LOC Frequent Nearly always\nFatigue and sleep afterwards Common, particularly in children Very common\nBlue face Rare Fairly often\nLOC = loss of consciousness; OH = orthostatic hypotension; VVS = vasovagal syncope.\nESC Guidelines 1931\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .................................................... 8.1.5 Cataplexy Cataplexy concerns paresis or paralysis triggered by emotions, usu- ally laughter, but also by a range of other triggers. 427   Patients are con- scious even when considered unconscious by eyewitnesses, and there is no amnesia. Cataplexy is a key feature of narcolepsy; other cardinal symptoms are excessive daytime sleepiness, sleep-onset paralysis, and hypnagogic hallucinations. Cataplexy may be mistaken for syncope, but also for PPS: a partial awareness of events may be present in PPS, and the falls of cataplexy are partly controlled because paralysis need not be immediately complete.\n8.1.6 Drop attacks The term drop attacks is confusing as it is variably used for Menie`re’s disease, atonic epileptic seizures, and unexplained falls. 387   A specific condition also labelled drop attacks concerns middle-aged women (rarely men) who suddenly find themselves falling. 428   They usually remember hitting the floor and can stand up immediately afterwards.\n",
      "keywords": [
        "conditions",
        "vasovagal",
        "nomic",
        "bradycardia",
        "disturbed",
        "pacemaker",
        "tachycardia",
        "warning",
        "auto",
        "orthostatic",
        "evaluation",
        "considered",
        "syncope",
        "clinical",
        "carotid",
        "tion",
        "presyncope",
        "neurological",
        "autonomic",
        "signs",
        "early",
        "hyposmia",
        "micturi",
        "failure",
        "level b",
        "should",
        "ecg",
        "impotence",
        "exercise",
        "may be considered"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 1931",
          "page_number": 48,
          "content": " | Table 10 Differentiating syncope from epileptic seizures9,50,410,411 |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Clinical feature | Syncope | Epileptic seizures | \n |  | Useful features |  |  | \n |  | Presence of trigger | Very often | Rare | \n |  | Nature of trigger | Differs between types: pain, standing, emo-\ntions for VVS; specific trigger for situational\nsyncope; standing for OH | Flashing lights is best known; also range of rare\ntriggers | \n |  | Prodromes | Often presyncope (autonomic activation in\nreflex syncope, light-headedness in OH, palpi-\ntations in cardiac syncope) | Epileptic aura: repetitive, specific for each patient.\nIncludes de´j\u0003a vu. Rising sensation in the abdomen\n(epigastric aura) and/or an unusual unpleasant\nsmell | \n |  | Detailed characteristics of\nmyoclonus | • <10, irregular in amplitude, asynchronous,\nasymmetrical\n• Starts after the onset of LOC | • 20–100, synchronous, symmetrical, hemilateral\n• The onset mostly coincides with LOC\n• Clear long-lasting automatisms as chewing or lip\nsmacking at the mouth | \n |  | Tongue bite | Rare, tip of tongue | Side of tongue (rarely bilateral) | \n |  | Duration of restoration of\nconsciousness | 10–30 seconds | May be many minutes | \n |  | Confusion after attack | No understanding of situation for <10 seconds\nin most syncope, full alertness and awareness\nafterwards | Memory deficit, i.e. repeated questions without\nimprinting for many minutes | \n |  | Features of limited utility |  |  | \n |  | Incontinence | Not uncommon | Common | \n |  | Presence of myoclonus (see below\nfor nature of myoclonus) | Very often | \u000560%, dependent on accuracy of observation | \n |  | Eyes open during LOC | Frequent | Nearly always | \n |  | Fatigue and sleep afterwards | Common, particularly in children | Very common | \n |  | Blue face | Rare | Fairly often | \n |  | LOC = loss of consciousness; OH = orthostatic hypotension; VVS = vasovagal syncope. |  |  | \n |  |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            47.904998779296875,
            59.81097412109375,
            548.1328681497013,
            536.0880126953125
          ],
          "function_potential": "raw"
        },
        {
          "title": "1932 ESC Guidelines",
          "page_number": 49,
          "content": " | Neurological evaluation |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Neurological evaluation is indicated\nwhen syncope is due to autonomic fail-\nure to evaluate the underlying disease. | I | C | \n |  | Neurological evaluation is indicated in\npatients in whom TLOC is suspected to\nbe epilepsy. | I | C | \n |  |  |  |  | \n |  |  |  |  | \n | TLOC = transient loss of consciousness.\naClass of recommendation. |  |  |  | \n | bLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            284.3153076171875,
            280.4432349571815,
            465.6759948730469
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "1932 ESC Guidelines",
          "page_number": 49,
          "content": " | Neurological tests |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | Recommendations | Classa | Levelb | \n |  | Brain MRI is recommended if neurological\nexamination indicates Parkinsonism, ataxia,\nor cognitive impairment. | I | C | \n |  | Screening for paraneoplastic antibodies and\nantiganglionic acetylcholine receptor anti-\nbodies is recommended in cases of acute or\nsubacute onset of multidomain autonomic\nfailure.432,433 | I | B | \n |  | EEG, ultrasound of neck arteries, and com-\nputed tomography or magnetic resonance\nimaging of the brain are not indicated in\npatients with syncope.178,435–440 | III | B | \n |  | Additional advice and clinical perspectives\nSeropositivity for any paraneoplastic antibody or for antigan-\nglionic acetylcholine receptor antibodies should prompt further\ninvestigations for occult malignancy. |  |  | \n |  |  |  |  | \n |  |  |  |  | \n | EEG = electroencephalogram; MRI = magnetic resonance imaging.\naClass of recommendation. |  |  |  | \n | bLevel of evidence. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            307.72900390625,
            289.1339823404948,
            544.5066128434806,
            602.9859619140625
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "36",
      "title": "8.2 Neurological tests A schematic comprehensive figure of neurological tests used for autonomic failure is shown in  Figure  17 .",
      "start_page": 49,
      "end_page": 49,
      "content": "8.2.1 Electroencephalography The results of interictal EEGs are normal in syncope. 410 , 430   An interic- tal normal EEG cannot rule out epilepsy and the EEG in epilepsy must always be interpreted in a clinical context. An EEG is not rec- ommended when syncope is the most likely cause of TLOC, but it is when epilepsy is the likely cause or when clinical data are equivocal. The EEG is also useful to establish PPS, if recorded during a provoked attack.\n8.2.2 Brain computed tomography and magnetic resonance imaging Computed tomography and MRI in uncomplicated syncope should be avoided. If neurological examination points out Parkinsonism, ataxia, or cognitive impairment, MRI is recommended. In cases of contraindication for MRI, computed tomography is recommended to exclude brain lesions.\n8.2.3 Neurovascular studies No studies suggest that carotid Doppler ultrasonography is valuable in patients with typical syncope.\n8.2.4 Blood tests An acute or subacute onset of multidomain autonomic failure sug- gests a paraneoplastic or autoimmune cause. Screening for specific paraneoplastic antibodies is recommended: the most common para- neoplastic antibodies are anti-Hu, while others are anti-Purkinje cell cytoplasmic autoantibody type 2 and anti-collapsin response media- tor protein 5. 431   Seropositivity for any of the above-mentioned anti- bodies may therefore prompt further investigation for occult malignancy (e.g. whole-body fluorodeoxyglucose-positron emission tomography). 432\nSeropositivity for antiganglionic acetylcholine receptor antibodies is the serological hallmark of autoimmune autonomic ganglionopathy. 433 , 434\n",
      "keywords": [
        "tests",
        "carotid",
        "recommended",
        "neurological",
        "contraindication",
        "autonomic",
        "mri",
        "figure",
        "used",
        "shown",
        "failure",
        "syncope",
        "comprehensive",
        "schematic"
      ],
      "tables": []
    },
    {
      "number": "37",
      "title": "9. Organizational aspects",
      "start_page": 49,
      "end_page": 49,
      "content": "",
      "keywords": [
        "aspects",
        "organizational"
      ],
      "tables": []
    },
    {
      "number": "38",
      "title": "9.1 Syncope (transient loss of consciousness) management unit Since the publication of the 2009 ECS Guidelines, the EHRA Task Force has published a further position statement on the rationale and requ",
      "start_page": 49,
      "end_page": 52,
      "content": "Neurological evaluation\nRecommendations Class a Level b\nNeurological evaluation is indicated\nwhen syncope is due to autonomic fail-\nure to evaluate the underlying disease.\nI C\nNeurological evaluation is indicated in patients in whom TLOC is suspected to\nbe epilepsy. I C\nTLOC = transient loss of consciousness. a Class of recommendation. b Level of evidence.\nNeurological tests\nRecommendations Class a Level b\nBrain MRI is recommended if neurological\nexamination indicates Parkinsonism, ataxia,\nor cognitive impairment.\nI C\nScreening for paraneoplastic antibodies and antiganglionic acetylcholine receptor anti-\nbodies is recommended in cases of acute or\nsubacute onset of multidomain autonomic failure. 432 , 433\nI B\nEEG, ultrasound of neck arteries, and com-\nputed tomography or magnetic resonance imaging of the brain are not indicated in\npatients with syncope. 178 , 435 – 440\nIII B\nAdditional advice and clinical perspectives\nSeropositivity for any paraneoplastic antibody or for antigan- glionic acetylcholine receptor antibodies should prompt further\ninvestigations for occult malignancy.\nEEG = electroencephalogram; MRI = magnetic resonance imaging. a Class of recommendation. b Level of evidence.\n1932 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ........... interested in establishing a syncope unit in their hospital so that they can meet the standards proposed by the ESC, the EHRA, and the Heart Rhythm Society. The following is the context and evidence for recommendations regarding syncope units ( Table  11 ).\n9.1.1 Definition of a syncope unit A syncope unit is a facility featuring a standardized approach to the diagnosis and management of TLOC and related symptoms, with dedicated staff and access to appropriate diagnostics and therapies.\nFigure 17  Diagnostic work-up of cardiovascular autonomic failure (adapted from Fanciulli  et al. 429 ). CNS = central nervous system; CRMP-5 = collapsin response mediator protein 5; DAT = dopamine active transporter; HbA1c = haemoglobin A1c; HIV = human immunodeficiency virus;   123 I- MIBG =   123 I-metaiodobenzylguanidine; MRI = magnetic resonance imaging; PCA-2 = Purkinje cell cytoplasmic autoantibody type 2; SPECT = single- photon emission computed tomography; SS-A = Sjogren’s syndrome-associated antigen A; SS-B = Sjogren’s syndrome-associated antigen B.\nTable 11 Key components of a syncope unit\n•   The syncope unit should take the lead in service delivery for syncope, and in education and training of healthcare professionals who encounter syncope.\n•   The syncope unit should be led by a clinician with speciﬁc knowledge of TLOC and additional necessary team members (i.e. clinical nurse special-\nist) depending on the local model of service delivery.\n•   The syncope unit should provide minimum core treatments for reﬂex syncope and OH, and treatments or preferential access for cardiac syn- cope, falls, psychogenic pseudosyncope, and epilepsy.\n•   Referrals should be directly from family practitioners, EDs, in-hospital and out-hospital services, or self-referral depending on the risk stratiﬁca-\ntion of referrals. Fast-track access, with a separate waiting list and scheduled follow-up visits, should be recommended.\n•   Syncope units should employ quality indicators, process indicators, and desirable outcome targets.\nED = emergency department; OH = orthostatic hypotension; TLOC = transient loss of consciousness.\nESC Guidelines 1933\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ...................................... 9.1.2 Definition of syncope specialist The syncope specialist is defined as one who has responsibility for the comprehensive management of the patient from risk stratification to diagnosis, therapy, and follow-up, through a standardized protocol. A syncope specialist is a physician who has sufficient knowledge of historical clues and physical findings to recognize all major forms of TLOC, including mimics, as well as syndromes of orthostatic intolerance.\n9.1.3 Goal of a syncope unit Although the benefit of a syncope unit or a syncope specialist in the different healthcare systems has not been exposed to rigorous\nscientific or economic scrutiny, the consensus is that a dedicated service (a syncope unit) affords better management of TLOC, from risk stratification to diagnosis, therapy, and follow-up, and better edu- cation and training of stakeholders. Further research is likely to have an important impact on our confidence in the estimate of effect.\n9.1.4 Model of a syncope unit The syncope unit should provide minimum core treatments for reflex syncope and OH, and treatments or preferential access for cardiac syncope, falls, psychogenic syncope, and epilepsy ( Table  12 ). The tests and assessments available in the syncope unit are detailed in  Table  13 .\nTable 12 Structure of the syncope unit\nStafﬁng of a syncope unit is composed of: (1) One or more physicians of any specialty who are syncope specialists. Owing to the multidisciplinary nature of TLOC management, each syn-\ncope unit should identify speciﬁc specialists for the syncope unit and for consultancies.\n(2) A staff comprising professionals who will advance the care of patients with syncope. These may be physicians, specialized nurses, or others who bring multidisciplinary skills to the facility, coupled with administrative support. The roles played by members of the team may vary according to\nlocal circumstances and individual skill. Nurses may be expected to take very important roles including initial assessment, follow-up clinic evalua-\ntion, selection of investigations (including tilt testing), and implantation/insertion of ECG loop recorders according to predeﬁned protocols and local regulations (see  Table  14 ).\n(3) Given that the syncope unit is integrated within a hospital organization, syncope specialists and staff are not necessarily employed full-time, but\nfrequently have other duties depending on the volume of activity in the unit.\nFacility, protocol, and equipment\n(1) A syncope unit will deliver most of its care to outpatients in addition to ED and inpatients.\n(2) The syncope unit should follow an internal protocol, which applies to diagnosis and management and is agreed by stakeholders. (3) An equipped facility must be available.\n(4) Essential equipment/tests:\n- 12-lead ECG and 3-lead ECG monitoring - Non-invasive beat-to-beat BP monitor with recording facilities for subsequent analysis\n- Tilt-table\n- Holter monitors/external loop recorders - ILRs\n- Follow-up of ILRs a\n- 24-hour BP monitoring - Basic autonomic function tests.\n(5) Established procedures for:\n- Echocardiography - EPS\n- Stress test\n- Neuroimaging tests. (6) Specialists’ consultancies (cardiology, neurology, internal medicine, geriatric, psychology), when needed.\nTherapy\nPatients with syncope will receive their therapy under the care of the syncope unit unless expertise outside that of the unit is required.\nDatabase management\nThe syncope unit is required to keep medical records that should also include follow-up when appropriate. The database will also offer the possibil-\nity of collaborative research with other syncope units.\nBP = blood pressure; ECG = electrocardiogram; ED = emergency department; EPS = electrophysiological study; ILR = implantable loop recorder;\nTLOC = transient loss of consciousness.\na Implantation of loop recorders may be performed either by syncope unit physicians or by external cardiologists at the request of the syncope unit physicians.\n1934 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ...................................................................... 9.1.5 Access and referrals to a syncope unit Referral can be direct from family practitioners, EDs, in-hospital and out-hospital services, or self-referral from the patient. Fast-track access with a separate waiting list and scheduled follow-up visits is recommended. In particular, patients at low/intermediate risk admit- ted to the ED should benefit from such fast-track facilities (so-called protected discharge or advanced access with an appointment for early assessment) to reduce hospitalization rates, directly from the ED or after a short stay in the short observation unit of the ED (see section 4.1.2).\n9.1.6 Outcomes and quality indicators The EHRA Task Force 63   has developed the following preliminary quality indicators, based on consensus, as a rough guide for practitioners:\n(1) Absolute rate of undiagnosed TLOC should be reduced by 20%; (2) Less than 20% of low-/intermediate-risk TLOC patients should be admitted from the ED; (3) The syncope unit should have a 20% reduction in costs relative to usual practice and improved outcomes (i.e. <5% readmissions for syncope and <20% of paced patients with recurrence at 1 year).\n",
      "keywords": [
        "requ",
        "since",
        "hba1c",
        "unit",
        "force",
        "management",
        "electrocardiogram",
        "orthostatic",
        "blood pressure",
        "risk stratification",
        "transient loss of consciousness",
        "ehra",
        "rationale",
        "syncope",
        "stress test",
        "statement",
        "position",
        "publication",
        "mri",
        "published",
        "guidelines",
        "echocardiography",
        "level b",
        "further",
        "ecg",
        "consciousness",
        "recommended",
        "task",
        "loss",
        "transient"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 1933",
          "page_number": 50,
          "content": " | \n | \n | \n | Figure 17 Diagnostic work-up of cardiovascular autonomic failure (adapted from Fanciulli et al.429). CNS = central nervous system; CRMP-5 =\ncollapsin response mediator protein 5; DAT = dopamine active transporter; HbA1c = haemoglobin A1c; HIV = human immunodeficiency virus; 123I-\nMIBG = 123I-metaiodobenzylguanidine; MRI = magnetic resonance imaging; PCA-2 = Purkinje cell cytoplasmic autoantibody type 2; SPECT = single-\nphoton emission computed tomography; SS-A = Sjogren’s syndrome-associated antigen A; SS-B = Sjogren’s syndrome-associated antigen B.\n | ",
          "bbox": [
            47.904998779296875,
            53.85816955566406,
            547.3298306672469,
            476.0509948730469
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 1933",
          "page_number": 50,
          "content": " | Table 11 Key components of a syncope unit | \n |  | \n |  | \n |  | • The syncope unit should take the lead in service delivery for syncope, and in education and training of healthcare professionals who encounter syncope.\n |  | • The syncope unit should be led by a clinician with specific knowledge of TLOC and additional necessary team members (i.e. clinical nurse special-\nist) depending on the local model of service delivery.\n |  | • The syncope unit should provide minimum core treatments for reflex syncope and OH, and treatments or preferential access for cardiac syn-\ncope, falls, psychogenic pseudosyncope, and epilepsy.\n |  | • Referrals should be directly from family practitioners, EDs, in-hospital and out-hospital services, or self-referral depending on the risk stratifica-\ntion of referrals. Fast-track access, with a separate waiting list and scheduled follow-up visits, should be recommended.\n |  | • Syncope units should employ quality indicators, process indicators, and desirable outcome targets.\n |  | \n |  | \n | ED = emergency department; OH = orthostatic hypotension; TLOC = transient loss of consciousness. | \n |  | ",
          "bbox": [
            47.904998779296875,
            485.00799560546875,
            547.3298306672469,
            670.0916646321615
          ],
          "function_potential": "raw"
        },
        {
          "title": "1934 ESC Guidelines",
          "page_number": 51,
          "content": " | Table 12 Structure of the syncope unit | \n |  | \n | Staffing of a syncope unit is composed of:\n(1) One or more physicians of any specialty who are syncope specialists. Owing to the multidisciplinary nature of TLOC management, each syn-\ncope unit should identify specific specialists for the syncope unit and for consultancies.\n(2) A staff comprising professionals who will advance the care of patients with syncope. These may be physicians, specialized nurses, or others who\nbring multidisciplinary skills to the facility, coupled with administrative support. The roles played by members of the team may vary according to\nlocal circumstances and individual skill. Nurses may be expected to take very important roles including initial assessment, follow-up clinic evalua-\ntion, selection of investigations (including tilt testing), and implantation/insertion of ECG loop recorders according to predefined protocols and\nlocal regulations (see Table 14).\n(3) Given that the syncope unit is integrated within a hospital organization, syncope specialists and staff are not necessarily employed full-time, but\nfrequently have other duties depending on the volume of activity in the unit.\nFacility, protocol, and equipment\n(1) A syncope unit will deliver most of its care to outpatients in addition to ED and inpatients.\n(2) The syncope unit should follow an internal protocol, which applies to diagnosis and management and is agreed by stakeholders.\n(3) An equipped facility must be available.\n(4) Essential equipment/tests:\n- 12-lead ECG and 3-lead ECG monitoring\n- Non-invasive beat-to-beat BP monitor with recording facilities for subsequent analysis\n- Tilt-table\n- Holter monitors/external loop recorders\n- ILRs\n- Follow-up of ILRsa\n- 24-hour BP monitoring\n- Basic autonomic function tests.\n(5) Established procedures for:\n- Echocardiography\n- EPS\n- Stress test\n- Neuroimaging tests.\n(6) Specialists’ consultancies (cardiology, neurology, internal medicine, geriatric, psychology), when needed.\nTherapy\nPatients with syncope will receive their therapy under the care of the syncope unit unless expertise outside that of the unit is required.\nDatabase management\nThe syncope unit is required to keep medical records that should also include follow-up when appropriate. The database will also offer the possibil-\nity of collaborative research with other syncope units. | \n |  | Staffing of a syncope unit is composed of:\n(1) One or more physicians of any specialty who are syncope specialists. Owing to the multidisciplinary nature of TLOC management, each syn-\ncope unit should identify specific specialists for the syncope unit and for consultancies.\n(2) A staff comprising professionals who will advance the care of patients with syncope. These may be physicians, specialized nurses, or others who\nbring multidisciplinary skills to the facility, coupled with administrative support. The roles played by members of the team may vary according to\nlocal circumstances and individual skill. Nurses may be expected to take very important roles including initial assessment, follow-up clinic evalua-\ntion, selection of investigations (including tilt testing), and implantation/insertion of ECG loop recorders according to predefined protocols and\nlocal regulations (see Table 14).\n(3) Given that the syncope unit is integrated within a hospital organization, syncope specialists and staff are not necessarily employed full-time, but\nfrequently have other duties depending on the volume of activity in the unit.\n |  | Facility, protocol, and equipment\n(1) A syncope unit will deliver most of its care to outpatients in addition to ED and inpatients.\n(2) The syncope unit should follow an internal protocol, which applies to diagnosis and management and is agreed by stakeholders.\n(3) An equipped facility must be available.\n(4) Essential equipment/tests:\n- 12-lead ECG and 3-lead ECG monitoring\n- Non-invasive beat-to-beat BP monitor with recording facilities for subsequent analysis\n- Tilt-table\n- Holter monitors/external loop recorders\n- ILRs\n- Follow-up of ILRsa\n- 24-hour BP monitoring\n- Basic autonomic function tests.\n(5) Established procedures for:\n- Echocardiography\n- EPS\n- Stress test\n- Neuroimaging tests.\n(6) Specialists’ consultancies (cardiology, neurology, internal medicine, geriatric, psychology), when needed.\n |  | Therapy\nPatients with syncope will receive their therapy under the care of the syncope unit unless expertise outside that of the unit is required.\n |  | \n |  | Database management\nThe syncope unit is required to keep medical records that should also include follow-up when appropriate. The database will also offer the possibil-\nity of collaborative research with other syncope units.\n |  | \n |  | BP = blood pressure; ECG = electrocardiogram; ED = emergency department; EPS = electrophysiological study; ILR = implantable loop recorder;\nTLOC = transient loss of consciousness.\n |  | \n | aImplantation of loop recorders may be performed either by syncope unit physicians or by external cardiologists at the request of the syncope unit physicians. | \n |  | ",
          "bbox": [
            44.220001220703125,
            239.52801513671875,
            545.3077632359096,
            760.6298014322916
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 1935",
          "page_number": 52,
          "content": " | Table 13 Test and assessments available in a syncope unit |  |  | \n |  |  |  | \n |  |  |  | \n |  | Initial assessment |  | \n |  | History and physical evaluation including 3-min orthostatic BP measurementa\n12-lead standard ECG |  | \n |  |  |  | \n |  | Subsequent tests and assessments (only when indicated) |  | \n |  | Blood tests | Electrolytes, haemoglobin, troponin, B-type natriuretic peptide, glucose, D-dimer, haemogas anal-\nysis/oxygen saturation | \n |  | Provocative tests | CSM, tilt testing | \n |  | Monitoring | External loop recording, implantable loop recording, ambulatory 1–7 days ECG monitoring,\n24–48-hour BP monitoring | \n |  | Autonomic function tests | Standing test, Valsalva manoeuvre, deep-breathing test, cold pressor test, and/or established pro-\ncedures for access to other autonomic function tests | \n |  | Cardiac evaluation | Established procedures for access to echocardiogram, stress test, electrophysiological study, cor-\nonary angiography | \n |  | Neurological evaluation | Established procedures for access to neurological tests (computed tomography, magnetic reso-\nnance imaging, EEG, video-EEG) | \n |  | Geriatric evaluation | Established procedures for access to fall risk assessment (cognitive, gait and balance, visual, envi-\nronmental) and for gait and balance retraining | \n |  | Psychological or psychiatric evaluation | Established procedures for access to psychological or psychiatric consultancy (mental health\nproblem or psychogenic syncope) | \n |  |  |  | \n |  |  |  | \n | BP = blood pressure; CSM = carotid sinus massage; ECG = electrocardiogram; EEG = electroencephalogram.\naPostural orthostatic tachycardia may require longer period of standing. |  |  | \n |  |  |  | ",
          "bbox": [
            47.904998779296875,
            59.811299641927086,
            548.6002284458706,
            423.4960021972656
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "39",
      "title": "9.2 The clinical nurse specialist in the syncope unit 9.2.1 Definition The syncope unit clinical nurse specialist is defined as an experienced practitioner who has sufficient knowledge of history feat",
      "start_page": 52,
      "end_page": 53,
      "content": "9.2.2 Role and skills of the clinical nurse specialist The clinical nurse specialist should be skilled in the performance and interpretation of structured history taking, 12-lead ECG and routine blood test results, tilt testing, active stand tests, autonomic function tests, ECG monitoring (Holter and/or external loop recorder), ABPM, ILR monitoring, and subsequent triaging of patients and moni- toring responses to therapy. Other skills will depend on the service model, e.g. pacemaker interrogation. The clinical nurse specialist may have responsibility for follow-up clinics for cardiovascular risk factor management, autonomic function testing and monitoring, manage- ment (including education in PCM) of VVS and OH, and follow-up\nTable 13 Test and assessments available in a syncope unit\nInitial assessment\nHistory and physical evaluation including 3-min orthostatic BP measurement a\n12-lead standard ECG\nSubsequent tests and assessments (only when indicated)\nBlood tests Electrolytes, haemoglobin, troponin, B-type natriuretic peptide, glucose, D-dimer, haemogas anal- ysis/oxygen saturation\nProvocative tests CSM, tilt testing\nMonitoring External loop recording, implantable loop recording, ambulatory 1–7 days ECG monitoring,\n24–48-hour BP monitoring\nAutonomic function tests Standing test, Valsalva manoeuvre, deep-breathing test, cold pressor test, and/or established pro- cedures for access to other autonomic function tests\nCardiac evaluation Established procedures for access to echocardiogram, stress test, electrophysiological study, cor-\nonary angiography\nNeurological evaluation Established procedures for access to neurological tests (computed tomography, magnetic reso- nance imaging, EEG, video-EEG)\nGeriatric evaluation Established procedures for access to fall risk assessment (cognitive, gait and balance, visual, envi-\nronmental) and for gait and balance retraining\nPsychological or psychiatric evaluation Established procedures for access to psychological or psychiatric consultancy (mental health\nproblem or psychogenic syncope)\nBP = blood pressure; CSM = carotid sinus massage; ECG = electrocardiogram; EEG = electroencephalogram. a Postural orthostatic tachycardia may require longer period of standing.\nESC Guidelines 1935\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .............................................. of external and internal loop and Holter monitors and ABPM 63\n( Table  14 ). The clinical nurse specialist should be key in developing and deliv- ering communication strategies and processes for the syncope unit for all stakeholders—patients and practitioners—and play a pivotal role in education and training together with the syncope specialist. The clinical nurse specialist should be involved in regular auditing and collection of data to inform quality indicators. See the video in  Web Practical Instructions  section 11.\nAlthough the skill mix of a clinical nurse specialist has not been exposed to rigorous scientific or economic scrutiny, the consen- sus is that the clinical nurse specialist should have the neces- sary skills to deliver assessment and treatment for syncope and TLOC. Further research is required to establish the benefits.\n",
      "keywords": [
        "experienced",
        "risk factor",
        "unit",
        "definition",
        "electrocardiogram",
        "pacemaker",
        "tachycardia",
        "defined",
        "knowledge",
        "glucose",
        "orthostatic",
        "blood pressure",
        "troponin",
        "practitioner",
        "syncope",
        "stress test",
        "clinical",
        "carotid",
        "history",
        "specialist",
        "ecg",
        "feat",
        "angiography",
        "cardiovascular risk",
        "sufficient",
        "nurse"
      ],
      "tables": [
        {
          "title": "1936 ESC Guidelines",
          "page_number": 53,
          "content": " | Table 14 The role of physicians and staff in performing procedures and tests |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  | Procedure or test | Syncope unit\nphysician | Syncope\nunit staff | Non-syncope\nunit personnel | \n |  | History taking | X |  |  | \n |  | Structured history taking (e.g. application of software technologies and algorithms) |  | X |  | \n |  | 12-lead ECG |  | X |  | \n |  | Blood tests |  | X |  | \n |  | Echocardiogram and imaging |  |  | X | \n |  | CSM | X |  |  | \n |  | Active standing test |  | X |  | \n |  | Tilt testing | (X)a | X |  | \n |  | Basic autonomic function test |  | X |  | \n |  | ECG monitoring (Holter, external loop recorder): administration and interpretation | X | X |  | \n |  | ILR | X | (X)b |  | \n |  | Remote monitoring |  | X |  | \n |  | Other cardiac tests (stress test, EPS, angiograms) |  |  | X | \n |  | Neurological tests (computed tomography, magnetic resonance imaging, EEG, video-EEG) |  |  | X | \n |  | Pacemaker and ICD implantation, catheter ablation |  |  | X | \n |  | Patient education, biofeedback training,c and instruction sheet on PCM | X | X |  | \n |  | Final report and clinic note | X |  |  | \n |  | Communication with patients, referring physicians, and stakeholders. | X | X |  | \n |  | Follow-up | X | X |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n | BP = blood pressure; CSM = carotid sinus massage; ECG = electrocardiogram; EEG = electroencephalogram; EPS = electrophysiological study; ICD = implantable cardioverter\ndefibrillator; ILR = implantable loop recorder; PCM = physical counter-pressure manoeuvres. |  |  |  |  | \n | aPhysician need not be in the room, but a physician adequately trained in resuscitation needs to be in the vicinity of the test.\nbCurrent practice limited to a few countries.\ncBiofeedback means that the PCM training session consists of biofeedback training using a continuous BP monitor. Each manoeuvre is demonstrated and explained. The manoeu-\nvres are practised under supervision, with immediate feedback of the recordings to gain optimal performance. |  |  |  |  | \n |  |  |  |  |  | ",
          "bbox": [
            41.66899871826172,
            52.441304524739586,
            543.7516047780107,
            532.4029541015625
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "40",
      "title": "10. Key messages",
      "start_page": 53,
      "end_page": 53,
      "content": "",
      "keywords": [
        "messages"
      ],
      "tables": []
    },
    {
      "number": "41",
      "title": "The ESC Task Force has selected 19 simple rules to guide the diagno- sis and management of syncope patients with TLOC according to the 2018 ESC Guidelines on syncope:",
      "start_page": 53,
      "end_page": 54,
      "content": "Diagnosis: initial evaluation\n(1) At the initial evaluation answer the following four key questions: \u0003  Was the event TLOC? \u0003  In cases of TLOC, are they of syncopal or non-syncopal origin? \u0003  In cases of suspected syncope, is there a clear aetiological diagnosis? \u0003  Is there evidence to suggest a high risk of cardiovascular events or death? (2) At the evaluation of TLOC in the ED, answer the following three key questions: \u0003  Is there a serious underlying cause that can be identified?\nTable 14 The role of physicians and staff in performing procedures and tests\nProcedure or test Syncope unit\nphysician\nSyncope\nunit staff\nNon-syncope\nunit personnel\nHistory taking X\nStructured history taking (e.g. application of software technologies and algorithms) X\n12-lead ECG X\nBlood tests X\nEchocardiogram and imaging X\nCSM X\nActive standing test X\nTilt testing (X) a X\nBasic autonomic function test X\nECG monitoring (Holter, external loop recorder): administration and interpretation X X\nILR X (X) b\nRemote monitoring X\nOther cardiac tests (stress test, EPS, angiograms) X\nNeurological tests (computed tomography, magnetic resonance imaging, EEG, video-EEG) X\nPacemaker and ICD implantation, catheter ablation X\nPatient education, biofeedback training, c   and instruction sheet on PCM X X\nFinal report and clinic note X\nCommunication with patients, referring physicians, and stakeholders. X X\nFollow-up X X\nBP = blood pressure; CSM = carotid sinus massage; ECG = electrocardiogram; EEG = electroencephalogram; EPS = electrophysiological study; ICD = implantable cardioverter deﬁbrillator; ILR = implantable loop recorder; PCM = physical counter-pressure manoeuvres. a Physician need not be in the room, but a physician adequately trained in resuscitation needs to be in the vicinity of the test. b Current practice limited to a few countries. c Biofeedback means that the PCM training session consists of biofeedback training using a continuous BP monitor. Each manoeuvre is demonstrated and explained. The manoeu- vres are practised under supervision, with immediate feedback of the recordings to gain optimal performance.\n1936 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .......................................................................................................................................................................... \u0003  If the cause is uncertain, what is the risk of a serious outcome? \u0003  Should the patient be admitted to hospital? (3) In all patients, perform a complete history taking, physical examina- tion (including standing BP measurement), and standard ECG. (4) Perform immediate ECG monitoring (in bed or telemetry) in high- risk patients when there is a suspicion of arrhythmic syncope. (5) Perform an echocardiogram when there is previous known heart disease, or data suggestive of structural heart disease or syncope secondary to cardiovascular cause. (6) Perform CSM in patients >40 years of age with syncope of unknown origin compatible with a reflex mechanism. (7) Perform tilt testing in cases where there is suspicion of syncope due to reflex or an orthostatic cause. (8) Perform blood tests when clinically indicated, e.g. haematocrit and cell blood count when haemorrhage is suspected, oxygen saturation and blood gas analysis when hypoxic syndromes are suspected, tro- ponin when cardiac ischaemia-related syncope is suspected, and D- dimer when pulmonary embolism is suspected, etc.\nDiagnosis: subsequent investigations\n",
      "keywords": [
        "selected",
        "force",
        "rules",
        "tloc",
        "management",
        "electrocardiogram",
        "pacemaker",
        "pulmonary embolism",
        "age",
        "orthostatic",
        "blood pressure",
        "syncope",
        "simple",
        "stress test",
        "icd",
        "carotid",
        "guide",
        "guidelines",
        "ecg",
        "patients",
        "diagno",
        "task",
        "according",
        "ablation"
      ],
      "tables": []
    },
    {
      "number": "42",
      "title": "9. Perform prolonged ECG monitoring (external or implantable) in patients with recurrent severe unexplained syncope who have all of the following three features: \u0003  Clinical or ECG features suggesting",
      "start_page": 54,
      "end_page": 54,
      "content": "Treatment\n",
      "keywords": [
        "clinical",
        "patients",
        "following",
        "three",
        "severe",
        "features",
        "perform",
        "implantable",
        "recurrent",
        "unexplained",
        "suggesting",
        "monitoring",
        "prolonged",
        "syncope",
        "external"
      ],
      "tables": []
    },
    {
      "number": "43",
      "title": "14. To all patients with reflex syncope and OH, explain the diagnosis, reassure, explain the risk of recurrence, and give advice on how to avoid triggers and situations. These measures are the corners",
      "start_page": 54,
      "end_page": 54,
      "content": "",
      "keywords": [
        "patients",
        "risk",
        "measures",
        "reflex",
        "give",
        "explain",
        "triggers",
        "these",
        "advice",
        "avoid",
        "situations",
        "corners",
        "reassure",
        "recurrence",
        "syncope",
        "diagnosis"
      ],
      "tables": []
    },
    {
      "number": "44",
      "title": "16. In patients with  OH , select one or more of the following additional specific treatments according to clinical severity: \u0003  Education regarding lifestyle manoeuvres. \u0003  Adequate hydration and sal",
      "start_page": 54,
      "end_page": 54,
      "content": "",
      "keywords": [
        "clinical",
        "patients",
        "following",
        "select",
        "according",
        "hydration",
        "additional",
        "education",
        "severity",
        "adequate",
        "regarding",
        "lifestyle",
        "treatments",
        "manoeuvres",
        "specific",
        "more"
      ],
      "tables": []
    },
    {
      "number": "45",
      "title": "11. Gaps in evidence and areas for future research",
      "start_page": 54,
      "end_page": 55,
      "content": "Clinicians responsible for managing patients with TLOC must fre- quently make treatment decisions without adequate evidence or a consensus of expert opinion. The following is a short list of selected, common issues that deserve to be addressed in future clinical research.\nDiagnosis: the gap between the best available scientific evidence and the need for the dissemination of these concepts into clinical practice There is wide variation in the practice of syncope evaluation, and wide variation in the adoption of recommendations from pub- lished guidelines. The absence of a systematic approach to TLOC incurs higher health and social care costs, unnecessary hospitaliza- tions and diagnostic procedures, prolongation of hospital stays, lower diagnostic rates, and higher rates of misdiagnoses and symp- tom recurrence. Therefore, there is a need for:\n1)  Large clinical studies that assess the diagnostic yield and compliance of a guideline-based standardized systematic approach\nDespite the recommendation from the ESC Guidelines on syncope, syncope units are not widely established in clinical practice. Barriers to establishing a syncope unit include lack of resources, lack of trained dedicated staff, and complex presentations to multiple settings, necessi- tating involvement from multiple disciplines. The evidence for the use- fulness of syncope units is controversial.\nESC Guidelines 1937\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .................................................................................... Therefore, there is a need for:\n2)  Large clinical studies that test the superiority of management in a dedicated syncope facility vs. conventional management\nDiagnosis: the need for new diagnostic tests and devices BP recording is crucial for the majority of clinical TLOC situations and will yield important information for the treatment of syncope. Unfortunately, current long-term BP (or surrogate) recording sys- tems are not optimal for diagnostic use in the syncope evaluation setting. Therefore, there is a need for:\n3) Development and validation of new diagnostic multiparametric devices that can record heart rhythm and BP (and possibly other physiological parameters such as cerebral saturation or EEG) at the time of a syncopal event.\nTreatment: lack of evidence of efficacy of most available therapies Only a few small RCTs have been conducted on treatment of syncope. In addition, syncopal recurrences are unpredictable and often decrease spontaneously after medical assessment, even in the absence of a specific therapy. The consequence of the spontaneous decrease is that any ther- apy for syncope prevention appears to be more effective than it actually is, making the results of observational data on therapy questionable in the absence of a control group. No therapy can be effective for all patients. Any therapy should be assessed in homogeneous subgroups.\n",
      "keywords": [
        "areas",
        "guideline",
        "gaps",
        "research",
        "syncope",
        "future",
        "evidence"
      ],
      "tables": [
        {
          "title": "1938 ESC Guidelines",
          "page_number": 55,
          "content": " |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  | Recommendations | Class | Level |  | \n |  | Diagnostic criteria with initial evaluation |  |  |  | \n |  | VVS is highly probable if syncope is precipitated by pain, fear, or standing, and is associated with typical progressive pro-\ndrome (pallor, sweating, and/or nausea).8,13–17 | I | C |  | \n |  | Situational reflex syncope is highly probable if syncope occurs during or immediately after specific triggers listed in Table 3.8,13–17 | I | C |  | \n |  | Syncope due to OH is confirmed when syncope occurs while standing and there is concomitant OH.18–24 | I | C |  | \n |  | Arrhythmic syncope is highly probable when the ECG shows25–39:\n• Persistent sinus bradycardia <40 b.p.m. or sinus pauses >3 s in the awake state and in the absence of physical training.\n• Mobitz II second- and third-degree AV block.\n• Alternating left and right BBB.\n• VT or rapid paroxysmal SVT.\n• Non-sustained episodes of polymorphic VT and long or short QT interval.\n• Pacemaker or ICD malfunction with cardiac pauses. | I | C |  | \n | Continued |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            464.3719889322917,
            548.0216064453125,
            700.3280029296875
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "46",
      "title": "Therefore, there is strong urgent need for RCTs on the efficacy of:",
      "start_page": 55,
      "end_page": 57,
      "content": "4) Pharmacological therapies targeted to specific subgroups of reflex syncope. 5) Pacemaker therapy targeted to specific subgroups of cardioinhibitory reflex syncope. 6) Pharmacological therapies of OH-mediated syncope. 7) ICD therapy targeted to specific subgroups of patients with unexplained syn- cope at risk of SCD.\nTreatment: the need for new therapies There is a need to move towards personalized medicine. Improving our knowledge of the biochemical mechanisms underlying specific forms of reflex syncope will allow the development of new therapies in such specific settings. For example, a low adenosine phenotype and a low norepinephrine phenotype have been recently identified. Therefore, there is a need for:\n8) Randomized clinical trials on the efficacy of theophylline (and other xantine antagonists) for low adenosine syncope and norepinephrine transport inhibi- tors for low epinephrine syncope.\nSyncope is a transient phenomenon. The ideal therapy should be one that is administered only when needed. Therefore, there is a need for:\n9) Randomized clinical trials of on-demand administration of specific therapy based on specific sensors similar to adrenalin injectors in asthma or nasal spray for paroxysmal SVT.\nRecommendations Class Level\nDiagnostic criteria with initial evaluation\nVVS is highly probable if syncope is precipitated by pain, fear, or standing, and is associated with typical progressive pro- drome (pallor, sweating, and/or nausea). 8 , 13 – 17 I C\nSituational reﬂex syncope is highly probable if syncope occurs during or immediately after speciﬁc triggers listed in  Table  3 . 8 , 13 – 17 I C\nSyncope due to OH is conﬁrmed when syncope occurs while standing and there is concomitant OH. 18 – 24 I C\nArrhythmic syncope is highly probable when the ECG shows 25–39 : •   Persistent sinus bradycardia <40 b.p.m. or sinus pauses >3 s in the awake state and in the absence of physical training. •   Mobitz II second- and third-degree AV block. •   Alternating left and right BBB. •   VT or rapid paroxysmal SVT. •   Non-sustained episodes of polymorphic VT and long or short QT interval. •   Pacemaker or ICD malfunction with cardiac pauses.\nI C\nContinued\n12. ‘What to do’ and ‘what not to do’ messages from the Guidelines\n1938 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\nManagement of syncope in the ED\nIt is recommended that patients with low-risk features, likely to have reﬂex or situational syncope or syncope due to OH,\nare discharged from the ED. 27 , 35 , 36 , 49 – 54 , 58 , 62 , 69 I B\nIt is recommended that patients with high-risk features receive an early intensive prompt evaluation in a syncope unit or in an ED observation unit (if available), or are hospitalized. 26 , 27 , 35 , 36 , 44 – 46 , 50 , 55 – 57 , 59 , 60 , 70 – 76 I B\nIt is recommended that patients who have neither high- nor low-risk features are observed in the ED or in a syncope unit\ninstead of being hospitalized. 40 , 63 – 65 , 77 I B\nCSM\nCSM is indicated in patients >40 years of age with syncope of unknown origin compatible with a reﬂex mechanism. 92 – 94 I B\nCSS is conﬁrmed if CSM causes bradycardia (asystole) and/or hypotension that reproduces spontaneous symptoms, and\npatients have clinical features compatible with a reﬂex mechanism of syncope. 89 , 90 , 92 , 93 , 98 – 102 I B\nActive standing\nIntermittent determination by sphygmomanometer of BP and HR while supine and during active standing for 3 min are indi-\ncated at initial syncope evaluation. 20 , 103 , 104 I C\nSyncope due to OH is conﬁrmed when there is a fall in systolic BP from a baseline value >_20 mmHg, diastolic BP >_10\nmmHg, or a decrease in systolic BP to <90 mmHg that reproduces spontaneous symptoms. 6 , 20 , 103 , 104 I C\nECG monitoring\nImmediate in-hospital monitoring (in bed or by telemetry) is indicated in high-risk patients (deﬁned in  Table  6 ). I C\nILR is indicated in an early phase of evaluation in patients with recurrent syncope of uncertain origin, absence of high-risk\ncriteria (listed in  Table  6 ), and a high likelihood of recurrence within the battery life of the device. 175 , 176 , 181 – 184 , 202 ,\nSupplementary Data Table 5\nI A\nILR is indicated in high-risk (criteria listed in  Table  6 ) patients in whom a comprehensive evaluation did not demonstrate a cause of syncope or lead to a speciﬁc treatment, and who do not have conventional indications for primary prevention ICD\nor pacemaker indication. 174 , 180 , 187 , 188 , 195 ,  Supplementary Data Tables 5 and 6\nI A\nArrhythmic syncope is conﬁrmed when a correlation between syncope and an arrhythmia (bradyarrhythmia or tachyar- rhythmia) is detected. 172 , 184 – 186 , 188 , 200 I B\nEPS\nIn patients with syncope and previous myocardial infarction or other scar-related conditions, EPS is indicated when syncope remains unexplained after non-invasive evaluation. 218 I B\nIn patients with unexplained syncope and bifascicular BBB, a pacemaker is indicated in the presence of either a baseline H-V\ninterval of >_70 ms, second- or third-degree His-Purkinje block during incremental atrial pacing, or with pharmacological\nchallenge. 188 , 214 – 217 , 221\nI B\nIn patients with unexplained syncope and previous myocardial infarction or other scar-related conditions, it is recom-\nmended that induction of sustained monomorphic VT is managed according to the current ESC Guidelines for VA. 46 I B\nIn patients without structural heart disease with syncope preceded by sudden and brief palpitations, it is recommended that\nthe induction of rapid SVT or VT, which reproduces hypotensive or spontaneous symptoms, is managed with appropriate therapy according to the current ESC Guidelines. 46 , 222\nI C\nEchocardiography\nEchocardiography is indicated for diagnosis and risk stratiﬁcation in patients with suspected structural heart disease. 235 , 236 I B\nExercise testing\nExercise testing is indicated in patients who experience syncope during or shortly after exertion. I C\nSyncope due to second- or third-degree AV block is conﬁrmed when the AV block develops during exercise, even without\nsyncope. 253 – 257 I C\nReﬂex syncope is conﬁrmed when syncope is reproduced immediately after exercise in the presence of severe hypotension. 250 – 252 I C\nContinued\nESC Guidelines 1939\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................. 13. Supplementary Data and Web Practical Instructions\nSupplementary Data with additional Web Tables complementing the full text, and an additional Web Practical Instructions document— with a glossary containing definitions of syncope and related concepts with tracings, videos, flow charts, and checklists—are available on the European Heart Journal  website and via the ESC Website at www. escardio.org/guidelines.\n",
      "keywords": [
        "bradycardia",
        "pacemaker",
        "systolic",
        "there",
        "efficacy",
        "age",
        "urgent",
        "scd",
        "rcts",
        "syncope",
        "diastolic",
        "arrhythmia",
        "icd",
        "need",
        "strong",
        "echocardiography",
        "ecg",
        "primary prevention",
        "exercise",
        "therefore",
        "recommended",
        "indication"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 1939",
          "page_number": 56,
          "content": " |  | Management of syncope in the ED |  |  |  | \n |  | It is recommended that patients with low-risk features, likely to have reflex or situational syncope or syncope due to OH,\nare discharged from the ED.27,35,36,49–54,58,62,69 | I | B |  | \n |  | It is recommended that patients with high-risk features receive an early intensive prompt evaluation in a syncope unit or in\nan ED observation unit (if available), or are hospitalized.26,27,35,36,44–46,50,55–57,59,60,70–76 | I | B |  | \n |  | It is recommended that patients who have neither high- nor low-risk features are observed in the ED or in a syncope unit\ninstead of being hospitalized.40,63–65,77 | I | B |  | \n |  | CSM |  |  |  | \n |  | CSM is indicated in patients >40 years of age with syncope of unknown origin compatible with a reflex mechanism.92–94 | I | B |  | \n |  | CSS is confirmed if CSM causes bradycardia (asystole) and/or hypotension that reproduces spontaneous symptoms, and\npatients have clinical features compatible with a reflex mechanism of syncope.89,90,92,93,98–102 | I | B |  | \n |  | Active standing |  |  |  | \n |  | Intermittent determination by sphygmomanometer of BP and HR while supine and during active standing for 3 min are indi-\ncated at initial syncope evaluation.20,103,104 | I | C |  | \n |  | Syncope due to OH is confirmed when there is a fall in systolic BP from a baseline value >20 mmHg, diastolic BP >10\n_ _\nmmHg, or a decrease in systolic BP to <90 mmHg that reproduces spontaneous symptoms.6,20,103,104 | I | C |  | \n |  | ECG monitoring |  |  |  | \n |  | Immediate in-hospital monitoring (in bed or by telemetry) is indicated in high-risk patients (defined in Table 6). | I | C |  | \n |  | ILR is indicated in an early phase of evaluation in patients with recurrent syncope of uncertain origin, absence of high-risk\ncriteria (listed in Table 6), and a high likelihood of recurrence within the battery life of the device.175,176,181–184,202,\nSupplementary Data Table 5 | I | A |  | \n |  | ILR is indicated in high-risk (criteria listed in Table 6) patients in whom a comprehensive evaluation did not demonstrate a\ncause of syncope or lead to a specific treatment, and who do not have conventional indications for primary prevention ICD\nor pacemaker indication.174,180,187,188,195, Supplementary Data Tables 5 and 6 | I | A |  | \n |  | Arrhythmic syncope is confirmed when a correlation between syncope and an arrhythmia (bradyarrhythmia or tachyar-\nrhythmia) is detected.172,184–186,188,200 | I | B |  | \n |  | EPS |  |  |  | \n |  | In patients with syncope and previous myocardial infarction or other scar-related conditions, EPS is indicated when syncope\nremains unexplained after non-invasive evaluation.218 | I | B |  | \n |  | In patients with unexplained syncope and bifascicular BBB, a pacemaker is indicated in the presence of either a baseline H-V\ninterval of >70 ms, second- or third-degree His-Purkinje block during incremental atrial pacing, or with pharmacological\n_\nchallenge.188,214–217,221 | I | B |  | \n |  | In patients with unexplained syncope and previous myocardial infarction or other scar-related conditions, it is recom-\nmended that induction of sustained monomorphic VT is managed according to the current ESC Guidelines for VA.46 | I | B |  | \n |  | In patients without structural heart disease with syncope preceded by sudden and brief palpitations, it is recommended that\nthe induction of rapid SVT or VT, which reproduces hypotensive or spontaneous symptoms, is managed with appropriate\ntherapy according to the current ESC Guidelines.46,222 | I | C |  | \n |  | Echocardiography |  |  |  | \n |  | Echocardiography is indicated for diagnosis and risk stratification in patients with suspected structural heart disease.235,236 | I | B |  | \n |  | Exercise testing |  |  |  | \n |  | Exercise testing is indicated in patients who experience syncope during or shortly after exertion. | I | C |  | \n |  | Syncope due to second- or third-degree AV block is confirmed when the AV block develops during exercise, even without\nsyncope.253–257 | I | C |  | \n |  | Reflex syncope is confirmed when syncope is reproduced immediately after exercise in the presence of severe hypotension.250–252 | I | C |  | \n | Continued |  |  |  |  | ",
          "bbox": [
            47.62200164794922,
            54.72521536690848,
            552.1884155273438,
            757.927978515625
          ],
          "function_potential": "raw"
        },
        {
          "title": "1940 ESC Guidelines",
          "page_number": 57,
          "content": " |  | Treatment of reflex syncope |  |  | \n |  | Explanation of the diagnosis, provision of reassurance, and explanation of the risk of recurrence and the avoidance of trig-\ngers and situations are indicated in all patients. Supplementary Data Table 10 | I | B | \n |  | Beta-adrenergic blocking drugs are not indicated.279,280 | III | A | \n |  | Cardiac pacing is not indicated in the absence of a documented cardioinhibitory reflex.299,300 | III | B | \n |  | Treatment of OH |  |  | \n |  | Explanation of the diagnosis, provision of reassurance, and explanation of the risk of recurrence and the avoidance of trig-\ngers and situations are indicated in all patients. | I | C | \n |  | Adequate hydration and salt intake are indicated.310,311 | I | C | \n |  | Treatment of syncope due to cardiac arrhythmias |  |  | \n |  | Cardiac pacing is indicated when there is an established relationship between syncope and symptomatic\nbradycardia.200,210–212,255,334–338,341 | I | B | \n |  | Cardiac pacing is indicated in patients with intermittent/paroxysmal intrinsic third- or second-degree AV block (including\nAF with slow ventricular conduction), although there is no documentation of a correlation between symptoms and ECG. | I | C | \n |  | Cardiac pacing is not indicated in patients when there are reversible causes for bradycardia. | III | C | \n |  | Cardiac pacing is indicated in patients with syncope, BBB, and a positive EPS or ILR-documented AV block.188,217 | I | B | \n |  | Catheter ablation is indicated in patients with syncope due to SVT or VT in order to prevent syncope recurrence. | I | C | \n |  | An ICD is indicated in patients with syncope due to VT and ejection fraction <35%.46\n_ | I | A | \n |  | An ICD is indicated in patients with syncope and previous myocardial infarction who have VT induced during EPS.218 | I | C | \n |  | ICD indications in patients with unexplained syncope and left ventricular systolic dysfunction |  |  | \n |  | ICD therapy is recommended to reduce SCD in patients with symptomatic heart failure (NYHA class II–III) and LVEF\n<35% after >3 months of optimal medical therapy, who are expected to survive for >1 year with good functional status.46\n_ _ _\nsystolic dysfunction | I | A | \n |  | Syncope in patients with comorbidity and frailty |  |  | \n |  | A multifactorial evaluation and intervention is recommended in older patients because more than one possible cause for\nsyncope and unexplained fall may be present.33,372–374,376–380 | I | B | \n |  | Neurological evaluation |  |  | \n |  | Neurological evaluation is indicated when syncope is suspected to be epilepsy or due to autonomic failure to evaluate the\nunderlying disease. | I | C | \n |  |  |  |  | \n |  |  |  |  | \n | AF = atrial fibrillation; AV = atrioventricular; BBB = bundle branch block; BP = blood pressure; b.p.m. = beats per minute; CSM = carotid sinus massage; CSS = carotid sinus syn-\ndrome; ECG = electrocardiogram; ED = emergency department; EPS = electrophysiological study; ESC = European Society of Cardiology; HR = heart rate; ICD = implantable |  |  |  | \n | cardioverter defibrillator; ILR = implantable loop recorder; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; OH = orthostatic hypotension;\nSCD = sudden cardiac death; SVT = supraventricular tachycardia; VA = ventricular arrhythmia; VT = ventricular tachycardia; VVS = vasovagal syncope. |  |  |  | \n |  |  |  |  | ",
          "bbox": [
            43.369998931884766,
            59.82720511300223,
            542.9855729442531,
            597.260009765625
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "47",
      "title": "14. Appendix",
      "start_page": 57,
      "end_page": 58,
      "content": "ESC Committee for Practice Guidelines (CPG):  Stephan Windecker (Chairperson) (Switzerland), Victor Aboyans (France), Stefan Agewall (Norway), Emanuele Barbato (Italy), He´ctor Bueno (Spain), Antonio Coca (Spain), Jean-Philippe Collet (France), Ioan Mircea Coman (Romania), Veronica Dean (France), Victoria Delgado (The Netherlands), Donna Fitzsimons (UK), Oliver Gaemperli (Switzerland), Gerhard Hindricks (Germany), Bernard Iung (France), Peter Ju¨ni (Canada), Hugo Albert Katus (Germany), Juhani\nTreatment of reﬂex syncope\nExplanation of the diagnosis, provision of reassurance, and explanation of the risk of recurrence and the avoidance of trig-\ngers and situations are indicated in all patients.  Supplementary Data Table 10 I B\nBeta-adrenergic blocking drugs are not indicated. 279 , 280 III A\nCardiac pacing is not indicated in the absence of a documented cardioinhibitory reﬂex. 299 , 300 III B\nTreatment of OH\nExplanation of the diagnosis, provision of reassurance, and explanation of the risk of recurrence and the avoidance of trig-\ngers and situations are indicated in all patients. I C\nAdequate hydration and salt intake are indicated. 310 , 311 I C\nTreatment of syncope due to cardiac arrhythmias\nCardiac pacing is indicated when there is an established relationship between syncope and symptomatic\nbradycardia. 200 , 210 – 212 , 255 , 334 – 338 , 341 I B\nCardiac pacing is indicated in patients with intermittent/paroxysmal intrinsic third- or second-degree AV block (including\nAF with slow ventricular conduction), although there is no documentation of a correlation between symptoms and ECG. I C\nCardiac pacing is not indicated in patients when there are reversible causes for bradycardia. III C\nCardiac pacing is indicated in patients with syncope, BBB, and a positive EPS or ILR-documented AV block. 188 , 217 I B\nCatheter ablation is indicated in patients with syncope due to SVT or VT in order to prevent syncope recurrence. I C\nAn ICD is indicated in patients with syncope due to VT and ejection fraction <_35%. 46 I A\nAn ICD is indicated in patients with syncope and previous myocardial infarction who have VT induced during EPS. 218 I C\nICD indications in patients with unexplained syncope and left ventricular systolic dysfunction\nICD therapy is recommended to reduce SCD in patients with symptomatic heart failure (NYHA class II–III) and LVEF\n<_35% after >_3 months of optimal medical therapy, who are expected to survive for >_1 year with good functional status. 46\nsystolic dysfunction\nI A\nSyncope in patients with comorbidity and frailty\nA multifactorial evaluation and intervention is recommended in older patients because more than one possible cause for syncope and unexplained fall may be present. 33 , 372 – 374 , 376 – 380 I B\nNeurological evaluation\nNeurological evaluation is indicated when syncope is suspected to be epilepsy or due to autonomic failure to evaluate the\nunderlying disease. I C\nAF = atrial ﬁbrillation; AV = atrioventricular; BBB = bundle branch block; BP = blood pressure; b.p.m. = beats per minute; CSM = carotid sinus massage; CSS = carotid sinus syn- drome; ECG = electrocardiogram; ED = emergency department; EPS = electrophysiological study; ESC = European Society of Cardiology; HR = heart rate; ICD = implantable cardioverter deﬁbrillator; ILR = implantable loop recorder; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; OH = orthostatic hypotension; SCD = sudden cardiac death; SVT = supraventricular tachycardia; VA = ventricular arrhythmia; VT = ventricular tachycardia; VVS = vasovagal syncope.\n1940 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................ Knuuti (Finland), Patrizio Lancellotti (Belgium), Christophe Leclercq (France), Theresa McDonagh (UK), Massimo Francesco Piepoli (Italy), Piotr Ponikowski (Poland), Dimitrios J. Richter (Greece), Marco Roffi (Switzerland), Evgeny Shlyakhto (Russia), Miguel Sousa- Uva (Portugal), Iain A. Simpson (UK), Jose Luis Zamorano (Spain).\nESC National Cardiac Societies  actively involved in the review process of the  2018 ESC Guidelines for the diagnosis and management of syncope:\nAustria:  Austrian Society of Cardiology, Franz Xaver Roithinger; Belarus:  Belorussian Scientific Society of Cardiologists, Alexandr Chasnoits; Belgium: Belgian Society of Cardiology, Yves Vandekerckhove;  Bulgaria:  Bulgarian Society of Cardiology, Vasil B. Traykov;  Croatia:  Croatian Cardiac Society, Davor Puljevic; Cyprus:  Cyprus Society of Cardiology, Elias Papasavvas;  Czech Republic:  Czech Society of Cardiology, Josef Kautzner;  Denmark: Danish Society of Cardiology, Henning Mølgaard;  Egypt:  Egyptian Society of Cardiology, Mostafa Nawar;  Finland:  Finnish Cardiac Society, Hannu Parikka;  The Former Yugoslav Republic of Macedonia : Macedonian FYR Society of Cardiology, Marija Vavlukis; France:  French Society of Cardiology, Olivier Piot;  Georgia: Georgian Society of Cardiology, Kakhaber Etsadashvili;  Germany: German Cardiac Society, Thomas Klingenheben;  Greece:  Hellenic Society of Cardiology, Spyridon Deftereos;  Hungary:  Hungarian Society of Cardiology, L \u0002 aszl \u0002 o S \u0002 aghy;  Iceland:  Icelandic Society of Cardiology, Kristjan Gudmundsson;  Israel:  Israel Heart Society, Roy Beinart;  Italy:  Italian Federation of Cardiology, Antonio Raviele; Kazakhstan:  Association of Cardiologists of Kazakhstan, Ayan Abdrakhmanov;  Kyrgyzstan:  Kyrgyz Society of Cardiology, Erkin Mirrakhimov,  Latvia:  Latvian Society of Cardiology, Oskars Kalejs; Libya:  Libyan Cardiac Society, Hisham A. Benlamin;  Lithuania: Lithuanian Society of Cardiology, Aras Puodziukynas;  Luxembourg: Luxembourg Society of Cardiology, Carlo Dimmer;  Malta:  Maltese Cardiac Society, Mark A. Sammut;  Moldova:  Moldavian Society of Cardiology, Aurica Raducan;  Montenegro:  Montenegro Society of Cardiology, Mihailo Vukmirovi \u0002 c;  Morocco:  Moroccan Society of Cardiology, Salima Abdelali;  The Netherlands : Netherlands Society of Cardiology, Martin E.W. Hemels;  Norway:  Norwegian Society of Cardiology, Kristina H. Haugaa;  Poland:  Polish Cardiac Society, Rafał Baranowski; Portugal: Portuguese Society of Cardiology, Pedro Silva Cunha;  Romania:  Romanian Society of Cardiology, Gheorghe-Andrei Dan;  Russian Federation:  Russian Society of Cardiology, Tatyana Tyurina;  San Marino:  San Marino Society of Cardiology, Luca Bertelli;  Slovakia:  Slovak Society of Cardiology, Peter Mitro;  Spain:  Spanish Society of Cardiology, Ignacio Fern \u0002 andez Lozano;  Sweden:  Swedish Society of Cardiology, Lennart Bergfeldt;  Switzerland:  Swiss Society of Cardiology, Stefan Osswald;  Tunisia:  Tunisian Society of Cardiology and Cardio- Vascular Surgery, Ben Halima Afef;  Turkey:  Turkish Society of Cardiology, H. Murat € Ozdem \u0002 ır; United Kingdom: British Cardiovascular Society, P. Boon Lim.\n",
      "keywords": [
        "ejection fraction",
        "older",
        "appendix",
        "vasovagal",
        "bradycardia",
        "sudden cardiac death",
        "electrocardiogram",
        "systolic",
        "tachycardia",
        "orthostatic",
        "scd",
        "blood pressure",
        "nyha",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "arrhythmia",
        "icd",
        "carotid",
        "ecg",
        "heart failure",
        "systolic dysfunction",
        "recommended",
        "class ii",
        "ablation"
      ],
      "tables": []
    },
    {
      "number": "48",
      "title": "15. References",
      "start_page": 58,
      "end_page": 58,
      "content": "",
      "keywords": [
        "references"
      ],
      "tables": []
    },
    {
      "number": "49",
      "title": "1. Mosqueda-Garcia R, Furlan R, Tank J, Fernandez-Violante R. The elusive patho- physiology of neurally mediated syncope.  Circulation  2000; 102 :2898–2906. 2. Morillo CA, Eckberg DL, Ellenbogen KA, ",
      "start_page": 58,
      "end_page": 58,
      "content": "",
      "keywords": [
        "mosqueda",
        "morillo",
        "elusive",
        "furlan",
        "patho",
        "tank",
        "mediated",
        "eckberg",
        "circulation",
        "physiology",
        "fernandez",
        "garcia",
        "syncope",
        "ellenbogen",
        "neurally",
        "violante"
      ],
      "tables": []
    },
    {
      "number": "50",
      "title": "3. Alboni P, Alboni M.  Vasovagal syncope . Heidelberg: Springer; 2015. p3–17. 4. Deharo JC, Guieu R, Mechulan A, Peyrouse E, Kipson N, Ruf J, Gerolami V, Devoto G, Marre V, Brignole M. Syncope withou",
      "start_page": 58,
      "end_page": 61,
      "content": "ESC Guidelines 1941\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .......................................................................................................................................................................... Antiarrhythmics Versus Implantable Defibrillators.  J Cardiovasc Electrophysiol 2001; 12 :996–1001. 30. Pezawas T, Stix G, Kastner J, Wolzt M, Mayer C, Moertl D, Schmidinger H. Unexplained syncope in patients with structural heart disease and no docu- mented ventricular arrhythmias: value of electrophysiologically guided implant- able cardioverter defibrillator therapy.  Europace  2003; 5 :305–312. 31. Olshansky B, Poole JE, Johnson G, Anderson J, Hellkamp AS, Packer D, Mark DB, Lee KL, Bardy GH, SCD-HeFT Investigators. Syncope predicts the out- come of cardiomyopathy patients: analysis of the SCD-HeFT study.  J Am Coll Cardiol  2008; 51 :1277–1282. 32. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, Maron BJ, Page RL, Passman RS, Siscovick D, Siscovick D, Stevenson WG, Zipes DP, American Heart Association, American College of Cardiology Foundation, Heart Rhythm Society. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninva- sive risk stratification techniques for identifying patients at risk for sudden car- diac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention.  Circulation  2008; 118 :1497–1518. 33. Del Rosso A, Alboni P, Brignole M, Menozzi C, Raviele A. Relation of clinical presentation of syncope to the age of patients. Am J Cardiol 2005; 96 :1431–1435. 34. Martin TP, Hanusa BH, Kapoor WN. Risk stratification of patients with syncope. Ann Emerg Med  1997; 29 :459–466. 35. Colivicchi F, Ammirati F, Melina D, Guido V, Imperoli G, Santini M, OESIL (Osservatorio Epidemiologico sulla Sincope nel Lazio) Study Investigators. Development and prospective validation of a risk stratification system for patients with syncope in the emergency department: the OESIL risk score.  Eur Heart J  2003; 24 :811–819. 36. Del Rosso A, Ungar A, Maggi R, Giada F, Petix NR, De Santo T, Menozzi C, Brignole M. Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general hospital: the EGSYS score. Heart 2008; 94 :1620–1626. 37. Mittal S, Hao SC, Iwai S, Stein KM, Markowitz SM, Slotwiner DJ, Lerman BB. Significance of inducible ventricular fibrillation in patients with coronary artery disease and unexplained syncope.  J Am Coll Cardiol  2001; 38 :371–376. 38. Alboni P, Brignole M, Menozzi C, Raviele A, Del Rosso A, Dinelli M, Solano A, Bottoni N. Diagnostic value of history in patients with syncope with or without heart disease.  J Am Coll Cardiol  2001; 37 :1921–1928. 39. Berecki-Gisolf J, Sheldon A, Wieling W, van Dijk N, Costantino G, Furlan R, Shen WK, Sheldon R. Identifying cardiac syncope based on clinical history: a literature-based model tested in four independent datasets. PLoS One 2013; 8 :e75255. 40. Casagranda I, Brignole M, Cencetti S, Cervellin G, Costantino G, Furlan R, Mossini G, Numeroso F, Pesenti Campagnoni M, Pinna Parpaglia P, Rafanelli M, Ungar A. Management of transient loss of consciousness of suspected syncopal cause, after the initial evaluation in the Emergency Department.  Emergency Care J  2016; 12 :25–27. 41. Crane SD. Risk stratification of patients with syncope in an accident and emer- gency department.  Emerg Med J  2002; 19 :23–27. 42. Sheldon R, Rose S, Ritchie D, Connolly SJ, Koshman ML, Lee MA, Frenneaux M, Fisher M, Murphy W. Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol  2002; 40 :142–148. 43. Numeroso F, Mossini G, Giovanelli M, Lippi G, Cervellin G. Short-term progno- sis and current management of syncopal patients at intermediate risk: results from the IRiS (Intermediate-Risk Syncope) study. Acad Emerg Med 2016; 23 :941–948. 44. Reed MJ, Newby DE, Coull AJ, Prescott RJ, Jacques KG, Gray AJ. The ROSE (Risk Stratification Of Syncope in the Emergency department) study.  J Am Coll Cardiol  2010; 55 :713–721. 45. Martin GJ, Adams SL, Martin HG, Mathews J, Zull D, Scanlon PJ. Prospective evaluation of syncope.  Ann Emerg Med  1984; 13 :499–504. 46. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ven- tricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).  Eur Heart J  2015; 36 :2793–2867. 47. Soteriades ES, Evans JC, Larson MG, Chen MH, Chen L, Benjamin EJ, Levy D. Incidence and prognosis of syncope.  N Engl J Med  2002; 347 :878–885. 48. Ricci F, Fedorowski A, Radico F, Romanello M, Tatasciore A, Di Nicola M, Zimarino M, De Caterina R. Cardiovascular morbidity and mortality related to\northostatic hypotension: a meta-analysis of prospective observational studies. Eur Heart J  2015; 36 :1609–1617. 49. Calkins H, Shyr Y, Frumin H, Schork A, Morady F. The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and neurocardiogenic syncope.  Am J Med 1995; 98 :365–373. 50. Sheldon R, Rose S, Connolly S, Ritchie D, Koshman ML, Frenneaux M. Diagnostic criteria for vasovagal syncope based on a quantitative history.  Eur Heart J  2006; 27 :344–350. 51. Lipsitz LA. Syncope in the elderly patient.  Hosp Pract (Off Ed)  1986; 21 :33–44. 52. Dermksian G, Lamb LE. Syncope in a population of healthy young adults; inci- dence, mechanisms, and significance.  J Am Med Assoc  1958; 168 :1200–1207. 53. Brignole M, Oddone D, Cogorno S, Menozzi C, Gianfranchi L, Bertulla A. Long- term outcome in symptomatic carotid sinus hypersensitivity.  Am Heart J 1992; 123 :687–692. 54. Jamjoom AA, Nikkar-Esfahani A, Fitzgerald JE. Operating theatre related syncope in medical students: a cross sectional study.  BMC Med Educ  2009; 9 :14. 55. Quinn JV, Stiell IG, McDermott DA, Sellers KL, Kohn MA, Wells GA. Derivation of the San Francisco Syncope Rule to predict patients with short- term serious outcomes.  Ann Emerg Med  2004; 43 :224–232. 56. Costantino G, Perego F, Dipaola F, Borella M, Galli A, Cantoni G, Dell’Orto S, Dassi S, Filardo N, Duca PG, Montano N, Furlan R, STePS Investigators. Short- and long-term prognosis of syncope, risk factors, and role of hospital admission: results from the STePS (Short-Term Prognosis of Syncope) study.  J Am Coll Cardiol  2008; 51 :276–283. 57. Colman N, Bakker A, Linzer M, Reitsma JB, Wieling W, Wilde AA. Value of history-taking in syncope patients: in whom to suspect long QT syndrome? Europace  2009; 11 :937–943. 58. Kapoor WN, Peterson J, Wieand HS, Karpf M. Diagnostic and prognostic impli- cations of recurrences in patients with syncope.  Am J Med  1987; 83 :700–708. 59. Oh JH, Hanusa BH, Kapoor WN. Do symptoms predict cardiac arrhythmias and mortality in patients with syncope?  Arch Intern Med  1999; 159 :375–380. 60. Grossman SA, Fischer C, Lipsitz LA, Mottley L, Sands K, Thompson S, Zimetbaum P, Shapiro NI. Predicting adverse outcomes in syncope.  J Emerg Med  2007; 33 :233–239. 61. Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, Rautaharju PM, van Herpen G, Wagner GS, Wellens H, American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology, American College of Cardiology Foundation, Heart Rhythm Society. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology.  J Am Coll Cardiol  2009; 53 :976–981. 62. Costantino G, Sun BC, Barbic F, Bossi I, Casazza G, Dipaola F, McDermott D, Quinn J, Reed MJ, Sheldon RS, Solbiati M, Thiruganasambandamoorthy V, Beach D, Bodemer N, Brignole M, Casagranda I, Del Rosso A, Duca P, Falavigna G, Grossman SA, Ippoliti R, Krahn AD, Montano N, Morillo CA, Olshansky B, Raj SR, Ruwald MH, Sarasin FP, Shen WK, Stiell I, Ungar A, Gert van Dijk J, van Dijk N, Wieling W, Furlan R. Syncope clinical management in the emergency department: a consensus from the first international work- shop on syncope risk stratification in the emergency department.  Eur Heart J 2016; 37 :1493–1498. 63. Kenny RA, Brignole M, Dan GA, Deharo JC, van Dijk JG, Doherty C, Hamdan M, Moya A, Parry SW, Sutton R, Ungar A, Wieling W. Syncope Unit: rationale and requirement–the European Heart Rhythm Association position statement endorsed by the Heart Rhythm Society.  Europace  2015; 17 :1325–1340. 64. Sun BC, McCreath H, Liang LJ, Bohan S, Baugh C, Ragsdale L, Henderson SO, Clark C, Bastani A, Keeler E, An R, Mangione CM. Randomized clinical trial of an emergency department observation syncope protocol versus routine inpa- tient admission.  Ann Emerg Med  2014; 64 :167–175. 65. Shen WK, Decker WW, Smars PA, Goyal DG, Walker AE, Hodge DO, Trusty JM, Brekke KM, Jahangir A, Brady PA, Munger TM, Gersh BJ, Hammill SC, Frye RL. Syncope Evaluation in the Emergency Department Study (SEEDS): a multi- disciplinary approach to syncope management.  Circulation  2004; 110 :3636–3645. 66. Thiruganasambandamoorthy V, Stiell IG, Wells GA, Vaidyanathan A, Mukarram M, Taljaard M. Outcomes in presyncope patients: a prospective cohort study. Ann Emerg Med  2015; 65 :268–276.e6. 67. Greve Y, Geier F, Popp S, Bertsch T, Singler K, Meier F, Smolarsky A, Mang H, Muller C, Christ M. The prevalence and prognostic significance of near syncope and syncope: a prospective study of 395 cases in an emergency department (the SPEED study).  Dtsch Arztebl Int  2014; 111 :197–204.\n1942 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ......................................................................................................................................................................... 68. Krahn AD, Klein GJ, Yee R, Skanes AC, REVEAL Investigators. Predictive value of presyncope in patients monitored for assessment of syncope.  Am Heart J 2001; 141 :817–821. 69. Huff JS, Decker WW, Quinn JV, Perron AD, Napoli AM, Peeters S, Jagoda AS, American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with syncope.  Ann Emerg Med  2007; 49 :431–444. 70. Thiruganasambandamoorthy V, Hess EP, Alreesi A, Perry JJ, Wells GA, Stiell IG. External validation of the San Francisco Syncope Rule in the Canadian setting. Ann Emerg Med  2010; 55 :464–472. 71. Brignole M, Menozzi C, Bartoletti A, Giada F, Lagi A, Ungar A, Ponassi I, Mussi C, Maggi R, Re G, Furlan R, Rovelli G, Ponzi P, Scivales A. A new management of syncope: prospective systematic guideline-based evaluation of patients referred urgently to general hospitals.  Eur Heart J  2006; 27 :76–82. 72. Del Greco M, Cozzio S, Scillieri M, Caprari F, Scivales A, Disertori M. Diagnostic pathway of syncope and analysis of the impact of guidelines in a dis- trict general hospital. The ECSIT study (epidemiology and costs of syncope in Trento).  Ital Heart J  2003; 4 :99–106. 73. McCarthy F, McMahon CG, Geary U, Plunkett PK, Kenny RA, Cunningham CJ, European Society of Cardiology. Management of syncope in the Emergency Department: a single hospital observational case series based on the application of European Society of Cardiology Guidelines.  Europace  2009; 11 :216–224. 74. Numeroso F, Mossini G, Spaggiari E, Cervellin G. Syncope in the emergency department of a large northern Italian hospital: incidence, efficacy of a short- stay observation ward and validation of the OESIL risk score.  Emerg Med J 2010; 27 :653–658. 75. Lin M, Wolfe RE, Shapiro NI, Novack V, Lior Y, Grossman SA. Observation vs admission in syncope: can we predict short length of stays?  Am J Emerg Med 2015; 33 :1684–1686. 76. Grossman AM, Volz KA, Shapiro NI, Salem R, Sanchez LD, Smulowitz P, Grossman SA. Comparison of 1-day emergency department observation and inpatient ward for 1-day admissions in syncope patients.  J Emerg Med 2016; 50 :217–222. 77. Ungar A, Tesi F, Chisciotti VM, Pepe G, Vanni S, Grifoni S, Balzi D, Rafanelli M, Marchionni N, Brignole M. Assessment of a structured management pathway for patients referred to the Emergency Department for syncope: results in a tertiary hospital.  Europace  2016; 18 :457–462. 78. Serrano LA, Hess EP, Bellolio MF, Murad MH, Montori VM, Erwin PJ, Decker WW. Accuracy and quality of clinical decision rules for syncope in the emer- gency department: a systematic review and meta-analysis.  Ann Emerg Med 2010; 56 :362–373.e1. 79. Dipaola F, Costantino G, Perego F, Borella M, Galli A, Cantoni G, Barbic F, Casella F, Duca PG, Furlan R, STePS investigators. San Francisco Syncope Rule, Osservatorio Epidemiologico sulla Sincope nel Lazio risk score, and clinical judgment in the assessment of short-term outcome of syncope.  Am J Emerg Med  2010; 28 :432–439. 80. Sheldon RS, Morillo CA, Krahn AD, O’Neill B, Thiruganasambandamoorthy V, Parkash R, Talajic M, Tu JV, Seifer C, Johnstone D, Leather R. Standardized approaches to the investigation of syncope: Canadian Cardiovascular Society position paper.  Can J Cardiol  2011; 27 :246–253. 81. Perego F, Costantino G, Dipaola F, Scannella E, Borella M, Galli A, Barbic F, Casella F, Solbiati M, Angaroni L, Duca P, Furlan R. Predictors of hospital admis- sion after syncope: relationships with clinical risk scores.  Int J Cardiol 2012; 161 :182–183. 82. Schladenhaufen R, Feilinger S, Pollack M, Benenson R, Kusmiesz AL. Application of San Francisco Syncope Rule in elderly ED patients.  Am J Emerg Med 2008; 26 :773–778. 83. Sun BC, Mangione CM, Merchant G, Weiss T, Shlamovitz GZ, Zargaraff G, Shiraga S, Hoffman JR, Mower WR. External validation of the San Francisco Syncope Rule.  Ann Emerg Med  2007; 49 :420–427, 427.e1–4. 84. Reed MJ, Henderson SS, Newby DE, Gray AJ. One-year prognosis after syn- cope and the failure of the ROSE decision instrument to predict one-year adverse events.  Ann Emerg Med  2011; 58 :250–256. 85. Birnbaum A, Esses D, Bijur P, Wollowitz A, Gallagher EJ. Failure to validate the San Francisco Syncope Rule in an independent emergency department popula- tion.  Ann Emerg Med  2008; 52 :151–159. 86. Costantino G, Casazza G, Reed M, Bossi I, Sun B, Del Rosso A, Ungar A, Grossman S, D’Ascenzo F, Quinn J, McDermott D, Sheldon R, Furlan R. Syncope risk stratification tools vs clinical judgment: an individual patient data meta-analysis.  Am J Med  2014; 127 :1126.e13–25. 87. Canzoniero JV, Afshar E, Hedian H, Koch C, Morgan DJ. Unnecessary hospital- ization and related harm for patients with low-risk syncope.  JAMA Intern Med 2015; 175 :1065–1067. 88. Thiruganasambandamoorthy V, Kwong K, Wells GA, Sivilotti ML, Mukarram M, Rowe BH, Lang E, Perry JJ, Sheldon R, Stiell IG, Taljaard M. Development of the\nCanadian Syncope Risk Score to predict serious adverse events after emer- gency department assessment of syncope.  CMAJ  2016; 188 :E289–E298. 89. Kerr SR, Pearce MS, Brayne C, Davis RJ, Kenny RA. Carotid sinus hypersensitiv- ity in asymptomatic older persons: implications for diagnosis of syncope and falls.  Arch Intern Med  2006; 166 :515–520. 90. Puggioni E, Guiducci V, Brignole M, Menozzi C, Oddone D, Donateo P, Croci F, Solano A, Lolli G, Tomasi C, Bottoni N. Results and complications of the caro- tid sinus massage performed according to the “method of symptoms”.  Am J Cardiol  2002; 89 :599–601. 91. Wieling W, Krediet CT, Solari D, de Lange FJ, van Dijk N, Thijs RD, van Dijk JG, Brignole M, Jardine DL. At the heart of the arterial baroreflex: a physiologi- cal basis for a new classification of carotid sinus hypersensitivity.  J Intern Med 2013; 273 :345–358. 92. Solari D, Maggi R, Oddone D, Solano A, Croci F, Donateo P, Brignole M. Clinical context and outcome of carotid sinus syndrome diagnosed by means of the ‘method of symptoms’.  Europace  2014; 16 :928–934. 93. Solari D, Maggi R, Oddone D, Solano A, Croci F, Donateo P, Wieling W, Brignole M. Assessment of the vasodepressor reflex in carotid sinus syndrome. Circ Arrhythm Electrophysiol  2014; 7 :505–510. 94. Brignole M, Ungar A, Casagranda I, Gulizia M, Lunati M, Ammirati F, Del Rosso A, Sasdelli M, Santini M, Maggi R, Vitale E, Morrione A, Francese GM, Vecchi MR, Giada F, Syncope Unit Project (SUP) investigators. Prospective multicentre systematic guideline-based management of patients referred to the Syncope Units of general hospitals.  Europace  2010; 12 :109–118. 95. Munro NC, McIntosh S, Lawson J, Morley CA, Sutton R, Kenny RA. Incidence of complications after carotid sinus massage in older patients with syncope. J Am Geriatr Soc  1994; 42 :1248–1251. 96. Ungar A, Rivasi G, Rafanelli M, Toffanello G, Mussi C, Ceccofiglio A, McDonagh R, Drumm B, Marchionni N, Alboni P, Kenny RA. Safety and tolerability of Tilt Testing and Carotid Sinus Massage in the octogenarians. Age Ageing 2016; 45 :242–248. 97. Davies AJ, Kenny RA. Frequency of neurologic complications following carotid sinus massage.  Am J Cardiol  1998; 81 :1256–1257. 98. Brignole M, Menozzi C, Lolli G, Bottoni N, Gaggioli G. Long-term outcome of paced and nonpaced patients with severe carotid sinus syndrome.  Am J Cardiol 1992; 69 :1039–1043. 99. Claesson JE, Kristensson BE, Edvardsson N, Wahrborg P. Less syncope and milder symptoms in patients treated with pacing for induced cardioinhibitory carotid sinus syndrome: a randomized study.  Europace  2007; 9 :932–936. 100. Menozzi C, Brignole M, Lolli G, Bottoni N, Oddone D, Gianfranchi L, Gaggioli G. Follow-up of asystolic episodes in patients with cardioinhibitory, neurally mediated syncope and VVI pacemaker.  Am J Cardiol  1993; 72 :1152–1155. 101. Maggi R, Menozzi C, Brignole M, Podoleanu C, Iori M, Sutton R, Moya A, Giada F, Orazi S, Grovale N. Cardioinhibitory carotid sinus hypersensitivity predicts an asystolic mechanism of spontaneous neurally mediated syncope.  Europace 2007; 9 :563–567. 102. Thomas JE. Hyperactive carotid sinus reflex and carotid sinus syncope.  Mayo Clin Proc  1969; 44 :127–139. 103. Smit AA, Halliwill JR, Low PA, Wieling W. Pathophysiological basis of ortho- static hypotension in autonomic failure.  J Physiol  1999; 519 :1–10. 104. Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment.  J Am Coll Cardiol  2015; 66 :848–860. 105. Kenny RA, Ingram A, Bayliss J, Sutton R. Head-up tilt: a useful test for investigat- ing unexplained syncope.  Lancet  1986; 1 :1352–1355. 106. Bartoletti A, Alboni P, Ammirati F, Brignole M, Del Rosso A, Foglia Manzillo G, Menozzi C, Raviele A, Sutton R. ‘The Italian Protocol‘: a simplified head-up tilt testing potentiated with oral nitroglycerin to assess patients with unexplained syncope.  Europace  2000; 2 :339–342. 107. Kenny RA, O’Shea D, Parry SW. The Newcastle protocols for head-up tilt table testing in the diagnosis of vasovagal syncope, carotid sinus hypersensitivity, and related disorders.  Heart  2000; 83 :564–569. 108. Benditt DG, Ferguson DW, Grubb BP, Kapoor WN, Kugler J, Lerman BB, Maloney JD, Raviele A, Ross B, Sutton R, Wolk MJ, Wood DL. Tilt table testing for assessing syncope. American College of Cardiology.  J Am Coll Cardiol  1996; 28 :263–275. 109. Morillo CA, Klein GJ, Zandri S, Yee R. Diagnostic accuracy of a low-dose iso- proterenol head-up tilt protocol.  Am Heart J  1995; 129 :901–906. 110. Forleo C, Guida P, Iacoviello M, Resta M, Monitillo F, Sorrentino S, Favale S. Head-up tilt testing for diagnosing vasovagal syncope: a meta-analysis.  Int J Cardiol  2013; 168 :27–35. 111. Parry SW, Gray JC, Newton JL, Reeve P, O’Shea D, Kenny RA. ‘Front-loaded‘ head-up tilt table testing: validation of a rapid first line nitrate-provoked tilt pro- tocol for the diagnosis of vasovagal syncope.  Age Ageing  2008; 37 :411–415. 112. Verheyden B, Gisolf J, Beckers F, Karemaker JM, Wesseling KH, Aubert AE, Wieling W. Impact of age on the vasovagal response provoked by sublingual nitroglycerine in routine tilt testing.  Clin Sci (Lond)  2007; 113 :329–337.\nESC Guidelines 1943\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................ 113. Nilsson D, Sutton R, Tas W, Burri P, Melander O, Fedorowski A. Orthostatic changes in hemodynamics and cardiovascular biomarkers in dysautonomic patients.  PLoS One  2015; 10 :e0128962. 114. Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS).  J Cardiovasc Electrophysiol  2009; 20 :352–358. 115. Petersen ME, Williams TR, Sutton R. Psychogenic syncope diagnosed by pro- longed head-up tilt testing.  QJM  1995; 88 :209–213. 116. Tannemaat MR, van Niekerk J, Reijntjes RH, Thijs RD, Sutton R, van Dijk JG. The semiology of tilt-induced psychogenic pseudosyncope. Neurology 2013; 81 :752–758. 117. Blad H, Lamberts RJ, van Dijk GJ, Thijs RD. Tilt-induced vasovagal syncope and psychogenic pseudosyncope: Overlapping clinical entities. Neurology 2015; 85 :2006–2010. 118. Moya A, Permanyer-Miralda G, Sagrista-Sauleda J, Carne X, Rius T, Mont L, Soler-Soler J. Limitations of head-up tilt test for evaluating the efficacy of thera- peutic interventions in patients with vasovagal syncope: results of a controlled study of etilefrine versus placebo.  J Am Coll Cardiol  1995; 25 :65–69. 119. Brignole M, Croci F, Menozzi C, Solano A, Donateo P, Oddone D, Puggioni E, Lolli G. Isometric arm counter-pressure maneuvers to abort impending vasova- gal syncope.  J Am Coll Cardiol  2002; 40 :2053–2059. 120. Krediet CT, van Dijk N, Linzer M, van Lieshout JJ, Wieling W. Management of vasovagal syncope: controlling or aborting faints by leg crossing and muscle tensing.  Circulation  2002; 106 :1684–1689. 121. van Dijk N, Quartieri F, Blanc JJ, Garcia-Civera R, Brignole M, Moya A, Wieling W, PCTrial Investigators. Effectiveness of physical counterpressure maneuvers in preventing vasovagal syncope: the Physical Counterpressure Manoeuvres Trial (PC-Trial).  J Am Coll Cardiol  2006; 48 :1652–1657. 122. Deharo JC, Jego C, Lanteaume A, Djiane P. An implantable loop recorder study of highly symptomatic vasovagal patients: the heart rhythm observed during a spontaneous syncope is identical to the recurrent syncope but not correlated with the head-up tilt test or adenosine triphosphate test.  J Am Coll Cardiol 2006; 47 :587–593. 123. Brignole M, Sutton R, Menozzi C, Garcia-Civera R, Moya A, Wieling W, Andresen D, Benditt DG, Grovale N, De Santo T, Vardas P, International Study on Syncope of Uncertain Etiology 2 (ISSUE 2) Group. Lack of correlation between the responses to tilt testing and adenosine triphosphate test and the mechanism of spontaneous neurally mediated syncope. Eur Heart J 2006; 27 :2232–2239. 124. Flevari P, Leftheriotis D, Komborozos C, Fountoulaki K, Dagres N, Theodorakis G, Kremastinos D. Recurrent vasovagal syncope: comparison between clomipr- amine and nitroglycerin as drug challenges during head-up tilt testing.  Eur Heart J  2009; 30 :2249–2253. 125. Petersen ME, Williams TR, Gordon C, Chamberlain-Webber R, Sutton R. The normal response to prolonged passive head up tilt testing. Heart 2000; 84 :509–514. 126. Furukawa T, Maggi R, Solano A, Croci F, Brignole M. Effect of clinical triggers on positive responses to tilt-table testing potentiated with nitroglycerin or clo- mipramine.  Am J Cardiol  2011; 107 :1693–1697. 127. Petix NR, Del Rosso A, Furlan R, Guarnaccia V, Zipoli A. Nitrate-potentiated head-up tilt testing (HUT) has a low diagnostic yield in patients with likely vaso- vagal syncope.  Pacing Clin Electrophysiol  2014; 37 :164–172. 128. Raviele A, Menozzi C, Brignole M, Gasparini G, Alboni P, Musso G, Lolli G, Oddone D, Dinelli M, Mureddu R. Value of head-up tilt testing potentiated with sublingual nitroglycerin to assess the origin of unexplained syncope.  Am J Cardiol 1995; 76 :267–272. 129. Ungar A, Sgobino P, Russo V, Vitale E, Sutton R, Melissano D, Beiras X, Bottoni N, Ebert HH, Gulizia M, Jorfida M, Moya A, Andresen D, Grovale N, Brignole M, International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators. Diagnosis of neurally mediated syncope at initial evaluation and with tilt table testing compared with that revealed by prolonged ECG monitor- ing. An analysis from the Third International Study on Syncope of Uncertain Etiology (ISSUE-3).  Heart  2013; 99 :1825–1831. 130. Brignole M, Gianfranchi L, Menozzi C, Raviele A, Oddone D, Lolli G, Bottoni N. Role of autonomic reflexes in syncope associated with paroxysmal atrial fibrilla- tion.  J Am Coll Cardiol  1993; 22 :1123–1129. 131. Leitch JW, Klein GJ, Yee R, Leather RA, Kim YH. Syncope associated with supraventricular tachycardia. An expression of tachycardia rate or vasomotor response?  Circulation  1992; 85 :1064–1071. 132. Sutton R, Brignole M. Twenty-eight years of research permit reinterpretation of tilt-testing: hypotensive susceptibility rather than diagnosis.  Eur Heart J 2014; 35 :2211–2212. 133. Taneja I, Marney A, Robertson D. Aortic stenosis and autonomic dysfunction: co-conspirators in syncope.  Am J Med Sci  2004; 327 :281–283. 134. Thomson HL, Morris-Thurgood J, Atherton J, Frenneaux M. Reduced cardiopul- monary baroreflex sensitivity in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol  1998; 31 :1377–1382.\n",
      "keywords": [
        "older",
        "vasovagal",
        "brignole",
        "sudden cardiac death",
        "guideline",
        "electrocardiogram",
        "pacemaker",
        "tachycardia",
        "kipson",
        "age",
        "tilt test",
        "orthostatic",
        "scd",
        "risk stratification",
        "transient loss of consciousness",
        "springer",
        "syncope",
        "ventricular tachycardia",
        "aortic",
        "carotid",
        "presyncope",
        "heidelberg",
        "devoto",
        "marre",
        "alboni",
        "guieu",
        "cardiomyopathy",
        "elderly",
        "ecg",
        "deharo"
      ],
      "tables": []
    },
    {
      "number": "51",
      "title": "135. Brignole M, Menozzi C, Gianfranchi L, Oddone D, Lolli G, Bertulla A. Neurally mediated syncope detected by carotid sinus massage and head-up tilt test in sick sinus syndrome.  Am J Cardiol  1991;",
      "start_page": 61,
      "end_page": 64,
      "content": "1944 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................ emergency department patients presenting with syncope useful tests? A pre- liminary investigation.  J Emerg Med  2014; 47 :113–118. 159. Benezet-Mazuecos J, Ibanez B, Rubio JM, Navarro F, Martin E, Romero J, Farre J. Utility of in-hospital cardiac remote telemetry in patients with unexplained syn- cope.  Europace  2007; 9 :1196–1201. 160. Croci F, Brignole M, Alboni P, Menozzi C, Raviele A, Del Rosso A, Dinelli M, Solano A, Bottoni N, Donateo P. The application of a standardized strategy of evaluation in patients with syncope referred to three syncope units.  Europace 2002; 4 :351–355. 161. Bass EB, Curtiss EI, Arena VC, Hanusa BH, Cecchetti A, Karpf M, Kapoor WN. The duration of Holter monitoring in patients with syncope. Is 24 hours enough?  Arch Intern Med  1990; 150 :1073–1078. 162. Rockx MA, Hoch JS, Klein GJ, Yee R, Skanes AC, Gula LJ, Krahn AD. Is ambula- tory monitoring for “community-acquired” syncope economically attractive? A cost-effectiveness analysis of a randomized trial of external loop recorders ver- sus Holter monitoring.  Am Heart J  2005; 150 :1065. 163. Kinlay S, Leitch JW, Neil A, Chapman BL, Hardy DB, Fletcher PJ. Cardiac event recorders yield more diagnoses and are more cost-effective than 48-hour Holter monitoring in patients with palpitations. A controlled clinical trial.  Ann Intern Med  1996; 124 :16–20. 164. Bruining N, Caiani E, Chronaki C, Guzik P, van der Velde E, Task Force of the e-Cardiology Working. Acquisition and analysis of cardiovascular signals on smartphones: potential, pitfalls and perspectives: by the Task Force of the e- Cardiology Working Group of European Society of Cardiology.  Eur J Prev Cardiol  2014; 21 :4–13. 165. Waks JW, Fein AS, Das S. Wide complex tachycardia recorded with a smart- phone cardiac rhythm monitor.  JAMA Intern Med  2015; 175 :437–439. 166. Locati ET, Moya A, Oliveira M, Tanner H, Willems R, Lunati M, Brignole M. External prolonged electrocardiogram monitoring in unexplained syncope and palpitations: results of the SYNARR-Flash study.  Europace  2016; 18 :1265–1272. 167. Linzer M, Pritchett EL, Pontinen M, McCarthy E, Divine GW. Incremental diag- nostic yield of loop electrocardiographic recorders in unexplained syncope.  Am J Cardiol  1990; 66 :214–219. 168. Schuchert A, Maas R, Kretzschmar C, Behrens G, Kratzmann I, Meinertz T. Diagnostic yield of external electrocardiographic loop recorders in patients with recurrent syncope and negative tilt table test.  Pacing Clin Electrophysiol 2003; 26 :1837–1840. 169. Drak-Hern \u0002 andez Y, Toquero-Ramos J, Fern \u0002 andez JM, Pe´rez-Pereira E, Castro- Urda V, Fern \u0002 andez-Lozano I. Effectiveness and safety of remote monitoring of patients with an implantable loop recorder.  Rev Esp Cardiol (Engl Ed) 2013; 66 :943–948. 170. Furukawa T, Maggi R, Bertolone C, Ammirati F, Santini M, Ricci R, Giada F, Brignole M. Effectiveness of remote monitoring in the management of syncope and palpitations.  Europace  2011; 13 :431–437. 171. Rothman SA, Laughlin JC, Seltzer J, Walia JS, Baman RI, Siouffi SY, Sangrigoli RM, Kowey PR. The diagnosis of cardiac arrhythmias: a prospective multi- center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring.  J Cardiovasc Electrophysiol  2007; 18 :241–247. 172. Farwell DJ, Freemantle N, Sulke N. The clinical impact of implantable loop recorders in patients with syncope.  Eur Heart J  2006; 27 :351–356. 173. Krahn AD, Klein GJ, Yee R, Skanes AC. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. Circulation  2001; 104 :46–51. 174. Da Costa A, Defaye P, Romeyer-Bouchard C, Roche F, Dauphinot V, Deharo JC, Jacon P, Lamaison D, Bathelemy JC, Isaaz K, Laurent G. Clinical impact of the implantable loop recorder in patients with isolated syncope, bundle branch block and negative workup: a randomized multicentre prospective study.  Arch Cardiovasc Dis  2013; 106 :146–154. 175. Podoleanu C, DaCosta A, Defaye P, Taieb J, Galley D, Bru P, Maury P, Mabo P, Boveda S, Cellarier G, Anselme F, Kouakam C, Delarche N, Deharo JC, FRESH investigators. Early use of an implantable loop recorder in syncope evaluation: a randomized study in the context of the French healthcare system (FRESH study).  Arch Cardiovasc Dis  2014; 107 :546–552. 176. Sulke N, Sugihara C, Hong P, Patel N, Freemantle N. The benefit of a remotely monitored implantable loop recorder as a first line investigation in unexplained syncope: the EaSyAS II trial.  Europace  2016; 18 :912–918. 177. Edvardsson N, Garutti C, Rieger G, Linker NJ, PICTURE Study Investigators. Unexplained syncope: implications of age and gender on patient characteristics and evaluation, the diagnostic yield of an implantable loop recorder, and the subsequent treatment.  Clin Cardiol  2014; 37 :618–625. 178. Edvardsson N, Wolff C, Tsintzos S, Rieger G, Linker NJ. Costs of unstructured investigation of unexplained syncope: insights from a micro-costing analysis of the observational PICTURE registry.  Europace  2015; 17 :1141–1148. 179. Brignole M, Vardas P, Hoffman E, Huikuri H, Moya A, Ricci R, Sulke N, Wieling W, Auricchio A, Lip GY, Almendral J, Kirchhof P, Aliot E, Gasparini M, Braunschweig F, Lip GY, Almendral J, Kirchhof P, Botto GL, EHRA Scientific\nDocuments Committee. Indications for the use of diagnostic implantable and external ECG loop recorders.  Europace  2009; 11 :671–687. 180. Menozzi C, Brignole M, Garcia-Civera R, Moya A, Botto G, Tercedor L, Migliorini R, Navarro X, International Study on Syncope of Uncertain Etiology (ISSUE) Investigators. Mechanism of syncope in patients with heart disease and negative electrophysiologic test.  Circulation  2002; 105 :2741–2745. 181. Linker NJ, Voulgaraki D, Garutti C, Rieger G, Edvardsson N, PICTURE Study Investigators. Early versus delayed implantation of a loop recorder in patients with unexplained syncope–effects on care pathway and diagnostic yield.  Int J Cardiol  2013; 170 :146–151. 182. Edvardsson N, Frykman V, van Mechelen R, Mitro P, Mohii-Oskarsson A, Pasquie JL, Ramanna H, Schwertfeger F, Ventura R, Voulgaraki D, Garutti C, Stolt P, Linker NJ, PICTURE Study Investigators. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry.  Europace  2011; 13 :262–269. 183. Lacunza-Ruiz FJ, Moya-Mitjans A, Martinez-Alday J, Baron-Esquivias G, Ruiz- Granell R, Rivas-Gandara N, Gonzalez-Enriquez S, Leal-del-Ojo J, Arcocha- Torres MF, Perez-Villacastin J, Garcia-Heil N, Garcia-Alberola A. Implantable loop recorder allows an etiologic diagnosis in one-third of patients. Results of the Spanish reveal registry.  Circ J  2013; 77 :2535–2541. 184. Brignole M, Sutton R, Menozzi C, Garcia-Civera R, Moya A, Wieling W, Andresen D, Benditt DG, Vardas P, International Study on Syncope of Uncertain Etiology 2 (ISSUE 2) Group. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope.  Eur Heart J  2006; 27 :1085–1092. 185. Brignole M, Menozzi C, Moya A, Andresen D, Blanc JJ, Krahn AD, Wieling W, Beiras X, Deharo JC, Russo V, Tomaino M, Sutton R, International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators. Pacemaker therapy in patients with neurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3): a randomized trial.  Circulation  2012; 125 :2566–2571. 186. Brignole M, Ammirati F, Arabia F, Quartieri F, Tomaino M, Ungar A, Lunati M, Russo V, Del Rosso A, Gaggioli G, Syncope Unit Project (SUP) Two Investigators. Assessment of a standardized algorithm for cardiac pacing in older patients affected by severe unpredictable reflex syncopes.  Eur Heart J 2015; 36 :1529–1535. 187. Brignole M, Menozzi C, Moya A, Garcia-Civera R, Mont L, Alvarez M, Errazquin F, Beiras J, Bottoni N, Donateo P, International Study on Syncope of Uncertain Etiology (ISSUE) Investigators. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test. Circulation 2001; 104 :2045–2050. 188. Moya A, Garcia-Civera R, Croci F, Menozzi C, Brugada J, Ammirati F, Del Rosso A, Bellver-Navarro A, Garcia-Sacristan J, Bortnik M, Mont L, Ruiz-Granell R, Navarro X, Bradycardia detection in Bundle Branch Block (B4) study. Diagnosis, management, and outcomes of patients with syncope and bundle branch block.  Eur Heart J  2011; 32 :1535–1541. 189. Ho RT, Wicks T, Wyeth D, Nei M. Generalized tonic-clonic seizures detected by implantable loop recorder devices: diagnosing more than cardiac arrhyth- mias.  Heart Rhythm  2006; 3 :857–861. 190. Petkar S, Hamid T, Iddon P, Clifford A, Rice N, Claire R, McKee D, Curtis N, Cooper PN, Fitzpatrick AP. Prolonged implantable electrocardiographic moni- toring indicates a high rate of misdiagnosis of epilepsy–REVISE study.  Europace 2012; 14 :1653–1660. 191. Maggi R, Rafanelli M, Ceccofiglio A, Solari D, Brignole M, Ungar A. Additional diagnostic value of implantable loop recorder in patients with initial diagnosis of real or apparent transient loss of consciousness of uncertain origin.  Europace 2014; 16 :1226–1230. 192. Armstrong VL, Lawson J, Kamper AM, Newton J, Kenny RA. The use of an implantable loop recorder in the investigation of unexplained syncope in older people.  Age Ageing  2003; 32 :185–188. 193. Ryan DJ, Nick S, Colette SM, Roseanne K. Carotid sinus syndrome, should we pace? A multicentre, randomised control trial (Safepace 2). Heart 2010; 96 :347–351. 194. Bhangu J, McMahon CG, Hall P, Bennett K, Rice C, Crean P, Sutton R, Kenny RA. Long-term cardiac monitoring in older adults with unexplained falls and syncope.  Heart  2016; 102 :681–686. 195. Krahn AD, Klein GJ, Norris C, Yee R. The etiology of syncope in patients with negative tilt table and electrophysiological testing. Circulation 1995; 92 :1819–1824. 196. Krahn AD, Klein GJ, Yee R, Takle-Newhouse T, Norris C. Use of an extended monitoring strategy in patients with problematic syncope. Reveal Investigators. Circulation  1999; 99 :406–410. 197. Krahn AD, Klein GJ, Yee R, Skanes AC. Detection of asymptomatic arrhythmias in unexplained syncope.  Am Heart J  2004; 148 :326–332. 198. Ermis C, Zhu AX, Pham S, Li JM, Guerrero M, Vrudney A, Hiltner L, Lu F, Sakaguchi S, Lurie KG, Benditt DG. Comparison of automatic and patient-\nESC Guidelines 1945\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................ activated arrhythmia recordings by implantable loop recorders in the evaluation of syncope.  Am J Cardiol  2003; 92 :815–819. 199. Moya A, Brignole M, Sutton R, Menozzi C, Garcia-Civera R, Wieling W, Andresen D, Benditt DG, Garcia-Sacristan JF, Beiras X, Grovale N, Vardas P, International Study on Syncope of Uncertain Etiology 2 (ISSUE 2) Group. Reproducibility of electrocardiographic findings in patients with suspected reflex neurally-mediated syncope. Am J Cardiol 2008; 102 :1518–1523. 200. Sud S, Klein GJ, Skanes AC, Gula LJ, Yee R, Krahn AD. Implications of mecha- nism of bradycardia on response to pacing in patients with unexplained syn- cope.  Europace  2007; 9 :312–318. 201. Olmos C, Franco E, Suarez-Barrientos A, Fortuny E, Martin-Garcia A, Viliani D, Macaya C, Perez de Isla L. Wearable wireless remote monitoring system: an alternative for prolonged electrocardiographic monitoring. Int J Cardiol 2014; 172 :e43–44. 202. Moya A, Brignole M, Menozzi C, Garcia-Civera R, Tognarini S, Mont L, Botto G, Giada F, Cornacchia D, International Study on Syncope of Uncertain Etiology (ISSUE) Investigators. Mechanism of syncope in patients with isolated syncope and in patients with tilt-positive syncope.  Circulation 2001; 104 :1261–1267. 203. Furukawa T, Maggi R, Bertolone C, Fontana D, Brignole M. Additional diagnostic value of very prolonged observation by implantable loop recorder in patients with unexplained syncope.  J Cardiovasc Electrophysiol  2012; 23 :67–71. 204. LaFrance WC Jr, Baker GA, Duncan R, Goldstein LH, Reuber M. Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force.  Epilepsia  2013; 54 :2005–2018. 205. Saal DP, Thijs RD, van Zwet EW, Bootsma M, Brignole M, Benditt DG, van Dijk JG. Temporal relationship of asystole to onset of transient loss of consciousness in tilt-induced reflex syncope.  JACC: Clinical Electrophysiology  2017; 3 :1592–1598. 206. Whittaker RG. Video telemetry: current concepts and recent advances.  Pract Neurol  2015; 15 :445–450. 207. Goodwin E, Kandler RH, Alix JJ. The value of home video with ambulatory EEG: a prospective service review.  Seizure  2014; 23 :480–482. 208. Stephenson J, Breningstall G, Steer C, Kirkpatrick M, Horrocks I, Nechay A, Zuberi S. Anoxic-epileptic seizures: home video recordings of epileptic seizures induced by syncopes.  Epileptic Disord  2004; 6 :15–19. 209. Linzer M, Yang EH, Estes NA III, Wang P, Vorperian VR, Kapoor WN. Diagnosing syncope. Part 2: Unexplained syncope. Clinical Efficacy Assessment Project of the American College of Physicians.  Ann Intern Med  1997; 127 :76–86. 210. Dhingra RC. Sinus node dysfunction. Pacing Clin Electrophysiol 1983; 6 :1062–1069. 211. Gann D, Tolentino A, Samet P. Electrophysiologic evaluation of elderly patients with sinus bradycardia: a long-term follow-up study. Ann Intern Med 1979; 90 :24–29. 212. Menozzi C, Brignole M, Alboni P, Boni L, Paparella N, Gaggioli G, Lolli G. The natural course of untreated sick sinus syndrome and identification of the varia- bles predictive of unfavorable outcome.  Am J Cardiol  1998; 82 :1205–1209. 213. McAnulty JH, Rahimtoola SH, Murphy E, DeMots H, Ritzmann L, Kanarek PE, Kauffman S. Natural history of “high-risk” bundle-branch block: final report of a prospective study.  N Engl J Med  1982; 307 :137–143. 214. Gronda M, Magnani A, Occhetta E, Sauro G, D’Aulerio M, Carfora A, Rossi P. Electrophysiological study of atrio-ventricular block and ventricular conduction defects. Prognostic and therapeutical implications. G Ital Cardiol 1984; 14 :768–773. 215. Bergfeldt L, Edvardsson N, Rosenqvist M, Vallin H, Edhag O. Atrioventricular block progression in patients with bifascicular block assessed by repeated elec- trocardiography and a bradycardia-detecting pacemaker. Am J Cardiol 1994; 74 :1129–1132. 216. Kaul U, Dev V, Narula J, Malhotra AK, Talwar KK, Bhatia ML. Evaluation of patients with bundle branch block and “unexplained” syncope: a study based on comprehensive electrophysiologic testing and ajmaline stress.  Pacing Clin Electrophysiol  1988; 11 :289–297. 217. Kalscheur MM, Donateo P, Wenzke KE, Aste M, Oddone D, Solano A, Maggi R, Croci F, Page RL, Brignole M, Hamdan MH. Long-term outcome of patients with bifascicular block and unexplained syncope following cardiac pacing.  Pacing Clin Electrophysiol  2016; 39 :1126–1131. 218. Olshansky B, Hahn EA, Hartz VL, Prater SP, Mason JW. Clinical significance of syncope in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. The ESVEM Investigators.  Am Heart J  1999; 137 :878–886. 219. Link MS, Kim KM, Homoud MK, Estes NA III, Wang PJ. Long-term outcome of patients with syncope associated with coronary artery disease and a nondiag- nostic electrophysiologic evaluation.  Am J Cardiol  1999; 83 :1334–1337. 220. Sroubek J, Probst V, Mazzanti A, Delise P, Hevia JC, Ohkubo K, Zorzi A, Champagne J, Kostopoulou A, Yin X, Napolitano C, Milan DJ, Wilde A, Sacher F, Borggrefe M, Ellinor PT, Theodorakis G, Nault I, Corrado D, Watanabe I,\nAntzelevitch C, Allocca G, Priori SG, Lubitz SA. Programmed ventricular stimu- lation for risk stratification in the Brugada syndrome: a pooled analysis. Circulation  2016; 133 :622–630. 221. Scheinman MM, Peters RW, Suave MJ, Desai J, Abbott JA, Cogan J, Wohl B, Williams K. Value of the H-Q interval in patients with bundle branch block and the role of prophylactic permanent pacing.  Am J Cardiol  1982; 50 :1316–1322. 222. Blomstro¨m-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW Jr, Stevenson WG, Tomaselli GF, Antman EM, Smith SC Jr, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO Jr, Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ, American College of Cardiology, American Heart Association Task Force on Practice Guidelines, European Society of Cardiology Committee for Practice Guidelines, Writing Committee to Develop Guidelines for the manage- ment of Patients With Supraventricular Arrhythmias. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias).  Circulation  2003; 108 :1871–1909. 223. Pfister R, Hagemeister J, Esser S, Hellmich M, Erdmann E, Schneider CA. NT- pro-BNP for diagnostic and prognostic evaluation in patients hospitalized for syncope.  Int J Cardiol  2012; 155 :268–272. 224. Costantino G, Solbiati M, Casazza G, Bonzi M, Vago T, Montano N, McDermott D, Quinn J, Furlan R. Usefulness of N-terminal pro-B-type natriu- retic Peptide increase as a marker for cardiac arrhythmia in patients with syn- cope.  Am J Cardiol  2014; 113 :98–102. 225. Thiruganasambandamoorthy V, Ramaekers R, Rahman MO, Stiell IG, Sikora L, Kelly SL, Christ M, Claret PG, Reed MJ. Prognostic value of cardiac biomarkers in the risk stratification of syncope: a systematic review.  Intern Emerg Med 2015; 10 :1003–1014. 226. Guieu R, Deharo JC, Ruf J, Mottola G, Kipson N, Bruzzese L, Gerolami V, Franceschi F, Ungar A, Tomaino M, Iori M, Brignole M. Adenosine and clinical forms of neurally-mediated syncope. J Am Coll Cardiol 2015; 66 :204–205. 227. Flammang D, Church TR, De Roy L, Blanc JJ, Leroy J, Mairesse GH, Otmani A, Graux PJ, Frank R, Purnode P, ATP Multicenter Study. Treatment of unex- plained syncope: a multicenter, randomized trial of cardiac pacing guided by adenosine 5’-triphosphate testing.  Circulation  2012; 125 :31–36. 228. Brignole M, Gaggioli G, Menozzi C, Gianfranchi L, Bartoletti A, Bottoni N, Lolli G, Oddone D, Del Rosso A, Pellinghelli G. Adenosine-induced atrioventricular block in patients with unexplained syncope: the diagnostic value of ATP testing. Circulation  1997; 96 :3921–3927. 229. Donateo P, Brignole M, Menozzi C, Bottoni N, Alboni P, Dinelli M, Del Rosso A, Croci F, Oddone D, Solano A, Puggioni E. Mechanism of syncope in patients with positive adenosine triphosphate tests.  J Am Coll Cardiol  2003; 41 :93–98. 230. Krishnan B, Patarroyo-Aponte M, Duprez D, Pritzker M, Missov E, Benditt DG. Orthostatic hypotension of unknown cause: unanticipated association with ele- vated circulating N-terminal brain natriuretic peptide (NT-proBNP).  Heart Rhythm  2015; 12 :1287–1294. 231. Fedorowski A, Burri P, Struck J, Juul-Moller S, Melander O. Novel cardiovascu- lar biomarkers in unexplained syncopal attacks: the SYSTEMA cohort.  J Intern Med  2013; 273 :359–367. 232. Li H, Kem DC, Reim S, Khan M, Vanderlinde-Wood M, Zillner C, Collier D, Liles C, Hill MA, Cunningham MW, Aston CE, Yu X. Agonistic autoantibodies as vasodilators in orthostatic hypotension: a new mechanism.  Hypertension 2012; 59 :402–408. 233. Li H, Yu X, Liles C, Khan M, Vanderlinde-Wood M, Galloway A, Zillner C, Benbrook A, Reim S, Collier D, Hill MA, Raj SR, Okamoto LE, Cunningham MW, Aston CE, Kem DC. Autoimmune basis for postural tachycardia syn- drome.  J Am Heart Assoc  2014; 3 :e000755. 234. Fedorowski A, Li H, Yu X, Koelsch KA, Harris VM, Liles C, Murphy TA, Quadri SMS, Scofield RH, Sutton R, Melander O, Kem DC. Antiadrenergic autoimmun- ity in postural tachycardia syndrome.  Europace  2017; 19 :1211–1219. 235. Recchia D, Barzilai B. Echocardiography in the evaluation of patients with syn- cope.  J Gen Intern Med  1995; 10 :649–655. 236. Sarasin FP, Junod AF, Carballo D, Slama S, Unger PF, Louis-Simonet M. Role of echocardiography in the evaluation of syncope: a prospective study.  Heart 2002; 88 :363–367. 237. Hoegholm A, Clementsen P, Mortensen SA. Syncope due to right atrial throm- boembolism: diagnostic importance of two-dimensional echocardiography.  Acta Cardiol  1987; 42 :469–473. 238. Omran H, Fehske W, Rabahieh R, Hagendorff A, Pizzulli L, Zirbes M, Luderitz B. Valvular aortic stenosis: risk of syncope.  J Heart Valve Dis  1996; 5 :31–34.\n1946 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .......................................................................................................................................................................... 239. Bogaert AM, De Scheerder I, Colardyn F. Successful treatment of aortic rupture presenting as a syncope: the role of echocardiography in diagnosis.  Int J Cardiol 1987; 16 :212–214. 240. Acikel M, Yekeler I, Ates A, Erkut B. A giant left atrial myxoma: an unusual cause of syncope and cerebral emboli.  Int J Cardiol  2004; 94 :325–326. 241. Nogueira DC, Bontempo D, Menardi AC, Vicente WV, Ribeiro PJ, Evora PR. Left atrial myxoma as the cause of syncope in an adolescent.  Arq Bras Cardiol 2003; 81 :206–209, 202–205. 242. Sinha AK, Singh BP. LA myxoma presenting as recurrent syncope.  Indian Heart J 2013; 65 :643. 243. Rahman MS, Michael H. A rare presentation of chest pain and syncope: massive right atrial myxoma.  Postgrad Med J  2012; 88 :671–672. 244. Han H, Li Y, Guo S, Yu X. Right atrial myxoma-induced syncope.  Postgrad Med J 2011; 87 :438–439. 245. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).  Eur Heart J  2014; 35 :2733–2779. 246. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction.  Circulation  2006; 114 :2232–2239. 247. Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, Ward D, Kohli SK, Page SP, Demetrescu C, Sevdalis E, Keren A, Pellerin D, McKenna WJ, Elliott PM. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardio- myopathy.  Heart  2008; 94 :1288–1294. 248. Dimitrow PP, Bober M, Michalowska J, Sorysz D. Left ventricular outflow tract gradient provoked by upright position or exercise in treated patients with hypertrophic cardiomyopathy without obstruction at rest.  Echocardiography 2009; 26 :513–520. 249. Marwick TH, Nakatani S, Haluska B, Thomas JD, Lever HM. Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy.  Am J Cardiol  1995; 75 :805–809. 250. Sneddon JF, Scalia G, Ward DE, McKenna WJ, Camm AJ, Frenneaux MP. Exercise induced vasodepressor syncope.  Br Heart J  1994; 71 :554–557. 251. Sakaguchi S, Shultz JJ, Remole SC, Adler SW, Lurie KG, Benditt DG. Syncope associated with exercise, a manifestation of neurally mediated syncope.  Am J Cardiol  1995; 75 :476–481. 252. Colivicchi F, Ammirati F, Biffi A, Verdile L, Pelliccia A, Santini M. Exercise- related syncope in young competitive athletes without evidence of structural heart disease. Clinical presentation and long-term outcome.  Eur Heart J 2002; 23 :1125–1130. 253. Woelfel AK, Simpson RJ Jr, Gettes LS, Foster JR. Exercise-induced distal atrio- ventricular block.  J Am Coll Cardiol  1983; 2 :578–581. 254. Byrne JM, Marais HJ, Cheek GA. Exercise-induced complete heart block in a patient with chronic bifascicular block.  J Electrocardiol  1994; 27 :339–342. 255. Aste M, Oddone D, Donateo P, Solano A, Maggi R, Croci F, Solari D, Brignole M. Syncope in patients paced for atrioventricular block. Europace 2016; 18 :1735–1739. 256. Sumiyoshi M, Nakata Y, Yasuda M, Tokano T, Ogura S, Nakazato Y, Yamaguchi H. Clinical and electrophysiologic features of exercise-induced atrioventricular block.  Am Heart J  1996; 132 :1277–1281. 257. Wissocq L, Ennezat PV, Mouquet F. Exercise-induced high-degree atrioventricu- lar block.  Arch Cardiovasc Dis  2009; 102 :733–735. 258. Anderson LL, Dai D, Miller AL, Roe MT, Messenger JC, Wang TY. Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry.  Am Heart J  2016; 176 :1–9. 259. El-Sayed H, Hainsworth R. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope. Heart 1996; 75 :134–140. 260. Solari D, Tesi F, Unterhuber M, Gaggioli G, Ungar A, Tomaino M, Brignole M. Stop vasodepressor drugs in reflex syncope: a randomised controlled trial. Heart  2017; 103 :449–455. 261. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood- Pressure Control.  N Engl J Med  2015; 373 :2103–2116. 262. Brignole M, Menozzi C, Gaggioli G, Musso G, Foglia-Manzillo G, Mascioli G, Fradella G, Bottoni N, Mureddu R. Effects of long-term vasodilator therapy in patients with carotid sinus hypersensitivity.  Am Heart J  1998; 136 :264–268.\n",
      "keywords": [
        "older",
        "brignole",
        "bradycardia",
        "electrocardiogram",
        "pacemaker",
        "bertulla",
        "tachycardia",
        "head",
        "gender",
        "massage",
        "age",
        "sick",
        "mediated",
        "sinus",
        "orthostatic",
        "nt-probnp",
        "hypertension",
        "syndrome",
        "risk stratification",
        "transient loss of consciousness",
        "syncope",
        "aortic",
        "menozzi",
        "arrhythmia",
        "carotid",
        "test",
        "oddone",
        "gianfranchi",
        "bnp",
        "echocardiography"
      ],
      "tables": []
    },
    {
      "number": "52",
      "title": "263. Kim KH, Cho JG, Lee KO, Seo TJ, Shon CY, Lim SY, Yun KH, Sohn IS, Hong YJ, Park HW, Kim JH, Kim W, Ahn YK, Jeong MH, Park JC, Kang JC. Usefulness of physical maneuvers for prevention of vasovagal",
      "start_page": 64,
      "end_page": 65,
      "content": "ESC Guidelines 1947\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ......................................................................................................................................................................... clonazepam as a first treatment choice among patients with neurocardiogenic syncope].  Gac Med Mex  2008; 144 :503–507. 284. Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Grubb BP. Use of octreotide in the treatment of refractory orthostatic intolerance.  Am J Ther  2012; 19 :7–10. 285. Brignole M, Solari D, Iori M, Bottoni N, Guieu R, Deharo JC. Efficacy of theo- phylline in patients affected by low adenosine syncope.  Heart Rhythm 2016; 13 :1151–1154. 286. Brignole M, Guieu R, Tomaino M, Iori M, Ungar A, Bertolone C, Unterhuber M, Bottoni N, Tesi F, Claude Deharo J. Mechanism of syncope without prodromes with normal heart and normal electrocardiogram. Heart Rhythm 2017; 14 :234–239. 287. Vaddadi G, Guo L, Esler M, Socratous F, Schlaich M, Chopra R, Eikelis N, Lambert G, Trauer T, Lambert E. Recurrent postural vasovagal syncope: sympa- thetic nervous system phenotypes.  Circ Arrhythm Electrophysiol  2011; 4 :711–718. 288. Schroeder C, Birkenfeld AL, Mayer AF, Tank J, Diedrich A, Luft FC, Jordan J. Norepinephrine transporter inhibition prevents tilt-induced pre-syncope.  J Am Coll Cardiol  2006; 48 :516–522. 289. Sheldon RS, Ritchie D, McRae M, Raj S. Norepinephrine transport inhibition for treatment of vasovagal syncope.  J Cardiovasc Electrophysiol  2013; 24 :799–803. 290. Pachon JC, Pachon EI, Cunha Pachon MZ, Lobo TJ, Pachon JC, Santillana TG. Catheter ablation of severe neurally meditated reflex (neurocardiogenic or vas- ovagal) syncope: cardioneuroablation long-term results. Europace 2011; 13 :1231–1242. 291. Aksu T, Gu¨ler TE, Bozyel S, € Ozcan KS, Yalin K, Mutluer FO. Cardioneuroablation in the treatment of neurally mediated reflex syncope: a review of the current literature.  Turk Kardiyol Dern Ars  2017; 45 :33–41. 292. Brignole M, Arabia F, Ammirati F, Tomaino M, Quartieri F, Rafanelli M, Del Rosso A, Rita Vecchi M, Russo V, Gaggioli G, Syncope Unit Project 2 (SUP 2) investigators. Standardized algorithm for cardiac pacing in older patients affected by severe unpredictable reflex syncope: 3-year insights from the Syncope Unit Project 2 (SUP 2) study.  Europace  2016; 18 :1427–1433. 293. Brignole M, Menozzi C. The natural history of carotid sinus syncope and the effect of cardiac pacing.  Europace  2011; 13 :462–464. 294. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).  Eur Heart J  2013; 34 :2281–2329. 295. Gaggioli G, Brignole M, Menozzi C, Devoto G, Oddone D, Gianfranchi L, Gostoli E, Bottoni N, Lolli G. A positive response to head-up tilt testing pre- dicts syncopal recurrence in carotid sinus syndrome patients with permanent pacemakers.  Am J Cardiol  1995; 76 :720–722. 296. Connolly SJ, Sheldon R, Roberts RS, Gent M. The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope.  J Am Coll Cardiol  1999; 33 :16–20. 297. Sutton R, Brignole M, Menozzi C, Raviele A, Alboni P, Giani P, Moya A. Dual- chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibi- tory syncope: pacemaker versus no therapy: a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators.  Circulation 2000; 102 :294–299. 298. Ammirati F, Colivicchi F, Santini M, Syncope Diagnosis and Treatment Study Investigators. Permanent cardiac pacing versus medical treatment for the pre- vention of recurrent vasovagal syncope: a multicenter, randomized, controlled trial.  Circulation  2001; 104 :52–57. 299. Connolly SJ, Sheldon R, Thorpe KE, Roberts RS, Ellenbogen KA, Wilkoff BL, Morillo C, Gent M, VPS II Investigators. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial.  JAMA  2003; 289 :2224–2229. 300. Raviele A, Giada F, Menozzi C, Speca G, Orazi S, Gasparini G, Sutton R, Brignole M, Vasovagal Syncope and Pacing Trial Investigators. A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The Vasovagal Syncope and Pacing Trial (SYNPACE).  Eur Heart J  2004; 25 :1741–1748. 301. Sud S, Massel D, Klein GJ, Leong-Sit P, Yee R, Skanes AC, Gula LJ, Krahn AD. The expectation effect and cardiac pacing for refractory vasovagal syncope.  Am J Med  2007; 120 :54–62. 302. Brignole M, Donateo P, Tomaino M, Massa R, Iori M, Beiras X, Moya A, Kus T, Deharo JC, Giuli S, Gentili A, Sutton R, International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators. Benefit of pacemaker therapy in patients with presumed neurally mediated syncope and documented asystole is greater when tilt test is negative: an analysis from the third International Study on Syncope of Uncertain Etiology (ISSUE-3).  Circ Arrhythm Electrophysiol 2014; 7 :10–16.\n",
      "keywords": [
        "park",
        "older",
        "hong",
        "vasovagal",
        "usefulness",
        "electrocardiogram",
        "pacemaker",
        "tilt test",
        "orthostatic",
        "syncope",
        "jeong",
        "carotid",
        "kang",
        "shon",
        "sohn",
        "prevention",
        "maneuvers",
        "ablation",
        "physical"
      ],
      "tables": []
    },
    {
      "number": "53",
      "title": "303. Baron-Esquivias G, Morillo CA, Moya-Mitjans A, Martinez-Alday J, Ruiz-Granell R, Lacunza-Ruiz J, Garcia-Civera R, Gutierrez-Carretero E, Romero-Garrido R. Dual-chamber pacing with closed loop sti",
      "start_page": 65,
      "end_page": 66,
      "content": "1948 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................ 324. Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a double-blind, placebo- controlled study with midodrine.  Am J Med  1993; 95 :38–48. 325. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.  JAMA  1997; 277 : 1046–1051. 326. Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, Low PA. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.  Neurology  1998; 51 :120–124. 327. van Lieshout JJ, ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic fail- ure.  Clin Auton Res  2000; 10 :35–42. 328. Finke J, Sagemuller I. [Fludrocortisone in the treatment of orthostatic hypoten- sion: ophthalmodynamography during standing(author’s transl)].  Dtsch Med Wochenschr  1975; 100 :1790–1792. 329. Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ, NOH301 Investigators. Droxidopa for neurogenic ortho- static hypotension: a randomized, placebo-controlled, phase 3 trial.  Neurology 2014; 83 :328–335. 330. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short- term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B).  Mov Disord  2015; 30 :646–654. 331. Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.  Hypertension 2015; 65 :101–107. 332. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis  2014; 4 :57–65. 333. Elgebaly A, Abdelazeim B, Mattar O, Gadelkarim M, Salah R, Negida A. Meta- analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypo- tension.  Clin Auton Res  2016; 26 :171–180. 334. Alboni P, Menozzi C, Brignole M, Paparella N, Gaggioli G, Lolli G, Cappato R. Effects of permanent pacemaker and oral theophylline in sick sinus syndrome the THEOPACE study: a randomized controlled trial. Circulation 1997; 96 :260–266. 335. Breivik K, Ohm OJ, Segadal L. Sick sinus syndrome treated with permanent pacemaker in 109 patients. A follow-up study. Acta Med Scand 1979; 206 :153–159. 336. Hartel G, Talvensaari T. Treatment of sinoatrial syndrome with permanent car- diac pacing in 90 patients.  Acta Med Scand  1975; 198 :341–347. 337. Rasmussen K. Chronic sinus node disease: natural course and indications for pacing.  Eur Heart J  1981; 2 :455–459. 338. Sasaki Y, Shimotori M, Akahane K, Yonekura H, Hirano K, Endoh R, Koike S, Kawa S, Furuta S, Homma T. Long-term follow-up of patients with sick sinus syndrome: a comparison of clinical aspects among unpaced, ventricular inhibited paced, and physiologically paced groups. Pacing Clin Electrophysiol 1988; 11 :1575–1583. 339. Sgarbossa EB, Pinski SL, Jaeger FJ, Trohman RG, Maloney JD. Incidence and pre- dictors of syncope in paced patients with sick sinus syndrome.  Pacing Clin Electrophysiol  1992; 15 :2055–2060. 340. Ng Kam Chuen MJ, Kirkfeldt RE, Andersen HR, Nielsen JC. Syncope in paced patients with sick sinus syndrome from the DANPACE trial: incidence, predic- tors and prognostic implication.  Heart  2014; 100 :842–847. 341. Langenfeld H, Grimm W, Maisch B, Kochsiek K. Course of symptoms and spon- taneous ECG in pacemaker patients: a 5-year follow-up study.  Pacing Clin Electrophysiol  1988; 11 :2198–2206. 342. Donateo P, Brignole M, Alboni P, Menozzi C, Raviele A, Del Rosso A, Dinelli M, Solano A, Bottoni N, Croci F. A standardized conventional evaluation of the mechanism of syncope in patients with bundle branch block.  Europace 2002; 4 :357–360. 343. Azocar D, Ruiz-Granell R, Ferrero A, Martinez-Brotons A, Izquierdo M, Dominguez E, Palau P, Morell S, Garcia-Civera R. Syncope and bundle branch block. Diagnostic yield of a stepped use of electrophysiology study and implant- able loop recorders.  Rev Esp Cardiol  2011; 64 :213–219. 344. Santini M, Castro A, Giada F, Ricci R, Inama G, Gaggioli G, Calo L, Orazi S, Viscusi M, Chiodi L, Bartoletti A, Foglia-Manzillo G, Ammirati F, Loricchio ML, Pedrinazzi C, Turreni F, Gasparini G, Accardi F, Raciti G, Raviele A. Prevention of syncope through permanent cardiac pacing in patients with bifascicular block and syncope of unexplained origin: the PRESS study.  Circ Arrhythm Electrophysiol 2013; 6 :101–107. 345. Englund A, Bergfeldt L, Rehnqvist N, Astrom H, Rosenqvist M. Diagnostic value of programmed ventricular stimulation in patients with bifascicular block: a pro- spective study of patients with and without syncope.  J Am Coll Cardiol 1995; 26 :1508–1515.\n",
      "keywords": [
        "civera",
        "romero",
        "moya",
        "esquivias",
        "morillo",
        "baron",
        "pacemaker",
        "chamber",
        "carretero",
        "loop",
        "orthostatic",
        "hypertension",
        "syncope",
        "granell",
        "dual",
        "mitjans",
        "garrido",
        "ecg",
        "gutierrez",
        "closed",
        "martinez",
        "pacing",
        "garcia",
        "lacunza",
        "alday",
        "ruiz"
      ],
      "tables": []
    },
    {
      "number": "54",
      "title": "346. Morady F, Higgins J, Peters RW, Schwartz AB, Shen EN, Bhandari A, Scheinman MM, Sauve MJ. Electrophysiologic testing in bundle branch block and unex- plained syncope.  Am J Cardiol  1984; 54 :587",
      "start_page": 66,
      "end_page": 68,
      "content": "ESC Guidelines 1948a\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. ............................................................................................................................................................................ Pelliccia A, Duru F, Protonotarios N, Estes NA III, McKenna WJ, Thiene G, Marcus FI, Calkins H. Treatment of arrhythmogenic right ventricular cardiomy- opathy/dysplasia: an international task force consensus statement.  Eur Heart J 2015; 36 :3227–3237. 363. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, Dalal D, Tedford R, Russell SD, Abraham T, Tandri H, Judge DP, Calkins H. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implant- able cardioverter-defibrillator implantation for primary prevention.  J Am Coll Cardiol  2011; 58 :1485–1496. 364. Jons C, Moss AJ, Goldenberg I, Liu J, McNitt S, Zareba W, Qi M, Robinson JL. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol  2010; 55 :783–788. 365. Giustetto C, Cerrato N, Ruffino E, Gribaudo E, Scrocco C, Barbonaglia L, Bianchi F, Bortnik M, Rossetti G, Carvalho P, Riccardi R, Castagno D, Anselmino M, Bergamasco L, Gaita F. Etiological diagnosis, prognostic signifi- cance and role of electrophysiological study in patients with Brugada ECG and syncope.  Int J Cardiol  2017; 241 :188–193. 366. Kubala M, Aissou L, Traulle S, Gugenheim AL, Hermida JS. Use of implantable loop recorders in patients with Brugada syndrome and suspected risk of ven- tricular arrhythmia.  Europace  2012; 14 :898–902. 367. Delise P, Allocca G, Marras E, Giustetto C, Gaita F, Sciarra L, Calo L, Proclemer A, Marziali M, Rebellato L, Berton G, Coro L, Sitta N. Risk stratifica- tion in individuals with the Brugada type 1 ECG pattern without previous car- diac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J  2011; 32 :169–176. 368. Maury P, Rollin A, Sacher F, Gourraud JB, Raczka F, Pasquie JL, Duparc A, Mondoly P, Cardin C, Delay M, Derval N, Chatel S, Bongard V, Sadron M, Denis A, Davy JM, Hocini M, Jais P, Jesel L, Haissaguerre M, Probst V. Prevalence and prognostic role of various conduction disturbances in patients with the Brugada syndrome.  Am J Cardiol  2013; 112 :1384–1389. 369. Maury P, Sacher F, Gourraud JB, Pasquie JL, Raczka F, Bongard V, Duparc A, Mondoly P, Sadron M, Chatel S, Derval N, Denis A, Cardin C, Davy JM, Hocini M, Jais P, Jesel L, Carrie D, Galinier M, Haissaguerre M, Probst V, Rollin A. Increased Tpeak-Tend interval is highly and independently related to arrhythmic events in Brugada syndrome.  Heart Rhythm  2015; 12 :2469–2476. 370. Morita H, Kusano KF, Miura D, Nagase S, Nakamura K, Morita ST, Ohe T, Zipes DP, Wu J. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome.  Circulation  2008; 118 :1697–1704. 371. Priori SG, Gasparini M, Napolitano C, Della Bella P, Ottonelli AG, Sassone B, Giordano U, Pappone C, Mascioli G, Rossetti G, De Nardis R, Colombo M. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 2012; 59 :37–45. 372. McIntosh SJ, Lawson J, Kenny RA. Clinical characteristics of vasodepressor, car- dioinhibitory, and mixed carotid sinus syndrome in the elderly.  Am J Med 1993; 95 :203–208. 373. Ungar A, Mussi C, Del Rosso A, Noro G, Abete P, Ghirelli L, Cellai T, Landi A, Salvioli G, Rengo F, Marchionni N, Masotti G, Italian Group for the Study of Syncope in the Elderly. Diagnosis and characteristics of syncope in older patients referred to geriatric departments.  J Am Geriatr Soc  2006; 54 :1531–1536. 374. Galizia G, Abete P, Mussi C, Noro G, Morrione A, Langellotto A, Landi A, Cacciatore F, Masotti G, Rengo F, Marchionni N, Ungar A. Role of early symp- toms in assessment of syncope in elderly people: results from the Italian group for the study of syncope in the elderly.  J Am Geriatr Soc  2009; 57 :18–23. 375. Romme JJ, van Dijk N, Boer KR, Dekker LR, Stam J, Reitsma JB, Wieling W. Influence of age and gender on the occurrence and presentation of reflex syn- cope.  Clin Auton Res  2008; 18 :127–133. 376. Bhangu JS, King-Kallimanis B, Cunningham C, Kenny RA. The relationship between syncope, depression and anti-depressant use in older adults.  Age Ageing  2014; 43 :502–509. 377. Jansen S, Frewen J, Finucane C, de Rooij SE, van der Velde N, Kenny RA. AF is associated with self-reported syncope and falls in a general population cohort. Age Ageing  2015; 44 :598–603. 378. Jansen S, Kenny RA, de Rooij SE, van der Velde N. Self-reported cardiovascular conditions are associated with falls and syncope in community-dwelling older adults.  Age Ageing  2015; 44 :525–529. 379. Aronow WS. Heart disease and aging.  Med Clin North Am  2006; 90 :849–862. 380. Jansen S, Bhangu J, de Rooij S, Daams J, Kenny RA, van der Velde N. The Association of Cardiovascular Disorders and Falls: a systematic review.  J Am Med Dir Assoc  2016; 17 :193–199. 381. van der Velde N, van den Meiracker AH, Pols HA, Stricker BH, van der Cammen TJ. Withdrawal of fall-risk-increasing drugs in older persons: effect on tilt-table test outcomes.  J Am Geriatr Soc  2007; 55 :734–739. 382. Ruwald MH, Hansen ML, Lamberts M, Hansen CM, Nume AK, Vinther M, Kober L, Torp-Pedersen C, Hansen J, Gislason GH. Comparison of incidence,\npredictors, and the impact of co-morbidity and polypharmacy on the risk of recurrent syncope in patients <85 versus >/=85 years of age.  Am J Cardiol 2013; 112 :1610–1615. 383. Mossello E, Pieraccioli M, Nesti N, Bulgaresi M, Lorenzi C, Caleri V, Tonon E, Cavallini MC, Baroncini C, Di Bari M, Baldasseroni S, Cantini C, Biagini CA, Marchionni N, Ungar A. Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. JAMA Intern Med 2015; 175 :578–585. 384. McLachlan CY, Yi M, Ling A, Jardine DL. Adverse drug events are a major cause of acute medical admission.  Intern Med J  2014; 44 :633–638. 385. Ungar A, Mussi C, Ceccofiglio A, Bellelli G, Nicosia F, Bo M, Riccio D, Martone AM, Guadagno L, Noro G, Ghidoni G, Rafanelli M, Marchionni N, Abete P. Etiology of syncope and unexplained falls in elderly adults with Dementia: Syncope and Dementia (SYD) study.  J Am Geriatr Soc  2016; 64 :1567–1573. 386. Ryan DJ, Harbison JA, Meaney JF, Rice CP, King-Kallimanis B, Kenny RA. Syncope causes transient focal neurological symptoms.  QJM  2015; 108 :711–718. 387. Parry SW, Kenny RA. Drop attacks in older adults: systematic assessment has a high diagnostic yield.  J Am Geriatr Soc  2005; 53 :74–78. 388. Parry SW, Steen IN, Baptist M, Kenny RA. Amnesia for loss of consciousness in carotid sinus syndrome: implications for presentation with falls.  J Am Coll Cardiol 2005; 45 :1840–1843. 389. O’Dwyer C, Bennett K, Langan Y, Fan CW, Kenny RA. Amnesia for loss of con- sciousness is common in vasovagal syncope.  Europace  2011; 13 :1040–1045. 390. Rafanelli M, Ruffolo E, Chisciotti VM, Brunetti MA, Ceccofiglio A, Tesi F, Morrione A, Marchionni N, Ungar A. Clinical aspects and diagnostic relevance of neuroautonomic evaluation in patients with unexplained falls.  Aging Clin Exp Res  2014; 26 :33–37. 391. Shaw FE, Bond J, Richardson DA, Dawson P, Steen IN, McKeith IG, Kenny RA. Multifactorial intervention after a fall in older people with cognitive impairment and dementia presenting to the accident and emergency department: rando- mised controlled trial.  BMJ  2003; 326 :73. 392. Frewen J, Finucane C, Savva GM, Boyle G, Kenny RA. Orthostatic hypotension is associated with lower cognitive performance in adults aged 50 plus with supine hypertension.  J Gerontol A Biol Sci Med Sci  2014; 69 :878–885. 393. Robertson DA, Savva GM, Coen RF, Kenny RA. Cognitive function in the pre- frailty and frailty syndrome.  J Am Geriatr Soc  2014; 62 :2118–2124. 394. Frewen J, King-Kallimanis B, Boyle G, Kenny RA. Recent syncope and unex- plained falls are associated with poor cognitive performance.  Age Ageing 2015; 44 :282–286. 395. Robertson DA, Savva GM, Kenny RA. Frailty and cognitive impairment–a review of the evidence and causal mechanisms.  Ageing Res Rev  2013; 12 :840–851. 396. Kenny RA, Richardson DA, Steen N, Bexton RS, Shaw FE, Bond J. Carotid sinus syndrome: a modifiable risk factor for nonaccidental falls in older adults (SAFE PACE).  J Am Coll Cardiol  2001; 38 :1491–1496. 397. Ungar A, Galizia G, Morrione A, Mussi C, Noro G, Ghirelli L, Masotti G, Rengo F, Marchionni N, Abete P. Two-year morbidity and mortality in elderly patients with syncope.  Age Ageing  2011; 40 :696–702. 398. Finucane C, O’Connell MD, Fan CW, Savva GM, Soraghan CJ, Nolan H, Cronin H, Kenny RA. Age-related normative changes in phasic orthostatic blood pres- sure in a large population study: findings from The Irish Longitudinal Study on Ageing (TILDA).  Circulation  2014; 130 :1780–1789. 399. DiMario FJ Jr. Prospective study of children with cyanotic and pallid breath- holding spells.  Pediatrics  2001; 107 :265–269. 400. Vlahos AP, Kolettis TM. Family history of children and adolescents with neuro- cardiogenic syncope.  Pediatr Cardiol  2008; 29 :227. 401. Vlahos AP, Tzoufi M, Katsouras CS, Barka T, Sionti I, Michalis LK, Siamopoulou A, Kolettis TM. Provocation of neurocardiogenic syncope during head-up tilt testing in children: comparison between isoproterenol and nitroglycerin. Pediatrics  2007; 119 :e419–425. 402. McLeod KA, Wilson N, Hewitt J, Norrie J, Stephenson JB. Cardiac pacing for severe childhood neurally mediated syncope with reflex anoxic seizures.  Heart 1999; 82 :721–725. 403. Raj V, Rowe AA, Fleisch SB, Paranjape SY, Arain AM, Nicolson SE. Psychogenic pseudosyncope: diagnosis and management.  Auton Neurosci  2014; 184 :66–72. 404. LaFrance WC Jr, Reuber M, Goldstein LH. Management of psychogenic nonepi- leptic seizures.  Epilepsia  2013; 54 :53–67. 405. Saal DP, Overdijk MJ, Thijs RD, van Vliet IM, van Dijk JG. Long-term follow-up of psychogenic pseudosyncope.  Neurology  2016; 87 :2214–2219. 406. LaFrance WC Jr, Baird GL, Barry JJ, Blum AS, Frank Webb A, Keitner GI, Machan JT, Miller I, Szaflarski JP, NES Treatment Trial (NEST-T) Consortium. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial.  JAMA Psychiatry  2014; 71 :997–1005. 407. Benbadis SR, Chichkova R. Psychogenic pseudosyncope: an underestimated and provable diagnosis.  Epilepsy Behav  2006; 9 :106–110. 408. Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK. Premotor signs and symptoms of multiple system atrophy.  Lancet Neurol  2012; 11 :361–368.\n1948b ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n. .............................................................................................. 409. Siderowf A, Lang AE. Premotor Parkinson’s disease: concepts and definitions. Mov Disord  2012; 27 :608–616. 410. Hoefnagels WA, Padberg GW, Overweg J, van der Velde EA, Roos RA. Transient loss of consciousness: the value of the history for distinguishing seiz- ure from syncope.  J Neurol  1991; 238 :39–43. 411. Benbadis SR, Wolgamuth BR, Goren H, Brener S, Fouad-Tarazi F. Value of tongue biting in the diagnosis of seizures.  Arch Intern Med  1995; 155 :2346–2349. 412. van der Lende M, Surges R, Sander JW, Thijs RD. Cardiac arrhythmias during or after epileptic seizures.  J Neurol Neurosurg Psychiatry  2016; 87 :69–74. 413. Rugg-Gunn FJ, Simister RJ, Squirrell M, Holdright DR, Duncan JS. Cardiac arrhythmias in focal epilepsy: a prospective long-term study. Lancet 2004; 364 :2212–2219. 414. Benditt DG, van Dijk G, Thijs RD. Ictal asystole: life-threatening vagal storm or a benign seizure self-termination mechanism?  Circ Arrhythm Electrophysiol 2015; 8 :11–14. 415. Rocamora R, Kurthen M, Lickfett L, Von Oertzen J, Elger CE. Cardiac asystole in epilepsy: clinical and neurophysiologic features.  Epilepsia  2003; 44 :179–185. 416. Schuele SU, Bermeo AC, Alexopoulos AV, Locatelli ER, Burgess RC, Dinner DS, Foldvary-Schaefer N. Video-electrographic and clinical features in patients with ictal asystole.  Neurology  2007; 69 :434–441. 417. Ghearing GR, Munger TM, Jaffe AS, Benarroch EE, Britton JW. Clinical cues for detecting ictal asystole.  Clin Auton Res  2007; 17 :221–226. 418. Bestawros M, Darbar D, Arain A, Abou-Khalil B, Plummer D, Dupont WD, Raj SR. Ictal asystole and ictal syncope: insights into clinical management.  Circ Arrhythm Electrophysiol  2015; 8 :159–164. 419. Lamberts RJ, Thijs RD, Laffan A, Langan Y, Sander JW. Sudden unexpected death in epilepsy: people with nocturnal seizures may be at highest risk. Epilepsia  2012; 53 :253–257. 420. Lamberts RJ, Blom MT, Wassenaar M, Bardai A, Leijten FS, de Haan GJ, Sander JW, Thijs RD, Tan HL. Sudden cardiac arrest in people with epilepsy in the community: Circumstances and risk factors.  Neurology  2015; 85 :212–218. 421. Horrocks IA, Nechay A, Stephenson JB, Zuberi SM. Anoxic-epileptic seizures: observational study of epileptic seizures induced by syncopes.  Arch Dis Child 2005; 90 :1283–1287. 422. Hennerici M, Klemm C, Rautenberg W. The subclavian steal phenomenon: a com- mon vascular disorder with rare neurologic deficits.  Neurology  1988; 38 :669–673. 423. Melgar MA, Weinand ME. Thyrocervical trunk-external carotid artery bypass for positional cerebral ischemia due to common carotid artery occlusion. Report of three cases.  Neurosurg Focus  2003; 14 :e7. 424. Dobkin BH. Orthostatic hypotension as a risk factor for symptomatic occlusive cerebrovascular disease.  Neurology  1989; 39 :30–34. 425. Savitz SI, Caplan LR. Vertebrobasilar disease.  N Engl J Med  2005; 352 :2618–2626.\n",
      "keywords": [
        "schwartz",
        "risk factor",
        "antihypertensive",
        "older",
        "family history",
        "vasovagal",
        "sauve",
        "scheinman",
        "gender",
        "age",
        "orthostatic",
        "hypertension",
        "blood pressure",
        "risk stratification",
        "transient loss of consciousness",
        "syncope",
        "shen",
        "arrhythmia",
        "carotid",
        "bhandari",
        "unex",
        "higgins",
        "peters",
        "cardiomyopathy",
        "ecg",
        "elderly",
        "bundle",
        "block",
        "primary prevention",
        "electrophysiologic"
      ],
      "tables": []
    },
    {
      "number": "55",
      "title": "426. Thijs RD, Kruit MC, van Buchem MA, Ferrari MD, Launer LJ, van Dijk JG. Syncope in migraine: the population-based CAMERA study. Neurology 2006; 66 :1034–1037. 427. Overeem S, van Nues SJ, van der ",
      "start_page": 68,
      "end_page": 68,
      "content": "ESC Guidelines 1948c\nDownloaded from https://academic.oup.com/eurheartj/article/39/21/1883/4939241 by guest on 14 January 2026\n",
      "keywords": [
        "nues",
        "launer",
        "camera",
        "buchem",
        "population",
        "study",
        "ferrari",
        "kruit",
        "neurology",
        "overeem",
        "migraine",
        "based",
        "syncope",
        "dijk",
        "thijs"
      ],
      "tables": []
    },
    {
      "number": "56",
      "title": "LITTMANN RATING 9/10",
      "start_page": 69,
      "end_page": 69,
      "content": "",
      "keywords": [
        "rating",
        "littmann"
      ],
      "tables": []
    },
    {
      "number": "57",
      "title": "LITTMANN RATING 10+",
      "start_page": 69,
      "end_page": 69,
      "content": "Delivering to 20+ European Countries.\n",
      "keywords": [
        "rating",
        "littmann"
      ],
      "tables": []
    },
    {
      "number": "58",
      "title": "FREE CASE ANY LITTMANN ®  CORE",
      "start_page": 69,
      "end_page": 69,
      "content": "FREECASE\nadd code at the checkout to apply\nSHOP NOW\n",
      "keywords": [
        "core",
        "free",
        "case",
        "littmann"
      ],
      "tables": []
    },
    {
      "number": "59",
      "title": "FREE CASE ANY LITTMANN ®  CARD IV",
      "start_page": 69,
      "end_page": 69,
      "content": "FREECASE\nadd code at the checkout to apply\nSHOP NOW\nTo deliver the best  patient care, you need the tools  to match.\nLittmann® Cardiology IV ™ & Littmann® CORE Digital Stethoscopes\nKeep your tools safe with laser engraving.\n♥☺♫★♠\n",
      "keywords": [
        "free",
        "case",
        "littmann",
        "card"
      ],
      "tables": []
    }
  ]
}